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 In a large Scottish family a high incidence of schizophrenia, bipolar disorder and major 
depressive disorder co-segregates with a balanced autosomal translocation 
(t(1;11)(q42.1;q14.3). The translocation disrupts Disrupted-in-Schizophrenia-1 (DISC1) and 
DISC2 on chromosome 1, and DISC1FP1 (Disrupted-in-Schizophrenia-Fusion-Partner-1), 
also known as Boymaw, on chromosome 11. DISC1 is a leading candidate gene for major 
mental illness and is involved in neurodevelopment and cellular signalling, whilst DISC2 and 
DISC1FP1 are apparently non-coding RNA genes that undergo alternative splicing and that 
are expressed in the brain. This thesis aimed to investigate putative mechanisms of 
pathogenesis that may result from the t(1;11), with the hope that pathogenic mechanisms 
identified in the t(1;11) pedigree might shed light upon mechanisms conferring risk for 
psychiatric illness in the wider population. 
Previous work had identified DISC1/DISC1FP1 chimeric transcripts in t(1;11)-family derived 
lymphoblastoid cell lines.  The detected transcripts include CP60 and CP69 which encode 
DISC1 aa1-597 plus an additional 60 or 69 amino acids from DISC1FP1, respectively. In this 
thesis a novel DISC1/DISC1FP1 transcript, CP1, was identified in t(1;11) lymphoblastoid  cell 
lines. The CP1 transcript encodes DISC1 aa1-597 plus one glycine. A truncated form of 
DISC1 comprising aa1-597 was previously suggested to be a putative product of the 
translocation and, as such, has been the focus of multiple studies. The identification of the CP1 
species is of interest as it differs from DISC1 aa1-597, by only a glycine. As glycines are 
simple uncharged aa’s, it is likely that these two DISC species share similar properties. 
In vitro exogenous expression of the three DISC1/DISC1FP1 protein species in both COS-7 
and primary neuron cultures revealed contrasting cellular phenotypes. CP1 showed a diffuse 
cellular localisation pattern with cells containing readily visible tubular mitochondria. This is 
indistinguishable from the staining pattern of DISC1 aa1-597, highlighting the high degree of 
similarity between these species. CP60 and CP69, however, appeared to be clustered in the 
perinuclear region of the cell. Initial staining attempts with MitoTracker Red to visualise 
mitochondria in CP60 and CP69 expressing cells resulted in fewer than 30% of cells being 
stained. In those that did stain, the mitochondria appeared clustered. The absence of 
MitoTracker Red staining in mitochondria may be due to the loss of the mitochondrial 
membrane potential, Δψm. The adoption of a co-staining protocol with antibodies for 
mitochondrial proteins enabled the visualisation of mitochondrial structure in all of the cells 
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exogenously expressing CP60 and CP69. All of these mitochondria possessed a clustered 
morphology, with which CP60 and CP69 expression was substantially co-localised.  
To see if MitoTracker staining was perturbed, in t(1;11) lymphoblastoid cell lines, as may 
occur if the DISC1/DISC1FP1 chimeras are expressed endogenously, the fluorescence of 
MitoTracker Red staining was investigated by FACS. Pooled analysis of experimental 
replicates revealed a negative result, with MitoTracker Red staining in t(1;11) lymphoblastoid 
cell lines not differing from controls. These findings indicate a need for further research using 
the mitochondrial membrane potential, Δψm as a metric as this would enable variations in 
mitochondrial mass to be accounted for.  
Prior to my arrival, an expression microarray had been carried out on lymphoblastoid cell line 
cDNA to assess gene expression differences resulting from the t(1;11). In order to identify 
putative pathogenic mechanisms, I carried out functional enrichment analysis of the expression 
array data using multiple analysis programs. Several programs detected dysregulation of the 
cell cycle and enrichment of altered expression of genes involved in the immune response and 
inflammation in t(1;11) carriers.  
The use of a rare variant investigative paradigm in this thesis furthers understanding of the 
putative pathogenic mechanisms that might act to increase risk for psychiatric illness in t(1;11) 
carriers. Moreover, it may aid the biological understanding of the aetiology of psychiatric 
illness in the general population. As such, improved understanding of the mechanisms of risk 
in the t(1;11) pedigree may eventually lead to the development of better treatments.  
In the intervening time since some of the research for thesis was published, two studies have 
emerged that may serve to highlight potential mechanisms of pathogenic action mediated by 
CP60 and CP69 expression. It has recently been observed that WT-DISC1 couples to the 
adaptor protein TRAK1 and the mitochondrial membrane anchor Miro1, which are part of the 
mitochondrial transport complex (Ogawa et al, 2014; Norkett et al, 2016). Furthermore, the 
exogenous expression of CP60 impairs bidirectional mitochondrial trafficking (Norkett et al, 
2016). This suggests that CP60 expression may impair interactions with TRAK1 and Miro1. 
Given the sequence homology between CP60 and CP69, mitochondrial transport deficits also 
likely arise with CP69 expression. It is therefore possible that the exogenously expressed CP60 
and CP69 proteins could be docked on stationary mitochondria, which may contribute to the 





In a large Scottish family, high levels of severe mental illness occur along with a rare genetic 
mutation. This thesis will look at the ways in which the rare mutation may affect the Scottish 
family. Such research may shed light into how mental illness may occur within the wider 
population of sufferers. 
Previous work has shown that the genetic mutation occurring in the Scottish family is due to 
changes in chromosome structure. This affects chromosomes 1 and 11. These chromosomes 
snap and then re-join with the opposite chromosome. Three genes, which are found in the 
brain, are rearranged due to the mutation. Two of these genes are on chromosome 1 and one 
is on chromosome 11. 
Due to the chromosome structure changes, mutant RNAs have been found in cell lines from 
the Scottish family. These RNAs contain the genetic code from both a chromosome 1 gene 
and the chromosome 11 gene. Therefore, any mutant proteins produced would have a mixed 
genetic background. Two of these mutant RNAs were found previously, a third was detected 
in Scottish family cell lines in this thesis. The mutant proteins these RNAs code for may be a 
mechanism of disease in the Scottish family. 
To look at possible disease mechanisms, the genetic code for the three mutant RNAs was put 
into cells to produce proteins. Two of the mutant proteins blocked staining with a dye targeted 
to the cells power supply centres – the mitochondria. The few mitochondria that stained had 
an unusual clustered shape, rather than a healthy tube-like shape. Dyeing the surface of the 
mitochondria lead to the ‘invisible’ mitochondria being seen. These mitochondria also had a 
clustered shape. The protein from the newly identified mutant RNA had no effect on 
mitochondrial shape or staining.  
The pattern of staining from the mutant proteins was also looked at. Proteins from the two 
previously identified mutant RNAs appeared clustered. Protein from the newly identified 
mutant RNA was spread throughout the cell. The staining patterns of the mutant proteins could 
be possible disease mechanisms.  
Cell lines from the Scottish family were stained with the mitochondrial dye that had shown 
reduced mitochondrial staining in mutant protein containing cells. This was an indirect means 
to see if these mutant proteins occurred naturally in Scottish family cell lines. However, no 
difference was seen in mitochondrial staining. It may be that a more sensitive test is needed. 
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The genetic mutation in the Scottish family may also effect the switching on and off of genes. 
This could be due to the rearrangement of the three genes by the mutation or by the three 
mutant proteins if they naturally occur. RNA levels were measured in cell lines from Scottish 
family members to calculate gene switching. Computer analysis found alterations to gene 
activity in the cell cycle, immune function and inflammation. These also represent possible 
disease mechanisms in the Scottish family.  
The understanding of how rare mutations lead to mental illness may lead to the development 
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Chapter 1 - Introduction 
 
1.1 Psychiatric illness 
 
1.1.1 The impact of psychiatric illness 
Mental illness represents a challenge in the 21st century due to the burden of disease, rising 
economic costs and requirement of better treatments (Collins et al, 2011). The economic 
burden of mental illness globally is predicted to more than double within 20 years, from an 
estimated US$ 2.5 trillion in 2010 rising to US$ 6.0 trillion by 2030 (Bloom et al, 2012). 
Combined, mental health and substance abuse problems account for 22.9% of the global years 
of life lived with disability (YLD). For the neuropsychiatric disorders of depression, 
schizophrenia and bipolar disorder which are described in the following section, the YLD as a 
proportion of the total mental health and substance abuse disorders is 42.5%, 7.9% and 7.4%, 
respectively. These mental disorders therefore contribute greatly to the global burden of 
disease (Whitehead 2013).  
The prevalence of these mental illnesses, is the proportion of people with a disorder at a given 
time point and those individuals and the people that suffered from the disorder up until the 
given time point. The lifetime prevalence of suffering from an episode of major depressive 
disorder ranges from 5.5% to 14.6% depending on the country surveyed (Bromet et al, 2011). 
For schizophrenia the lifetime prevalence is 0.4% (Eaton et al, 2011). The lifetime prevalence 
for bipolar disorder type I is 0.6% and for bipolar disorder type II is 0.4% (Merikangas et al, 
2011).  
A greater understanding of the brain from basic science research is needed for the effective 
treatment of mental illnesses, including depression, schizophrenia and bipolar disorder. The 
knowledge gained by investigating the molecular pathogenesis of mental illnesses could 
potentially be translated to develop novel diagnostic tools and therapies. This approach may  









1.1.2 Major depressive disorder, bipolar disorder and schizophrenia 
Diagnosis of a mental illness requires assessment by a psychiatrist. For diagnosis purposes 
mental illnesses are clearly categorised in diagnostic manuals. In the UK the ICD-10 is the 
commonly used diagnostic manual for mental illness whereas the USA favours the DSM-5. 
 
Major depressive disorder 
Major depressive disorder is also known as unipolar depression. The ICD-10 states the major 
depressive disorder is a mood disorder that can be primarily characterised by lowered mood 
and a reduction in interest or pleasure, which cumulates in fatigue and a reduction in levels of 
activity (WHO, 1992). Furthermore, depressed individuals may possess the following 
symptoms: lowered self-esteem; a pessimistic worldview; impaired concentration; a 
persistence of guilt; feelings of uselessness and impairments to sleep and appetite (WHO, 
1992). Increased severity of depression is indicative of a heightened likelihood of suicidal 
ideation being present (WHO, 1992).  
 
Bipolar Disorder 
This is a mood disorder and was formerly known as manic depression. The ICD-10 specifies 
that sufferers of this syndrome must experience two or more instances of disturbance to their 
mood and activity levels that include both an episode of depression and an episode of 
hypomania or mania (WHO, 1992). Hypomania entails a moderate heightening of mood and 
activity level (WHO, 1992). Affected individuals suffer impairments in daily function arising 
from the development of interests in novel social and economic pursuits. Behaviourally, social 
inhibition is reduced and talkativeness increases, a mild impairment in concentration is also 
frequently present. In Mania the symptomology of hypomania is exacerbated. Mood is 
exuberant and activity levels are abnormally elevated (WHO, 1992). Sufferers experience a 
loss of social inhibition and regularly engage in the impulsive undertaking of detrimental 
social and economic actives to excess. Behaviour is frequently grandiose and may deteriorate 
to aggression, speech becomes rapid-fire, both concentration and attention are significantly 
impaired and the need for sleep is severely diminished. Severe prolonged mania potentially 
leads to development of psychosis, which may be comprised of hallucinations and grandiose, 








Schizophrenia is a complex heterogeneous syndrome characterised by disturbances in 
cognition, perception and emotion (WHO, 1992). These alterations are partially classified as 
positive and negative symptoms. The positive symptoms are additional to normal experience 
and include delusions and hallucinations. The ICD-10 lists a variety of delusions potentially 
occurring in schizophrenia (WHO, 1992). This includes: delusions of control; the belief in 
thought insertion or broadcasting; delusions of irrelevant everyday stimuli having special 
meaning and delusions that are contrary to cultural norms, for example, holding the belief that 
one can control the climate. Hallucinations are principally auditory but can encompass any 
sensory modality (WHO, 1992). In comparison, the negative symptoms are subtractive to 
normal experience (WHO, 1992). These include a marked reduction in speech, apathy and the 
blunting of emotions. The persistence of negative emotions may lead to social withdrawal 
(WHO, 1992). Schizophrenia is also associated with cognitive defects including working 
memory and attention.   
 
1.1.3 The genetic contribution to psychiatric illness 
Twin, family and adoption studies are supportive of a role of genetics in the aetiology of 
schizophrenia (Cardno & Gottesman, 2000; Craddock et al, 2005; Sullivan et al, 2003) bipolar 
disorder (Craddock et al, 2005; Smoller & Finn, 2003) and major depressive disorder (Kendler 
et al, 2006; Sullivan et al, 2000). A review of the literature by Cardno & Gottesman (2000) 
regarding twin studies and schizophrenia, observes concordance rates for monozygotic (MZ) 
twins of 41-65% and concordance rates of 0-28% for dizygotic (DZ) twins. A higher 
concordance of MZ/DZ twins is suggestive of a genetic cause to an illness. The heritability 
estimate for schizophrenia, the amount of phenotypic variations between individuals that can 
be ascribed to genetic variation, was estimated to be approximately 80-85% (Cardno & 
Gottesman, 2000). Similarly, a meta-analysis of schizophrenia twin studies estimates 
heritability to be 81% (Sullivan et al, 2003). Reviewing the genetic epidemiology of bipolar 
disorder Smoller & Finn (2003) found the concordance rate of MZ twins to be 38.5-62%, while 
for DZ twins this was 8-9.1%, with heritability estimated at 59-87%. In a study from the 
Swedish national twin register into the hereditability of major depressive disorder  Kendler et 
al., (2006) performed analysis with respect to gender. The correlation of female MZ twins for 
occurrence of lifetime major depressive disorder was 0.44, for male MZ twins this was 0.31 
while in female DZ twins a correlation of 0.16 was identified, for male DZ twins this was 0.11 
and for male-female DZ twins the correlation was 0.11, hereditability of major depressive 
disorder was estimated to be 38% (Kendler et al, 2006). The hereditability estimate of  Kendler 
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et al., (2006) closely resembles a hereditability estimate of 37% identified by Sullivan et al., 
(2000) from the meta-analysis of twin studies studying the genetics of major depressive 
disorder. The evidence from twin studies clearly demonstrates a genetic cause to major 
psychiatric illness, however, that neither the concordance rate of MZ twins nor the estimation 
of hereditability are 100% in these studies indicates that there is a proportion of phenotypical 
variance that is dependent upon the influence of environmental factors (Craddock et al, 2005; 
Smoller & Finn, 2003; Sullivan et al, 2000).  
Adoption studies are able to provide evidence of the genetic transmission of a disorder. This 
is shown if the illness of an adoptee proband shows greater occurrence in biological relatives 
over adoptive relatives. For adoptees with chronic schizophrenia a 10-fold higher prevalence 
of the disorder were observed in biological relatives than controls (Kety et al, 1994). Wender 
et al., (1986) observed an 8-fold increase in unipolar depression in the biological relatives of 
the affected adoptees. The study by Wender et al., (1986) also suggests evidence for a genetic 
basis for bipolar disorder under the guise of major mood disorders. However, when compiling 
this category, the proband or the relatives were considered affected if they had bipolar disorder 
or unipolar depression.  
The identification that a genetic contribution underpins major psychiatric illness from the 
observations of twin, family and adoption studies has led to numerous studies that have 
attempted to identity candidate genes. However, genetic heterogeneity, loosely defined traits 
and incomplete penetrance has impeded the identification of specific genetic rick factors 
(Burmeister et al, 2008). In the ongoing quest for identifying genes associated with major 
psychiatric illness, two non-mutually exclusive hypotheses have been pursued. The common 
disease-common variant hypothesis (CD-CV hypothesis) proposes that the variation in 
complex traits such as those evident in psychiatric illnesses, arises from the contribution of 
100s or 1000s of common variants - polygenicity, of low penetrance that occur at appreciable 
frequencies within the population (Gibson, 2012; Schork et al, 2009). The CD-CV hypothesis 
has been investigated using large scale genome-wide association studies (GWAS) that 
characterise 100,000s of single nucleotide polymorphisms (SNPs) from populations of cases 
and controls (Gershon et al, 2011). Recently a schizophrenia GWAS identified 108 associated 
loci, 83 of which were novel findings (Consortium, 2014). Several of these SNPs were 
associated with genes with a role in glutamatergic neurotransmission and associations were 
also identified with the dopamine receptor D2 (D2). In two separate bipolar disorder GWAS 
(Ferreira et al, 2008; Sklar et al, 2011), SNPs have been associated with the gene Calcium 
Channel, Voltage-dependent, L Type, Alpha 1C Subunit (CACNA1C), this concordance 
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suggests a role for CACNA1C in this disorder. In comparison to schizophrenia or bipolar 
disorder studies GWAS of major depressive disorder has met with limited success (Flint & 
Kendler, 2014). A recent GWAS mega-analysis failed to identify any SNP associations at 
genome wide significance (Ripke et al, 2013b).  
The contrasting school of thought to the CD-CV hypothesis is the common disease rare variant 
hypothesis (CD-RV hypothesis), whereby multiple rare variants of moderately high 
penetrance contribute to psychiatric illness (Gibson, 2012; Schork et al, 2009). The CD-RV 
hypothesis assumes genetic heterogeneity, whereby mutations in different genes affect 
different individuals and families (Mitchell & Porteous, 2011). The CD-RV hypothesis has 
until recently been pursued mostly by linkage, small family and single case studies. The t(1;11) 
pedigree which has multiple individuals affected by major mental illness co-segregating with 
a  balanced translocation (Blackwood et al, 2001) that disrupts Disrupted-In-Schizophrenia 1 
(DISC1), Disrupted-In-Schizophrenia 2 (DISC2) (Millar et al, 2000b) and Disrupted-In-
Schizophrenia 1 Fusion Partner 1 (DISC1FP1) also known as Boymaw (Eykelenboom et al, 
2012; Zhou et al, 2010; Zhou et al, 2008), is an example of a rare variant that has been 
identified in a family study and will be discussed further later in this chapter. Recent advances 
in technology have allowed rare variants such as CNVs (Copy number variations), point 
mutations and small insertions and deletions (indels) to be analysed by microarray and next 
generation sequencing. Case control and family studies have repeatedly found the enrichment 
of CNVs in individuals with schizophrenia with the loci for CNVs being spread throughout 
the genome (Malhotra & Sebat, 2012). Generally, CNV studies into schizophrenia implicate 
genes associated with neuronal function that possibly act on synaptic activity and 
neurodevelopment (Malhotra & Sebat, 2012). De novo (non-inherited) CNVs have been 
identified that occur with 8-fold greater frequency in sporadic schizophrenia than healthy 
controls (Xu et al, 2008). The role of CNVs in bipolar disorder is controversial with 
inconsistencies occurring between studies (Craddock & Sklar, 2013). However, the data 
suggests a role for CNVs in a sub-type of bipolar disorder with an early age of onset (Craddock 
& Sklar, 2013). Furthermore, few schizophrenia loci appear to be shared with bipolar disorder 
(Malhotra & Sebat, 2012). The investigation into CNVs as mediators of depression has 
produced mixed and contradictory results, though this represents an emerging field and 
presently few studies have been published (O'Dushlaine et al, 2014; Rucker et al, 2013; Rucker 
et al, 2015).  
Major psychiatric disorders may not necessarily ‘breed true’, whereby relatives to a proband 
with a psychiatric illness may be at risk from suffering from another psychiatric disorder as 
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well as being at risk from suffering the same disorder. For example, the risk of major 
depressive disorder to a relative of a proband with bipolar disorder was increased 
approximately 2-fold compared to controls, in comparison the risk to relatives of suffering 
bipolar disorder was increased approximately 9-fold (Merikangas & Yu, 2002).  In a twin 
study where the proband was diagnosed with bipolar disorder, the heritability estimate was 
increased when compared to a broad concordance measure in which the co-twin suffered from 
either unipolar depression or bipolar disorder over a narrow concordance whereby the co-twin 
was diagnosed with bipolar disorder (McGuffin et al, 2003). Another twin study highlights the 
underlying common genetic contributions to the psychotic disorders schizophrenia, bipolar 
disorder and schizoaffective disorder, which were identified along with disorder specific 
genetic contributions (Cardno et al, 2002). The co-aggregation of bipolar disorder and 
schizophrenia has been identified in a large scale Swedish family study, whereby first degree 
relatives of probands with schizophrenia were found to have increased risk of bipolar disorder 
and vice versa (Lichtenstein et al, 2009). GWAS may have detected some of the common 
genes underpinning these observations, shared loci have been identified for autism spectrum 
disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, 
and schizophrenia (Consortium, 2013). Additionally, GWAS by Purcell et al., (2009b) 
observed common SNPs that were present in both schizophrenia and bipolar disorder cases. 
 
1.1.4 The environmental contribution to psychiatric illness 
 
1.1.4.1 Schizophrenia 
A role for an environmental contribution to the aetiology of major mental illness is evidenced 
by the observation that neither the concordance for MZ twins nor the hereditability estimates 
for these disorders are 100% (Craddock et al, 2005; Smoller & Finn, 2003; Sullivan et al, 
2000). Environmental risk factors for schizophrenia have been identified that occur at various 
instances in throughout development from preconception to adulthood (Opler et al, 2013; 
Schmitt et al, 2014; Sullivan, 2005). Furthermore, both place of birth and season of birth are 
risk factors for schizophrenia, with urbanicity and winter having the greatest effect size, 
respectively (Sullivan, 2005). At preconception, an environmental risk factor for 
schizophrenia is paternal age, with advanced paternal age conferring the greatest risk of 
producing offspring with schizophrenia (Brown et al, 2002; Malaspina et al, 2001; Sipos et al, 
2004). This research generated the following results regarding advanced parental age being 
predictive of schizophrenia in offspring, per 10 year increase in paternal age: the risk of 
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schizophrenia is 1.89 (Brown et al, 2002); the rate of schizophrenia is 1.45 (Malaspina et al, 
2001) and the hazard ratio is 1.47 (Sipos et al, 2004). These analyses are adjusted with respect 
to maternal age. Nominal results were observed in separate analyses focussing on maternal 
age that adjusted for paternal age (Malaspina et al, 2001; Sipos et al, 2004).The effect of 
advanced paternal age is believed to be due to the increased generation of de novo mutations 
in sperm with increased age (Brown et al, 2002; Malaspina et al, 2001).  
Epidemiological studies have highlighted maternal immune activation during the prenatal 
period as a possible means of conferring the risk of schizophrenia to the foetus (Brown & 
Derkits, 2010). The exposure in utero to pathogens resulting in infection may propagate an 
altered and deleterious neurodevelopment trajectory by common or novel pathways. Several 
pathogens have been positively associated with the risk of developing schizophrenia following 
maternal immune activation including: herpes simplex virus type-2 (Buka et al, 2008), 
influenza (Mednick et al, 1994) and the parasite T.gondii (Mortensen et al, 2007). Prenatal 
malnutrition is also a risk factor for schizophrenia. Retrospective studies into both the Dutch 
Hunger Winter of 1944–1945 (Hoek et al, 1998; Susser et al, 1996; Susser & Lin, 1992) and 
the Chinese famine of 1959–1961 (St Clair et al, 2005; Xu et al, 2009) identify that subjects 
in gestation during these periods as having an elevated risk of schizophrenia.  
Perinatal obstetric complications show small effects sizes with schizophrenia (Cannon et al, 
2002). These include complications during delivery such as asphyxia or emergency caesarean 
section and abnormal foetal growth and development such as low birth weight and reduced 
head circumference. Furthermore, the effects of labour-delivery problems have been related 
to schizophrenia associated alterations in brain structure (McNeil et al, 2000).  
Cannabis use is a component cause in the liability to schizophrenia (Henquet et al, 2005). In 
adolescence, the age at which cannabis use occurs is important for the later development of 
schizophrenia symptomology (Arseneault et al, 2002). Early cannabis use aged 15 is a greater 
risk factor for developing schizophrenia than cannabis use at age 18. Additionally, the risk of 
conferring schizophrenia due to cannabis use is dependent on the number of times cannabis is 







1.1.4.2 Affective disorders 
For affective disorders stressful life events is a risk factor that is seen to be predictive to 
susceptibility to both depression (Kendler et al, 1999; Mazure, 1998; Tennant, 2002) and 
bipolar disorder (Brietzke et al, 2012; Weiss et al, 2015). Additionally, life stressors are one 
of the strongest predictors of relapse in bipolar disorder (Altman et al, 2006). The exposure to 
childhood maltreatment has been associated with increased risk of developing depression that 
has poorer long-term outcomes (Nanni et al, 2012), while childhood trauma that is inclusive 
of abuse has been frequently associated with bipolar disorder (Etain et al, 2008). It has been 
suggested that the occurrence of this childhood trauma may be instrumental to early 
perturbations of neurodevelopment that result in bipolar disorder.  
Preterm birth has been observed to be an obstetric complication that is linked to affective 
disorders. A study using the Swedish medical birth register, found that births of less than 32 
weeks gestation were 2.9 times likely to develop a depressive illness and 7.4 times likely 
bipolar disorder, in comparison to term births (Nosarti et al, 2012). A recent study on Finnish 
sufferers of bipolar disorder has identified birth by caesarean section as an obstetric 
complication associated with bipolar disorder (Chudal et al, 2014). However, in comparison 
to schizophrenia, research studies into obstetric complications in bipolar disorder have 
suffered from methodological problems due to the small scale of the studies and issues with 
defining the complications (Scott et al, 2006).  
The relationship between maternal immune activation and bipolar disorder has been 
investigated, regarding infections from herpes simplex virus types 1 & 2, cytomegalovirus, 
T.gondii, influenza and febrile cold (Mortensen et al, 2003; Mortensen et al, 2011; Stöber et 
al, 1997). However, the limited number of studies attempted in this field have produced 
negative results. Likewise a cohort study by Pang et al., (2009) failed to find an association 
between depression and prenatal viral infection. In contrast, an increase in the number of 
individuals that develop major depressive disorder following gestational exposure to influenza 
has been detected by Machon et al., (1997).  
Cannabis use is also an environmental risk factor for bipolar disorder. A dose dependent effect 
of cannabis use and the onset of bipolar symptomology has been identified by Lagerberg et 
al., (2014) whereby higher rates of cannabis use may result in earlier illness onset. The long 
term use of cannabis in the general population may lead to the symptoms of mania in a dose 
dependent manner, with increased frequency of cannabis use increasing manic symptoms 
(Henquet et al, 2006). Furthermore, in established bipolar disorder the co-occurrence of a 
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cannabis usage disorder is associated with a greater frequency of both manic/hypomanic and 
depressive episodes (Lev-Ran et al, 2013). 
Tobacco smoking is also an environmental risk factor in bipolar disorder. In comparison to 
nonsmokers with bipolar disorder, affected smokers show higher morbidity, with an earlier 
age of onset, poorer functioning, increased co-morbidity, a greater number of episodes and a 
broader array of symptoms (Baek et al, 2013; Ostacher et al, 2006; Waxmonsky et al, 2005). 
Furthermore, increased levels of tobacco smoking are correlated with greater severity of 
psychotic symptoms in bipolar disorder (Corvin et al, 2001). Tobacco smoking in bipolar 
disorder is also associated with a history of suicide attempts, OR 1.5-2.3 (Baek et al, 2013; 
Ostacher et al, 2006; Waxmonsky et al, 2005). Moreover, it is possible the smoking status in 
bipolar disorder may be predictive of future suicide risk. In line with this, affected smokers 
show a greater incidence of suicide attempts in the 9-month period following initial suicidal 
ideation assessment, than nonsmokers with bipolar disorder, OR 5.25 (Ostacher et al, 2009).  
Alcohol represents a significant environmental risk factor for bipolar disorder, with the co-
morbidity of alcohol use disorder and bipolar disorder commonly occurring (Farren et al, 
2012). Alcohol use disorder has been associated with a poorer longitudinal outcome in bipolar 
disorder via a destabilisation of the illness, with increased frequency of mood switching and 
number of episodes occurring (Rakofsky et al, 2013). Similarly, using the criteria of alcohol 
abuse or dependence, co-occurring with bipolar disorder, worse functional outcomes, earlier 
age of onset, increased severity of depressive symptoms and a severe increase in the number 
of suicide attempts have been observed (Cardoso et al, 2008). Moreover, meta-analysis 
identifies an elevated incidence of suicide attempts in individuals with bipolar disorder 
comorbid with alcohol use disorder compared to sufferers of bipolar disorder without alcohol 
use disorder, OR 1.72 (Carrà et al, 2014). 
 
1.2 Disrupted-in-Schizophrenia 1 (DISC1) 
 
1.2.1 The t(1;11) pedigree 
In 1968 a cytogenetic investigation into boys being allocated to Scottish borstals identified an 
18 year old boy with a balanced translocation between chromosome 1 and a C group 
chromosome (Jacobs et al, 1970). This chromosome abnormality was examined in four 
generations of the pedigree.  
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20 years later, the initial pedigree studied by Jacobs et al., (1970) was identified from records 
in the MRC Cytogenetics Registry, Edinburgh and by follow-up reports from GPs as having 
multiple family members that had been referred to psychiatric services (St Clair et al, 1990). 
The interest in the potential relationships between the chromosomal translocation, now 
identified as a balanced t(1;11) (q43p21), with mental illness prompted the characterisation of 
the psychiatric disorder in the t(1;11) pedigree by structured interviews with psychiatrists. The 
t(1;11) was established as co-segregating with mental illness. 49% of translocation carriers 
had a psychiatric diagnosis, including several incidences of major mental illness, with sufferers 
of major depressive disorder, schizophrenia and schizoaffective disorder identified (St Clair 
et al, 1990). In contrast, the karyotypically normal family members were found to suffer from 
only minor mental disorders.  
An in depth clinical follow-up of the t(1;11) pedigree 10 years after St Clair et al., (1990) 
identified 87 family members, 37 of whom carry the translocation (Blackwood et al, 2001). 
Within the translocation carriers, seven had schizophrenia, one had bipolar disorder and ten 
suffered from major depressive disorder. Following this, the linkage of the t(1;11) to 
schizophrenia generated a logarithm of odds (LOD) score of 3.6. If the incidences of bipolar 
disorder and major depressive disorder are also included, the linkage of the t(1;11) to major 
mental illness produces an LOD score of 7.1 . These results indicate that the t(1;11) is linked 
to the instances of major mental illness seen in the t(1;11) pedigree and it is most likely that 
the translocation is the aetiological mechanism precipitating these disorders.  
Members of the t(1;11) pedigree have been assessed using the p300 event related potential 
(ERP) as a means to identify possible deficits in cognition that may be conferred by the 
translocation (Blackwood et al, 2001). The p300 ERP occurs following the presentation of a 
random ‘oddball’ stimulus that may be visual, auditory or somatosensory and is seen as a 
measure of selective attention and working or short term memory (Blackwood, 2000). Deficits 
in the p300 ERP have been seen to be a trait marker for schizophrenia (Blackwood, 2000). In 
the t(1;11) pedigree the performance of translocation carriers, including those that did not 
exhibit major mental illness was seen to be impaired and similar to individuals with 
schizophrenia. This performance differed from non-translocation carrying t(1;11) pedigree 
members and healthy controls (Blackwood et al, 2001). The results of the p300 ERP findings 
on the t(1;11) pedigree indicate the translocation may intrinsically induce cognitive deficits. 
Given that p300 ERP testing establishes impairments to memory and attention in t(1;11) 
carriers, future neuropsychiatric assessment of the pedigree could focus on the further 
investigation of cognitive deficits associated with the translocation. 
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An aetiological mechanism by which the translocation could propagate the major mental 
illness observed in the t(1;11) carriers was thought to be via the interruption of genes spanning 
the chromosome 1 and chromosome 11 breakpoints. Therefore in the periods between the 
publication of St. Clair et al., (1990) and Blackwood et al., (2001),  a series of studies focussed 
on both the fine-mapping of the translocation and aimed to identify genes that may be affected 
by the potential gene disruption at these locations (Devon et al, 1997; Evans et al, 1995; 
Fletcher et al, 1993; Millar et al, 1998; Muir et al, 1995; Semple et al, 2001). Following these 
efforts the breakpoint was confirmed as being located at 1q42.1 and 11q14.3.  
 
1.2.2 The identification of genes at the t(1;11) breakpoints 
At the chromosome 1 breakpoint two novel genes were observed to be interrupted by the 
translocation: Disrupted-in-Schizophrenia 1 (DISC1) and Disrupted-in-Schizophrenia 2 
(DISC2) (Millar et al, 2000b). The t(1;11) breakpoint lies in intron 8 between exons 8 and 9 
of DISC1 (Millar et al, 2001) (see figure 1.2A). DISC1 was found to be comprised of 13 exons 
and identified as being a protein coding gene encoding an 854aa species (Millar et al, 2001; 
Millar et al, 2000b). DISC1 has been observed to be expressed in multiple brain regions 
(Chubb et al, 2008). In t(1;11)-family derived lymphoblastoid cell lines, the levels of DISC1 
are reduced by approximately 50% in comparison to karyotypically normal controls (Millar et 
al, 2005b). This is evidence of the haploinsufficiency of DISC1 that may occur in t(1;11) 
carriers as a mechanism of pathogenesis.  
DISC2 has been identified as brain expressed non-coding RNA and is located antisense to 
DISC1 (see figure 1.2A), encompassing a single exon that overlaps with DISC1 exon 9 (Millar 
et al, 2001; Millar et al, 2000b). Given the antisense proximity of DISC2 to DISC1 and that 
DISC2 is a non-coding RNA, it is possible that DISC2 may function as a negative regulator of 
DISC1 transcription (Chubb et al, 2008), however further studies are required to establish this.   
At the chromosome 11 breakpoint, initial research found no evidence of genes immediately in 
the proximity of the 11q14.3 region (Devon et al, 1997; Millar et al, 1998; Semple et al, 2001). 
However, a brain expressed non-coding RNA named Disrupted-in-Schizophrenia Fusion 
Partner 1 (DISC1FP1) (Eykelenboom et al, 2012) also known as Boymaw (Zhou et al, 2010; 
Zhou et al, 2008) has been identified to span the chromosome 11 breakpoint (see figure 1.2A). 
Furthermore, a recent study suggests that Boymaw may actually a protein coding gene that is 
targeted to the mitochondria (Ji et al, 2015). Alternative splices of this species have been 
proposed to be able to splice  with DISC1 at the t(1;11) breakpoints (Zhou et al, 2008) and 
have since been identified as being capable of generating chimeric transcripts with DISC1 
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(Eykelenboom et al, 2012). The topic of DISC1/DISC1FP1 chimeric transcripts will be 
covered in greater detail in section 1.2.10.  
 
 
Figure 1.2.A: Relative locations of DISC1, DISC2 and DISC1FP1 to the 
translocation breakpoint on both normal and derived chromosomes. Dashed 
vertical line indicates translocation breakpoint, exons: DISC1 (red), DISC2 
(Purple), DISC1FP1 (Green). Arrows denote direction of transcription.  
 
1.2.3 DISC1 protein structure 
Western blotting in conjunction with use of antibodies targeted to different epitopes on DISC1 
protein has resulted in the detection of multiple isoforms of human DISC1. Frequently a 
DISC1 species of ~100 kDa protein has been observed and this is presumed to be the 
translation product of the Long (L)-isoform of DISC1 (Soares et al, 2011). This isoform 
encodes all 13 of the exons originally identified in the DISC1 gene (Millar et al, 2000b). 
Furthermore additional DISC1 proteins have been detected, this includes, but is not exclusive 
to: 71, 70-85, 75, 80, 98, 150 and 200kDa species (James et al, 2004; Sawamura et al, 2005; 
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Soares et al, 2011). It is possible that the DISC1 protein species detected as running between 
71-75 kDa may represent the translation of a short DISC1 transcript, the S-isoform (Chubb et 
al, 2008; Taylor et al, 2003). The 150 and 200kDa species may arise from the 
homodimerization of 75 and 100 kDa species, respectively. Such an occurrence is likely given 
that DISC1 is capable of self-associating (Kamiya et al, 2005). The correct assignment of other 
DISC1 protein isoforms to known DISC1 transcripts may be encumbered due to post-
translational modifications, which could impact upon the molecular weight a given species 
migrates at. 
The full length 854aa DISC1 protein represents a unique protein, in that there is no significant 
similarity between its aa sequence and that of known proteins (Millar et al, 2000b). 
Conservation of DISC1 has been studied in multiple vertebrate species with orthologues 
identified in mammals, fish and birds (Bord et al, 2006; Chubb et al, 2008; Ma et al, 2002; 
Taylor et al, 2003). Outside of primate species the conservation of DISC1 is relatively poor 
(Bord et al, 2006; Chubb et al, 2008). For example the mouse Disc1 gene has a 60% identity 
with full-length DISC1 (Ma et al, 2002). This reduction in conservation may be indicative that 
DISC1 is a gene that has undergone rapid evolution in primates (Bord et al, 2006). 
Additionally, DISC1 orthologues have been identified within invertebrates, plants and algae 
(Sanchez-Pulido & Ponting, 2011).  
At present no 3-D crystal structure of full-length DISC1 has been produced. Investigations 
into structural information regarding DISC1 have primarily focused on bioinformatics 
approaches and additionally the biophysical characterisation of DISC1 (Chubb et al, 2008; 
Soares et al, 2011). In silico analysis suggests that full length DISC1 can be divided into two 
domains based on overall structural differences, an N-terminal ’head’ region comprising aa1-
350 that is of low complexity  and a more structurally diverse C-terminal region encompassing 
aa351-854 (Millar et al, 2000; Soares et al, 2011) (see figure 1.2.B). The N-terminal is 
frequently predicted to fold into a ‘globular domain’ in that this region contains amino acids 
that fail to fold into a set 3-D structure (Soares et al, 2011). As a disordered protein structure, 
it is likely that the N-terminal region will adopted a folded protein structure upon interaction 
with another protein (Fink, 2005). The N-terminal sequence is also poorly conserved (Taylor 
et al, 2003). However, within the N-terminal there are two motifs that are notably well 
conserved, an arginine-rich nuclear localisation signal comprising aa35-44 (Ma et al, 2002; 
Taylor et al, 2003) and a serine and phenylalanine-rich (SF-rich) motif of unknown function 
spanning aa206-217 (Taylor et al, 2003) (see figure 1.2.B). The use of structural prediction 
programs suggests that the C-terminal region contains several α-helices, a minimum of four 
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coiled coils at aa347-393, aa452-499, aa603-680 and aa805-828 (see figure 1.2.B), while some 
of the coiled coils leucine zipper motifs may be present at aa458-486, aa607-628, aa808-829 
(Chubb et al, 2008; Soares et al, 2011). 
DISC1 has been found to form complexes of varying molecular weights via self-interaction. 
The identification of DISC1 species of 200-250kDa, led Brandon et al., (2004) to infer that 
that these proteins were complexes of smaller DISC1 isoforms. A subsequent study by Kamiya 
et al., (2005) identified a DISC1 self-association region at aa403-504 using domain mapping. 
Biophysical characterisation of DISC self-association has been further investigated using C-
terminal fragments of DISC (Leliveld et al, 2008; Leliveld et al, 2009). DISC1 was observed 
to exist in complexes as either dimers, oligomers or multimers (Leliveld et al, 2008). The 
characterisation also revealed that the third coiled coil domain facilitates dimerisation and the 




Figure 1.2.B: Full-length DISC1 aa854 protein structure and conservation. 
Adapted from Soares et al., (2011). The figure visualises the secondary 
structure, coiled-coils (green), regular α-helixes (pink), ambiguous 
helixes (light green). The nuclear localisation signal (NLS) and serine-
phenylalanine-rich (SF-rich) motif are highlighted. Brown triangles 
represent phosphorylation sites. Dashed vertical band represents the 
translocation breakpoint at DISC1 aa597. Beneath the structure is a band 




1.2.4 DISC1 tissue expression and subcellular protein distribution 
The analysis of DISC1 expression in adult derived tissues observes strong mRNA expression 
in the brain, heart and placenta with weaker expression evident in the kidney and pancreas 
(Millar et al, 2000b). While in foetal tissues, DISC1 expression at the mRNA level has been 
found in the brain, heart, kidney, limb and spleen. Similarly, DISC1 protein can be detected in 
foetal tissue, with greatest prominence in the kidney and is also observed in the brain, heart, 
liver and limb (James et al, 2004). The expression of DISC1 mRNA in multiple brain regions 
was highlighted by Millar et al., (2000b), including the amygdala, caudate nucleus, corpus 
callosum, hippocampus, substantia nigra, subthalmic nucleus, thalamus and the whole brain. 
The levels of DISC1 transcripts have been found to be higher in the embryonic period and 
undergo a gradual decline in the postnatal period (Nakata et al, 2009). DISC1 protein 
expression is highly prominent within a subset of granule cells within the dentate gyrus of the 
hippocampus, a lower level of  DISC1 expression is also detected in areas cornu ammonis 1-
3 (CA1-3) of the hippocampus (James et al, 2004). Using post-mortem brain tissue, modest 
increases in the levels of DISC1 have been identified in the hippocampus of individuals with 
schizophrenia compared to heathy controls (Lipska et al, 2006b). An increase in DISC1 
immunoreactivity has also been observed post-mortem in the fronto-parietal white matter of 
sufferers of paranoid schizophrenia compared to healthy controls or individuals with 
undifferentiated schizophrenia (Bernstein et al, 2015). In contrast, the post-mortem levels of 
a 75-85kDa DISC1 species detected in the orbitofrontal cortex of individuals with major 
depressive disorder, bipolar disorder and schizophrenia, did not differ from controls 
(Sawamura et al, 2005). Additionally, in post-mortem hippocampal and dorsolateral prefrontal 
cortex (DLPFC) tissue, no alterations in DISC1 variant mRNA levels were detected between 
sufferers of schizophrenia and healthy controls (Lipska et al, 2006b).  
Two studies have addressed DISC1 tissue expression in primates. Austin et al., (2003) assayed 
mRNA levels in several brain areas of the adult African green monkeys, finding high 
expression in the dentate gyrus and lateral septum and lower expression in the amygdala, 
cerebellum, cortex, and interpeduncular nucleus. Bord et al., (2006), studied both mRNA and 
protein levels of DISC1 in the rhesus monkey, observing the highest expression in the 
hippocampus as well as high expression in the frontal, occipital, parietal and temporal lobes 
and lower expression in the cerebellum. Both of these studies therefore support a notion for 
high DISC1 expression in the hippocampus or hippocampal sub-regions.  
Rodents show the highest expression of Disc1 mRNA in the heart, with expression also 
detected in the brain, kidney, skeletal muscles and testis (Ma et al, 2002; Ozeki et al, 2003). 
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In line with this, DISC1 protein in the rat is found most prominently within the heart as well 
as in the brain, kidney liver, skeletal muscles and thymus (Ozeki et al, 2003). Rodent Disc1 
mRNA expression is observed in specific brain areas including, the granule cell layer of the 
dentate gyrus where expression is notably high, as well as in the amygdala, brainstem, 
cerebellum, corpus callosum, cortex, hippocampus, hypothalamus and olfactory bulb (Ma et 
al, 2002; Miyoshi et al, 2004; Osbun et al, 2011; Schurov et al, 2004). Similarly, in the rat, 
DISC1 protein has been found to have high expression in the cortex, hippocampus and 
olfactory bulb, with lower expression observed in the cerebellum (Ozeki et al, 2003) The 
expression levels within the mouse brain of an 100 kDa isoform of DISC1 have been observed 
to peak at E13.5, a period of intense neurogenesis and cell migration and also at P35 onwards 
to 6 months, a time point that is analogous to puberty (Schurov et al, 2004). Further studies in 
rodents have observed a gross postnatal peak in Disc1 mRNA (Austin et al, 2004; Honda et 
al, 2004) or protein (Kuroda et al, 2011) followed by a gradual decline.  In contrast, Disc1 
mRNA levels in the hippocampus has been found to be high at all developmental stages and 
is detectable from E14, peaking at P21, with Disc1 mRNA levels remain prominent into 
adulthood (Austin et al, 2004). These observations suggest a role of Disc1 in the patterning 
and connecting of hippocampal neurons during development. Supporting this notion, is the 
finding that mouse DISC1 is observed to localise in the dentate gyrus to regions where granule 
cell progenitors occur (Meyer & Morris, 2008). Within the subgranular zone of the dentate 
gyus, DISC1 co-localises with the cell cycle marker Ki67, highlighting the proliferation 
occurring in this region. 
In summary, both DISC1 and Disc1 have been detected in multiple CNS and non-CNS tissues. 
The hippocampus and hippocampal sub-regions often show the most prominent expression of 
DISC1 and Disc1, this of relevance to the consideration of DISC1 as a candidate gene for 
schizophrenia, given multiple studies associate the hippocampal formation with this disorder 
(Tamminga et al, 2010). 
 
1.2.5. DISC1 sub-cellular distribution 
DISC1 has been observed to localise to multiple subcellular compartments, this is reviewed in 
Chubb et al., (2008), Soares et al., (2011) and Thomson et al., (2013), a summary of the main 
findings adapted from Soares et al., (2011) is presented in table 1.2.A. The 
compartmentalisation of DISC1 to a variety of sub-cellular locations is in line with the notion 
that DISC1 participates in wide assortment of cellular functions that are mediated by multiple 
protein-protein interactions in discrete cellular compartments (Bradshaw & Porteous, 2012; 
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Brandon et al, 2009; Thomson et al, 2013) (1.2.A). The targeting of DISC1 to subcellular 
locations may be facilitated by interactions with binding partners or via signalling peptides 
structurally located within DISC1 (Soares et al, 2011; Thomson et al, 2013). The localisation 
of DISC1 to the centrosome will be further covered in section 1.2.7 DISC1 in 
neurodevelopment, plasticity and cellular signalling, whilst localisation of DISC1 to the 





Details and associated functions of DISC1 References 
Aggresome DISC1 aggregates recruited to the aggresome for degradation. (Atkin et al, 2012) 
Centrosome 
Involved in the recruitment of kendrin, dynein and dynactin subunits, LIS1, NDEL1, 
PCM1, ninein and CAMDI to the centrosome. Also interacts with PDE4B, PDE4D, 
NDE1 and BBS4. These interactions include those both important for microtubule aster 
formation, neurite outgrowth and neuronal migration. 
(Bradshaw et al, 2009; Bradshaw et al, 
2008; Fukuda et al, 2010a; Kamiya et al, 
2005; Kamiya et al, 2008; Kamiya et al, 
2006; Miyoshi et al, 2004; Morris et al, 
2003; Shimizu et al, 2008) 
Cilia 
Found at the base of primary cilia and appears to regulate their formation and/or 
maintenance. Knock-down of endogenous DISC1 leads to marked reduction of primary 
cilia. Other DISC1 interactors found at the base of primary cilia include BBS4 and 
PCM1. 
(Marley & von Zastrow, 2010) 
Cytoskeleton 
Seen along both actin filaments and microtubules. Expression of DISC1 aa1-597 leads 
to a disorganised microtubule network 
(Kamiya et al, 2005; Miyoshi et al, 2003; 





Seen in association with the membrane structures of the golgi apparatus in hippocampal 
neurones and astrocytes. May participate in vesicle movement from the Golgi apparatus 
 
(Kuroda et al, 2011) 
Growth 
Cones 
Found here in the hippocampus and is involved in the recruiting proteins including 
LIS1, NDEL1, 14-3-3ε and girdin via kinesin-based transport along the cytoskeleton. 
Also important for axonal elongation. 
(Enomoto et al, 2009; Miyoshi et al, 
2003; Shinoda et al, 2007; Taya et al, 
2007) 
Membranes 
Found in membrane fractions where it interacts with APP, which is important in cortical 
precursor formation. 
(Brandon et al, 2005; Ozeki et al, 2003; 
Young-Pearse et al, 2010) 
Mitochondria 
Found at mitochondria present on microtubules and regulates trafficking. Can cause 
mitochondria to form ‘ring’ structures. Interacts with mitofilin within the mitochondria 
and is required for correct electron transport chain, monoamine oxidase and Ca2+ 
activity. 37W variant results in clustered peri-nuclear mitochondria. Associates with 
TRAK1 and Miro1 as part of the mitochondrial transport complex. Promotes 
anterograde mitochondrial movement. Localises with ATF4 at mitochondria. 
(Atkin et al, 2011; Brandon et al, 2005; 
James et al, 2004; Malavasi et al, 2012; 
Millar et al, 2005a; Ogawa et al, 2014; 





Found at the chromatin, promyelocytic leukemia (PML) bodies and outer layers of the 
nuclear membrane. Represses ATF4 transcriptional activity and transcription of N-
cadherin and alters sleep homeostasis in Drosophila. DISC1 variants 37W and 607F 
independently disrupt DISC1 nuclear targeting 
(Hattori et al, 2010; James et al, 2004; 
Kirkpatrick et al, 2006; Malavasi et al, 
2012; Sawamura et al, 2008) 
Synapse 
Seen at the post-synaptic density along with PDE4 and NDE1. Interacts with and inhibits 
TNIK here, leading to degradation of key synaptic proteins. Also affects spine formation 
through modulation of PSD-95/Kal7/Rac1 complexes here. 
(Bradshaw et al, 2008; Clapcote et al, 
2007; Hayashi-Takagi et al, 2010; 
Kirkpatrick et al, 2006; Wang et al, 2011) 
 
Table 1.2.A: Subcellular localisation of DISC1. Adapted from Soares et al., (2011). DISC1 rare variant 37W and common variant 




1.2.6. DISC1 binding partners 
Multiple large-scale yeast-two hybrid studies have been implemented that have identified 
numerous DISC1 interactors (Brandon et al, 2004; Camargo et al, 2006; Millar et al, 2003; 
Miyoshi et al, 2004; Morris et al, 2003; Ozeki et al, 2003; Shinoda et al, 2007; Taya et al, 
2007). At present more than 200 potential DISC1 interactors have been identified, for a 
minority of these species the interaction with DISC1 has been further validated by co-
immunoprecipitation, GST-pulldown or co-localisation studies. In some instances domain 
mapping has been pursued to identify protein-protein interactions using deletion mutants, 
which can confirm a specific protein binding region or abolish protein binding. Alternatively, 
peptide arrays have also been used for fine mapping of interaction sites. The use of both of 
these processes to identify novel interactions with DISC is reviewed in Soares et al., (2011). 
The DISC1 interactome study by Camargo et al., (2006) combined yeast-2-hybrid screening 
with bioinformatics analysis, characterising pathway and functional roles of putative DISC1 
interactors. 289 potential interactors were identified 34 of which were identified as high 
confidence interactors. Gene ontology analysis (GO) on these species identified that DISC1 
interactors can be associated with functions involved in cytoskeletal organisation and 
biogenesis, mRNA/protein synthesis, cell cycle/division, intracellular transport and signal 
transduction processes. 
The number of DISC1 interactors coupled with the extensive expression of DISC1 at the 
cellular and tissue level has led to the proposal that DISC1 is a ‘hub’ protein. A number of 
DISC1 interactors have been independently associated with psychiatric illness, these findings 
establish networks linked to psychopathology within which DISC1 functions as a hub 
(Bradshaw & Porteous, 2012).   
A search of NCBI PubMed in June 2015 for DISC1 in title/abstract retrieves 500+ papers. The 
sizeable nature of the DISC1 literature puts a comprehensive review of DISC1 interactors and 
their functions beyond the scope of this thesis. The following section 1.2.7 DISC1 in 
neurodevelopment, plasticity and cellular signalling will cover material on several interactors 






1.2.7 DISC1 in neurodevelopment, plasticity and cellular signalling 
In eukaryotes the centrosome is the major microtubule organising centre of the cell and 
establishes and coordinates microtubule arrays to other intracellular structures during cell 
division (Dehay & Kennedy, 2007). The centrosome is essential for the regulation of the 
cytoskeleton and the maintenance of polarisation. In addition to being a hub for the 
microtubule array the centrosome also provides signalling for neuronal guidance. Together 
these centrosomal mechanisms enable neurogenesis, neuronal migration and differentiation to 
occur efficiently (Higginbotham & Gleeson, 2007). 
Several studies have observed the localisation of DISC1 to the centrosome, here DISC1 
interacts with various proteins that are established as being involved in centrosome mediated 
facets of neurogenesis. This includes Bardet-Beidel Syndrome 4 Protein (BBS4), kendrin (also 
known as pericentrin), lissencephaly 1 (LIS1), NudE Neurodevelopment Protein 1-Like 1 
(NDEL1) (Bradshaw et al, 2009; Brandon et al, 2004; Kamiya et al, 2008; Millar et al, 2003; 
Miyoshi et al, 2004; Morris et al, 2003; Shinoda et al, 2007). Subsequently, a role for DISC1 
in the recruitment and anchoring of several of these proteins at the centrosome has been 
identified. For example, centrosomal DISC1 interacts with kendrin which facilitates 
microtubule network formation (Shimizu et al, 2008). Furthermore, DISC1 and the DISC1 
interactor BBS4 act synergistically in the recruitment of  Pericentriolar Material 1 (PCM1) to 
the centrosome (Kamiya et al, 2008). Knockdown of each of these protein species results in 
neuronal migration deficits. 
DISC1 is a constituent of the dynein motor complex which facilitates retrograde movement 
along the axon (Kamiya et al, 2005). DISC1 is required for the stabilisation and localisation 
of the dynein complex at the centrosome in conjunction with LIS and NDEL, thus maintaining 
microtubule organisation and dynamics. DISC1 is also involved in anterograde transport via 
interactions with the motor protein kinesin-1 (KIF5A) and Growth Receptor Bound Protein 2 
(Grb2), which transport the NDEL1/LIS1/14-3-3ε complex to the distal axon and this process 
is required for axonal elongation (Shinoda et al, 2007; Taya et al, 2007). 
DISC1 participates in the maintenance of the neural progenitor pool (Mao et al, 2009).  Neural 
progenitor proliferation can be regulated by the binding and inhibition of Glycogen Synthase 
Kinase 3 Beta (GSK3β) by DISC1 which prevents GSK3β autophosphorylation (Mao et al, 
2009). Within the canonical Wnt signalling pathway GSK3β phosphorylates β-catenin, which 
is then targeted for destruction, preventing downstream gene activation by β-catenin that 
would otherwise mediate neuronal proliferation (Wu & Pan, 2010). Knockdown of DISC1 
increases both phospho-β-catenin and GSK3β autophosphorylation as well as reducing 
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proliferation, whist overexpression of DISC1 acts with opposite effects (Mao et al, 2009). The 
DISC1-GSK3β interaction therefore stabilises the cellular pool of β-catenin allowing gene 
transcription to occur and promotes proliferation. The co-regulation of Wnt-GSK3β/β-catenin 
signalling and neural progenitor proliferation has been observed to occur via the interaction of 
DIX Domain Containing-1 (DIXDC1) with DISC1 (Singh et al, 2010). This interaction has 
been found to function in an additive fashion. Furthermore, these Wnt-GSK3β/β-catenin 
signalling findings are of interest regarding the treatment of bipolar disorder, as lithium 
chloride is a potent inhibitor of GSK3β and one of the most successful drug treatments to 
combat this disorder (Klein & Melton, 1996). 
A switch in DISC1 phosphorylation governs the transition from the regulation of the 
proliferation of mitotic progenitor cells to the maintenance of the migration of post-mitotic 
neurones (Ishizuka et al, 2011). The switch is facilitated by phosphorylation at S713 in DISC1 
and S710 in mouse DISC1. The absence of phosphorylation at DISC1 S710 positively 
regulates Wnt-GSK3β/β-catenin signalling, with both WT-DISC1 and phospho-dead mutant 
DISC1 A710 capable of rescuing downstream β-catenin signalling following DISC1 
knockdown, but phospho-mimic mutant DISC1 E710 is unable to do so. Furthermore GSK3β 
binding is enhanced with phospho-dead mutant DISC1 A710 but not phospho-mimic mutant 
DISC1 E710 (Ishizuka et al, 2011). In contrast, the expression of the phospho-mimic mutant 
DISC1 E710 results in enhanced DISC1/BBS binding and increased localisation of these 
interacting species at the centrosome. A previous study has highlighted the importance of 
DISC1 interacting with BSS proteins and identified a role for these protein complexes at the 
centrosome in regulating neural migration so promoting cortical development (Kamiya et al, 
2008). Further evidence supporting DISC1 pS710 as a molecular switch in neurodevelopment 
are rescue experiments following the knockdown of WT-DISC1. Proliferation deficits could 
only be rescued by WT-DISC1 or phospho-dead mutant DISC1 A710 whereas migration 
deficits could be rescued by WT-DISC1 or phospho-mimic mutant DISC1 E710 (Ishizuka et 
al, 2011).   
Neural migration is also affected by the interaction of DISC1 with DIXDC1. This appears to 
be dependent on the phosphorylation of DIXDC1 by Cyclin-dependent Kinase 5 
(CDK5) which regulates NDEL binding and promotes the formation of a DIXDC1/DISC1/ 
NDEL complex (Singh et al, 2010).  
A role for DISC1 in the maturation and integration of neurones is in the hippocampus has been 
highlighted by DISC1 complexing with girdin (also known as KIAA1212) (Enomoto et al, 
2009; Kim et al, 2009). This interaction is known to inhibit signalling through the 
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serine/threonine kinase V-Akt1 Murine Thymoma Viral Oncogene Homolog 1 (Akt1), 
whereas the overexpression of girdin alone potentiates Akt1 signalling (Kim et al, 2009). The 
knockdown of DISC1 in the adult mouse hippocampus produces neuronal morphological 
abnormalities that closely resemble the effects of either girdin overexpression or the 
expression of a constitutively active form of Akt1. These morphological deficits can be 
ameliorated following treatment with rapamycin, an inhibitor of the Akt1 effector, 
Mechanistic Target of Rapamycin (mTOR) (Kim et al, 2009). Together these results suggest 
that DISC1, girdin and Akt1 exist in a pathway within the adult hippocampus, regulating 
neuronal morphology. However, a parallel study by Enomoto et al., (2009) addressing 
DISC1/girdin interaction and the effects on neuronal maturation in the dentate gyrus, observed 
that the morphological abnormalities present with girdin knockdown could not be rescued by 
constitutively active Akt1, implying that girdin acts downstream of Akt1. 
Hippocampal maturation by DISC1 has also been identified to require signalling by the γ-
aminobutyric acid A (GABAA) receptor to activate depolarization via the Na-K-Cl 
cotransporter NKCC1 (Kim et al, 2012). In adult-borne neurones in the dentate gyrus, the 
knockdown of DISC1 produces multiple neuronal deficits including accelerated dendrite 
growth. The knockdown of either NKCC1 or the GABAA receptor subunit γ2 are capable of 
rescuing DISC1 knockdown solely with respect to the dendritic growth deficits. The 
knockdown of NKCC1 or GABAA receptor subunit γ2 co-occurring with DISC1 knockdown 
also attenuates the increased Akt1 signalling that is evident with DISC1 knockdown alone 
(Kim et al, 2012). These findings suggest that DISC1 together with GABA signalling act 
synergistically to modulate the Akt1/mTOR pathway and regulate dendritic growth in adult 
neurogenesis. DISC1 knockdown or the exposure of mice to maternal deprivation stress 
individually have no effect on neuronal morphology. However, when the genetic and 
environmental insults are combined, a synergistic effect is noted with the early-postnatal 
dentate gyrus neurones bearing the same deficits as seen with DISC1 knockdown in adult-
borne neurones (Kim et al, 2012). For the maternal stress/DISC1 knockdown neuronal deficits 
to be apparent in early-postnatal neurogenesis, depolarisation via GABA signalling appears to 
be required, as knockdown of NKCC1 rescues the majority of the morphological defects. 
Likewise, Akt1-mTOR signalling is involved in early-postnatal neurogenesis to produce the 
neuronal deficits following maternal stress/DISC1 knockdown as rapamycin could rescue the 
neuronal morphology. These findings indicate a conserved mechanism between DISC1, 
GABA signalling and the Akt1/mTOR pathway in the maintenance of neurogenesis with 
regard to early-postnatal neurones exposed to stress and adult-borne neurones within the 
dentate gyrus (Kim et al, 2012). 
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Recently further evidence has emerged regarding DISC1 signalling, the mTOR pathway and 
neuronal maturation. In adult mice, the selective knockdown of DISC1 in proliferating neural 
progenitors within the dentate gyrus induces a variety of dendritic abnormalities as well as 
cognitive and behavioural disturbances, with mice exhibiting a depression/anxiety-like 
phenotype (Zhou et al, 2013). Treatment of these animals with the mTOR inhibitor rapamycin 
rescued the neuronal abnormalities, reducing the number of primary dendrites and 
mispositioned neurones as well as ameliorating the cognitive and behavioural defects.     
In addition to functional roles in regulating neuronal proliferation, migration and maturation, 
DISC1 is also known to participate in specific synaptic transmission and plasticity events 
which underpin the cellular basis of learning and memory (Hayashi-Takagi et al, 2010; Wang 
et al, 2011; Wei et al, 2014). Multiple studies on primate, human and rodent brain tissue 
samples and neurons have detected an enrichment of DISC1 expression within the post-
synaptic density (PSD) (Bradshaw et al, 2008; Hayashi-Takagi et al, 2010; Kirkpatrick et al, 
2006; Paspalas et al, 2013; Wang et al, 2011). The PSD is an electron and protein dense region 
of the postsynaptic neuron containing a network of signalling and structural molecules and is 
typically located at the tip of dendritic spines (Sheng & Kim, 2011). TRAF2 and NCK 
Interacting Kinase (TNIK) has been identified as a regulator of the actin cytoskeleton is 
enriched in the PSD and also binds to DISC1 (Wang et al, 2011). The kinase activity of TNIK 
is negatively regulated by DISC1. Studies that inhibit TNIK activity with a peptide designed 
to mimic DISC1 binding suggest that the interaction between these two molecules promotes 
degradation of synaptic proteins including, the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor regulatory protein stargazin, the AMPA receptor 
subunit glutamate receptor, ionotropic, AMPA 1 (GluR1), and the scaffold protein and 
Postsynaptic Density Protein 95 (PSD-95) (Wang et al, 2011). Furthermore the interaction of 
TNIK with the DISC1 mimetic peptide reduces AMPA receptor miniature excitatory 
postsynaptic current (mEPSC) frequency and amplitude. Together these data suggest DISC1 
may negatively regulate AMPA signalling at the PSD via interaction and inhibition of TNIK. 
A signalosome between DISC1, the GDP/GTP exchange factor kalirin-7 (Kal7) and the Rho 
GTPase Ras-related C3 Botulinum Toxin Substrate 1 (Rac1) which regulates dendritic spine size 
has been identified (Hayashi-Takagi et al, 2010). Mechanistically the signalosome functions 
whereby DISC1 binds to and anchors Kal7, preventing both the access of Rac1 to Kal7 and 
subsequent Rac1 activation. The activity dependent stimulation of N-methyl-D-aspartate 
receptors (NMDAR) results in Kal7 release from DISC1 and access to Rac1 enabling the 
regulation of spinal morphology by activated Rac1 (Hayashi-Takagi et al, 2010).  
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DISC1 knockdown has been observed to result in an increase in NMDAR currents 
predominantly mediated by effects of glutamate receptor, ionotropic, N-Methyl D-Aspartate 
2A (GluN2A) subunits (Wei et al, 2014). Likewise, the GluN2A subunits are also identified 
to be elevated by DISC1 gene silencing. These findings are thought to be underpinned by 
increased Protein kinase A (PKA) signalling. This may be mediated by the inhibition of the 
enzyme Phosphodiesterase 4 (PDE4), due to DISC1 knockdown. In the absence of DISC1 
silencing, PDE4 has been observed to be sequestered by DISC1and then released in an active 
state, in response to elevated cellular cyclic adenosine monophosphate (cAMP) (Millar et al, 
2005b; Murdoch et al, 2007). Active PDE4 then hydrolyses cAMP, resulting in the 
downstream reduction of PKA levels and cAMP Response Element-binding Protein (CREB) 
signalling. Wei et al., (2014) suggest that following DISC1 silencing and subsequent PDE4 
inhibition CREB is phosphorylated due to elevated levels of PKA. CREB then translocates to 
the nucleus to promote gene transcription of GluN2A, which then results in altered NMDAR 
signalling. This indicates a role of DISC1 and signalling downstream of DISC1 in the 
maintenance of NMDAR function.  The results of the studies into TNIK, Kal7 and the 
NMADR have highlighted the role of DISC1 in glutamatergic neuronal transmission 
(Hayashi-Takagi et al, 2010; Wang et al, 2011; Wei et al, 2014). This is highly relevant to 
schizophrenia research as glutamatergic hypofunction is a known mechanism of pathogenesis 
in this disorder (Coyle, 2012).  
In addition to the PSD, DISC1 has also been detected at the perisynaptic and extrasynaptic 
regions of dentritic spines of pyramidal neurones within layers II/III of the prefrontal cortex 
(PFC) (Paspalas et al, 2013). DISC1, PDE4 and dopamine receptor D1 co-localise here with 
hyperpolarisation activated cyclic nucleotide gated channels (HCN), which regulate neuronal 
network firing. A cAMP signalplex is proposed by Pasapalas et al., (2013) to dynamically 
regulate HCN channel gating. This would arise due to the close proximity of DISC1 and 
PDE4B, which together can modulate cAMP signalling (Millar et al, 2005b; Murdoch et al, 
2007) along with co-localisation of D1, activation which elevates cAMP levels, at the HCN 
channels. 
Perturbations to dopamine (DA) signalling are of relevance to schizophrenia research given 
that the dopaminergic hypothesis proposes deficits in dopaminergic signalling at the synapse 
as a mechanism of pathogenesis with this disorder (Howes & Kapur, 2009). The knockdown 
of DISC1 in pyramidal neurones of the mouse PFC during early development results in 
reduced extracellular levels of DA, deficits in the maturation of axon terminals within the 
dopaminergic projection and a hypersensitivity to methamphetamine that are observed 
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postnatally (Niwa et al, 2010). Methamphetamine is a stimulant that acts upon the 
dopaminergic system and can induce schizophrenia-like symptoms (Robinson & Becker, 
1986).  
DA receptors D1, D2, and D5 are targeted to primary cilia (Marley & von Zastrow, 2010). The 
knockdown of DISC1 in primary striatal neurons or cultured NIH3T3 cells reduces the number 
of primary cilia. This highlights a potential relationship between DISC1 and dopaminergic 
signalling.  
The 100P mice contain ENU induced point mutations to DISC1 that cause amino acid changes 
(L100P) and result in a schizophrenia-like phenotype (Clapcote et al, 2007). When 100P mice 
are treated with the dopaminergic stimulant amphetamine, they display defects across a range 
of cognitive-behavioural assays in comparison to wild type controls (Lipina et al, 2010). The 
cognitive and behavioural impairments in 100P mice can be rescued following treatment with 
the typical antipsychotic haloperidol. A D2/DISC1 complex has been identified that is 
dependent on D2 activation (Su et al, 2014). The complex has been observed to be increased 
in post-mortem brain tissue from sufferers of schizophrenia and 100P mice. D2/DISC1 
complex formation reduces the phosphorylation of GSK3β at serine 9, which increases the 
availability of the GSK3β active site favouring GSK3β pathway upregulation. Su et al., (2014) 
developed an interfering peptide to disrupt the D2/DISC1 interaction and prevent the 
modulation of GSK3β phosphorylation. The interfering peptide also proved capable of 
rescuing the schizophrenia-like behaviours of the 100P mice. Evidence of dopaminergic 
dysfunction in DISC1 C-terminal truncated mice is detailed in section 1.2.9.  
 
1.2.8 In vitro overexpression of DISC1 aa1-597 in cultured cells 
The concept of a dominant-negative truncated DISC1 species encoded by the DISC1 ORF 
proximal to the t(1;11) was first proposed by Millar et al., (2000). Consequently several 
laboratories have investigated the functional properties of the species that could potentially be 
encoded, DISC1 aa1-597. The existence of DISC1 aa1-597 as a mechanism of pathogenesis 
within the t(1;11) pedigree is non-mutually exclusive to the haploinsufficiency of DISC1  
(Millar et al, 2005b). In vitro, the overexpression of DISC1 aa1-597 along with DISC1 causes 
the dominant-negative redistribution of DISC1, from a punctate localisation to the diffuse 
cytoplasmic distribution typical of DISC1 aa1-597 expression. This phenomenon is a due to a 
self-association domain located in DISC1 aa403-504 that is retained in DISC1 aa1-597 
(Kamiya et al, 2005). As such, when DISC1 is co-expressed with DISC1 aa1-597, the 
anchoring of the dynein motor protein by DISC1 to the centrosome is perturbed. The 
28 
 
overexpression of DISC1 aa1-597 in COS-7 cells can also produce a lariat or ‘ring’ shaped 
mitochondrial morphology, in a subset of transfected cells (Millar et al, 2005a). 
Complementary to the structural mitochondrial alterations due to the overexpression of DISC1 
aa1-597 that were reported by Millar et al., (2005a), is research showing that DISC1 aa1-597 
overexpression is detrimental to mitochondrial function. The overexpression of a mouse 
equivalent of DISC1 aa1-597 alters mitochondrial bioenergetics, reducing both NADPH 
dehydrogenase activity (respiratory chain complex I) and ATP levels (Park et al, 2010). 
Regarding neuronal-like cellular functions, the expression of DISC1 aa1-597 in vitro impairs 
neurite outgrowth in PC12 cells with both transient transfection (Ozeki et al, 2003) and 
inducible DISC1 aa1-597 (Pletnikov et al, 2007). DISC1 aa1-597 also inhibits axon elongation 
in hippocampal cultures (Taya et al, 2007). DISC1 has been identified as negatively regulating 
oligodendrocyte differentiation, in contrast the exogenous expression of DISC1 aa1-597 
promotes oligodendrocyte differentiation (Hattori et al, 2014) The in vitro expression of 
DISC1 aa1-597 has a multitude of deleterious effects that could perturb normal cell 
functioning. However at present endogenous DISC1 aa1-597 has not been detected.  
 
1.2.9. DISC1 C-terminal truncated mouse models 
 
1.2.9.1 Neuronal transgene expression in C-terminal truncated DISC1/Disc1 
models 
Three transgenic mouse models have been created that express human DISC1 aa1-597 
neuronally (Hikida et al, 2007; Niwa et al, 2013; Pletnikov et al, 2008) (see table 1.2.B). Two 
of these transgenic models use a Ca2+/Calmodulin-dependent Protein Kinase II (CaMKII) 
promoter to drive human DISC1 aa1-597 transgene expression. In the Hikida et al, (2007) 
murine model, referred to as the DN-DISC1 mouse, the transgene is constitutively active. In 
contrast, the ΔhDISC1 mouse (Pletnikov et al, 2008), uses an inducible induction system. This 
is due to the incorporation of a Tet-off system that regulates the CaMKII promoter activity. 
Most recently, the third mouse line, expressing a human DISC1 aa1-597 transgene, has been 
generated. The DISC1-DN-Tg-PrP mouse line uses a prion promoter to express truncated 
DISC1 (Niwa et al, 2013). The use of a prion promoter, as opposed to the CaMKII promoters 
used in previous DISC1 aa1-597 models (Hikida et al, 2007; Pletnikov et al, 2008), appears 
to produce a transgene expression profile with greater similarity to endogenous DISC1 
expression (Niwa et al, 2013). 
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A transgenic mouse model has been produced that expresses a truncated Disc1 species (Shen 
et al, 2008) (see table 1.2.B). The Disc1tr mice express two copies of Disc1 exons 1-8, from a 
mouse BAC, with the truncated expression driven by endogenous promoters (Shen et al, 
2008). This is important when making comparison to murine transgenic models that express 
DISC1 aa1-597 using constitutively active CaMKII (Hikida et al, 2007) and prion promoters 
(Niwa et al, 2013) or an inducible CaMKII promoter (Pletnikov et al, 2008). Beyond this 
intrinsic difference in promoter expression and the use of truncated mouse DISC1 as opposed 
to DISC1 aa1-597, the Disc1tr is conceptually very similar to the DISC1 1-597 mouse models. 
 
1.2.9.2 Behavioural alterations associated with C-terminal truncated 
DISC1/Disc1 models 
The NMDA receptor hypofunction theory of schizophrenia (or glutamatergic hypofunction 
theory) proposes that alterations to NMDA receptor function in neurodevelopment and the 
consequential disruption to neuronal structure and function underpin the pathogenesis of 
schizophrenia (Coyle, 2012). The NMDA receptor antagonists, MK-801, phencyclidine (PCP) 
and ketamine, have been used to investigate and validate components of this theory in human 
and animal models and subsequently these compounds are now used to pharmacologically 
model schizophrenia-like behaviour (Bubeníková-Valešová et al, 2008). The ΔhDISC1 male 
mice show an increase in locomotor activity following treatment with MK-801 that is 
significantly higher than the increase that is observed in control mice (Ayhan et al, 2011). This 
observed hyperlocomotion may be regarded as a greater propensity to psychosis-like 
behaviour in the context of the antagonism of NMDA receptor activity (Bubeníková-Valešová 
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Key to table 1.2.B. 
L†  Left lateral ventricle increase, reverts at 3 months old 
¥   ameliorated by treatment with the glucocorticoid antagonist RU38486 
-   No response to drug treatment 
+   Positive response to drug treatment 
♂  Male 
♀  Female 
↑  Increase 
↓  Decrease 
→  No change 
BAC  Bacterial artificial chromosome  
CaMKII  Ca2+/calmodulin activated kinase II 
CL  Clozapine 
CR   Calretinin 
dB  Decibels 
D2  Dopamine receptor D2 
DA  Dopamine 
DAT  Dopamine active transporter 
dB  Decibels  
DN  Dominant negative 
DOPAC  3,4-Dihydroxyphenylacetic acid 
Excel BL  Extracellular baseline dopamine  
Excel DA  Extracellular dopamine 
Excel mth  Extracellular dopamine following methamphetamine challenge  
FC   Frontal cortex 
Hal  Haliperidol 
HC  Hippocampus 
LI  Latent inhibition 
LV  Lateral ventricles  
N  Tested on given behavioural assay but did not show significant change lower case 
denotes this in gene environment model 
PPI    Prepulse inhibition 
PV   Parvalbumin 
Y Shows significant change, lower case is significant change in gene environmental 
model 
T. Hydroxylase Tyrosine Hydroxylase   
 
The open field activity is a general measure of the locomotor activity and has been frequently 
used in the testing of anxiolytic compounds, whereby the increased activity of the mouse is 
seen to represent the animals level of stress (Prut & Belzung, 2003). However, how the 
measurement of locomotor activity varies between mouse lines and specific protocols can 
impair inter-experimental comparison (Stanford, 2007). Open field activity is observed to be 
increased in the DN-DISC1 and male ΔhDISC1 mice (Hikida et al, 2007; Pletnikov et al, 
2008), suggesting that these mice have an anxiety-like behavioural phenotype.  
Forced swim test (FST) deficits are observed in two of the models expressing DISC1 aa1-597 
(Hikida et al, 2007; Pletnikov et al, 2008) and are also seen in the Disc1tr mice (Shen et al, 
2008). This assay measures the amount of time a mouse spends immobile following immersion 
in a water filled tube. In a similar behavioural assay, the tail suspension test (TST), mice are 
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hung by their tails and the time the animal spends immobile is recorded. Both female ΔhDISC1 
(Ayhan et al, 2011) and the Disc1tr mice (Shen et al, 2008) show an increased time immobile 
during tail suspension. These assays have been described in papers as ‘depression tests’ (Shen 
et al, 2008); as a means to ‘test depression-like behaviours’ (Ayhan et al, 2011); or assays that 
‘may parallel anhedonia seen in schizophrenia’ (Hikida et al, 2007). However, both the FST 
and TST were developed as rapid means to screen antidepressant effects within pharmaceutical 
animal trials. Due to the inherent “black box” design of these tests, their validity as  measures 
of depression-like behaviour is contentious (Nestler & Hyman, 2010).  
Functional impairments in cognition are associated with schizophrenia (Green et al, 2000) and 
are now thought to be core features of the illness (Keshavan et al, 2011). Deficits in spatial 
learning memory had been detected in the female ΔhDISC1 mice following Morris water maze 
trials (Pletnikov et al, 2008). Regarding psychiatric illness, the meta-analysis of working 
memory studies assessing the task performance in schizophrenia groups, identifies defects to 
this cognitive system. Within these analyses, a domain specific impairment to visuospatial 
working memory is also identified (Forbes et al, 2009; Lee & Park, 2005). The degree of 
impairment in verbal and spatial working memory task performance in both individuals with 
bipolar disorder and those with schizophrenia is similar (Glahn et al, 2006). However, the 
spatial working memory deficits seen in bipolar disorder are specific to those patients with 
history of psychosis (Glahn et al, 2006). Therefore, it may be that the repeated occurrence of 
psychosis impairs this cognitive function or that the impairment represents underlying aberrant 
neurodevelopment associated with psychosis proneness. The investigation of working 
memory problems within depression has produced mixed results. This appears to be the 
consequence of methodological problems and measured deficits actually originating from non-
specific effects. It remains possible that working memory impairment per se is simply 
associated with mental illness (Gotlib & Joormann, 2010). 
The Disc1tr mice have impaired latent inhibition (LI) (Shen et al, 2008). Latent inhibition 
occurs when prior exposure to a stimulus, such as an acoustic tone, later has the effect of 
inhibiting the association between the noise and an unconditioned stimulus, such as a food 
pellet (Arguello & Gogos, 2006). LI is believed to be a measure of attention. In relation to 
schizophrenia, reduced LI is seen in unmedicated patients and this can be ameliorated by 
antipsychotic medication. In line with this, in mouse models, LI phenomena are reduced by 
dopaminergic agonism and are increased with dopaminergic antagonism (Lubow, 2005). 
In the initial characterisation, the DN-DISC1 mice possess an impairment in prepulse 
inhibition (PPI) that was identified at 74dB (Hikida et al, 2007). The PPI assay is a measure 
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of sensorimotor gating. It is the attenuation of startle response to a loud noise, whereby before 
the delivery of the loud noise the subject is exposed to an initial pre-pulse stimulus of low 
intensity noise. PPI results when the low intensity noise diminishes the following response to 
the loud noise. As such, PPI is seen as a measure of the ability to gate superfluous sensory data 
(Arguello & Gogos, 2006). PPI deficits have been repeatedly identified in individuals with 
schizophrenia and there is a degree of cross species similarity between rodent and human PPI 
results. However, impairment in PPI is not specific to sufferers of schizophrenia although the 
bulk of research into PPI has predominantly focussed on schizophrenia (Swerdlow et al, 2008). 
Compared to schizophrenia, relatively few studies have been conducted into PPI in bipolar 
disorder. Abnormal PPI performance has been investigated in eurhythmic bipolar patients and 
shows sexual dimorphism, in which the PPI response is increased in females and decreased in 
males (Gogos et al, 2009). Interestingly, the PPI impairment that is detected in bipolar patients 
that are suffering from acute mania with psychosis and individuals with schizophrenia do not 
differ significantly (Perry et al, 2001).  
The male ΔhDISC1 mice show evidence of abnormal murine social interaction and have an 
increase in aggressive behaviours (Ayhan et al, 2011; Pletnikov et al, 2008). Such aberrant 
behaviours may be seen as analogous to deficits in social cognition which are frequently seen 
as a core symptom of schizophrenia (Couture et al, 2006). 
 
1.2.9.3 Histopathology & morphology of C-terminal truncated DISC1/Disc1 
models  
The DN-DISC1 (Hikida et al, 2007), ΔhDISC1 (Pletnikov et al, 2008) and Disc1tr (Shen et al, 
2008) mice all possess enlarged lateral ventricles. This gross anatomical abnormality is the 
most common pathophysiological feature detected in sufferers of schizophrenia in magnetic 
resonance imaging  (MRI) studies (Shenton et al, 2001). Unusually, in the DN-DISC1 mice, 
the lateral ventricular abnormality reverts to normal by three months of age (Hikida et al, 
2007). Furthermore, enlarged lateral ventricular phenotype in the ΔhDISC1mice appears to be 
dependent on postnatal transgene expression (Ayhan et al, 2011). In the ΔhDISC1 mice, the 
lateral ventricular observations may partly be accounted for by a reduction in the arborisation 
of primary neurones that is observed (Pletnikov et al, 2008). Unusually, when the DISC1-DN-
Tg-PrP transgene is expressed alone, in the absence of environmental stress modelling, lateral 
ventricular enlargement is absent. This could possibly be a consequence of the use of a prion 
promoter in this model (Niwa et al, 2013).   
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The number of GABAergic parvalbumin-positive interneurones in the PFC is reduced in the 
Disc1tr (Shen et al, 2008), ΔhDISC1 (Ayhan et al, 2011) and DN-DISC1 mice (Hikida et al, 
2007). Parvalbumin-positive interneurones and the consequential altering of neuronal 
inhibition have been associated with schizophrenia. In particular, with the presence of 
cognitive deficits (Lewis et al, 2012; Lewis et al, 2005). In the Disc1tr model, the parvalbumin 
staining is also observed to be reduced in the hippocampus (Shen et al., 2008). 
The Disc1tr (Shen et al, 2008) mice also possess a partial agenesis of the corpus callosum, the 
largest fibre tract in the brain, which connects both hemispheres. The meta-analysis of MRI 
studies concerning schizophrenia and the corpus callosum observes the reduction of callosal 
fibres is seen in patients with schizophrenia (Arnone et al, 2008).  
Total cortex volume is seen to be reduced in both the Disc1tr (Shen et al, 2008) and the 
ΔhDISC1 mice (Ayhan et al, 2011). Reduced cortical thickness is apparent in schizophrenia 
(Rimol et al, 2012) and is even detected in first episode sufferers (Schultz et al, 2010). In 
bipolar disorder, a subgroup of patients show evidence of reduced cortical thickness that is 
specific to the frontal lobes (Rimol et al, 2012). The Disc1tr (Shen et al, 2008) mice 
additionally possess a reduction in total brain volume that is specific to the male mice. Meta-
analysis of MRI publications reveals that total brain volume is frequently decreased in cases 
of first episode schizophrenia (Steen et al, 2006) and that, over time, the loss of brain volume 
in individuals with schizophrenia occurs at an increased rate compared to controls (van Haren 
et al, 2008).  
Additionally, in both the ΔhDISC1 (Pletnikov et al, 2008)  Disc1tr mice (Shen et al, 2008), 
reduced neurite outgrowth is evident in primary neurone cultures. This is an autonomous cell 
mechanism that is thought to partially explain the gross anatomical anomalies that are seen in 
these mouse models.  
 
1.2.9.4 Dopaminergic alterations in C-terminal truncated DISC1/Disc1 models  
The dopaminergic hypothesis of schizophrenia has been central to psychiatric research for 
decades. A current iteration of this hypothesis involves alterations to dopaminergic function 
at the synapse which cumulates in the induction of psychosis within vulnerable individuals 
predisposed by both genetic and environmental risk factors (Howes & Kapur, 2009). The 
assessment of the impact of methamphetamine treatment on the locomotion of mice in the 
open field is seen as a measure of psychosis-like behaviour. This concept originates from 
clinical findings that chronic amphetamine users would frequently go on to develop psychosis 
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and other symptoms of schizophrenia whilst positive symptoms of schizophrenia are 
exacerbated by amphetamine use. Subsequently, the treatment of rodents with amphetamine 
is observed to elicit behavioural hyperactivity and stereotypy which is seen to be a model of 
possible dopaminergic dysfunction in schizophrenia (Robinson & Becker, 1986). The 
augmentation of hyperlocomotion is observed in both male DN-DISC1 (Jaaro-Peled et al, 
2013) and ΔhDISC1 (Ayhan et al, 2011) mice following treatment with methamphetamine 
and d-amphetamine respectively. In the male ΔhDISC1 mice, the levels of DA and DOPAC, 
a DA metabolite, are decreased in the frontal cortex (FC). The reduced DA levels in the FC 
may contribute to the augmentation of locomotion following amphetamine treatment (Ayhan 
et al, 2011). 
Converging evidence that includes neuroimaging, autoradiography and molecular biology, 
detects evidence of dysfunction within the dopaminergic system of the DN-DISC mice. In the 
striatum, the levels of D2 receptors and the DA transporter (DAT) are increased while baseline 
DA levels are reduced (Jaaro-Peled et al, 2013). Within the striatum, in populations with 
schizophrenia, a small, but significant, increase in D2 receptor levels is frequently observed 
(Brunelin et al, 2013). For DAT, with a role in the reuptake of DA at the synapse, the majority 
of studies have found no evidence of abnormal DAT density in schizophrenia. However, in 
addition to this, there is evidence that the DAT density may be increased in major depressive 
disorder (Brunswick et al, 2003; Laasonen-Balk et al, 1999).  
 
1.2.9.5 Gene-environment interactions in C-terminal truncated DISC1 models 
The DN-DISC1 (Hikida et al, 2007) and the ΔhDISC1 (Pletnikov et al, 2008) mouse models 
have been used to simulate gene-environment effects on neurodevelopment. This involved the 
injection of neonatal DN-DISC1 mice with poly I:C in the early postnatal period  (Ibi et al, 
2010; Nagai et al, 2011) or the exposure of mice in utero to poly I:C in parallel with prenatal 
transgene activation in the ΔhDISC1 mice (Abazyan et al, 2010). The administration of poly 
I:C, an inflammatory agent, mimics viral infection, and is commonly used in  animal models 
of schizophrenia (Meyer & Feldon, 2012). It is thought that prenatal viral infection as an 
environmental factor has a role in the aetiology of schizophrenia by perturbing 
neurodevelopment (Brown & Derkits, 2010).  
The DISC1-DN-Tg-PrP mouse (Niwa et al, 2013) has primarily been used in a gene-
environment paradigm to investigate the effects of stress isolation in adolescence as an 
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environmental factor in conjunction with a genetic risk - the expression of hDISC1 aa-1-597 - 
on dopaminergic function. 
 
1.2.9.6 Behavioural alterations associated with gene-environment C-terminal 
truncated DISC1 models 
The male ΔhDISC1/poly I:C mice have increased locomotor activity and spend less time in 
the open arms of the elevated plus-maze (Abazyan et al, 2010). These behavioural alterations 
are indicative of increased anxiety-like behaviours (Prut & Belzung, 2003; Walf & Frye, 
2007). In itself, anxiety can be a mental illness and anxiety disorders often occur comorbid 
with schizophrenia (Achim et al, 2011), bipolar disorder (Keller, 2005) and depression 
(Kessler et al, 2005). Furthermore, the male ΔhDISC1/poly I:C mice show evidence of 
abnormal social interaction and spend a significant time immobile in the forced swim test 
(Abazyan et al, 2010). The abnormal social interaction may be evidence of deficits in social 
cognition, a core feature of schizophrenia (Couture et al, 2006), while the forced swim test is 
a “black box” test used to trial susceptibility to antidepressant drugs (Nestler & Hyman, 2010). 
The DN-DISC1/poly I:C mice have multiple behavioural deficits. Cognition is affected, 
including hippocampus-dependent fear memory and short term memory deficits. Social 
interaction is also reduced and the DN-DISC1/poly I:C mice show more aggressive behaviours 
(Ibi et al, 2010; Nagai et al, 2011). The social interaction abnormalities are not rectified 
following the administration of the antipsychotics, clozapine and haloperidol (Nagai et al, 
2011). This finding is relevant to schizophrenia, in that, negative symptoms in affected 
individuals, such as social withdrawal, are less responsive to treatment with both first 
generation antipsychotics, including haloperidol, or second generation antipsychotics, such as 
clozapine (Tandon et al, 2010). Conversely, when a pharmacological challenge, using the 
NMDAR antagonist MK-801, is applied to the DISC1/poly I:C to induce NMDA receptor 
hypofunction and pharmacologically model schizophrenia (Bubeníková-Valešová et al, 2008), 
these mice have a greater susceptibility to MK-801 induced hyperactivity than controls (Ibi et 
al, 2010; Nagai et al, 2011). The augmentation of locomotion seen in the DISC1/poly I:C can 
be ameliorated by treatment with antipsychotics. This observation reflects that the positive 
symptoms of schizophrenia, which are seen as additional to normal experience and are 
responsive to treatment with antipsychotics (Tandon et al, 2010), such behaviours can be seen 
to be psychosis-like (Bubeníková-Valešová et al, 2008).  
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The DN-DISC1/poly I:C mice display reduced performance in the Y-maze, a behavioural 
assay that assesses  spatial working memory function (Ibi et al, 2010). This observation 
highlights a deficit to working memory resulting from truncated DISC1 expression. 
Additionally, the DN-DISC1/poly I:C mice have an impairment in fear conditioning (Ibi et al, 
2010). This behavioural learning and memory paradigm involves associative learning of an 
unconditioned stimulus such as a tone with a fear inducing conditioned stimulus, e.g. electric 
shock. Typically, the fear conditioning model is used to study the amygdala molecular 
pathways and synaptic plasticity mechanisms involved in the learning of fearfulness (Johansen 
et al, 2011). The fear conditioning behavioural assay, performed by the DN-DISC1/poly I:C 
mice, is contextual (Ibi et al, 2010) and as such would involve hippocampal signalling to 
enable the processing of fear memories (Lee et al, 2004). The insights resulting from fear 
conditioning studies may be translatable to the investigation of anxiety disorders (Johansen et 
al, 2011).  
In the DISC1 aa1-597 expression by social isolation gene environment paradigm that was 
initiated by Niwa et al, (2013), the mice showed deficits in PPI and FST, as well as 
hyperlocomotion at both basal levels and following methamphetamine treatment. These 
behavioural abnormalities are indicative of sensorimotor impairment (Arguello & Gogos, 
2006) and positive symptoms of schizophrenia (i.e. psychosis) (Robinson & Becker, 1986), as 
well as the increased immobility in FST which could be indicative of antidepressant 
responsiveness (Nestler & Hyman, 2010). Following treatment with the glucocorticoid 
antagonist RU38486, all of these behavioural defects are ameliorated (Niwa et al, 2013). This 
occurs as stress activates glucocorticoids which in turn increase DA levels leading to 
psychosis-like behaviour (Corcoran et al, 2003). 
 
1.2.9.7 Histopathology & morphology of C-terminal truncated DISC1 gene-
environment models 
Unusually, it appears that the poly I:C treatment, in conjunction with the transgene expression, 
may attenuate the enlargement of the lateral ventricles (Abazyan et al, 2010) compared to the 
enlargement seen with expression of the transgene alone in the ΔhDISC1 mice (Pletnikov et 





1.2.3.8 Dopaminergic alterations in C-terminal truncated DISC1 gene-
environment models 
Following the isolation stress, the DISC1-DN-Tg-PrP mice show a range of perturbations to 
DA function as well as elevated glucocorticoid levels (Niwa et al, 2013) (see table 1.2.B). The 
majority of these alterations to measures of dopaminergic function within this gene-
environment paradigm can be ameliorated following the treatment of the mice with RU38486, 
a glucocorticoid antagonist. Specifically, the alterations to the dopaminergic system with the 
DISC1-DN-Tg-PrP/social stress mice are isolated to both the FC and nucleus accumbens. Of 
the two brain regions, it is the dopaminergic impairment tractable to the FC which is associated 
with epigenetic modification of the tyrosine hydroxylase promoter by increased methylation.  
Tyrosine hydroxylase is of fundamental importance to dopaminergic neurotransmission as this 
enzyme converts tyrosine into DOPA prior to DOPA being synthesised into DA by DOPA 
decarboxylase (Rang et al, 2003). This modification occurs via the mesocortical pathway 
which projects between the ventral tegmental area and the FC. This methylation of the tyrosine 
hydroxylase promoter, specific to the mesocortical pathway, is reduced when the mice are 
treated with the glucocorticoid antagonist, RU38486. It is proposed by Niwa et al, (2013) that 
the DISC1-DN-Tg-PrP gene environment paradigm used is a model of psychotic depression. 
 
1.2.3.9 Expression of truncated DISC1 species in glial cells 
The ΔhDISC1 mouse model has also been used to investigate oligodendrocyte development 
in relation to the expression of DISC1 aa1-597 (Katsel et al, 2011) (see table 1.2.C). 
Perturbation to myelination and abnormalities to oligodendrocytes are detectable in 
schizophrenia (Flynn et al, 2003; Tkachev et al, 2003). In 12 month old ΔhDISC1 mice, 
oligodendrocyte lineage genes are strongly upregulated in both the FC and the white matter. 
In line with this finding, genes related to glial progenitor cells and oligodendrocytes show a 
strong trend to upregulation at E15. Upregulation at P1 is markedly reduced from the levels of 
E15 but the trend is still that of a statistically significant increase in gene expression. These 
early developmental alterations are thought to be underpinned by a dysregulation of cell cycle 
genes. This is interpreted by Kastel et al, (2011) to be causative to an increase in the 
proliferation of oligodendrocyte precursors in the absence of differentiation at E15 followed 
by a premature increase in differentiation at P1. The expression of the neuregulin signalling 
genes, Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3), ERBB4 and Neuregulin 1 (NRG1) are 
also altered. These three genes show a trend towards upregulation in the forebrain in early 
neurodevelopment and white matter at 12 months. NRG1 signalling may underpin the 
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oligodendrocyte abnormalities seen in the ΔhDISC1 mouse model, given that NRG1 signalling 
can promote the myelination of oligodendrocytes (Taveggia et al, 2008). Overall, the Katsel 
et al, (2011) manipulation of the ΔhDISC1 mouse line indicate a possible role for DISC1 in 
the proliferation and differentiation of oligodendrocytes that may relate to clinical 
observations seen in schizophrenia. 
A novel adaption to study the effects of expression of human DISC1 aa1-597 in a mouse is the 
ΔC-hDISC1 mouse line (see table 1.2.C). In these transgenic mice, human DISC1 aa1-597 can 
be expressed in astrocytes via an inducible Glial Fibrillary Acidic Protein (GFAP) promoter 
(Ma et al, 2012). Such a model enables the investigation of truncated DISC1 expression along 
with theories of NMDA hypofunction (Coyle, 2012). This is because  astrocytes contain serine 
racemase, the enzyme which synthesises D-serine, a potent NMDAR co-agonist (Wolosker et 
al, 1999). The selective expression of DISC1 aa1-597 transgene is associated with both a 
reduction in D-serine in adult ΔC-hDISC1 mice that had the transgene induced throughout 
their life span. These mice displayed abnormalities in both MK-801 induced hyperactivity in 
the open field and to MK-801 facilitated PPI. The administration of exogenous D-serine 
rectified the locomotion abnormalities in male and female ΔC-hDISC1 mice and partially 
ameliorated the PPI response in male mice (Ma et al, 2012). The work of Ma et al, (2012), 
highlights how glial mediated glutamatergic neurotransmission can be altered following the 




































































































































































































































































































































































































































































Key to table 1.2.B. 
 
12MO  12 Months old 
♂  Male 
↑  Increase 
↓  Decrease 
CaMKII Ca2+/calmodulin activated kinase II 
Ctx Cortex 
ds Ameliorated by D-serine treatment 
E15 Embryonic day 15 
FB Forebrain 
GFAP Glial fibrillary acidic protein 
p Prepulse intensity above background level of 70 dB 
P0  Postnatal day 0 
P1 Postnatal day 1 
P21 Postnatal day 21 
P.Ast Primary Astrocytes 
SR Serum racemase 
WM  White matter 
Y Shows significant change 
 
1.2.10 DISC1/DISC1FP1 chimeras to date 
Following the isolation of the DISC1FP1 gene (Eykelenboom et al, 2012) also known as 
Boymaw at 11q14.3 (Zhou et al, 2010; Zhou et al, 2008), a novel mechanism of pathogenesis 
was proposed whereby DISC1 may fuse with DISC1FP1 to produce abnormal chimeric 
transcripts. This had the potential to produce both der1 and der11 aberrant protein species. 
Since this initial observation 3 DISC1/DISC1FP1 chimeric transcripts have been identified in 
t(1;11)-family derived lymphoblastoid cell lines (Eykelenboom et al, 2012). The der 1 
DISC1/DISC1FP transcripts of Chimeric Proteins 60 and 69 (CP60) and (CP69) arise from 
the splicing of exon 8 of DISC1 to exon 4 of the DISC1FP1 ESTs CK000409 or BU599486, 
respectively (Eykelenboom et al, 2012) (see figure 1.2.C). CP60 encodes DISC1 aa1-597 plus 
an additional 60aa from DISC1FP1 whilst CP69 encodes DISC1 aa1-597 plus a further 69 aa 
from DISC1FP1. It is possible that CP60 and CP69 could be expressed endogenously in the 
t(1;11) family under the DISC1 promoter and that the novel protein structure of these species 
may confer gain of function or dominant negative effects that are functionally different to the 
established roles of DISC1. As such putative pathogenic mechanisms of CP60 and CP69 
require further investigation. 
The third DISC1/DISC1FP1 transcript identified by Eykelenboom et al., (2012) is a der 11 
species and is produced by the splicing of DISC1FP1 exon 2 to DISC1 exon 8. In the der 11 





Figure 1.2.C: Schematic of DISC1FP1 (not to scale). (A) Genomic structure of 
DISC1FP1 denoting exons, arrow indicates alternatively spliced exon 5, vertical 
dashed line demarks translocation breakpoint. (B) DISC1FP1 ESTs: CK000409 
encodes CP60 and BU599486 encodes CP69 which comprise DISC1 aa1-597 
plus an additional 60 or 69aa from DISC1FP1, respectively. The investigation 
into species encoded by AB371558, will be a component of this thesis. 
Asterisks indicate predicted stop codons. Adapted from Eykelenboom et al., 
(2012).  
 
encodes aa669–854 of the DISC1 C-terminus, which would suggest it is unlikely that this 
transcript would be expressed endogenously. Interestingly, a transgenic mouse model has been 
produced that expresses DISC1 aa671–852 in the forebrain (Li et al, 2007). These animals had 
a schizophrenia-like phenotype that includes deficits to working memory and reduced 
dendritic complexity.  
 
Since the identification of the three DISC1/DISC1FP1 transcripts by Jennifer Eykelenboom 
another DISC1FP1 EST, AB371558 has been identified (see figure 1.2.B.). Further 
investigation is needed to detect possible der 1 and der 11 DISC1/DISC1FP1 transcripts that 




1.2.11 DISC1 and mitochondrial function 
Several studies highlight the importance of DISC1 on mitochondrial function. 71 kDa and 75 
kDa isoforms of DISC1 have been isolated in the mitochondrial fraction (James et al, 2004) 
and DISC1 co-localises with mitochondria in cell lines (James et al, 2004; Millar et al, 2005) 
and primary cortical neurons (Brandon et al, 2005). Further studies have also been performed 
that suggest DISC1 is located on the inside of the outer mitochondrial membrane (James et al, 
2004; Park et al, 2010). Additionally investigations by Ramsey et al., (2011) and Paspalas et 
al., (2013) observe DISC1 at the mitochondria but fail to give precise details of localisation. 
A recent study by Ogawa et al., (2014) indicates that DISC1 is also located on the outside of 
the mitochondria as a component of the mitochondrial transport complex. Within this complex 
DISC1 interacts with the milton homolog, Trafficking Protein, Kinesin Binding 1 (TRAK1) 
an adaptor protein, as well the mitochondrial membrane anchor Mitochondrial Rho GTPase 1 
(Miro1). The variant R37W is an ultra-rare DISC1 mutation that has been identified in an 
individual with schizophrenia (Song et al, 2008) and within a Scottish family. Here, DISC1 
R37W occurs in two sufferers of major depressive disorder and one of generalised anxiety 
(Thomson et al, 2014). The cellular expression of DISC1-37W is associated with the 
redistribution of DISC1 and the formation of clustered peri-nuclear mitochondria (Ogawa et 
al, 2014). These effects are likely mediated via an increased association DISC1-37W shows 
for TRAK1. Furthermore, an uncoupling effect of DISC1-37W on TRAK1-Miro1 interaction 
was also observed 
 
Given the association of DISC1 with the mitochondrial transport complex, Ogawa et al,. 
(2014) assessed the effect of DISC1 on mitochondrial movement. While DISC1 promotes 
anterograde mitochondrial movement, DISC1-37W has no effect on anterograde transport. A 
previous study by Atkin et al., (2011) noted an increase in total mitochondrial movement. 
Methodological differences likely underpin the lack of concordance of this result with the 
observations of Ogawa et al., (2014). Interestingly, Atkin et al., (2011) also observed that the 
common DISC1 variant DISC1 607F (L607F) proved incapable of fully rescuing DISC1 
knockdown, with mitochondria in cells expressing DISC1 607F showing reduced movement.  
 
Mitofilin is a protein important to the maintenance of cristae morphology, knockdown of 
mitofilin impairs the mitochondrial inner membrane formation of cristae, promotes apoptosis 
and reduces proliferation (John et al, 2005). DISC1 has been identified as interacting with 
mitofilin and has suggested a role of DISC1 in regulating mitochondrial bioenergetics (Park 
et al, 2010). The knockdown of either mouse DISC1 or mitofilin results in the reduction of 
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cellular adenosine triphosphate (ATP) and NADH dehydrogenase (complex I), as well as Ca2+ 
buffering. Similar bioenergetic results are seen with the expression of truncated mouse DISC 
an orthologue of DISC1 aa1-597. This perturbation of mitochondrial bioenergetics caused by 
a reduction in mouse DISC1 levels can be partially rescued by the overexpression of mitofilin, 
supporting a notion of common mitochondrial functions between the two proteins. 
Additionally, a role of DISC1 in the stability of mitofilin is indicated by the observation that 
the knockdown of mouse DISC1 promotes mitofilin ubiquitination. DISC1 has also been 
identified to interact with the inner mitochondrial membrane protein Coiled-coil Helix Cristae 
Morphology 1/CHCHD6 (CHCM1/CHCHD6) (An et al, 2012). The established functional 
effects of CHCM1/CHCHD6 bear similarity to observations for mitofilin (John et al, 2005; 
Park et al, 2010). Deficits in CHCM1/CHCHD6 affect cristae morphology, ATP levels as well 
as O2 consumption (An et al, 2012). However, functional mitochondrial effects of DISC1-
CHCM1/CHCHD6 interactions have not been characterised.   
 
1.3 Mitochondria  
 
1.3.1 The mitochondrial membrane potential, Δψm 
This section serves to introduce background material on the mitochondrial membrane 
potential, Δψm, which will feature in chapters 4 and 5, as such the information here may aid 
in the interpretation of subsequent data. The proton gradient generated by respiratory chain 
activity in the inner mitochondrial membrane gives rise to both the mitochondrial membrane 
potential, Δψm and a pH gradient (Chen, 1988). In combination with the pH gradient, the 
mitochondrial membrane potential, Δψm contains the energy to produce torque via proton 
movement that drives the synthesis of ATP by F0F1ATPase activity. The quantitative 
measurement of the mitochondrial membrane potential, Δψm in primary cultured rat cortical 
neurons by Gerencser et al., (2012), identifies a value of −139 mV at rest. This mitochondrial 
membrane potential, Δψm was found to vary between −108 mV and −158 mV due to demands 
on ATP biosynthesis, and Ca2+mediated metabolic activation.  
In the intrinsic apoptotic pathway, the mitochondrial membrane potential, Δψm has frequently 
been observed to be dissipated (Ly et al, 2003). However, the specific details regarding the 
sequence in which this pathway activation occurs is unclear. Depending on the cell systems 
and apoptotic stimuli used, the loss of the mitochondrial membrane potential, Δψm may take 
place in early apoptosis or arise in late apoptosis following the activation of signalling 
pathways. Furthermore, the relationship between cytochrome c, an inner membrane protein 
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released from mitochondria during apoptosis (Liu et al, 1996) and the mitochondrial 
membrane potential, Δψm is also uncertain (Ly et al, 2003). It has been suggested that 
mitochondrial membrane potential, Δψm dissipation accompanies cytochrome c release 
(Heiskanen et al, 1999) and is a principle requirement for this to occur (Yoshino et al, 2001). 
However, cytochrome c release has also been observed to be independent of mitochondrial 
membrane potential, Δψm loss (Goldstein et al, 2005) or may occur prior to this event 
(Goldstein et al, 2000). Methodological differences may account for these conflicting results.  
The mitochondrial membrane potential, Δψm also has a role in mitochondrial fission-fusion 
dynamics. Collapse of the mitochondrial membrane potential, Δψm by the ionophore carbonyl 
cyanide m-chlorophenylhydrazone (CCCP) leads to the fragmentation of mitochondria and an 
inhibition of fusion (Ishihara et al, 2003; Legros et al, 2002). This mitochondrial fragmentation 
occurs due to the impairment of mitochondrial inner membrane fusion (Malka et al, 2005). 
Specifically, fusion is impaired by the proteolytic inactivation of the fusion protein Optic 
Atrophy 1 (OPA1) by OPA1 Zinc Metallopeptidase (OMA1), a process which is dependent 
on the loss of the mitochondrial membrane potential, Δψm (Ehses et al, 2009; Head et al, 
2009).  
 
1.3.2 Mitochondrial morphology  
Mitochondria are dynamic organelles capable of altering their shape due to changing 
environmental and metabolic demands (Benard & Rossignol, 2008). Underpinning the ability 
of the mitochondrial network to rapidly alter its structure, is the fission-fusion dynamics of the 
mitochondrial membranes (Chan, 2006). Primarily, the fission-fusion machinery is composed 
of Dynamin-1-like Protein (Drp1) and Fission 1 (Fis1) which mediate membrane fission 
(Mozdy et al, 2000; Smirnova et al, 2001),  whereas inner membrane fusion is facilitated by 
OPA1 and outer membrane fusion is  promoted by mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2) 
(Song et al, 2009). The functional relationship between fission and fusion must be managed 
to maintain an optimal mitochondrial network structure, dominance of unrestrained fission 
will ultimately lead to fragmentation of mitochondria whereas maintained fusion will lead to 
elongation of the mitochondrial network (Chan, 2006). For example, Drp1 null-mutant cells 
(Ishihara et al, 2009) or Drp1 knockdown cells (Youle & van der Bliek, 2012) possess 
elongated tubular networks of mitochondria with fission being absent. In contrast, the 
knockdown of OPA1 induces mitochondrial fragmentation (Ishihara et al, 2006), likewise 
Mfn1 and Mfn2 null-mutant cells (Koshiba et al, 2004) display a mitochondrial network that 
is fully fragmented with a total absence of fusion. 
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Mitochondrial bioenergetics influence the morphology of the mitochondrial network  (Benard 
& Rossignol, 2008). Westermann et al., (2012) proposes a model to explain the role of fission-
fusion dynamics in regard to respiratory demand. Under basal conditions the mitochondrial 
network undergoes constant remodelling due to cycles of dynamic fusion and fission, with the 
mitochondria neither being fully fused nor fully fragmented. At extremes of respiratory 
activity the mitochondrial morphology adapts to cope with demands. High energy demand 
may result in the hyperfusing of the mitochondrial network to allow maximal ATP production 
whereas low energy demand may give rise to fragmentation of the mitochondrial network and 
mitochondria existing in a resting state. Furthermore, mitochondrial network fragmentation is 
frequently observed following the impairment of oxidative phosphorylation (OXPHOS) by the 
use of chemical inhibitors to specific electron transport chain (ETC) complexes, or the use of 
uncoupling agents to collapse the membrane potential, Δψm (Benard & Rossignol, 2008). It 
may also be that compromised mitochondrial function in general promotes fragmentation.  A 
RNA interference (RNAi) screen in C.elegans identified that of 719 genes associated with 
mitochondria function, knockdown of ~80% of genes resulted in mitochondrial fragmentation 
and in only 3.5% of cases, elongation was observed (Ichishita et al, 2008). It appears that the 
impairing of OXFOS or perhaps broader mitochondrial function leads to a morphological shift 
towards fragmentation. However, the exact signalling methods to initiate the changes in 
fission-fusion dynamics in relation to the bioenergetics are at present poorly understood 
Processes of autophagy involve alterations to mitochondrial morphology. Mitophagy is a 
means to ensure the quality control of mitochondria enabling the removal of compromised or 
excess mitochondria (Kanki & Klionsky, 2010). The fragmentation of the mitochondrial 
network is observed to occur before the onset of mitophagy (Gomes & Scorrano, 2008; Twig 
et al, 2008). In part this is a prerequisite for the mitochondria to be able to fit inside the 
autophagosome prior to degradation (Gomes & Scorrano, 2013). Mitochondria are selected 
for mitophagy following a process of fission-fusion events that leaves a sub-population of 
mitochondria with a low membrane potential, Δψm and reduced levels of OPA1 (Twig et al, 
2008). These organelles display abnormal bioenergetic processes. The mitophagy of the 
degraded aberrant mitochondria is observed to be dependent on Drp1 to initiate the structural 
fragmentation.  
Macroautophagy is the principle pathway of autophagy and is a less selective process than 
mitophagy, involving the generalised elimination of proteins and organelles within the cell to 
maintain homeostasis and cell survival (Yang & Klionsky, 2010). The induction of 
macroautophagy results in the elongation of the mitochondrial network which spares the 
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mitochondria from degradation. The initiation of unbalanced fusion is responsible for this 
elongation, which results from the inhibition of the fission protein Drp1 due to the serum 
starvation used to initiate the macroautophagy (Gomes et al, 2011). The sparing of the 
elongated mitochondria in macroautophagy is likely a consequence of this highly fused 
mitochondrial network being too large to be engulfed by the autophagosome (Gomes & 
Scorrano, 2013). 
 
1.3.3 Mitochondrial trafficking in neurones 
The long range transport of mitochondria is required to maintain a sufficient supply of ATP 
and regulate intracellular Ca2+ by buffering within the highly specialised morphology of the 
neurone (Lin & Sheng, 2015). The trafficking of mitochondria within the cell is driven by 
motor proteins that depend on ATP hydrolysis to move along the microtubule network 
(Hirokawa et al, 2010). Kinesin-1 motor proteins generate anterograde movement from the 
soma to the distal region, conversely dynein motor proteins facilitate retrograde movement 
from distal regions towards the soma. Kinesin-1 and dynein both form trafficking motor 
complexes with the mitochondrial membrane anchor Miro1 which interacts with the 
mitochondrial outer membrane as well as the adaptor protein milton, which links Miro1 to the 
given motor protein (Schwarz, 2013).  Mitochondrial respiration appears to be the principle 
source of ATP for the motor proteins, as the blocking of respiration rapidly abolishes 
mitochondrial transport, therefore mitochondria likely fuel their own motility (Zala et al, 
2013). The motility of mitochondria within neurons is often complex and dynamic, with 
mitochondria moving over long distances then pausing and sometimes changing direction, 
showing bi-directional movement (Sheng, 2014). In cultured hippocampal neurones it has 
been observed that ~20-30% of mitochondria are motile within the axon, some of this 
population moves to and from the synaptic bouton, while the remaining ~ 70-80% of axonal 
mitochondria remain stationary (Kang et al, 2008). Stationary mitochondria may become 
motile again following metabolic or synaptic changes (Sheng, 2014). Furthermore, there are 
twice as many motile mitochondria within the axon than the dendrites (Overly et al, 1996). 
Mitochondrial trafficking dynamics are proportional to the level of neuronal activity that is 
occurring within the cell (MacAskill & Kittler, 2010). For example, the rise in intracellular 
adenosine diphosphate (ADP) at the synapse due to metabolic activity may result in an increase 
in the targeting of mitochondria to this region via trafficking (Mironov, 2007). This is likely 
to supply the localised demand for further ATP. Mitochondria may also be trafficked to the 
synapse following increases in intracellular Ca2+  levels there (Lin & Sheng, 2015). However, 
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the exact mechanisms as to how energy consumption or Ca2+ increases result in mitochondrial 
trafficking to the synapse are not fully clear and are the subject of ongoing research. 
 
1.3.4 Mitochondrial function in psychiatric illness 
 
1.3.4.1 Major depressive disorder 
Evidence from cellular based studies suggests a role of mitochondrial dysfunction in major 
depressive disorder. Gardiner et al., (2003) found a reduction in the mitochondrial ATP 
production rate and in the ratios of the electron transport chain (ETC) respiratory complexes 
I+III/IV as well as II+III/IV, in muscle cells obtained from sufferers of major depressive 
disorder displaying somatisation. These sufferers had common features of both depression and 
mitochondrial disorders. Karabatsiakis et al., (2014) observed lowered levels of respiration, 
ATP turnover related respiration and OXPHOS coupling efficiency in peripheral blood 
monocytes (PBMCs) from patients with major depressive disorder versus healthy controls. 
Furthermore, a correlation between the severity of the depression and the intensity of the 
respiratory dysfunctions was noted. The mitochondrial membrane potential, Δψm was found 
to be increased in platelets from sufferers of major depressive disorder in comparison to 
healthy controls (Moreno et al, 2013). In another study using platelets to monitor 
mitochondrial function in depression, Hroudová et al., (2013) detected reductions in the 
respiratory rate following complex I inhibition and in the maximal capacity of the ETC in 
depressed patients showing partial remittance. However, no differences were observed 
between depressed patients in the absence of remittance compared to healthy controls. Overall, 
these studies suggest a generalised deficit in respiration may occur in peripheral cells in 
sufferers of major depressive disorder that is possibly underpinned by abnormal functioning 
in some of the ETC complexes. 
Animal models suggest that mitochondrial abnormalities may in part mediate the pathogenesis 
of depression. Chronic mild stress can be used as an experimental model of depression. In rats 
subjected to this paradigm, reduced activity of the mitochondrial respiratory chain complexes 
I, III and IV was identified in both the cerebellum and the cortex (Rezin et al, 2008). Further 
work by the same group identified increased reactive oxygen species (ROS) as measured by 
increased levels of superoxide in the hippocampus, PFC and cortex following chronic mild 
stress (Lucca et al, 2009). Inducing depression via chronic mild stress in mice, Gong et al., 
(2011) found impaired mitochondrial respiratory function in the hippocampus, hypothalamus 
and cortex. The mitochondrial membrane potential, Δψm was also observed to be reduced in 
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these brain areas. Additionally, mitochondrial morphology appeared altered, with evidence of 
abnormalities to the mitochondrial cristae and membranes apparent. Mitochondrial 
abnormalities have also been identified in the Flinders-sensitive rat line (FSL), which possess 
a genetic predisposition to depression-like behaviours (Chen et al, 2013). Within the CA1 of 
the hippocampus of the FSL rats, a reduced number of mitochondria were present, these 
mitochondria also had a greater volume than that of matched controls. It was possible to rectify 
the mitochondrial deficit in the FSL rats following treatment with the antidepressant 
imipramine, which increased the number of mitochondria. 
 
1.3.4.2 Bipolar disorder 
Studies using post-mortem brain tissue have identified associations between bipolar disorder 
and mitochondrial impairment. Post-mortem analysis of the PFC of sufferers of bipolar 
disorder reveals reduced mitochondrial size in comparison to healthy controls (Cataldo et al, 
2010). The study of post-mortem PFC brain tissue from bipolar patients has also identified a 
reduction in the activity levels of respiratory complex I activity (Andreazza et al, 2010). This 
may be associated with the increased levels of oxidative damage to proteins that was likewise 
observed in the tissue sections. Gene expression micro-array analysis of the post-mortem PFC 
from bipolar individuals has revealed downregulation to components of the ETC (Sun et al, 
2006). This included genes encoding subunits of respiratory complexes I, IV and V (F1F0 ATP 
synthase). Overall these post-mortem studies indicate that within the PFC of bipolar 
individuals there may be deficits to respiratory complexes, the dysfunction of which may have 
downstream effects mediating oxidative damage, perturbing mitochondrial function.   
Animal models highlight a role of mitochondrial dysfunction that suggest an involvement with 
the presentation of mania. The pharmacological modelling of mania can be induced by the 
treatment of animals with amphetamines. In rats treated with amphetamines, the activity of 
respiratory complexes I, II, III and IV was reduced in the PFC, striatum and hippocampus 
(Valvassori et al, 2010). Treatment with the mood stabiliser valproic acid was capable of 
ameliorating all of the respiratory complex deficits measured. In a similar mania model Fery 
et al., (2006) found an increase in oxidative stress markers within the hippocampus, striatum 
and cortex. Recently, Valvassori et al., (2014) observed a reduction in tricarboxylic acid cycle 
(TCA) enzyme activity within the FC, hippocampus and striatum of rats following treatment 
with amphetamine. The TCA enzyme reduction was inversely correlated with the degree of 





There is evidence that the distribution and number of mitochondria are altered in 
schizophrenia. Examination of post-mortem brains from individuals with schizophrenia 
revealed an average 26-30% reduction in mitochondrial density per synapse quantified, 
specific to the striatum, versus healthy controls (Somerville et al, 2011a). Similarly, an average 
37% decrease in mitochondrial density was observed per synapse quantified, in the putamen 
and caudate nucleus of schizophrenia patients (Somerville et al, 2011b). Deficits in the 
mitochondria number has also been found to occur within oligodendrocytes in both the PFC 
and caudate nucleus in post-mortem brain tissue from sufferers of schizophrenia (Uranova et 
al, 2001). It is possible that these regionalised reductions in mitochondria could impinge upon 
localised synaptic signalling and myelination in individuals with schizophrenia. 
Multiple studies have identified an association between schizophrenia and perturbations to 
cellular energy generation. Using a proteomics, metabolomics and transcriptomics approach 
to analysing the post-mortem PFC from patients with schizophrenia Prabakaran et al., (2004) 
found downregulation of metabolic pathways. This included components of glycolysis, 
oxidative phosphorylation (OXPHOS) and ATP synthesis alongside the upregulation in ROS 
associated pathways. In line with the possibility of impairments of OXPHOS in schizophrenia, 
reductions is the activity levels of respiratory complexes have been identified in post-mortem 
brain tissue from individual with schizophrenia, occurring to complex IV within the FC and 
temporal cortex and to complexes I and III in  the temporal cortex and basal ganglia (Maurer 
et al, 2001). Complex I activity has also been found to be reduced in peripheral blood 
monocytes form individuals with schizophrenia in comparison to healthy controls (Gubert et 
al, 2013). In vivo, 31p-MRS neuroimaging has identified reductions to ATP in patients with 
schizophrenia specific to the basal ganglia (Fujimoto et al, 1992) and the frontal lobes (Volz 
et al, 2000).  
A recent study provides some evidence that mitochondrial dynamics is altered in 
schizophrenia. Reduced mitochondrial network connectivity was identified in patient derived 
lymphoblastoid cell lines from individuals with schizophrenia (Rosenfeld et al, 2011). Such 
an observation suggests that a shift in mitochondrial dynamics to favour fission has occurred. 
In line with this, OPA1 levels were found to be lowered in both lymphoblastoid cell lines and 
post-mortem brain tissue from patients with schizophrenia (Rosenfeld et al, 2011). 
Animal models of schizophrenia highlight mitochondrial dysfunction. The facilitation of 
social isolation rearing in rats produces a neurodevelopmental model of schizophrenia, in these 
animals cortico-straital abnormalities in ATP are evident (Möller et al, 2013). A reduction in 
51 
 
ATP in the FC was observed which may underpin negative schizophrenia-like symptomology 
in the social isolation model, while conversely ATP levels in the striatum were increased, that 
could perhaps in part explain positive symptoms observed. Mitochondrial complex activity 
has been investigated within a pharmacological model of schizophrenia using ketamine in rats 
(De Oliveira et al, 2011). Mitochondrial complex activity was monitored in the striatum, 
hippocampus, PFC at three time point’s post-ketamine injection. In each of the brain regions 
tested, some degree of abnormal mitochondrial complex activity was detected within the total 
time course. It was thought these respiratory chain alterations impacting on brain energy status 
may be linked to the hyperlocomotor abnormalities that are also evident in this rat model.  
 
1.4 Summary 
From the introduction, it can be seen that the field of psychiatric genetics is making useful 
progress towards understanding these complex disorders. One clear message however is that 
psychiatric disorders are more complex and heterogeneous than is perhaps suggested by the 
over-simplified DSM and ICD categorizations. On the other hand, it is also becoming evident 
that the underlying biology transcends these boundaries, with findings being applicable to 
multiple disorders. The example of DISC1 may be rare in terms of genetic origin, but the 
biological insights that have emerged, point to convergences on biological processes that are 
generally held to relate directly to mental illness across the spectrum from schizophrenia to 













The t(1;11) co-segregates with multiple instances of major mental illness in a large Scottish 
family. Until the identification of the chimeric DISC1/DISC1FP1 transcripts CP60 and CP69 
by Jennifer Eykelenboom, the only mechanism of pathogenesis proposed for the t(1;11) family 
was a model invoking the haploinsufficiency of DISC1. However it is possible that the t(1;11) 
is associated with additional potential mechanisms of pathogenesis including the expression 
of aberrant DISC1/DISC1FP1 chimeric proteins, which could possess a dominant-negative or 
gain of function effect. Recently a further DISC1FP1 EST has been identified: AB371558. 
This suggests that other DISC1/DISC1FP1 chimeric transcripts may exist.  
 
It is of interest to observe how the addition of amino acids from DISC1FP1 to DISC1 aa1-597 
will affect the function and localisation of chimeric DISC1/DISC1FP1 proteins given the 
established studies into DISC1 aa1-597 in vitro and in vivo. To investigate this, the der 1 
DISC1/DISC1FP1 chimeric species will be exogenously expressed in cell lines as well as 
mouse primary cortical neurones and characterised. This will include the analysis of cellular 
expression and investigation into the mitochondrial phenotype of these species. 
Characterisation of mitochondrial expression is of interest given that DISC1 has been 
frequently localised to the mitochondria and has established roles in mitochondrial function, 
while DISC1 mutants have been associated with mitochondrial dysfunction.  
If mitochondrial pathology is induced by the exogenous expression of DISC1/DISC1FP1 
chimeric proteins it is possible that evidence of such a deficit can also be detected in t(1;11)-
family derived cell lines. The staining of lymphoblastoid cell lines with Mitotracker Red and 
subsequent detection of fluorescence will give a proxy indication as to the integrity of the 
mitochondrial membrane potential, Δψm in these cells. 
It is currently unknown as to whether the t(1;11) confers an alteration to gene expression, 
although this seems possible given the established roles and sub-cellular localisations of 
DISC1 not to mention any potential roles of DISC1FP1 or DISC2. Recently t(1;11) 
lymphoblastoid cells were assayed on a gene expression microarray by Merck Sharp and 
Dohme. Consequently, these data will be analysed by gene ontology and pathway analysis 
programs, using over representation analysis. Further putative mechanisms of pathogenesis 
may be uncovered following data analysis with multiple functional enrichment programs. 
Overall this study aims to identify putative pathogenic mechanisms within the t(1;11) family 
which may be translatable to the mechanisms of psychiatric illness in the general population. 
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The aims of this thesis were as follows: 
 To identify novel DISC1/DISC1FP1 transcripts that arise from the splicing of DISC1 
and the DISC1FP1 EST AB371558.  
 To characterise the exogenously expressed DISC1/DISC1FP1 proteins.  
 To investigate mitochondrial fluorescence in t(1;11) lymphoblastoid cell lines. 
 To perform gene ontology and pathway analysis on t(1;11) microarray data.   
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2.1.1 Identification of EST AB371558 chromosomal co-ordinates 
Sequence data and chromosomal location of the DISC1/DISC1FP1 EST AB371558 was 
acquired from UCSC genome browser. 
2.1.2 Translation predication 
The Sequence Manipulation Suite’s Translation tool was used to translate nucleotide 
sequences into protein open reading frames.  
2.1.3 Sequence comparison 
For the initial analysis of BigDye sequencing traces for cloning data, FinchTV software was 
used. Following this, BLAST (bl2seq) was used to align two given nucleic acid sequences. 
2.1.4 Restriction enzyme mapping 
To map a nucleotide sequence for the presence of restriction sites that are substrates for 
commercially available restriction enzymes, NEBcutter was used.   
2.1.5 Gene enrichment analysis for t(1;11) microarray data 
For the analysis of the microarray gene enrichment data, the WEB-based Gene Set Enrichment 
Analysis Toolkit (WebGestalt) (Wang et al, 2013; Zhang et al, 2005) software was used. All 
data was analysed using hypergeometric statistical analysis. 
2.1.6 Generation of genes of interest lists for t(1;11) microarray data 
The initial microarray analysis of t(1;11) lymphoblastoid cDNA was performed by Miguel 
Camargo of Merck Sharp & Dohme. Following this initial round of analysis, the t(1;11) 
microarray dataset was then filtered to isolate genes showing differential expression that had 
both a fold change of +/- 1.3 and a p≤0.05. Such a cut-off was used as it is the threshold for 
reliable detection. This filtering process created the initial t(1;11) Genes of Interest List (GOI). 
The original GOI list was then subjected to a second filtering process; this stage removed non-
neuronally expressed genes present in the lymphoblastoid cDNA from the dataset. The aim of 
the second round of filtering was to create a GOI list with an expression profile that was more 
in line with a post-mortem brain tissue derived GOI list than the initial original unfiltered GOI 
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list. Underpinning this filtering is the observation that gene expression in the blood can 
significantly differ from that found in the brain using gene expression microarray analysis (Cai 
et al, 2010; Sullivan et al, 2006). In order to create the second gene list the original unfiltered 
GOI list was analysed using Ingenuity Pathway Analysis (IPA) and the GOI list was then 
filtered by nervous system and CNS cell line expression creating a neuronally filtered GOI list 
that contained only neuronally expressed genes. The filtering of both of the GOI lists produced, 
was performed in collaboration with Ruth Boxall, a PhD student under the supervision of 
David Porteous. 
 
In the generation of both reference and genes of interest lists for WebGestalt analysis a 
minority of  gene names needed altering to synonyms or prior names to be accepted by 
WebGestalt. This entailed both the consultation of NCBI gene, GeneCards and the use of the 
HGNC list search tool.   
The microarray study was conducted by Merck Sharp & Dohme using a proprietary in house 
Rosetta chip based analysis. As such a limitation of this study is that the raw data was not 
available. Consequently, for data analysis it was not possible to align the results directly with 
other public domain data as is widely practiced using the Illumina chips.  
 
2.1.7 Web pages of online programs 
BLAST http://blast.ncbi.nlm.nih.gov/ 
GeneCards http://www.genecards.org/ 
HGNC list search http://www.genenames.org/hgnc-searches 
NCBI Gene http://www.ncbi.nlm.nih.gov/gene 
NEBcutter http://tools.neb.com/NEBcutter2/ 
Sequence Manipulation Suite http://www.bioinformatics.org/sms2/  







Below are listed the details of the chemical reagents used in the production of this thesis. The 
source of each chemical reagent is stated alongside, in brackets. Where relevant, the buffer 
that a reagent is suspended in is stated. 
 
 Agar (BD Bioscience) 
 Agarose (Invitrogen) made up using TAE buffer 
 Ampicillin (Sigma) made up using TAE buffer 
 Bromophenol blue (Sigma)  
 BSA (Sigma) made up using PBS  
 DABCO (Sigma) 
 DAPI (Sigma) 
 DMSO (Sigma) 
 D-PBS (Invitrogen) 
 Dried milk powder (Marvel) made up using PBS 
 EDTA (Sigma) made up in dH2O  
 Ethanol (Fischer) dH2O used to dilute as needed 
 FACS Sheath Solution (BD Biosciences) 
 Formalin (Sigma)  made up using PBS 
 Glycerol (Promega) 
 Glycogen (Sigma) 
 Isoproponol (Fischer) 
 Kanamycin (Sigma) 
 Magnesium chloride solution, PCR grade (Invitrogen) 
 Methanol (Fischer) 
 Mowiol (Sigma) 
 NP-40 (Sigma) 
 Orange G (Sigma) 
 Phenol/chloroform/isoamyl alcohol (Invitrogen)  
 Protease Inhibitor Cocktail (Roche) made up in dH2O 
 SDS (Fischer) made up in  dH2O 
 Sodium Azide (Sigma) made up in  dH2O 
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 Sodium Chloride (Fischer) made up in dH2O 
 Sodium Deoxycholate (Fischer) made up in dH2O 
 Tris (Fischer) 
 Tris-HCL (Fischer) 
 TRIS-SDS Running Buffer 
 Tryptone (BD Biosciences) 
 TWEEN-20 (Sigma) 
 X-Gal (Invitrogen)  
 Yeast Extract (BD Bioscences) 
 
2.2.2 Solutions and buffers  




 50 g  Tryptone 
 25 g   Yeast Extract 
 50 g   Sodium Chloride 
 Up to 5l with dH2O 
Adjust the pH to 7.2. Pour into a bottle with 1.5g of Agar/100ml of medium. Stored at 4 ̊C. 
Prior to usage, melt in a microwave, when cool enough to touch add ampicillin or kanamycin 
to 50ng/ml. Use immediately. 
 
L Broth/ampicillin/kanamycin 
 50 g  Tryptone 
 25 g   Yeast Extract 
 50 g   Sodium Chloride 
 Up to 5l with dH2O 







Membrane wash buffers 
The basic membrane wash buffer used was prepared as follows: 
100 ml  10xPBS 
10 ml   TWEEN-20 
Up to 1l with dH2O 
Membrane wash buffers were kept at room temperature.  
 
Mowiol mounting solution 
 7.5 g   Mowiol 
 10 ml   Glycerol 
 25 ml   dH2O 
Solution then incubated overnight at room temperature. 
 50 ml   Tris-HCL(pH 8.5) 
Solution then heated to 100 ̊C for 20 min and allowed to cool. 
 1.75 g   DABCO 
Solution then stored at -20 ̊C, with working stock stored at 4 ̊C. 
 
PBS-Triton lysis buffer 
 5 ml   10x PBS 
 5 ml  10% Triton X-100 
 Up to 50 ml  dH2O 
1 tablet  Protease inhibitor cocktail 
Buffer stored at 4 ̊C prior to addition of the protease inhibitor tablet. Following tablet 
addition, buffer stored at -20 ̊C. 
 
Protein sample buffer  
 6.25 ml  1M Tris (pH 6.8) 
 10 ml   Glycerol  
 10 ml  20% SDS 
 13.75 ml  dH2O 
 1 ml  0.1% Bromophenol blue 






RIPA lysis buffer 
 2.5 ml  1M Tris-HCl (pH 7.5) 
 2.5 ml  3M Sodium Chloride 
 0.5 ml   NP-40 
2.5 ml   10% Sodium deoxycholate 
250 ul   20% SDS 
Up to 50 ml  dH2O 
1 tablet  Protease Inhibitor Cocktail 
Buffer stored at 4 ̊C prior to addition of the protease inhibitor tablet. Following tablet 
addition, buffer stored at -20 ̊C. 
 
2.3 Cell Culture  
 
2.3.1 Cell line maintenance 
Both the lymphoblastoid and COS-7 cell lines were cultured in a Galaxy S incubator (scientific 
laboratory supplies), at 37°C and 5% CO2. All of the cell culture was carried out in an Envair 
Bio2+ Class II Safety Cabinet following containment level 1 measures.  
The COS-7 cells were grown in in Cellstar T25 or T75 flasks (Greiner Bio-One) and split at 
80-90% confluence. To split a COS-7 culture, the media was aspirated and the cells washed 
twice in PBS (Invitrogen), following this 5mls of TrypLE Express (Invitrogen) was applied to 
the cells. The COS-7 cells were then incubated at 37°C and 5% CO2 for 2-5 minutes until the 
cells detached from the basal membrane. The suspension was then centrifuged at 1,000rpm for 
10 minutes and the supernatant removed. The cell pellet was then resuspended in 1ml of pre-
warmed media (see table 2.3.A). For the generation of Western Blot lysates, the suspended  
 
 
Cell line Source Medium Serum 
COS-7 ECACC DMEM 10% foetal calf serum 
KK (Millar et al, 2005b) RPMI 10% foetal calf serum 
 
Table 2.3.A:  Media in which cell lines were cultured: all media was supplied by 




cell volume was diluted with prewarmed media (see table 2.3.A) to enable cells to be aliquoted 
in 10mls media (see table 2.3.A) per 10cm tissue culture dish (Iwoki) at a density of 2.5x106 
cells per plate. For immunocytochemistry, 12 well Costar plates (Corning), each well 
containing a 16mm sterile glass cover slip (VWR) were seeded with 0.5-1x105 COS-7 cells in 
1ml of media (see table 2.3.A). The cells seeded for Western Blot or immunocytochemistry 
were grown overnight, then transfected. 
The lymphoblastoid cell lines were initially grown in Cellstar T25 flasks (Greiner Bio-One) 
and fed three times weekly. For feeding, 2/3 of the conditioned media was aspirated and 
replaced with pre-warmed media (see table 2.3.A). Following feeding, flocculations of 
cultured lymphoblastoid cell lines were agitated by gentle pipetting to promote cell growth. 
At confluence, a portion of conditioned media was aspirated and the lymphoblastoid cell 
flocculation’s disrupted by pipetting. Then 4/5 of the cells suspended in the media were 
transferred to a T75 flasks (Greiner Bio-One). The T25 and T75 flasks containing 
lymphoblastoid cell lines were then refilled with prewarmed media (see table 2.3.A). Prior to 
the harvesting of lymphoblastoid cell lines for use in FACS analysis, confluent flasks were 
first fed with 10ml of pre-warmed media (see table 2.3.A) for three consecutive days. For cell 
counting a 20ul sample of the suspended cells was injected into a counting chamber (Nexcelom 
Bioscience) and analysed by a Cellometter Auto T4 Cell Counter (Nexcelom Bioscience). 
Following this, four samples of each culture, each containing 1x106 cells were aliquoted into 
15ml Falcon tubes and centrifuged at 500rpm for five minutes. The supernatant was then 
removed and the cell pellet was resuspended in 1ml of the conditioned media specific to the 
cell line. The resuspended cells were then aliquoted into 12-well dishes generating four wells 
per plates of the same cell line each with 1x106 cells in lml of media (see table 2.3.A) and 
placed in the incubator at 37°C and 5% CO2 for 20 minutes, prior to MitoTraker Red treatment. 
 
2.3.2 Transfection of plasmids into eukaryotic cells 
To transfect plasmid DNA into cells for the exogenous expression of protein, Lipofectamine 
2000 (Invitrogen) was used in conjunction with Opti-MEM (Invitrogen) as per manufacturer’s 
instructions. The amount of plasmid DNA transfected was: 2µg per well 12-well plate, 5.6µg 
per 10cm dish. The cells were incubated with the transfection media at 37 °C and 5% CO2 for 
4-6 hours. The transfection media was aspirated and replaced with prewarmed media (see table 
2.3.A). The transfected cells were harvested 18-24 hours later. The plasmids used in this thesis 








Plasmid Protein Tag Source 
pcDNA 3.1(+) Empty vector None Invitrogen 
pcDNA 3.1(+) FLAG Empty vector FLAG Fumiaki Ogawa 
pcDNA 3.1(+) FLAG-DISC1 DISC1 FLAG Nick Brandon1  (Brandon et al, 2004)  
pDEST40 Empty vector HIS Novagen 
pETG20a Empty vector TRX Novagen 
pETG30a Empty vector GST Novagen 
pETG40a Empty vector MBP Novagen 
 
 





2.3.3 Drug treatment 
For mitochondrial staining 1mM MitoTracker Red (Invitrogen) was diluted 1:20 in DMSO 
into 50µM aliquots that were then snap frozen on dry ice for future use. For 
immunocytochemistry MitoTracker Red was used at 1:1000 to a final concentration of 50nM 
in 2ml of media per well. Following the addition of MitoTracker Red, the cells were returned 
to the incubator for 30 minutes and maintained at 37°C and 5% CO2. The 12-well plate 
containing the MitoTracker stained cells was then wrapped in aluminium foil between the 
entire cell fixation and blocking steps to prevent the loss of MitoTracker florescence due to 
excitation of the fluorescent probe by ambient light. 
For the initial FACS analysis with lymphoblastoid cell lines, the end concentration of 
MitoTracker Red was 50nM in 1ml of media (see table 2.3.A). Following the addition of 
MitoTracker Red or sham DMSO treatment, the cells, were returned to the incubator for 45 
minutes and maintained at 37°C and 5% CO2. To determine an optimal incubation time for the 
staining of lymphoblastoid cell lines with 50nM MitoTracker Red, incubation times of 60, 45, 
30 and 15 minutes were tested. In the generation of experimental data the incubation time was 
15 minutes, in the presence of 30nM MitoTracker Red. Prior to FACS analysis the 
MitoTracker Red treated lymphoblastoid cells were centrifuged at 500rpm, the supernatant 
removed and the pellet resuspended in warm PBS. The cells in solution were then passed 
through a BD Falcon 100µM Cell Strainer (BD Biosciences) into a FACS tube. All samples 
were then kept wrapped in aluminium foil to prevent excitation of the probe by ambient light.  
 
2.4 Protein-related methods 
 
2.4.1 Antibodies 
A variety of antibodies were used in this project. Details of the antibodies and the conditions 





























Rabbit Invitrogen N/A 
1:5000 




CVα CVα Mouse Mitoscience/Abcam N/A 
1:3000 




Cytochrome c Cy c Mouse Mitoscience/Abcam N/A 
1:2000/1:30001 
















Mouse Ig Goat Invitrogen N/A 1:2000 1 hour 
Secondary 
Fluorescent 488 nm 
Alexa-Flour 594 
Goat-anti-mouse 
Mouse Ig Goat Invitrogen N/A 1:2000 1 hour 
Secondary 
Fluorescent 544 nm 
Alexa-Flour 488 
Goat-anti-rabbit 
Rabbit Ig Rabbit Invitrogen N/A 1:2000 1 hour 
Secondary 








Mouse Ig Chicken Invitrogen N/A 1:2000 1 hour Secondary 
Fluorescent 647 nm 
 
Table 2.4.A: A list of all of the antibodies used in this thesis and the conditions under which they were used. WB refers to western 
blotting and ICC refers to immunocytochemistry, whilst species refers to the species in which the antibody was raised.
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2.4.2 Cell lysates 
 
2.4.2.1 Production of cell lysates and processing of the cell pellet 
Cells were cultured for lysis on 10cm dishes to 75-90% confluence. Cell media was then 
aspirated and the cells washed with 10mls of 4 ̊C PBS. This was then aspirated and between 
500 and 1000ul of lysis buffer (either PBS-Triton or RIPA) was applied to the culture dish. 
The dish was rotated so that the lysis buffer covered all of the adherent cells. Following this a 
cell scraper was used to mechanically detach the cells from the culture dish and the whole cell 
lysate was then transferred to an eppendorf.    
Two methods of pellet processing were used in order to extract exogenously expressed CP60 
and CP69 protein for Western blot analysis and were adapted from a protocol by Keryer-
Bibens et al., (2006), with additional input from the Millar group senior postdoc Shaun 
Mackie. These experiments aimed to determine if the chimeric proteins were isolated in the 
membrane fraction.  
Condition 1: The whole cell lysate was placed on a rotary wheel at 20-30rpm for 2 hours at 
4°C and then spun at 13,000rpm by centrifuge for 30 minutes. The soluble protein lysate was 
then separated from the insoluble pellet fraction by pipette, snap frozen on dry ice and stored 
at -20 or -70 ̊C. The pellet was then resuspended in 20µl buffer by pipette. An ultrasonic probe 
then applied sonication to the pellet solution in the eppendorf in an attempt to disrupt proteins 
in the solution. The ultrasonic probe was set on drive with 3x 10 second bursts of sonication 
administered. During operation of the sonicator the eppendorf containing the pellet in solution, 
was packed in ice within a beaker to minimise possible protein degradation occurring due to 
sonication during sample processing. The solubilised pellet was then combined with an equal 
volume of 2x Protein sample buffer (PSB) and heated to 100°C for 5 minutes on a hotblock. 
Condition 2: The whole cell late was solubilised on a rotary wheel at 20-30rpm for 2 hours at 
4°C. The eppendorf containing the whole cell lysate was then subjected to 10 minutes of 
sonication in an ultra-sonic bath. The sonication was used in an attempt to disrupt proteins in 
the cell lysate. The disrupted whole cell lysate was then spun at 13,000rpm by centrifuge for 
30 minutes. Following this, the soluble protein lysate was then separated from the insoluble 
pellet fraction by pipette, snap frozen on dry ice and stored at -20 or -70 ̊C. The pellet was then 
resuspended in 50µl RIPA and combined with an equal volume of 2x PSB. The pellet in PSB 
was then vortexed for 1 minute, heated to 100°C for 5 minutes on a hotblock, vortexed for 1 
minute and heated to 100°C for 5 minutes. This cycle of heating and vortexing was thought to 
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be a means of fractionating insoluble proteins from the pellet into solution. Cell pellet fractions 
were typically stored at -20 or -70 ̊C. 
However, in retrospect it should be noted that these methods simply isolate CP60 and CP69 to 
a fraction that is insoluble by RIPA alone. Future studies could be implemented to determine 
which specific sub-cellular compartments these chimeric species partition to. Such a suitable 
fractionation protocol to partition proteins to multiple sub-cellular compartments is provided 
by Rockstroh et al., (2010).  
 
2.4.2.2 Measuring the protein concentration of cell lysates 
The concentration of protein lysates was determined using the BioRad protein assay. This used 
25ul of each of 6 BSA protein standards with concentrations ranging from 0-1mg/ml that 
increased in 0.2mg/ml increments. 2.5ul of protein lysate sample were made up to 25ul using 
dH2O. To each sample and standard, 125ul of reagent A and 1ml of reagent B was added. The 
reactions were left to incubate at room temperature for 25 minutes. The absorbance readings 
of the reactions was then taken at 750nm using an Ultrospec 3000 optical reader (Pharmacia 
Biotech). The 750nm readings from the protein standards were then used to plot a standard 
curve of protein concentration versus absorbance. The interpretation of the standard curve then 
enabled the determination of the protein concentration for the sample protein lysates.  
 
2.4.3 Western blotting 
 
2.4.3.1 Sample preparation 
Prior to Western analysis the cell lysates were combined with an equal volume of PSB. This 
sample was then heated to 100°C for 5 minutes on a hotblock. The heating of the solution 
aimed to both denature the proteins and disrupt the interactions between proteins in the 
solution.  
 
2.4.3.2 Invitrogen system 
Western blotting firstly involves the process of electrophoresis to drive the movement of 
proteins through the gel with the distance moved being dependent on the molecular weight 
(Mw) of the given protein species. The Western blotting method used is the Invitrogen system. 
Pre-cast 7% Tris-Acetate gels (Invitrogen) were used for gel electrophoresis and were held in 
a XCell Surelock gel tank. The experimental samples and All Blue Marker (Bio-Rad) where 
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then loaded and the gel immersed in 400ml 1x NuPage Tris-Acetate SDS Running Buffer 
(Invitrogen). The gel electrophoresis was performed for 90 minutes at 150V using a Power 
Pac 3000 (BioRad). 
Following this, a 500ml of 1X NuPage Transfer Buffer (Invitrogen) containing 20% methanol 
was made up. A PDVF membrane (Invitrogen) was briefly immersed in methanol, then soaked 
along with five sponge pads in NuPage Transfer Buffer /20% methanol for ~5 minutes prior 
to transfer. Upon completion of the gel electrophoresis the gel casing was opened and the gel 
aligned with the membrane. Two sponge pads were then put into the transfer chamber with 
the gel and then membrane, followed by three sponges. When two gels were transferred at 
once, a sponge was used to separate the gels with two sponges either side. The transfer 
chamber was then closed, inserted back into the XCell tank. The transfer chamber was then 
surrounded with H20 to dissipate heat as the transfer electrophoresis was active. The transfer 
ran for 60 minutes at 30V using a Power Pac 3000 (BioRad). The membrane was then washed 
three times in dH20 over 5 minutes and then in blocking buffer for 30 minutes at room 
temperature or overnight in at 4°C. 
 
2.4.3.3 Immunostaining 
Following blocking, the membrane was incubated with the primary antibody in blocking 
buffer. This process took between 1-2 hours at room temperature or overnight in at 4°C, 
depending on the primary antibody used. The membrane was then washed three times over 15 
minutes with wash buffer. After this the membrane was incubated with a secondary antibody 
in blocking solution for 30 minutes at room temperature. The membranes was then washed 
three times over 15 minutes in wash buffer and then with PBS. For both antibody incubations 
and the washes, the immersed membranes were rocked at ~15rpm. Details of both the primary 
and secondary antibody incubation times are given in table (see table 2.4.A). The membrane 
was then placed on cling film to air dry. 
For development of the membrane onto photosensitive film (Scientific Laboratory Supplies), 
5ml of ECL Plus (Amersham) development reagent was applied to the air-dried membrane for 
~5 minutes. The ECL Plus was then removed from the membrane and the membrane was then 
exposed to photosensitive film in order to visualise the antibody binding to a given protein 
species. The time period for the exposure to the film ranged from 1 second to 16 hours. The 







2.4.4.1 Cell fixation 
Prior to the addition of antibodies to cells exogenously expressing protein, the cells were fixed 
and permeabilized. Fixation terminates biochemical reactions but preserves protein-protein 
interactions. Permeabilisation results in protein epitopes potentially being accessible for the 
binding of primary antibodies.  
The cells were washed twice with warm PBS (Gibco), each PBS wash was aspirated from the 
well. Following this the cells were fixed with 0.5mls of 3.7% formaldehyde (Sigma) per well, 
and left at room temperature for 10 minutes. A second series of two PBS washes was then 
applied. The cells were then permeabilized with 0.5mls of chilled methanol per well. The 12-
well plate was then placed in the -20°C freezer for 5 minutes, following this, the cells were 
washed twice in PBS. 
 
2.4.4.2 Immunostaining 
Each well received 1ml of blocking solution PBS/3% BSA vol/wt and was rocked at 25-30rpm 
at room temperature for 30 minutes. All further immunostaining was carried out at room 
temperature. Following blocking, the primary antibodies were applied to the fixed and 
permeabilized cells in 450µl PBS/ 3% BSA vol/wt. The 12-well plate was rocked at 25-30rpm 
1 hour for COS-7 immunostaining and for 2 hours for primary neuron immunostaining. The 
concentrations of the primary and secondary antibodies used in immunocytochemistry are 
shown in table 2.4.A. Three washes of PBS/ 3% BSA were then applied to the cells to remove 
unbound primary antibody. The fluorescent conjugated secondary antibodies were then 
applied in 400µl PBS/3% BSA and incubated for 1 hour and rocked at 25-30rpm 1 hour. 
During this period the 12-well plate was wrapped in aluminium foil to prevent the loss of 
secondary antibody florescence due to excitation of the fluorescent probe by ambient light. 
Three washes of PBS/3% BSA were then applied to the cells to remove unbound secondary 
antibody. The coverslips were then mounted onto slides using mowiol mounting medium with 







Fluorescence Microscopy was performed on a Zeiss Axioskop 2 MOT epifluorescence 
microscope with Image J software used for image processing. This was used for the 
visualisation of immunocytochemistry for both qualitative analysis and for optimisation of 
antibody staining. The fluorescence microscopy can visualise dual colour fluorescence in the 
Green (FITC) and Red (Texas Red) spectra. The integrity of staining following 
immunocytochemistry was checked on the fluorescence microscope and images were then 
acquired using confocal microscopy on the Zeiss LSM510. The use of confocal microscopy 
enabled the acquisition of optical sections of the immunocytochemically stained cells that were 
of greater resolution than images produced by fluorescence microscopy. The LSM510 also 
allowed a greater number of fluorescent conjugated antibodies to be used within an 
experiment, in particular, conjugated antibodies that fluoresced in the far red (Cy-5) spectrum. 
This enabled the implementation of a triple-staining protocol. 
 
2.4.4.4 Qualitative analysis of immunocytochemistry 
Qualitative analysis of immunocytochemistry on COS-7 cells exogenously expressing FLAG-
tagged: CP60, CP69, WT-DISC1 and DISC1 aa1-597 was used to characterise the cellular 
expression pattern and the Mitotracker Red staining associated with CP60 and CP69 protein. 
All of the plasmids were transfected into COS-7 cells under blinding with three experimental 
replicates produced. Based on previous observation of these DISC species, the cellular 
phenotype categories for the gross anti-FLAG staining used, were: punctate; diffuse and 
clustered. The Mitotracker Red staining categories firstly addressed whether the mitochondria 
were stained and secondly, if so, was the mitochondrial network tubular or clustered. 
Fluorescence microscopy was used to qualitatively categorise the cells. For each cell assessed, 
first the cellular phenotype, the ant-FLAG staining was observed using the Green (FITC) 
channel and the morphology noted, then the Red (Texas Red) channel used to visualise 
mitochondrial network staining with Mitotracker Red. For the qualitative analysis a random 
field was used to select cells. Per experiment one cover slip per DISC species was produced, 
with 20 fluorescing cells analysed per cover slip in a single session. Each cover slip was 
analysed three times and the results from each experimental replicate set of coverslips then 
averaged. This gave 60 cells counted per transfected DISC species. When all qualitative data 





2.5 Molecular biology methods 
 
2.5.1 Primers 
Details of all of the oligonucleotide primers used in this thesis may be found in table 2.5.A. 
Primer-blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) was frequently used to design 
primers.  
 
2.5.2 PCR reactions 
 
2.5.2.1 RT-PCR to amplify CP1 
The RT-PCR to detect the CP1 transcript used the following reaction mix: 
Forward primer         50pmol  
Reverse primer        50pmol 
GoTaq green master mix (Promega)       25 µl 
cDNA     1 µl 
dH2O     to 50 µl 
 
RT-PCR thermal cycle:   
95°C 2min 
95°C 30s 
60°C 30s            x35 cycles 
72°C 30s* 
72°C 4min 
4°C for ever 




Purpose Name Direction Sequence 
Untagged pcDNA3.1(+) 
DISC1 aa1-598 
WT DISC 1 Eco 5’ GATCGAATTCGCCACCATGCCAGGCGGGGGTCCTCAGGGCGCC 
DISC1 598 Not1 3’ GATCGCGGCCGCTTATCCTGATATGGCATGCATTTTGGCTTCAAG 
FLAG pcDNA3.1(+) 
DISC1 aa1-597 
FLAG DISC1 5’  GATCGAATTCGCCGCCATGGATTACAAG GATGACGACGATAAG 
DISC1 597 Not1 3’ GATCGCGGCCGCCTATGATATGGC ATGCATTTTGGCTTCAAG 
FLAG pcDNA3.1(+) 
DISC1 CP1 
FLAG DISC 1 5’ GATCGAATTCGCCGCCATGGATTACAAGGATGACGACGATAAG 
DISC1 598 Not1 3’ GATCGCGGCCGCTTATCCTGATATGGCATGCATTTTGGCTTCAAG 
FLAG pcDNA3.1(+) 
CP69 
DISC1 Eco Start 5’  GATCGAATTCCCAGGCGGG GGTCCTCAG GGC 




DISC1 Eco Start 5’ GATCGAATTCCCAGGCGGGGGTCCTCAGGGC 
FTS 60 Not1 3’ GATCGCGGCCGCCTACCAGAA 
AATATTCTTTTGGAGTCTCCAATG 
3’primers to confirm 
start codon in 
sequence and frame of 
ΔNCP69 
 
Trunc69R80 3’ AGCAGACAATCACGCAGC 
Trunc69R160 3’ CTGCTTTATCATAATCATCG 
5’ Primers to confirm 
stop codon presence in 
ΔNCP69 
 
Trunc69F100 5’ GTTCTGGGTTTTAGCTATCTG 





FMutTrunc69 5’ AAATGCATGCAATTAGCTAATAAGGCACCACCGATCGTAGTCTG 
RMutTrunc69 3’ CAGACTACGATCGGTGGTGCCTTATTAGCTAATTGCATGCATTT 
Primers to sequence 
the insert region of 
ΔNCP69 
 
F1T69 5’ TCATCACCACCACGATTATG 
F2T69 5’ GATACCCATACACCGCTGC 
F3T69 5’ AACGTATTAAAAGCCTGAATC 
R1T69 3’ CCTGCAGGGCTTTGCTAAC 
R2T69 3’ ACTTTTTGCAGACGCCAATG 









Table 2.5.A: Details of all of the primers used in this thesis. 
 
RT-PCR to detect CP1 
species 
 
ABFUS1C 3’ CAAGAAATGCCAAAGTGAGTTC 
 pETG-Seq 20F 5’ GGTTCTGGTTCTG 
 pETG-Seq 30F 5’ CGACCATCCTCC 
 pETG-Seq 40F 5’ GCGCAGACTCC 
 pETG-Seq R 3’ GTGGTGGTGCTC 
 pDEST14 Seq F 5’ CGTAGAGGATCGAG 
 pDEST14 Seq R 3’ CGGGCTTTGTTAGC 
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2.5.2.2 Pfu Ultra II fusion PCR 
For the generation of FLAG-tagged constructs of CP1, CP60 and CP69, the standard PCR 
thermal cycle conditions detailed in section 2.1.2.1 were used in conjunction a high fidelity 
polymerase. This enabled open reading frames to be amplified that were flanked 5’ and 3’ 
restriction sites. Here the * extension step 30s is sufficient for DNA products <2kb, with the 
following reaction mix: 
Forward primer            50pmol  
Reverse primer           50pmol 
Pfu Ultra II Fusion HS DNA polymerase (Aglient Technologies) 1µl 
Template (5-0.1ng)          1µl 
dNTPS         1.25µl  
10x Buffer (Aglient Technologies)     5µl 
dH2O                         to 50µl 
For the generation of the CP60 and CP69 inserts an additional 0.75µl and 1.5µl of 50mM 
MgCl (Sigma) was added to the PCR reaction. 
  
2.5.2.3 Touchdown PCR  
To amplify a 597 insert a touchdown PCR thermal cycle was used in conjunction with the Pfu 
Ultra II fusion reaction mix (see section 2.1.2.2). The touchdown PCR initially progresses 
through a thermal cycle and has an annealing temperature that decreases by 1°C per cycle. 
After 9 cycles an annealing temperature of 55°C is initiated and maintained for 19 cycles. 
Touchdown PCR thermal cycle:   
95°C 2min 
95°C 20s 






55 °C 20s             x19 cycles 
72°C 30s 
72°C 3min 
4°C for ever 
 
2.5.2.4 BigDye sequencing PCR 
To sequence the PCR products generated, the BigDye Terminator v3.1 Ready Reaction Mix 
(Life Technologies) was used. The reactions were either assembled in eppendorfs or 96 well 
plates. The reaction mix used was as follows: 
Primer     1µl (3.2pmol) 
5x Sequencing Buffer  1.5µl 
2.5x Ready reaction Mix  1µl 
Template (PCR product)  1µl 
dH2O      5.5µl 
BigDye Terminator v3.1 PCR thermal cycle: 
96°C 1min 
96°C 10s 
50°C 5s                  x24 cycles 
60°C 4min 





2.5.2.5 Site-directed mutagenesis PCR 
A QuickChange Lightning site-directed mutagenesis kit (Agilent Technologies) was used to 
insert a double stop codon into the sequence of ΔNCP69. This generated an open reading frame 
that encoded ΔN597.  The reaction mix used is as follows: 
Forward primer            1.25µl (125ng)             
Reverse primer           1.25µl (125ng)              
Template (300ng)          3µl 
dNTPS (Agilent Technologies)     1µl    
10x Buffer (Agilent Technologies)     5µl 
Quick solution (Agilent Technologies)    1.5µl     
dH2O        to 50µl 
Then QuikChange Lightning enzyme (Agilent Technologies) 1 µl  
      
Site-Directed Mutagenesis thermal cycle: 
95°C 2min 
95°C 20s 
60°C 10s                     x18 cycles 
68°C 2min 30s 
68°C 5min 
4°C for ever 
 
2.5.3 Sequencing PCR products and plasmids 
The BigDye Terminator v.3.1 cycle sequencing kit (Invitrogen) was used to sequence both 
plasmids and DNA amplified by PCR. This protocol required further PCR reactions to be 
performed on the initial  sample of DNA prior to sequencing (see section 2.1.2.2) This BigDye 
PCR used a single 5’ or 3’ primer to bind to and amplify regions of DNA. When amplifying 
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regions of DNA ~>300bp, sets of primers were designed that would create partially 
overlapping chromatogram reads from the products of separate BigDye reactions. 
The BigDye sequencing reactions were carried out in either 96-well plates or eppendorfs. 
Following generation of the PCR product on the thermal cycler, each eppendorf had 2.5µl of 
125mM EDTA added and 30µl of 100% ethanol. The tubes were then vortexed briefly and left 
to incubate at room temperature for 15 minutes. The sequencing reaction was then centrifuged 
at 13,000 at 4°C for 20 minutes and again, for 2 minutes. After each centrifugation the 
supernatant was then removed by pipette. 30µl of 70% ethanol added and the sequencing 
reaction which was then centrifuged at 13,000 at 4°C for 5 minutes and again, for 2 minutes. 
After each centrifugation the supernatant was then removed by pipette. The eppendorfs were 
then dried at 37°C to remove and residual ethanol for 2-3 minutes. 
The BigDye PCR reactions were analysed by Agnes Gallacher (Medical Research Council 
Human Genetics Unit). The Sequence chromatograms traces were visualised using FinchTV 
v.1.3.1 software (http://www.geospiza.com/Products/finchtv.shtml). BLAST was used to 
align nucleotide sequences (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The Sequence 
manipulation suite (http://www.bioinformatics.org/sms2), Translate application was used to 
convert nucleotide sequences into amino acid sequences; The ORF Finder application was 
used to identify ORF’s within a nucleotide sequence.  
 
2.5.4 Purification of PCR products 
The QIAquick PCR purification kit (Qiagen) was used to purify both the DISC1 ORF’s 
generated by PCR also the CP1 transcript amplified by RT-PCR. The PCR purification 
removed contaminants from the PCR product which may have otherwise impaired the actions 
of T4 DNA ligase (Roche) or the TOPO-TA cloning, respectively. The purified PCR products 
were eluted into dH2O or 10mM Tris·Cl, pH 8.5 (Quiagen). 
 
2.5.5 Making and running agarose gels 
To prepare agarose gels, TAE buffer and the required mass of powdered agarose were 
combined and heated using a microwave until the agarose melted. The agarose gels produced 
are described by wt/vol; a 1% agarose gel made with 70ml TAE contained 0.7g of powdered 
agarose.  SYBR Safe DNA Gel Stain (Life Technologies) was added to the warm agarose gel 
to enable DNA detection. 1% agarose gels were used to detect linear DNA >500bp and 
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contained SYBR Safe at a final dilution of 1:10,000, 2% agarose gels were used to detect linear 
DNA <500bp and contained  SYBR Safe at a final dilution of 1:3,333. The warm agarose gel 
was poured into a casing tray and a comb inserted into the liquid. The gel cooled at room 
temperature for 10+ minutes.  
The electrophoresis tank (Applied Biosciences) was filled with TAE. The agarose gel was then 
submerged in the tank, the comb removed and the DNA product loaded into the wells. 2% 
agarose gels were ran with a 50bp ladder (Invitrogen); 1% agarose gels were ran with a 1kb 
DNA Ladder (Invitrogen) and a λHindIII DNA Ladder (Invitrogen). The gel electrophoresis 
was ran at 50-100V for 30-90 minutes. The linear DNA that had migrated through the agarose 
gel was visualised and photographed using an Uvidoc light box. 
 
2.5.6 cDNA production 
The cDNA used in this thesis was produced by Jennifer Eykelenboom. The RT-PCR product 
sequenced in section 3.2 uses lymphoblastoid cDNA from cell lines, KK107 for the t(1;11) 
family member and KK47 for the karyotype control.  
 
2.5.7 Culture of bacteria transformed with plasmid constructs 
 
2.5.7.1 Transformation of bacteria with plasmid constructs 
To transform the FLAG-tagged constructs into cells, the following process was used: DH5 
chemically competent E. coli were thawed on ice, then 5µl of the ligation reaction was added 
to 50µl of the DH5 cells and mixed gently. The DH5 cells were then incubated on ice for 
30 minutes. The DH5 cells were heat shocked at 42°C for 20 seconds and then placed on ice 
for two minutes. 400µl of room temperature SOC media (Sigma) was added to the cells. The 
cells were then incubated at 37°C in an Innova 4300 incubator shaker (New Brunswick 
Scientific) at 225rpm for one hour.  
Following the initial incubation, a bacterial cell spreader was used to spread 50-150ul of the 
bacterial culture per L Agar/ampicillin plate. The agar plates were then incubated for 16-22 
hours at 37°C and 5% CO2 in a Plus II incubator (Gallencamp), by which time bacterial 
colonies were typically visible.  
Molecular biology kits recommended specific cells for transformation of constructs. The 
TOPO-TA (Invitrogen) cloning of the CP1 RT-PCR product, used TOP10 chemically 
78 
 
competent E. coli (Invitrogen). The sight directed mutagenesis reactions used XL10-Gold 
ultracompetent cells (Aglient). The protocol for each of these competent cell types is similar 
to that covered above for the DH5 cells. The bacterial cultures for the site directed 
mutagenesis to generate ΔN597 used L Agar/ kanamycin plates, given the destination vector 
mutated encoded ampicillin resistance. 
 
2.5.7.2 Blue/white screening of transformed bacteria 
The pCR 2.1-TOPO vector that the CP1 ORF was TOPO-TA cloned into can be blue/white 
screened using L Agar/x-gal plates. The x-gal is a substrate for -galactosidase. In the presence 
of functional -galactosidase, the hydroxylation of x-gal results in blue colonies. However -
galactosidase requires the LacZ peptide to function. The LacZ  gene which is encoded in 
the pCR 2.1-TOPO vector is disrupted, as a result of the insertion of the CP1 ORF within the 
TOPO vector cloning cassette. The screening process therefore enables the identification of E. 
coli colonies where the insert and TOPO vector have recombined (white) Vs colonies 
containing TOPO vector only (blue). 
The transformed TOPO-TA bacterial cultures were spread onto L Agar plates that had been 
pretreated with 40ul of x-gal. The L Agar/x-gal plates were then incubated for 16-22 hours at 
37°C and 5% CO2 in a Plus II incubator by which time both blue and white bacterial colonies 
were typically visible.  
 
2.5.7.3 Amplification of plasmid constructs 
Single transformed bacterial colonies form the L Agar/ampicillin or L Agar/kanamycin plates 
could be picked to grow larger bacterial cultures. These large bacterial cultures were grown in 
L-broth media with the appropriate antibiotic, ampicillin or kanamycin, for 16-18 hours at 
37°C in an Innova 4300 incubator shaker at 200rpm. Small cultures of bacteria were pelleted 
by centrifugation at 13,000rpm for 1-2 minutes using a bench top centrifuge. The bacterial 
pellets were then lysed and the DNA prepped using the QIAprep Spin Miniprep Kit (Qiagen) 
as per manufacturer’s instructions. For larges bacterial cultures of 200mls, the bacteria were 
isolated using centrifugation at 5,000rpm at 4°C for 10 minutes using an Avanti J-201 
centrifuge. The bacterial pellets were then lysed and the DNA prepped the Plasmid Maxiprep 
Kit (Qiagen) or Endofree Plasmid Maxiprep Kit (Qiagen). The plasmid DNA was eluted into 




2.5.7.4 Measuring plasmid DNA concentration 
A NanoDrop 1000 spectrophotometer was used to measure plasmid DNA concentration. Prior 
to the analysis of plasmid DNA, the NanoDrop 1000 first took a blank read from 1µl of dH2O 
then from the buffer the plasmid was solubilised in e.g. TE buffer. 1µl of plasmid DNA was 
then analysed and the concentration in ng/µl of the plasmid DNA calculated. The 260/280nm 
and 260/230nm absorbance ratios were also calculated by the Nanodrop. Both ratios can 
inform how free of protein contaminates the plasmid DNA is. For the 260/280 read-out a ratio 
of 1.8 indicates DNA that is free of impurities. A 260/230nm absorbance >2.0 was indicative 
of DNA containing impurities. 
 
2.5.8 Cloning techniques 
 
2.5.8.1 Site-directed mutagenesis 
The insertion of additional nucleotides into DNA sequence was performed using a 
QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies). 5’ and 3’ 
primer pairs that encoded the additional nucleotides and existing regions of the plasmid ORF 
were used in the site directed mutagenesis PCR reaction (see section 2.5.2.5). Following the 
site-directed mutagenesis PCR, 2µl of DpnI was added to the PCR product, which was 
immediately incubated at 37°C for five minutes. The DpnI enzyme digested the unmodified 
template plasmid. The mutated plasmid DNA was then transformed into E. coli (see section 
2.5.7.1) and the bacteria cultured and then DNA isolated (see section 2.5.7.3). The mutated 
plasmid ORF was confirmed by sequencing (see section 2.5.3) 
 
2.5.8.2 Restriction digests 
Restriction enzymes were used to digest both vector and insert DNA at given restriction sites 
to created ‘sticky’ ends for ligation of vector and insert. The FLAG-tagged plasmids created 
in this thesis all contain EcoR1 and Not1 restriction sites. 
 
Restriction enzyme nucleotide cleavage sites. 
EcoRI  5'G^AATTC   3'CTTAA^G  
Not1  5'GC^GGCCGC  3'CGCCGG^CG 
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Insert Digest  
PCR product 55µl 
EcoR1 (Roche) 4µl 
Not1 (Roche) 4µl 
10x buffer H (Roche) 10µl 
Incubated overnight at 37°C 
 
Vector Digest 
Vector DNA 3µl (3ng)  
EcoR1 2µl 
10x buffer H 5µl 
dH2O 40µl 
The digestion reaction was incubated for 37°C for two hours. Then, 2µl Not1 was added to the 
digest, which was then incubated a further two hours at 37°C. 
The restriction digest products were analysed on agarose gels (see section 2.1.5) to confirm 
DNA digestion. 
 
2.5.8.3 Phenol–chloroform extraction 
Phenol–chloroform extraction was used to remove proteins and lipids from the DNA product 
following restriction digest and prior to ligation. 100µl digest product and 100µl 
phenol/chloroform/isoamyl alcohol were briefly vortexed, then centrifuged at 13,000rpm for 
two minutes. 70µl of the aqueous phase was extracted to an eppendorf. 40µl of EB buffer 
(Qiagen) was then added to the Phenol–chloroform, briefly vortexed, and then centrifuged at 
13,000rpm for two minutes. 60µl was then extracted from the aqueous phase and combined 
with the initial extraction, to give a total volume of 130µl extracted. 
Following the phenol-chloroform extraction the DNA in the extraction product was 
precipitated. To the extraction product 2x of 100% ethanol and 1:10 3M pH5.2 sodium acetate 
were added. Extraction products containing DNA inserts received an additional 1ul of 
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20mg/ml Glycogen. The solution was then precipitated at -20°C for two hours then centrifuged 
at 13,000rpm for 30 minutes. The supernatant was removed and 100µl of 70% ethanol added, 
then centrifuged at 13,000rpm for five minutes. The supernatant was removed and the DNA 
pellet dried at 37°C for five minutes. The DNA pellet was then resuspended in dH2O or 10mM 
Tris·Cl, pH8.5 (Quiagen). 
 
2.5.8.4 SAP treatment 
SAP treatment of the vector DNA prior to ligation, removes phosphates groups which have 
the potential to detrimentally affect the ligation of the insert to the vector. The SAP treatment 
was performed on the vector DNA following ethanol precipitation.  The SAP reaction mixture 
was as follows: 
Vector DNA   10ul (100ng/ul) 
SAP Buffer (USB)  8.5ul 
SAP Phosphatase (USB) 1.5µl  
The reaction was incubated at 37°C for 30 minutes and then incubated at 65°C for 10 minutes. 
 
2.5.8.5 Ligation reaction 
A rapid DNA ligation Kit (Roche) was used to ligate the insert DNA to the linear plasmid 
DNA via complimentary restriction sites. The ligation reaction mixture was as follows: 
Insert DNA  4µl 
Plasmid DNA  1µl (50ng) 
1xBuffer (Roche) 5µl 
2xBuffer (Roche) 10µl 
T4 Ligase (Roche) 1µl 
The ligation reaction was incubated at room temperature for one hour prior to transformation 
into DH5 cells (see section 2.5.7.1). 
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2.5.8.6 Gateway cloning 
Gateway cloning was used to move both ΔNCP69 and ΔNCP597 ORFs from a pENTR221 
donor vector backbone and into a tagged destination vector. The gateway cloning used the 
Gateway LR Clonase II enzyme kit (Invitrogen) and the reaction was as follows: 
 
Donor vector containing ORF  1µl (100ng) 
Destination vector   1µl (150ng) 
TE Buffer   6µl 
LR Clonase (Invitrogen)  2µl 
Vortex LR Clonase reaction twice briefly, centrifuge briefly. Incubate the LR Clonase reaction 
at 25°C for 25 minutes. Add 1µl of Proteinase K (Invitrogen) to each tube, vortex. Incubate 
LR Clonase reaction at 37°C for one hour. The LR Clonase reaction was then transformed into 
DH5 cells (see section 2.5.7.1). 
 
2.5.8.7 TOPO cloning 
The CP1 PCR product was TOPO-TA (Invitrogen) cloned to generate sufficient DNA to 
sequence. The reaction mix was as follows: 
PCR product   2µl 
Salt Solution (Invitrogen) 0.5µl 
TOPO vector (Invitrogen) 0.5µl 
The reaction was mixed gently and incubated at room temperature for five minutes, then 







2.6 FACS analysis 
FACS analysis was performed using a FACSCalibur flow cytometer (BD Biosciences) using 
an argon laser (488nm). The cytometer parameters set for measurement were: Forward scatter 
(FSC), Side scatter (SSC), FL1 (FITC 530 nm emission bandpass), FL2 (PE 585 nm emission 
bandpass).  BD FACSFlow Sheath Fluid (BD Bioscience) was used as the sheath fluid for 
FACS analysis.  
Data analysis was performed using CellQuest software (BD Biosciences). Prior to data 
acquisition, presaved instrument settings specific to the cell line assayed, COS-7 or 
lymphoblastoid, were loaded into CellQuest. All FACS analysis was graphed as dot plots. For 
each FACS analysis, 10,000 events were measured and displayed on a dot plot, with the GMFI 
measured for the gated events. The use of a dot plot over a histogram enabled the visualisation 
of individual events that have high fluoresce.  
The control cells were ran by FACS analysis firstly using the FSC Vs. SSC parameters, which 
measure the cell size and cell complexity, respectively. Following this the FL1 Vs. FL2 
parameters were used to acquire the baseline fluorescence of the control cells. A subjective 
gate was drawn in either the FL1 or FL2 region to measure the fluorescing cells. For the 
measurement of the geometric mean fluorescence intensity (GMFI) of the COS-7 cells 
expressing exogenous GFP, the subjective gate was drawn in the FL1 region. In the 
quantification of Mitotracker Red fluorescence in stained lymphoblastoid cell lines, a 
subjective gate drawn was the FL2 region. The fluorescing cells were then analysed by FACS 
and the percentage of cells gated and the populations GMFI acquired. The FSC Vs. SSC was 
then measured for the given fluorescing cell line being assayed.   
 
2.7 t(1;11) gene expression microarray protocol  
Karyotype control and t(1;11) lymphoblastoid cells lines were cultured concurrently. RNA 
was then prepared from these cell lines by colleagues at the University of Edinburgh using a 
RNAeasy kit (Qiagen), followed by treatment with TurboDNA-free (Ambion). This total RNA 
was provided to Merck Sharpe and Dohme (MSD) as collaborators for the purposes of a 
collaborative research agreement under a materials transfer agreement. MSD then performed 
cDNA synthesis and subsequent quality control. Samples were then run on a Rosetta/Merck 
Human 44k 1.1 dual channel microarray platform (GEO platform identifier: GPL4372). This 
is a proprietary ink jet array created by Rosetta under contract to MSD, containing 39,302 
probes. The resulting data was analysed by MSD’s proprietary Rosetta Resolver gene 
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The t(1;11) pedigree are a large Scottish family with members that suffer from major 
depressive disorder, schizophrenia and bipolar disorder (Blackwood et al, 2001). In the 
pedigree, a balanced autosomal t(1;11) co-segregates with these  mental illnesses, meaning 
that only translocation carriers within the pedigree are affected by these psychiatric diseases. 
There are t(1;11) carriers who are unaffected by illness. However, these individuals share 
cognitive deficits in common with affected t(1;11) carriers. Two genes, DISC1 and the 
antisense encoded DISC2 gene, are located at 1q42 and are disrupted as a consequence of the 
t(1;11) (Millar et al, 2000b). The gene DISC1FP1, also known as Boymaw, is located at 
11q14.3. Here the DISC1FP1 ESTs CK000409 and BU599486 span the t(1;11) breakpoint 
region. With genes identified as being disrupted at both 1q42 and 11q14.3, it was proposed 
that chimeric DISC1/DISC1FP1 transcripts may be produced from the derived chromosomes 
1 and 11 (Zhou et al, 2008).                 
 
The majority of the work that comprises this chapter is also included in Eykelenboom et al., 
(2012). In this study, DISC1FP1 was also disrupted by the translocation and was cryptically 
spliced to DISC1 generating DISC1/DISC1FP1 transcripts that were detected by RT-PCR in 
t(1;11) lymphoblastoid cell lines. Two der 1 chimeric transcripts were detected, CP60 and 
CP69, transcripts that encode DISC1 aa1-597 plus an additional 60 and 69 novel amino acid 
originating from DISC1FP1 (Eykelenboom et al, 2012). A single novel der 11 transcript has 
also been detected. However, this species possesses an internal ORF of DISC1 aa669–854, 
and encodes a distal DISC1 C-terminus fragment (Eykelenboom et al, 2012; Zhou et al, 2010; 
Zhou et al, 2008). Given this it was decided to investigate the exogenous expression of CP60 
and CP69 as these der 1 species are aligned to use the endogenous DISC1 promoter. 
Importantly, if CP60 and CP69 were expressed endogenously (Eykelenboom et al, 2012; Zhou 
et al, 2008) it is possible that the presence of the additional amino acids from DISC1FP1 would 
confer aberrant function to CP60 and CP69 protein. This may produce gain of function or 
dominant negative effects that are functionally different to the established roles of DISC1. 
  
Since the detection of the three DISC1/DISC1FP1 chimeric transcripts (Eykelenboom et al, 




breakpoint region at 11q14.3. This raises the possibility that further novel DISC1/DISC1FP1 
transcripts may be present in t(t1;11) lymphoblastoid cells as a consequence of DISC1 being 
spliced to AB371558. The detection of other novel chimeric transcripts would add greater 
complexity to possible mechanisms of pathogenesis in the t(1;11) pedigree. This chapter will 
cover the use of RT-PCR on t(1;11) lymphoblastoid cell lines to detect a DISC1/AB371558 
transcript. 
The detection of the chimeric transcripts in t(1;11) lymphoblastoid cell lines (Eykelenboom et 
al, 2012), furthers the investigation into  the pathophysiology underlying the high incidence 
of major mental illness observed in translocation carriers (Blackwood et al, 2001). It is 
important to build upon the discovery of the chimeric transcripts by expressing and 
characterising chimeric DISC1/DISC1FP1 protein species to look for possible 
pathophysiological mechanisms.  Presently the single transgenic mouse model encoding 
chimeric DISC1/DISC1FP1 protein species expresses only CP60 and the C-terminus DISC1 
fragment (Ji et al, 2014), whilst post mortem t(1;11) brain tissue is not available. Therefore, 
to characterise DISC1/DISC1FP1 protein, investigations will focus on in vitro expression of 
constructs encoding the chimeric species.  
This chapter will also look at the exogenous expression of CP60 and CP69 and the subsequent 
Western blot analysis of the respective chimeric protein species. In this chapter the basic 
characterisation of exogenously expressed CP60 and CP69 protein by Western blot will be 
addressed. This aims to (1) determine the protein fraction each chimeric protein is isolated in; 
(2) validate each protein species predicted molecular weight; (3) detail the cell lysate 
processing methods used. Research published since the investigations in this thesis were 
completed, has isolated an exogenously expressed der 1 chimera protein in the lysate pellet 
fraction by Western analysis, this was identified as exogenously expressed CP60 protein (Ji et 
al, 2014; Zhou et al, 2010).  
Expanding on the initial investigations into the exogenous expression of DISC1/DISC1FP1 
protein required the generation of further chimeric constructs. The development of FLAG-
tagged chimeric constructs would enable the immunolabeling of exogenously expressed 
protein using commercial FLAG antibodies, removing the requirement for N-terminal DISC1 
antibodies. The method development of der 1 chimeric FLAG-tagged construct generation and 
that of relevant controls is covered in this chapter. The method development for construct 




DISC1FP1 in the species CP69, will also feature. The biophysical investigation itself was 
conducted by Nicholas Bradshaw and Dinesh Soares (Eykelenboom et al, 2012).  
 
3.2 Detection of the DISC1/AB371558 chimeric transcript CP1     
 
3.2.1 In silico predictions of DISC1 and AB371558 chimeric transcripts 
AB371558, like BU599486 and CK000409 is an EST specified by DISC1FP1 that in 
karyotypically normal genomes spans the region of the t(1;11) breakpoint at 11q14.3. In 
t(1;11) carriers, it is possible that AB371558 and DISC1 fuse, producing both der 1 and der 11 
DISC1/DISC1FP1 chimeric transcripts and that these chimeric transcripts could be detected 
by RT-PCR. Prior to carrying out RT-PCR, sequences of the possible der 1 and 
DISC1/AB371558 and der 11 AB371558/DISC1 chimeric transcripts were generated. 
The putative der 1 DISC1/AB371558 chimeric transcript is encoded by DISC1 exons 1-8 
proximal to the translocation breakpoint which are spliced to exon 3a of AB371558 distal to 
the breakpoint. This gives an in silico predicted ORF encoding DISC1 aa1-597 plus a glycine 
(see figure 3.2.A). The glycine at aa598 is encoded by nucleotides from both DISC1 and 
AB371558. Importantly DISC1 aa598 is also a glycine, although a different codon is used 
(Eykelenboom et al, 2012). Following on from the nomenclature used for CP60 and CP69, 
the putative chimera was named CP1, given this chimeric transcript derives a single amino 
acid as a consequence of the fusion of DISC1 and AB371558. RT-PCR of t(1;11) 
lymphoblastoid cell lines needed to be performed to detect this novel der 1 species, CP1, which 
at the level of amino acid sequence coding is indistinguishable from DISC1 aa1-598. 
 
In silico predictions of the der 11 AB371558/DISC1 transcript, encoded by the splicing of 
AB371558 to exons 1c-2 to DISC1 exons 9-13, show only an internal open reading frame that 
encodes a C-terminus DISC1 fragment as detected by Eykelenboom et al. (2012) (see figure 
3.2.B). As the der 11 product would replicate the RT-PCR results of Jennifer Eykelenboom, 







Figure 3.2.A: Predicted sequence of the der 1 DISC1/AB371558 chimera CP1. 
This is a consequence of splicing of exons 1-8 of DISC1 proximal to the t(1;11) 
to the exons 3a-6 DISC1FP1 EST AB371558 distal to the breakpoint. The 
resulting CP1 transcript encodes the same amino acid sequence as DISC1 up 
to aa1-598 before terminating at a stop codon. Note that aa598 in CP1 and DISC1 
is a glycine, though with different codon usage. For clarity these sequences 
start at aa593 (top line), and show amino acids (middle line), and nucleotides 










Figure 3.2.B: Predicted sequence of the der 11 AB371558/DISC1 chimera. This 
is a consequence of splicing of exons 1c-2 AB371558 proximal to the 
translocation breakpoint, to DISC1 exons 9-13 distal to the breakpoint. This 
transcript only possesses an internal ORF of DISC1 aa669-854 (blue text), and 




3.2.2 Detection of the CP1 transcript by RT-PCR 
RT-PCR was performed on t(1;11) lymphoblastoid cell lines to detect the CP1 transcript. This 
was a similar method to that used by Eykelenboom et al., (2012) to identify the 
DISC1/DISC1FP1 transcripts CP60 and CP69. In the RT-PCR reaction to amplify CP1, the 
forward primer used was complimentary to DISC1 exon 7 and the reverse primer to exon 3a 
of AB371558 (see figure 3.2.C.i).  
A cDNA template from t(1;11) lymphoblastoid cell lines was used to detect a CP1 band, (T). 
No PCR product is detected in the negative control (N) and normal karyotype control (K) (see 
figure 3.2.C.ii). The CP1 chimeric transcript product was verified by sequencing. The region 
of RT-PCR product that was analysed by sequencing spanned the der 1 t(1;11) breakpoint 
region and contains both DISC1 and AB371558 coding sequence and encodes a stop codon 
(see figure 3.2.C.iii). The CP1 transcript encodes the same amino acid sequence as DISC1 
aa1-598. However, the codon usage for aa598, a glycine differs between the two species. CP1 
uses the codon GGT while DISC1 uses GGA. The sequencing results match the in silico 
prediction (see figure 3.2.A). This establishes the existence of a third DISC1/DISC1FP1 
transcript detected in t(1;11) lymphoblastoid cells.  
The chimeric transcript, CP1, is a comparable species to DISC1 aa1-597. The DISC1 aa1-597 
ORF has been expressed in vitro (Brandon et al, 2005; Hattori et al, 2014; Kamiya et al, 2005; 
Millar et al, 2005a; Morris et al, 2003; Ozeki et al, 2003; Pletnikov et al, 2007; Taya et al, 
2007) and in vivo (Hikida et al, 2007; Niwa et al, 2013; Pletnikov et al, 2008) within the field 
of DISC1 research as a potential C-terminal DISC1 truncated protein that may have been 









Figure 3.2.C: Detection of the CP1 transcript in t(1;11) lymphoblastoid cell lines. i): RT-PCR primer location (red arrows). ii): 
Detection of the CP1 transcript by RT-PCR. (T) is a t(1;11) cell line, (N) is a normal karyotype control, (-Ve) is negative control. iii): 




3.3 Detection of exogenously expressed CP60 and CP69 protein by 
Western blot 
 
3.3.1 Exogenously expressed CP60 and CP69 protein is detected in the 
pellet fraction 
In order to exogenously express and characterise CP60 and CP69 proteins, untagged ORFs 
encoding these two species were synthesized in a pcDNA3.1(+) vector backbone by 
GENEART. The untagged CP60 and CP69 constructs were transiently transfected into COS-
7 cells and both the cell lysate and pellet fraction were analysed by Western blot. The blots 
were probed with the antibody, R47, which has an epitope in the N-terminal of DISC1 located 
at aa191-202 (James et al, 2004). The R47 antibody is capable of detecting exogenously 
expressed DISC1 aa1-597 in the cell lysate fraction (Millar et al, 2005b). This is important 
given that the CP60 and CP69 transcripts encode DISC1 aa1-597 plus an additional 60 and 69 
aa from DISC1FP1, respectively. R47, therefore, seems suitable for the detection of these der 
1 chimeric protein species. 
The COS-7 cell lysates were produced using both PBS-Triton and the more potent lysis buffer, 
RIPA, as the optimal lysis buffer to isolate exogenously expressed CP60 and CP69 protein 
was not known. Pre-experimental data suggested that these chimeric proteins could not be 
detected in the lysate with overnight exposures (see annex A2). Probing with the R47 antibody, 
both CP60 and CP69 proteins are only detected in the cell pellet, at a molecular weight of 
~75kDa (see figure 3.3.A) irrespective of the potency of the lysis buffer used. These 
observations are comparable with the predicted molecular weights of CP60 and CP69, 72kDa 
and 73kDa respectively. In contrast, full-length wild-type FLAG-DISC1 was detected in both 
the cell lysate and pellet fractions, at a molecular weight of ~100kDa. This is as expected for 
FLAG-DISC1.  
 
3.3.2 An alternate pellet processing method to detect exogenously 
expressed CP60 and CP69 protein  
An alternative method of processing the cell pellet for Western analysis was carried out. This 
was performed as it was unusual to detect the exogenously expressed CP60 and CP69 protein 
in the cell pellet (see section 3.3.1). It was a possibility that an alternative method of processing 
the cell pellet may have detected other protein species in the cell pellet, or was more efficient 




sonication with an ultrasonic probe to disrupt the cell pellet. A second pellet processing 
method was devised; this involved use of an ultrasonic bath to disrupt the pellet followed by 
repeated cycles of heating and vortexing to solubilise the pellet in PSB. Both pellet processing 
methods were used on RIPA COS-7 cell lysates exogenously expressing either CP60 or CP69. 
The use of the ultrasonic bath pellet processing method on COS-7 cell lysates exogenously 
expressing CP60 and CP69 protein, mirrors the results of an ultrasonic probe processing 
method (see figure 3.3.B). Again CP60 and CP69 proteins are only detected in the pellet 
fraction, at approximately 75kDa irrespective of the processing method used on the COS-7 
pellet fractions. FLAG-DISC1 is detected in both cell lysate and pellet fractions. These results 
are indistinguishable from the previous RIPA or PBS-Triton cell pellet blots detecting 
exogenously expressed CP60 and CP69 (figure 3.3.A). 
 
 
Figure 3.3.A: Detection of CP60 and CP69 protein in the pellet fraction. Western 
blotting detects exogenously expressed untagged CP60 and CP69 protein in 
COS-7 cells in the cell pellet at ~75kDa using the N-terminal DISC1 antibody R47 
(1:1000). In these experiments no CP60 or CP69 protein is detected in the cell 
lysate. This observation is seen with both PBS-triton and RIPA lysis buffers and 
follows the transient transfection (24hr) of untagged pcDNA3.1(+), FLAG-DISC1 
pcDNA3.1(+), CP60 pcDNA3.1(+) and CP69 pcDNA3.1(+) constructs into COS-7 
cells. In comparison to CP60 and CP69, FLAG-DISC1 is seen in both the 






Figure 3.3.B: An alternate pellet processing method to detect exogenous CP60 
and CP69 protein. Western blotting detects exogenously expressed untagged 
CP60 and CP69 protein is COS-7 cells in the cell pellet at ~75kDa using the N-
terminal DISC1 antibody R47 (1:1000). This is following the use of bath 
sonication and probe sonication methodologies to disrupt the cell pellet. 
Detection of the chimeric protein in these two methodologies is highly similar. 
In these experiments, no CP60 or CP69 protein is detected in the cell lysate. In 
comparison, FLAG-DISC1 is seen in both the supernatant and pellet fractions 
at ~100kDa. E.V is the empty vector condition, pcDNA3.1(+). 
 
The exogenously expressed CP60 and CP69 protein is detectable in the pellet fraction with the 
DISC1 N-terminal antibody R47. This contrasts with the DISC1 aa1-597 species, which, when 
exogenously expressed, can be detected in the cell lysate by the R47 antibody (Millar et al, 
2005b). It may be that the additional 60 and 69 novel amino acids from DISC1FP1 interact 
with DISC1 aa1-597 also encoded in the chimeric species, resulting in the detection of CP60 
and CP69 protein in the pellet fraction. The further characterisation of these chimeric protein 
species may reveal potential molecular pathophysiology mechanisms relating to the major 
mental illness seen in the t(1;11) pedigree (Blackwood et al, 2001). A range of chimeric 
constructs were designed for exogenous expression to enable immunocytochemistry and 
biophysical characterisation of CP60 and C69 protein species. This construct generation is 




3.4 Generation of DISC/DISC1FP1 constructs for mammalian expression 
 
3.4.1 Rationale for der 1 DISC1/DISC1FP construct production for 
expression in mammalian cell lines 
To further investigate exogenously expressed DISC1/DISC1FP1 protein, several tagged 
constructs needed to be produced. Tagged CP1, CP60 and CP69 constructs would aid the 
detection of these exogenously expressed species in cell lines in vitro using 
immunofluorescence. Without the addition of peptide or protein tags, the DISC1/DISC1FP1 
species can only be detected by N-terminal DISC1 antibodies such as R47 (James et al, 2004) 
of which there are limited stocks. Therefore, it was decided to use N-terminal FLAG-tags 
(Einhauer & Jungbauer, 2001) upstream of the chimeric ORF in the generation of further 
DISC1/DISC1FP1 constructs. This would enable the expressed FLAG-tagged der 1 species to 
be detected using commercial FLAG antibodies. 
The possibility of endogenous der 1 protein expression in t(1;11) lymphoblastoid cell lines 
also needed to be investigated. In these experiments Western blotting would be used to analyse 
cell lysates and pellets from both t(1;11) lymphoblastoid cell lines and cell lines exogenously 
expressing the extant untagged DISC1/DISC1FP1 species. The resulting protein bands 
detected with N-terminal DISC1 antibodies would then be compared to see if the t(1;11) 
lymphoblastoid cell lysates and pellets provide evidence of endogenously expressed der 1 
chimeric protein (Eykelenboom et al, 2012). An untagged CP1 construct needed to be 
generated for these experiments. This construct would be expressed in parallel with the 
existing untagged CP60 and CP69 constructs. 
A FLAG-tagged DISC1 aa1-597 construct also needed to be generated for use as both a 
control, and to provide comparison with the exogenous expression of CP1. This was required 
because all of the DISC1/DISC1FP1 transcripts partially encode DISC1 aa1-597 
(Eykelenboom et al, 2012), and CP1 encodes DISC1 aa1-598 (see section 3.2.2). At an early 
stage in method development, a pEF1 FLAG-DISC1 aa1-597 construct had been proposed. 
The Elongation Factor-1 Alpha (EF-1 alpha) promoter in the pEF1a vector produces less off-
target lentiviral transduction into neurones (Jakobsson et al, 2003) than the hCMV promoter, 
which is found in pcDNA3.1(+) DISC1/DISC1FP constructs. This was initially seen as a 
means of delivering the der 1 chimeric species to neurone cultures in vitro. The idea was 
abandoned after single pEF1a construct pEF1 FLAG-DISC1 aa1-597 was generated; this will 




As the initial untagged CP60 and CP69 constructs from GENEART were housed in a 
pcDNA3.1(+) vector backbone, it was decided to use this vector to house the additional 
DISC1/DISC1FP1 constructs and controls. Figure 3.4.A shows cartoons of all the constructs 
generated, illustrating tagging, DISC1 and DISC1FP1 components. 
 
3.4.2 DISC1/DISC1FP construct generation for expression in mammalian 
cell lines 
A breakdown of the protocols used for cloning these constructs and their order of 
implementation is detailed in figure 3.4.B. The inserts for both the DISC1/DISC1FP1 
constructs and the DISC1 aa1-597 constructs were produced by PCR (see figure 3.4.Ci-Hi). 
All of these inserts had 5’ EcoR1 and 3’ Not1 restriction sites flanking the ORF, which were 
incorporated into the primer pair design. The addition of FLAG-Tags to ORFs was a 
















Figure 3.4.A: Cartoon depicting der 1 DISC1/DISC1FP and DISC1 aa1-597 
constructs produced for expression in mammalian cell lines. Top to bottom:  
pEF1a-FLAG-DISC1-aa1-597, pcDNA3.1(+)-FLAG-DISC1-aa1-597, untagged 
pcDNA3.1(+)-CP1; pcDNA3.1(+)-FLAG-CP1; pcDNA3.1(+)-FLAG-CP60, 
pcDNA3.1(+)-FLAG-CP69. N-terminal FLAG-tag (red), DISC1 ORF (green), 




















Following amplification of the insert, both vector and insert underwent restriction digestion 
with EcoR1 and Not1 to create sticky ends. The resultant vectors then underwent phenol-
chloroform extraction to remove the by-products of the restriction digests and were then 
concentrated by ethanol precipitation. Prior to ligation, vectors were SAP treated to remove 
phosphates. The vectors and inserts were then ligated, and the ligation products transformed 
into E.coli. The bacteria were then cultured, lysed and plasmid DNA preps produced. The 
putative plasmid DNA was then digested using EcoR1/Not1 restriction digests to isolate the 
insert from the vector, and analysed by gel electrophoresis (see figure 3.4.Cii-Hii). Plasmid 
preparations that released inserts approximate to the predicted size of the ORF in question 
were then sequenced (see figure 3.4.Ciii-iv-Hiii-iv). 
It should be noted that the template for both the untagged and FLAG-tagged CP1 constructs 
was pcDNA 3.1 (+) DISC1. The CP1 transcript itself encodes DISC1 aa1-598. However the 
constructs generated use the codon GGA for the glycine at aa598 as is found in DISC1. The 














Figure 3.4.B: Cloning procedure for generating DISC1/DISC1FP1 constructs for 
expression in mammalian cell lines. The flow diagram shows an approximation 
of the steps taken to generate the following constructs: pEF1α-FLAG-DISC1 
aa1-597, pcDNA3.1(+)-FLAG-DISC1 aa1-597, untagged pcDNA3.1(+)-CP1; 
cDNA3.1(+)-FLAG-CP1; pcDNA3.1(+)-FLAG-CP60, pcDNA3.1(+)-FLAG-CP69. 
PCR amplification of insert with 5’ ECoR1 and 3’NOT1 restriction sites 
EcoR1/Not1 restriction digest of insert and vector to create sticky ends 
Phenol-chloroform extraction of insert and vector 
SAP treatment of vector to remove phosphates 
Ligation of insert to vector and transformation in E. coli and cultured 
Construct DNA prepped, EcoR1/Not1 restriction digest to isolate insert 




















Figure 3.4.C: Creation of the pcDNA3.1(+)-CP1 construct. i) PCR band of EcoR1-DISC1 aa1-598-Not1 product. ii) EcoR1/Not1 restriction digest 
confirming the DISC1 aa1-598 insert (lower band). Linearized vector (upper band). iii) 5’ sequence chromatogram of pcDNA3.1 (+) DISC1 
aa1-598. iv) 3’ sequence chromatogram of pcDNA3.1 (+) DISC1 aa1-598. Chromatogram key: Cloning cassette (pale pink), EcoR1 
site (yellow), Kozak sequence (light grey), Methionine (dark grey), DISC1 ORF (blue), Stop codon (pink), Not1 site (green). 
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Figure 3.4.D: Creation of the pcDNA3.1(+)-FLAG-CP1 construct. i) PCR band of EcoR1-FLAG-DISC1 aa1-598-Not1 product. ii) EcoR1/Not1 
restriction digest confirming the FLAG-DISC1 aa1-598 insert (lower band). Linearized vector (upper band). iii) 5’ sequence chromatogram 
of pcDNA3.1 (+) FLAG-DISC1 aa1-598. iv) 3’ sequence chromatogram of pcDNA3.1 (+) FLAG-DISC1 aa1-598. Chromatogram key: Cloning 
cassette (pale pink), EcoR1 site (yellow), Kozak sequence (light grey), Methionine (dark grey), FLAG-tag (dark blue), DISC1 ORF (blue), Stop 
codon (pink), Not1 site (green). 
  
    iii) 
    iv) 




















Figure 3.4.E: Creation of the pcDNA3.1(+)-FLAG-CP60 construct. i) PCR band of EcoR1-FLAG-CP60-Not1 product. ii) EcoR1/Not1 restriction 
digest confirming the FLAG-CP60 insert (lower band). Linearized vector (upper band). iii) 5’ sequence chromatogram of pcDNA3.1 (+) 
FLAG-CP60. iv) 3’ sequence chromatogram of pcDNA3.1 (+) FLAG-DISC1 CP60. Chromatogram key: Cloning cassette (pale pink), EcoR1 site 
(yellow), Kozak sequence (light grey), Methionine (dark grey), FLAG-tag (dark blue), DISC1 ORF (blue), Stop codon (pink), Not1 site (green). 
  
    iii) 
    iv) 




















Figure 3.4.F: Creation of the pcDNA3.1(+)-FLAG-CP69 construct. i) PCR band of EcoR1-FLAG-CP69-Not1 product. ii) EcoR1/Not1 restriction 
digest confirming the FLAG-CP60 insert (lower band). Linearized vector (upper band). iii) 5’ sequence chromatogram of pcDNA3.1 (+) 
FLAG-C69. iv) 3’ sequence chromatogram of pcDNA3.1 (+) FLAG-DISC1 CP69. Chromatogram key: Cloning cassette (pale pink), EcoR1 site 
(yellow), Kozak sequence (light grey), Methionine (dark grey), FLAG-tag (dark blue), DISC1 ORF (blue), Stop codon (pink), Not1 site (green). 
  
    iii) 
    iv) 




















Figure 3.4.G: Creation of the pEF1α-FLAG-DISC1 aa1-597 construct. i) PCR band of EcoR1-FLAG-DISC1 aa1-597-Not1 product. ii) EcoR1/Not1 
restriction digest confirming the FLAG-DISC1 aa1-597 insert (lower band). Linearized vector (upper band). iii) 5’ sequence chromatogram  
of pEF1a FLAG-DISC1 aa1-597. iv) 3’ sequence chromatogram of pEF1a FLAG-DISC1 aa1-597. Chromatogram key: Cloning cassette (pale 
pink), EcoR1 site (yellow), Kozak sequence (light grey), Methionine (dark grey), FLAG-tag (dark blue), DISC1 ORF (blue), Stop codon (pink), 
Not1 site (green). 
  
    iii) 
    iv) 






















Figure 3.4.H: Creation of the pcDNA3.1(+)-FLAG-DISC1 aa1-597 construct. i) PCR band of EcoR1-FLAG-DISC1 aa1-597-Not1 product. 
ii) EcoR1/Not1 restriction digest confirming the FLAG-DISC1 aa1-597 insert (lower band). Linearized vector (upper band).  
iii) 5’ sequence chromatogram of pcDNA3.1 (+) FLAG-DISC1 aa1-597. iv) 3’ sequence chromatogram of pcDNA3.1 (+) FLAG-DISC1 aa1-
597. Chromatogram key: Cloning cassette (pale pink), EcoR1 site (yellow), Kozak sequence (dark green), Methionine (dark grey), FLAG-tag 
(dark blue), DISC1 ORF (blue), Stop codon (pink), Not1 site (green). 
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    iv) 






As the nucleotide coding in question is synonymous there should be no issue with this 
difference in nucleotide use. In total the der 1 DISC1/DISC1FP constructs for expression in 
mammalian cell lines produced were: untagged pcDNA3.1(+)-CP1, pcDNA3.1(+)-FLAG-
CP1, pcDNA3.1(+)-FLAG-CP60, pcDNA3.1(+)-FLAG-CP69, pEF1α-FLAG-DISC1 aa1-
597,  pcDNA3.1(+)-FLAG-DISC1 aa1-597. 
 
3.5 Generation of der 1 DISC1/DISC1FP constructs for expression in 
E.coli 
 
3.5.1 Production of ΔNCP69 constructs for expression in E.coli 
Exogenously expressed CP60 and CP69 are predominantly located in the pellet fraction. This 
observation suggests that the addition of 60 or 69 novel aa from DISC1FP1 spliced to DISC1 
aa1-597 produces abnormal protein species. A biophysical approach was proposed to 
investigate the possibility of structural changes induced by the extra DISC1FP1 aa’s. An N-
terminal truncated species encoding DISC1 aa326-597 and 69 aa from DISC1FP1, with codon 
usage optimised for bacterial expression was synthesised by GENEART, named 
pENTRΔNCP69. The N-terminal head region is absent as the protein structure there is  
predicted to be highly disordered (Soares et al, 2011) and is believed to be the reason that 
DISC1 is difficult to purify. Only CP69 was chosen as the model for the DISC1/DISC1FP1 
N-terminal truncate as CP60 and CP69 have high sequence homology. 
For bacterial expression, the ΔNCP69 insert needed to be housed in bacterial expression 
vectors that also encoded protein tags to enable affinity purification of expressed protein. The 
ΔNCP69 insert was sub-cloned into four bacterial expression vectors using gateway cloning 
(see figure 3.5.A). Following the gateway cloning, the putative constructs were transformed 
and DNA prepared. PCR was then performed with vector specific primers on the four ΔNCP69 
constructs to confirm construct generation (see figure 3.5.B). PCR was then used to verify that 
the ΔNCP69 insert was in frame and that the insert ORF was error free. This produced 
pDST14-HIS-ΔNCP69; pETG20a-TRX-ΔNCP69; pETG30a-GST-ΔNCP69 and pETG40a-





3.5.2 Production of MBP-ΔN597 construct for expression in E.coli 
To discern the contribution of the novel 69 aa from DISC1FP1 to ΔNCP69 protein 
characteristics, a DISC1 aa326-597 construct for bacterial expression needed to be produced 
(see figure 3.5.A).  Site directed mutagenesis was performed using the pENTRΔNCP69 
construct as a template to insert a double stop codon, TAATAA, after DISC1 aa597. This 
produced a pENTRΔN597 construct with an ORF optimised for bacterial expression that 
encoded DISC1 aa326-597. The choice of double stop codon rather than a single, was a 
precautionary measure to ensure that translation terminated and no ΔNCP69 protein was 
produced (see figure 3.5.C). Initially all four bacterial expression vectors were going to be 
produced and protein expression tests carried out to select the most promising construct/tag 
combination. As the MBP-ΔNCP69 protein proved to produce the largest quantities of purified 
protein, it was decided to only fully sequence the pETG40a-MBP- ΔN597 construct.  
 
 
Figure 3.5.A: Cartoon depicting ΔNCP69 and ΔN597 constructs for bacterial 
expression. Top to bottom: pDST14-HIS-ΔNCP69; pETG20a-TRX-ΔNCP69; 
pETG30a-GST-ΔNCP69; pETG40a-MBP-ΔNCP69 and pETG40a-MBP-ΔN597. 
Dashed vertical line represents cleavage point whereby the protein tag can be 
separated from the protein of interest. Protein tags (red), 6xHis peptide tag 





Figure 3.5.B: Generation of tagged ΔNCP69 and ΔN597 in bacterial expression 
vectors. This is the PCR product using vector specific primers following 
gateway sub-cloning of pENTRΔNCP69 and pENTRΔN597 into tagged 
destination vectors. Top row details tagged insert, bottom row, brackets, is the 
bacterial expression vector.  
 
The PCR product confirming the pETG40a-MBP-ΔN597 construct generation is shown in 
figure 3.5.A. It would have been possible to introduce a double stop codon upstream of the 
aa326 in the MBP-ΔNCP69 construct using site directed mutagenesis, to create expression of 
the MBP tag only. This could have been used to remove the signal associated with the MBP 
protein from the biophysical experiments. 
The biophysical experiments contrasting MBP-ΔNCP69 and MBP-ΔN597 protein were 
carried out by Dinesh Soares and Nicholas Bradshaw (Eykelenboom et al, 2012). This work 
addressed how the additional 69 aa confer altered protein structure over DISC1 aa 1-597. 
Dynamic light scattering indicates that MBP-ΔNCP69 produces protein species of greater size 
than MBP-ΔN597. The MBP-ΔNCP69 species also exhibit a higher melting point than MBP-
ΔN597, indicative of greater stability. Far-UV circular dichroism spectra were ascertained to 
provide insight into the secondary structure of the protein species.  MBP-ΔNCP69 was 
identified as containing 1.4-1.8 more α-helices with a reduced incidence of β-strands than that 
observed for MBP-ΔN597. These results suggest that the addition of a novel 69 aa to DISC1 
aa1-597 results in larger protein assemblies being formed that exhibit increased stability and 






Figure 3.5.C: Generation of pETG40a-MBP-ΔN597. Sequence chromatogram of pETG40a-MBP-ΔN597 depicting the double stop 
codon TAATAA (top), that were introduced by site directed mutagenesis to the donor vector. This is contrasted with the pETG40a-
MBP-ΔNCP69 sequence chromatogram depicting the DISC1 and DISC1FP1 ORF in the same region (bottom). The presence of the 
stop codons in pETG40a-MBP-ΔN597 terminate transcription following DISC1 aa597, resulting in the encoding of the N-terminal 






3.6.1 Relevance of the CP1 transcript to the field 
Canonically, in DISC1 research, DISC1 aa1-597 has been investigated both in vitro (Brandon 
et al, 2005; Hattori et al, 2014; Kamiya et al, 2005; Millar et al, 2005a; Morris et al, 2003; 
Ozeki et al, 2003; Pletnikov et al, 2007; Taya et al, 2007) and in vivo (Hikida et al, 2007; 
Niwa et al, 2013; Pletnikov et al, 2008) as a C-terminal truncated DISC1 species that may 
have been produced as a result of the t(1;11) from the proximal der 1 chromosome, that 
possesses novel pathogenic properties. However, there is no evidence that a DISC1 transcript 
encoding DISC1 aa1-597 exists, although the CP1 transcript, if translated in t(1;11) carriers 
would give a protein that differs from DISC1 aa1-597 by only a single glycine at aa598 
(Eykelenboom et al, 2012). Therefore, a summary of the behavioural and histological evidence 
from the in vivo expression of C-terminal truncated DISC and Disc1 species in transgenic 
models will be covered in the following section in relation to the potential phonotypes that 
could be produced by CP1 if it is expressed in vivo. The high degree of sequence homology 
between DISC1 aa1-597 and the CP1 species, means that the C-terminal truncated 
DISC1/Disc1 models may be informative as to CP1 mechanisms of pathogenesis in vivo as 
they are almost hypothetical CP1 transgenic models.  
 
3.6.2 C-terminal truncated DISC1/Disc1 mouse models may give insight into the 
effects of CP1 protein expression in vivo  
This discussion section summarises the findings of key papers on C-terminal truncated 
DISC1/Disc1 mouse models (see introduction) as a means to see how such models could be 
informative as to what phenotypes would be produced by the expression of an endogenous 
CP1 species in vivo. This is given that the CP1 transcript essentially encodes DISC1 aa1-598 
(Eykelenboom et al, 2012). Assuming that the glycine at aa598 is uncharged and that it makes 
little or no difference to the expressed CP1 protein structure in comparison to DISC1 aa1-597. 
Then, at the very least, CP1 expression in vivo could bare great similarity to the human DISC1 
aa1-597 mice models, ΔhDISC1 (Pletnikov et al, 2008) and DN-DISC1 (Hikida et al, 2007). 
Based on the common functions between these two models, CP1 expression in vivo might be 
expected to produce a histological profile of lateral ventricular enlargement and a reduction in 
parvalbumin-positive interneurones in the PFC as well as behavioural abnormalities in open 
field locomotor activity, a degree of amphetamine hyperactivity and increased forced swim 




Ultimately, in relation to the high incidence of major mental illness in the t(1;11) pedigree 
(Blackwood et al, 2001), some qualification must be made as to how similar to major mental 
illness the phenotype of such a hypothetical endogenous expression of CP1 in vivo would be. 
Regarding the common findings between ΔhDISC1 (Pletnikov et al, 2008) and DN-DISC1 
(Hikida et al, 2007) mice that may feature in such an expression of CP1 in vivo, lateral 
ventricular enlargement is the most common observation in individuals with schizophrenia 
seen in MRI studies (Shenton et al, 2001). The reduction in parvalbumin-positive staining 
interneurones in these mouse models is in line with observed deficiencies in parvalbumin-
positive neuronal sub-populations in individuals with schizophrenia (Lewis et al, 2012; Lewis 
et al, 2005). Therefore, the two common histological findings from the DN-DISC1 (Hikida et 
al, 2007) and ΔhDISC1 (Pletnikov et al, 2008) mice that could possibly be seen with CP1 
expression in vivo can be seen to be schizophrenia-like. The common behavioural observations 
between these models possess a broader spectrum of phenotypes. In the hyperlocomotion in 
the open field, the activity measured is relative to the level of stress the animal is undergoing. 
As such, this test is seen to be a measure of anxiety-like behaviour (Prut & Belzung, 2003). In 
contrast, the use of amphetamines in the open field can be seen to be a model of psychosis-
like behaviour (Robinson & Becker, 1986). However, the FST is not a measure of a 
depression-like behaviour phenotype per se but a screen for sensitivity to antidepressant 
compounds. Therefore, from the ΔhDISC1 (Pletnikov et al, 2008) and DN-DISC1 (Hikida et 
al, 2007) models it can be inferred that the expression of CP1 in vivo could possibly produce 
a schizophrenia/anxiety-like phenotype.  
However, there is a caveat in deriving a possible in vivo CP1 expression phenotype from the 
ΔhDISC1 (Pletnikov et al, 2008) and DN-DISC1 (Hikida et al, 2007) models. Both of these 
transgenic models use a CaMKII promoter and, as such, do not recapitulate endogenous 
expression. The Disc1tr mice though, express truncated Disc1 endogenously from a BAC 
(Shen et al, 2008). Fortunately, this is the most comprehensively histologically phenotyped 
model, and, along with the ΔhDISC1 (Pletnikov et al, 2008) and DN-DISC1 (Hikida et al, 
2007) models, also has the schizophrenia-like morphology of lateral ventricle enlargement and 
a reduction in parvalbumin-positive interneurones. This makes it more likely that the 
endogenous expression of CP1 protein in vivo could produce these aberrations than from the 
evidence of the ΔhDISC1 (Pletnikov et al, 2008) and DN-DISC1 (Hikida et al, 2007) models 
alone. It is possible that the expression of CP1 in vivo could also produce some of the other 




Though included in this discussion, the DN-DISC1/poly I:C (Ibi et al, 2010; Nagai et al, 2011) 
or ΔhDISC1/poly I:C (Abazyan et al, 2010) mouse models may not translate directly to the 
investigation of CP1 in the pathogenesis of mental illness in the t(1;11) family. This is because 
it would seem unlikely that the pedigree have all succumbed to a viral infection around birth. 
However, these models are informative as to the prospect of gene-environment interactions 
and the resulting phenotypical changes over expression of the transgene alone. Conversely, 
the gene-environmental interaction by Niwa et al., (2013) of isolation stress and humanised 
DISC1 aa1-597 expression is perhaps more likely a model to translate to the possibility of CP1 
in vivo expression within the t(1;11) pedigree. It would seem feasible that, in their 
development, members of the t(1;11) pedigree have been exposed to stress as an environmental 
insult. This suggests that CP1 in vivo expression could possibly produce a range of 
dopaminergic dysfunctions, as seen in Niwa et al., (2013), provided the expression was against 
a background of stress within translocation carriers. 
It is possible that in vivo expressed CP1 would affect glia. The exogenous expression of CP1 
could, like that of human DISC1 aa1-597, induce abnormal oligodendrocyte proliferation and 
differentiation (Katsel et al, 2011), albeit with the use of an endogenous, as opposed to a 
CaMKII, promoter. An endogenous CP1 species could also possibly perturb the function of 
serine racemase to synthesise D-serine causing glutamatergic dysfunction in astrocytes, as this 
has been observed for DISC1 aa1-597, expressed under a  GFAP promoter (Ma et al, 2012). 
However, it would be a prerequisite that CP1 in vivo was expressed endogenously in 
astrocytes.   
In summary, it seems possible that the endogenous expression of CP1 in vivo would, at the 
very least, induce a histological phenotype that is schizophrenia-like and would involve the 
features of enlarged lateral ventricles and a reduction in parvalbumin-positive interneurones. 
Such expression of CP1 could likely also include other features that have been identified in 
the ΔhDISC1 (Pletnikov et al, 2008) DN-DISC1 (Hikida et al, 2007) and Disc1tr mice (Shen 
et al, 2008). It is also equally possible that the expression of CP1 in vivo may have an effect 
on the proliferation and differentiation of oligodendrocytes (Katsel et al, 2011) as well as 
glutamatergic function as facilitated by astrocytes (Ma et al, 2012). Lastly, the possibility 
remains that CP1 expression could produce further phenotypic change if expressed in t(1;11) 
carriers against an environmental insult such as stress, which in Niwa et al, (2013) produces a 





3.6.3 Detection of exogenously expressed CP60 and CP69 protein in the 
cell pellet 
It is surprising to find the CP60 and CP69 protein isolated in the pellet fraction. The cell pellet 
typically contains high molecular weight structures including: polymerised microtubules, 
hydrophobic membrane structures and fragmented membranes. This suggests that CP60 and 
CP69 protein may possess novel aberrant properties and warrants further investigation, and 
may be informative to the pathogenesis of major mental illness in the t(1;11) pedigree 
(Blackwood et al, 2001).  
The observation that the exogenously expressed CP60 and CP69 chimeric proteins are isolated 
in the cell pellet is in agreement with two published reports that have emerged in the time since 
these experiments were completed.  Zhou et al, (2010) detected protein in the cell pellet, from 
the expression of the DB7 construct that encodes CP60 in HEK293 cells. Here the chimeric 
protein was tagged with HA at the C-terminus. A repeat of this experiment carried out in both 
HEK293 and COS-7 cells again detected low levels of CP60 protein specifically in the pellet 
fraction (Ji et al, 2014). The expression of CP60 both in vitro and in vivo has been associated 
with a decrease in the reduction of MTT and a reduction in both translation and rRNA levels. 
Furthermore, converging lines of evidence suggest that the CP60 species undergoes 
degradation once expressed (Ji et al, 2014) which may partly explain why CP60 and CP69 are 
only observed in the pellet fraction in the Western blotting in this chapter. 
 
3.6.4 Conclusions from the biophysical characterisation of MBP-ΔNCP69 
MBP-ΔNCP69 produces large stable protein assemblies with a greater proportion of α-helices 
than MBP-ΔN597 (Eykelenboom et al, 2012). The addition of the extra 69 novel aa from 
DISC1FP1 to DISC1 aa326-597 results in the alteration of the structure of aa326-597. It is 
likely that this is also the case for CP60 given the high degree of homology between CP60 and 
CP69. It is possible therefore that CP60 and CP69 protein possess novel properties that differ 
from either the CP1 or DISC1 aa1-597 species due to these biophysical findings. These results 
may also in part explain the isolation of CP60 and CP69 in the pellet as a consequence of 
altered protein structure. 
This chapter has highlighted that CP1, CP60 and CP69 may possess novel properties that could 
result in protein behaviour that differs from that of WT-DISC1. The next chapter will focus 




COS-7 cell lines and primary cortical neuron cultures in order to characterise potential 









Chapter 4 - The detection of overexpressed 
DISC1/DISC1FP chimeric proteins by 
immunofluorescence 
  
4.1 Introduction  
The existence of DISC1/DISC1FP1 chimeric transcripts adds further complexity to the 
mechanism of pathogenesis of mental illness in t(1;11) carriers. Prior to the detection of the 
DISC1/DISC1FP1 transcripts (Eykelenboom et al, 2012), haploinsufficiency of DISC1 was 
proposed as the mechanism of pathogenesis of mental illness in t(1;11) carriers (Millar et al, 
2005b). The discovery of DISC1/DISC1FP1 transcripts raises the possibility of additional 
pathogenic mechanisms. This requires that the DISC1/DISC1FP1 transcripts that have been 
detected are translated into aberrant proteins in t(1;11) carriers. Presently, post-mortem 
neuronal t(1;11) tissue is not available to investigate endogenous expression of 
DISC1/DISC1FP1 chimeric proteins. It is possible, however, to look at the in vitro expression 
of FLAG-tagged: CP1, CP60, and CP69 in both COS-7 cells and primary mouse cortical 
neurones using immunofluorescence. COS-7, a monkey kidney cell line, was initially chosen 
for use in immunocytochemistry specifically due to the large size of these cells. The sizable 
cell body and organelles in COS-7 cells make any changes due to the mis-localisation of 
exogenous proteins readily visible. The use of neurones when investing phenotypes or 
potential pathogenic properties of the proteins pertaining to mental illness was essential, with 
any findings in COS-7 cells hopefully replicating those observed in neurones.  
Previous immunofluorescence experiments to detect exogenously expressed DISC1 have 
shown a predominantly punctate localisation, whereas the expression of exogenous 
DISC1aa1-597 displayed a predominantly diffuse staining pattern (Brandon et al, 2005; Millar 
et al, 2005a; Morris et al, 2003; Ozeki et al, 2003). The CP1 open reading frame is highly 
similar to that of DISC1 aa1-597, differing only by the addition of a glycine at aa598 
(Eykelenboom et al, 2012). It therefore seems reasonable to assume that the localisation of 
expressed CP1 protein will closely resemble that of DISC1 aa1-597 rather than full length 
DISC1, and may likewise produce a diffuse staining pattern. It seems unlikely that the presence 





It is likely that expressed CP60 and CP69 will differ from CP1 expression. This is due to the 
additional 60 and 69 amino acids from DISC1FP following DISC1 aa1-597 in CP60 and CP69, 
respectively. Zhou et al., (2010) expressed the DB7 construct, that corresponds to CP60, in a 
rat neuronal-like cell line and observed a punctate staining pattern, rather than the diffuse 
staining of DISC1 aa1-597, with localisation present in the cytoplasm and neuronal periphery.  
In this chapter, immunofluorescence was utilised as a technique to characterise the expression 
of FLAG-tagged CP1, CP60 and CP69 protein, in both COS-7 cells and mouse primary 
cortical neurones. The characterisation of these exogenously expressed abnormal chimeric 
DISC1/DISC1FP1 proteins may provide additional insight into the pathogenesis of the major 
mental illness seen in t(1;11) carriers. The majority of the immunofluorescence work in this 
chapter is published in Eykelenboom et al., (2012). 
 
4.2 When expressed in COS-7 cells, CP60 and CP69 are targeted to 
mitochondria where they induce extreme dysfunction  
 
4.21 Exogenous CP60 or CP69 localise as perinuclear clusters in COS-7 
cells 
In order to investigate any possible pathophysiological properties of CP60 and CP69, the 
localisation patterns of FLAG-CP60, FLAG-CP69, FLAG-DISC1 aa1-597 and full-length 
FLAG-DISC1 were investigated after overexpression in COS-7 cells. The cells were then 
immunostained with anti-FLAG (M2) antibody in the presence of the mitochondrial dye, 
MitoTracker Red. When stained with anti-FLAG antibody, overexpressed CP60 or CP69 
protein localises as perinuclear clusters (see figure 4.2.A-B). In figure 4.2.A, a-c depict 
increasing levels of CP60 protein expression. Such variation in expression can also be seen for 
CP69 (data not shown). There is no apparent difference in the localisation pattern between 
CP60 and CP69. The clustered localisation pattern of exogenously expressed CP60 or CP69 
differs from the localisation of overexpressed WT-DISC1, which displays a predominantly 
punctate pattern. In contrast DISC1 aa1-597, is diffusely expressed throughout the cytoplasm. 
CP60 and CP69 encode DISC1 aa1-597 fused to 60 or 69 novel aa, respectively, from 
DISC1FP1 (Eykelenboom et al, 2012). The difference in localisation observed from the 
expression of DISC1 aa1-597 versus that of either CP60 or CP69 therefore arises as a 





Figure 4.2.A: Expression of exogenous CP60 and CP69 in COS-7 cells. Immunostaining: FLAG (green) and MitoTracker Red. Lower case a-c 
demarks increasing expression of CP60 protein; asterisks denote expression of CP69 protein. CP60 and CP69 localise as clusters and COS-7 





Figure 4.2.B: Clustered MitoTracker Red staining is evident in a subpopulation of COS-7 cells exogenously expressing CP60 and CP69. 




CP60 and CP69 proteins may have novel properties differing from other DISC1 species 
(Eykelenboom et al, 2012).  
This initial immunofluorescence evidence indicated that exogenously expressed CP60 and 
CP69 proteins localise in a novel manner, as clusters. Additional experiments, using 
qualitative analysis of overexpressed CP60 and CP69 protein in COS-7 cells,  were needed to 
determine how consistently this novel localisation pattern was observed, and indeed if the 
localisation of CP60 and CP69 differed. 
 
4.2.2 Exogenous CP60 or CP69 impair MitoTracker Red uptake 
DISC1 is known to be targeted to the mitochondria (James et al, 2004; Millar et al, 2005a; 
Norkett et al, 2016; Ogawa et al, 2014; Park et al, 2010) and the expression of DISC1 aa1-
597 in COS-7 cells induces the formation of ‘ring’ mitochondria in a sub-population of 
transfected cells (Millar et al, 2005a). It is therefore plausible that the expression of exogenous 
CP60 or CP69 may produce a mitochondrial phenotype detectable by immunofluorescence. 
In the majority of COS-7 cells expressing exogenous CP60 or CP69, the staining of 
mitochondria by MitoTracker Red was absent (see figure 4.2.A). In contrast, cells 
overexpressing WT-DISC1 or DISC 1 aa1-597, MitoTracker Red displayed stained tubular 
mitochondria. However, a sub-population of CP60 and CP69 expressing cells were stained, 
displaying clustered mitochondria (see figure 4.2.B).  
MitoTracker Red is a dye that fluoresces upon entering respiring cells where it is sequestered 
by the mitochondria. The staining of mitochondria by MitoTracker dyes can be influenced by 
both oxidative stress and changes in the mitochondrial membrane potential, Δψm (Buckman 
et al, 2001). The absence of MitoTracker Red staining seen in COS-7 cells expressing CP60 
and CP69 may be due to impairment in the uptake of MitoTracker due to alterations in the 
mitochondrial membrane potential, Δψm. This observation suggests that the expression of 
CP60 and CP69 produces mitochondrial dysfunction. Further investigation using qualitative 
analysis of overexpressed CP60 and CP69 protein in COS-7 cells was needed to determine 





4.2.3 Qualitative analysis of the localisation of expressed exogenous 
CP60 and CP69  
To further characterise the expression pattern of CP60 and CP69 protein, a blinded counting 
paradigm was adopted. Three independent immunofluorescence experiments were performed 
under blinding. Again, these were performed by transfecting FLAG-CP60, FLAG-CP69, 
FLAG-DISC1 aa1-597 and FLAG-WT-DISC1 into COS-7 cells, immunostaining with anti-
FLAG (M2) antibody and then mitochondrial staining with MitoTracker Red 24hrs post- 
transfection. Using fluorescence microscopy, the expression pattern of the anti-FLAG staining 
was tallied as either ‘punctate’, ‘diffuse’ or ‘clustered’. These categories of expression pattern 
represented the observed WT-DISC1, DISC1aa1-597 and CP60 or CP69 protein localisation 
seen previously (see figure 4.2.A-B). In total, the expression pattern of anti-FLAG 
immunostaining of 60 transfected cells was categorized per construct.  
It may be that when a greater population of transfected cells were observed and characterised, 
that the expression pattern of overexpressed CP60 and CP69 protein may have been more 
heterogeneous than initial observations suggested. It was possible that a variety of localisation 
patterns could be present. For example, Brandon et al., (2005), identified three different 
expression patterns for the exogenous expression of WT-DISC1 or DISC1 aa1-597 in HeLa 
cells. The WT-DISC1 expression was primarily observed as punctate but diffusely distributed 
or aggregated staining was also evident, while the DISC1 aa1-597 expression pattern was 
predominantly diffuse with some cells observed to be aggregated or punctate. 
Figure 4.2.C collates the data for fluorescence staining patterns. The predominant expression 
pattern of CP60 and CP69 in COS-7 cells was evident as perinuclear clustering and this 
expression pattern, like those of the other DISC1 species, was highly uniform. The clustered 
phenotype was seen in 99% and 97% of CP60 and CP69 overexpressing cells, respectively. In 
99% of WT-DISC1 overexpressing cells the expression pattern was characterised as punctate. 
Likewise, 99% of DISC1 aa1-597 overexpressing cells were noted as having a diffuse 
cytoplasmic distribution. The predominant WT-DISC1 and DISC1 aa1-597 expression 
patterns observed were similar to previously published qualitative observations (Brandon et 
al, 2005; Millar et al, 2005a). 
The overexpression of CP60 and CP69 protein produces a novel clustered perinuclear cellular 
expression pattern, with no significant difference between CP60 and CP69 localisation 




homology between CP60 and CP69. The perinuclear clustering of exogenously CP60 or CP69 
in vitro may be indicative of a role of these chimeras in the pathogenesis of major mental 
illness in the t(1;11) pedigree.  
 
 
Figure 4.2.C: Qualitative analysis of the expression pattern of 
overexpressed CP60 and CP69 protein in COS-7 cells. CP60 and CP69 
show a clustered expression pattern in COS-7 cells. In contrast the 
predominant expression of WT-DISC1 and DISC1 aa1-597 was 
characterised as punctate, and as being diffusely distributed throughout 
the cytoplasm, respectively. The phenotyping involved blinded counting 
of 60 COS-7 cells per construct. The COS-7 cells were visualized by anti-
FLAG immunostaining. Data are ± SD and from n=3 independent 
experiments.  
 
4.2.4 Qualitative analysis of MitoTracker Red staining in COS-7 cells 
expressing CP60 and CP69 
It was possible to investigate the staining of mitochondria using MitoTracker Red, in COS-7 
cells expressing CP60 and CP69 and using the same data collation/fluorescence paradigm as 




presence or absence of MitoTracker Red staining was noted. Mitochondrial staining and 
mitochondria shape were analysed, appearing tubular or clustered. Tubular staining was 
descriptive of the typical mitochondrial structural organisation observed with the 
overexpression of WT-DISC1 and DISC1 aa1-597 (see figure 4.2.A-B). Clustered 
mitochondrial staining described the structure of mitochondria seen in COS-7 cells expressing 
exogenous CP60 or CP69 when MitoTracker Red staining was visible (see figure 4.2.B). 
Importantly, the absence of mitochondrial staining was also noted.  
Less than 30% of the COS-7 cells expressing exogenous CP60 and CP69 stain with 
MitoTracker Red (see figure 4.2.D). The MitoTracker staining data was analysed with One-
way ANOVA, p=0.0001, followed by paired Bonferroni post-tests. The COS-7 cells 
overexpressing exogenous WT-DISC1 predominantly show punctate staining in combination 
with a tubular mitochondrial morphology and combined, these staining patterns differ 
significantly from the other DISC1 species expressed. Difference in the % of cells exhibiting 
punctate anti-FLAG staining and tubular mitochondria vs cells expressing WT-DISC1, WT-
DISC1 vs DISC1 aa1-597, p<0.001, WT-DISC1 vs CP60, p<0.001, WT-DISC1 vs CP69, 
p<0.001. Similarly, with DISC1 1-597 the diffuse cellular staining along with the detection of 
tubular mitochondria is prominent with DISC1 aa1-597 expression and significantly differs 
from other expressed species. Difference in % of cells exhibiting diffuse DISC1 staining and 
tubular mitochondria vs cells expressing DISC1 aa1-597, DISC1 aa1-597 vs WT-DISC1 vs, 
p<0.001, DISC1 aa1-597 vs CP60, p<0.001, DISC1 aa1-597 vs CP69, p<0.001. The principal 
effect of CP60 and CP60 exogenous expression is clustered cellular staining coupled with 
clustered MitoTracker staining, although as noted previously the latter is frequently absent. 
The staining that is evident differs significantly from that of WT-DISC1 and DISC1 aa1-597. 
Interestingly the staining pattern differs significantly between CP60 and CP69, CP69 is 
observed to show greater mitochondrial staining (see figure 4.2D).  Difference in the % of 
cells exhibiting clustered DISC1 staining and clustered mitochondria vs cells expressing CP60 
or CP69, WT-DISC1 vs CP60, p<0.001, CP60 vs DISC1 aa1-597, p<0.001, CP60 vs CP69, 
p<0.001, CP69 vs WT-DISC1, p<0.001, CP69 vs DISC1 aa1-597, p<0.001.In summary the 
overexpression of CP60 or CP69 in COS-7 impairs mitochondrial staining with MitoTracker 
Red. The mitochondria that do stain are clustered, and differ from the tubular mitochondria 
seen in COS-7 cells expressing exogenous WT-DISC1 and DISC1 aa1-597. The clustered 
mitochondria may possess novel pathophysiological properties. Alterations in mitochondrial 




(Benard & Rossignol, 2008). Given this link between mitochondrial structure to function, the 
bioenergetics of clustered mitochondria may differ from tubular mitochondria. 
 
 
Figure 4.2.D: Qualitative analysis of MitoTracker Red staining of mitochondria 
in COS-7 cells expressing exogenous CP60 and CP69.  The mitochondria of 
COS-7 cells expressing exogenous CP60 and CP69 frequently do not show 
MitoTracker Red staining. When staining is present in cells expressing CP60 
and CP69, mitochondria appear fragmented. One-way ANOVA, p=0.0001, paired 
Bonferroni post-tests: difference in % of cells exhibiting punctate anti-FLAG 
staining and tubular mitochondria vs cells expressing WT-DISC1, WT-DISC1 vs 
DISC1 aa1-597, p<0.001 (***), WT-DISC1 vs CP60, p<0.001, WT-DISC1 vs CP69, 
p<0.001. Difference in % of cells exhibiting diffuse DISC1 staining and tubular 
mitochondria vs cells expressing DISC1 aa1-597, DISC1 aa1-597 vs WT-DISC1 
vs, p<0.001, DISC1 aa1-597 vs CP60, p<0.001, DISC1 aa1-597  vs CP69, p<0.001. 
Difference in % of cells exhibiting clustered DISC1 staining and clustered 
mitochondria vs cells expressing CP60 or CP69, WT-DISC1 vs CP60, p<0.001, 
CP60 vs DISC1 aa1-597 , p<0.001, CP60 vs CP69, p<0.001, CP69 vs WT-DISC1, 
p<0.001, CP69 vs DISC1 aa1-597, p<0.001. The mitochondrial staining of 60 anti-





The large pool of COS-7 cells overexpressing CP60 and CP69 that do not stain with 
MitoTracker Red needed to be visualised. The existence of mitochondrial structures had to be 
verified by some other means. An alternative mitochondrial dye or immunostaining targeted 
to mitochondrial protein were two possibilities. If this was carried out in conjunction with 
MitoTracker Red staining, mitochondria that did not stain could be visualised alongside those 
that take up MitoTracker.  
 
4.3 Expression of CP1 in COS-7 cells 
 
4.3.1 Expression of pcDNA DISC1 aa1-597 in COS-7 cells 
The initial immunofluorescence expression and characterisation of CP60 and CP69 was 
performed comparing the expression pattern of a FLAG-DISC1 aa1-597 construct with a 
pEF1a backbone (see figures 4.2.A-D). However, the other constructs: FLAG-WT-DISC1; 
FLAG-CP60; FLAG-CP69, used in these experiments had a pcDNA3.1(+) backbone. At the 
time the initial FLAG-CP1 expression experiments where to be performed, a FLAG-tagged 
DISC1 aa1-597 construct was produced that had been cloned into a pcDNA3.1(+) backbone. 
There is no apparent difference between the pEF1a or pcDNA3.1(+) FLAG DISC1 aa1-597 
cellular expression or mitochondrial morphology seen in transfected COS-7 cells as visualised 
by anti-FLAG and MitoTracker Red immunofluorescence (see figure 4.3.A). Both constructs 
express diffusely throughout the cytoplasm and show tubular mitochondria. The diffuse 
cytoplasmic staining of expressed DISC1 aa1-597 in COS-7 cells mirrors previous research 
(Brandon et al, 2005; Kamiya et al, 2005; Millar et al, 2005a). The use of the pcDNA3.1(+) 
vector for FLAG-DISC1 aa1-597 expression, seemed prudent given that FLAG-CP1 also 
possessed  a pcDNA3.1(+) vector backbone. 
 
4.3.2 Expressed CP1 is indistinguishable from DISC1 aa1-597 in COS-7 
cells 
The CP1 open reading frame differs from that of DISC1 aa1-597 only by the coding of a single 
aa, a glycine at position 598 (Eykelenboom et al, 2012). Amino acid 598 in the translated 
DISC1 open reading frame is also a glycine. Therefore, CP1 is essentially DISC1 aa1-598. 




           
Figure 4.3.A: Expression of exogenous FLAG-tagged DISC1 aa1-597 in pcDNA 3.1(+) (pc) and pEF1a (pEF) vectors; and FLAG-tagged CP1 in 




overexpression of DISC1 aa1-597. It was predicted, given that the overexpressed proteins only 
differ by a single glycine, that the observed staining would be extremely similar.  
The exogenous expression of CP1 in COS-7 cells, produces diffuse cytoplasmic anti-FLAG 
staining and the mitochondria stain with MitoTracker Red, appearing tubular (see figure 
4.3.A). These observations are indistinguishable from both the anti-FLAG and mitochondrial 
staining seen in COS-7 cells overexpressing DISC1 aa1-597. This is not surprising, given the 
extremely high degree of sequence homology between the two species. Importantly, the CP1 
expression differs from the other two DISC1/DISC1FP1 chimeras, CP60 and CP69, which 
show clustered anti-FLAG staining and frequently inhibit MitoTracker dye uptake (see figure 
4.2.A). The differences in CP1 and CP60 and CP69 protein expression patterns may be 
indicative of alternate and independent molecular mechanisms of pathogenesis. This initial 
immunofluorescence needed to be followed up with the expression of all three der 1 
DISC1/DISC1FP1 chimaeras utilising multiple mitochondrial markers. 
 
4.4 Expression of CP1, CP60 and CP69 in COS-7 cells with multiple 
mitochondrial markers 
 
4.4.1 Optimization of mitochondrial antibodies for a triple staining 
immunofluorescence protocol in COS-7 cells 
To further investigate the mitochondrial phenotype seen in COS-7 cells expressing CP60 or 
CP69, double immunofluorescence staining was conducted using anti-Flag in conjunction with 
either MitoTracker Red or the mitochondrial targeted antibodies, anti-CVα or anti-cytochrome 
c. This was an optimisation protocol before conducting a triple staining immunofluorescence 
experiments with anti-FLAG, MitoTracker Red and CVα or cytochrome c staining. The aim 
was to visualise the mitochondria that could not otherwise be seen with MitoTracker Red in 
cells transfected with CP60 or CP69. 
Mitochondrial Complex V-alpha Subunit (CVα) is a subunit of ATP synthase and is located 
within the inner portion of the mitochondrial membrane (Nakamoto et al, 2008). Given the 
location of CVα protein, anti-CVα staining should give a gross visualization of mitochondrial 
structure. Cytochrome c is a mitochondrial protein, located in the inter membrane space, that 
effluxes from mitochondria in cells undergoing apoptosis (Liu et al, 1996; Yang et al, 1997). 




efflux of cytochrome c from a population of cells overexpressing CP60 or CP69, then this 
could possibly be an indicator of apoptosis occurring as a consequence of aberrant protein 
expression. 
The overexpression of CP60 or CP69 impairs mitochondrial staining with the dye MitoTracker 
Red (see figure 4.4.A). However, the mitochondria in cells overexpressing CP60 or CP69 can 
be alternately visualised with antibodies to CVα or cytochrome c (see figures 4.4.B and 4.4.C 
respectively). These mitochondria appear clustered, similar in shape to the CP60 and CP69 
anti-FLAG expression pattern. Comparing the CVα and cytochrome c stained images, it does 
not appear that CP60 or CP69 expression causes efflux of cytochrome c from the 
mitochondria. It was suspected that the CP60 and CP69 expressing cells may be prone to 
apoptosis. Two observations suggested that apoptosis may be occurring, firstly the 
mitochondrial membrane potential, Δψm had collapsed in many cells,  which is associated 
with apoptosis (Ly et al, 2003). Secondly, the mitochondrial clustering that is evident bears 
resemblance to the fission prompted fragmentation of the mitochondrial network that occurs 
in apoptosis (Martinou & Youle, 2011). A possible interpretation of the absence of cytochrome 
c efflux may indicate that the COS-7 cells overexpressing CP60 and CP69 are undergoing a 
pathology that is independent of apoptosis, or that precedes apoptosis. For example, an 
alternative to apoptosis occurring may be mitophagy mediated by the PTEN-induced Kinase 
1 (PINK1)-parkin pathway, this mechanism targets depolarised mitochondria and results in 
the promotion of fission within the mitochondrial network (Gomes & Scorrano, 2013; Van 
Laar & Berman, 2013). These are optimisation experiments and are not intended to correlate 
the mitochondrial dysfunction evident by impaired MitoTracker staining with staining from 
antibodies targeted to the mitochondria. This is the aim of the triple staining 
immunofluorescence experiment with multiple mitochondrial markers.  
The observations show that the population of mitochondria in cells overexpressing CP60 and 
CP69 can be visualised and show a clustered morphology when stained with anti-CVα and 
anti-cytochrome c (see figures 4.4.B and 4.4.C, respectively). This enabled the development 
of a triple staining immunofluorescence paradigm, that would use anti-FLAG, MitoTracker 
Red and either anti-CVα and anti-cytochrome c, to visualise the mitochondria in COS-7 cells 







Figure 4.4.A: Optimisation for triple staining with multiple mitochondrial markers I: MitoTracker Red staining. Expression of exogenous FLAG-
tagged CP1, CP60, and CP69 in COS-7 cells. Immunostaining: FLAG (green); mitochondrial detection, MitoTracker Red. Asterisks indicate cells 






Figure 4.4.B: Optimisation for triple staining with multiple mitochondrial markers II: anti-CVα staining. Expression of exogenous FLAG-tagged 
CP1, CP60, and CP69 in COS-7 cells. Immunostaining: FLAG (green); mitochondrial detection, anti-CVα (red). Asterisks indicate cells 





Figure 4.4.C: Optimisation for triple staining with multiple mitochondrial markers III: anti-cytochrome c staining. Expression of exogenous 
FLAG-tagged CP1, CP60, and CP69 in COS-7 cells. Immunostaining: FLAG (green); mitochondrial detection, anti-cytochrome c, CYT C, (red). 




4.4.2 Expression of exogenous der 1 DISC1/DISC1FP1 chimeras in COS-
7 cells visualised with multiple mitochondrial markers 
The triple staining immunofluorescence protocol was designed to investigate the cellular 
expression and mitochondrial morphology of CP1, CP60 and CP69. This involved staining 
with anti-FLAG, MitoTracker Red and an antibody targeted to the mitochondrial protein, 
either anti-cytochrome c or anti-CVα.  
In terms of cellular expression pattern and mitochondrial structure, CP1 and DISC1 aa1-597 
display very similar behaviour, while CP60 and CP69 are also similar to one another (see 
figures 4.4.D and 4.4.E). As previously seen, the mitochondria in the majority of cells 
expressing CP60 or CP69 do not stain with MitoTracker Red. However, the co-staining with 
anti-cytochrome c or anti-CVα visualises these mitochondria. The perturbation of MitoTracker 
dye uptake appears to be dose dependent. The COS-7 Cells labelled a-c in figure 4.4.E show 
that the increase in both CP60 and CP69 protein expression is accompanied by a decrease in 
observed MitoTracker Red staining. The reduction or absence of MitoTracker staining is most 
likely indicative of a detrimental alteration to the mitochondrial membrane potential, Δψm, 
which MitoTracker Red dye activity is sensitive to (Buckman et al, 2001) with increasing 
doses of CP60 or CP69 correlating with greater mitochondrial dysfunction. These abnormal 
clustered mitochondria are likely to have altered biogenetic properties. It seems unlikely 
though that the mitochondrial dysfunction is part of an apoptotic process, given that the there 
is no evidence of an efflux of cytochrome c from the mitochondria. The visualisation of 
cytochrome c in the cytoplasm may be observed by immunocytochemistry following the 
promotion of apoptosis (Lagna et al, 2006). However, here the anti-cytochrome c and anti-





Figure 4.4.D: Expression of exogenous FLAG-tagged CP1, CP60, and CP69 in COS-7 cells with multiple mitochondrial markers I. 




                
Figure 4.4.E: Expression of exogenous FLAG-tagged CP1, CP60, and CP69 in COS-7 cells with multiple mitochondrial markers II. 
Immunostaining: FLAG (green); mitochondrial detection, MitoTracker Red and anti-cytochrome c (pink). Scale bar represents 20μM. Text a-c 




4.4.3 Initial Expression of exogenous of DISC1/DISC1FP1 chimeras in 
primary mouse cortical neurones  
To investigate the potential role for the DISC1/DISC1FP1 chimeras in major mental illness, it 
was necessary that CP1, CP60, and CP69 were expressed in a more relevant disease 
model/culture system, primary cultured neurones. It seemed likely CP1 would express in 
neurones in a similar way to DISC1 aa1-597 given the high similarity between the two species, 
and previous observations from COS-7 cells (see figure 4.3.A). DISC1 aa1-597 has been 
overexpressed in human NT2N neurones (Morris et al, 2003) and primary mouse cortical 
neurones (Brandon et al, 2005) and is observed to be diffusely distributed throughout the 
cytoplasm. A construct that encodes CP60 has been overexpressed in a rat neuronal-like cell 
line HCN-B27. The expression pattern is described as appearing punctate and is visible 
throughout cytoplasm and neuronal processes (Zhou et al, 2010). A more clustered staining 
pattern is seen in primary neurones from the DISC1-Boymaw mouse which expresses CP60 
(Ji et al, 2014). Given the previous observations of both CP60 and CP69 expression in COS-
7 cells, and the great degree of sequence homology between the two chimeras, it seemed likely 
that the expression of these two species would be indistinguishable from one another. 
The DISC1/DISC1FP1 chimeras were overexpressed in C57BL/6 mouse primary cortical 
neurones at 11 days in vitro (see figure 4.4.F). The chimeric proteins were visualised with the 
same dual staining paradigm as had been used for the initial COS-7 based experiments. Anti-
FLAG detection was used to visualise chimeric protein localisation and MitoTracker Red to 
stain mitochondrial structures and visualised with fluorescence microscopy. The 
overexpressed CP60 and CP69 cellular expression pattern were indistinguishable from one 
another and were similar to those seen by Ji et al., (2014) when expressing CP60 from the 
DB7 gene in primary neurones from the DISC1-Boymaw mouse model. It should be noted 
that the Ji et al., (2014) paper came out after these experiments were completed and published. 
The clustered anti-FLAG staining localises predominantly to the cell soma, with little 
expression in peripheral neuronal processes. Importantly, there is evidence of mitochondrial 
dysfunction as indicated by the frequent absence of MitoTracker Red staining in the cell soma. 
The CP1 anti-FLAG staining appears diffuse throughout the cell soma and larger processes, 
with MitoTracker Red staining observed in the same regions. In this experiment, the DISC1 
aa1-597 and the WT-DISC1 fluorescence for both anti-FLAG and MitoTracker Red are 





 Figure 4.4.F: Expression of exogenous FLAG-tagged CP1, CP60, and CP69 in cultured 
C57BL/6 primary mouse cortical neurones (11 DIV). Immunostaining: FLAG (green); 
mitochondrial detection, MitoTracker Red. Asterisks indicate cells transfected with 
CP60 or CP69. Scale bar represents 10μM. In this experiment all of the neuronal culture, 






4.4.4 Expression of exogenous of der 1 DISC1/DISC1FP1 chimeras in 
primary cultured neurones visualised with multiple mitochondrial 
markers 
To further investigate the mitochondria in primary cortical neurones overexpressing CP1, 
CP60 or CP69, the mitochondrial structure needed to be visualised by a means other than 
MitoTracker Red, which was frequently absent in cells overexpressing CP60 and CP69. This 
was achieved by using the triple staining paradigm that had been initially carried out on COS-
7 cells (see figures 4.4.D and 4.4.E). The triple staining involved anti-FLAG and MitoTracker 
Red staining in the presence an antibody targeted to mitochondrial protein, either cytochrome 
c or CVα, and was visualised with confocal microscopy.  
The der 1 DISC1/DISC1FP1 chimeras were overexpressed in CD1 primary cortical neurones 
at five days in vitro (see figures 4.4.G and 4.4.H). Of primary importance in these two 
experiments was that the mitochondria in neurones overexpressing CP60 or CP69 that do not 
stain with MitoTracker Red can be seen when they are co-stained with either anti-cytochrome 
c or anti-CVα. These mitochondria appear clustered, co-localising with the clustered anti-
FLAG staining in the CP60 or CP69 overexpressing cells. The anti-FLAG staining itself is 
largely confined to the soma with little peripheral staining evident. This indicates that the 
degree of mitochondrial dysfunction, initially observed in COS-7 cells, is also fully apparent 
in primary cortical neurones when either CP60 or CP69 are overexpressed.  
In the CD1 neurones, the WT-DISC1 overexpression staining appears punctate with 
mitochondria in the soma and large processes. The CP1 overexpression staining is diffuse 
throughout the cell body with similar peripheral mitochondrial staining to WT-DISC1. The 
DISC1 aa1-597 staining pattern is highly similar to that seen for the overexpression of CP1. 
The immunofluorescence co-staining for either cytochrome c or CVα does not substantially 
differ in the pattern of mitochondrial protein visualised for any of the der 1 DISC1/DISC1FP1 
chimeric overexpressed proteins. This would suggest apoptosis by way of the intrinsic 
apoptotic pathway (Elmore, 2007), whereby cytochrome c effluxes from the mitochondria, 
does not occur in any of the DISC1/DISC1FP1 overexpressing neurones.  Alternatively it may 
be that the apoptotic process occurring is not advanced enough to be detectable. This 
observation is particularly important with regard to neurones overexpressing either CP60 or 
















Figure 4.4.G: Expression of exogenous FLAG-tagged CP1, CP60, and CP69 in cultured CD1 primary mouse cortical neurones (5 DIV) with 
multiple mitochondrial markers I. Immunostaining: FLAG (green); mitochondrial detection, MitoTracker Red and anti-CVα (pink). Asterisks 
indicate cells transfected with CP60 or CP69. Scale bar represents 10μM. In this experiment, all of the neuronal culture and transfections were 




                               
Figure 4.4.H: Expression of exogenous FLAG-tagged CP1, CP60, and CP69 in cultured CD1 primary mouse cortical neurones (5DIV) with 
multiple mitochondrial markers II. Immunostaining: FLAG (green); mitochondrial detection, MitoTracker Red and anti-cytochrome c (pink). 
Asterisks indicate cells transfected with CP60 or CP69. Scale bar represents 10μM. In this experiment, all of the neuronal culture and 




The 129S6/SvEv mouse line carries a mutation that results in both a frame shift and the 
premature termination of Disc1 open reading frame (Koike et al, 2006). This results in a 
truncated abnormal DISC1 protein species being produced.  The use here of both CD1 and 
C57BL/6 primary cultures that produce converging results, eliminates any concern arising 
from the use of the CD1 mouse line for immunofluorescence some of which may contain the 
same mutation as 129S6/SvEv mice.  
The observations from the immunofluorescence on the overexpression of CP1, CP60 or CP69 
in primary cortical neurones co-stained for multiple mitochondrial markers mirror the 
conclusions from the COS-7 immunofluorescence. CP1 expression is markedly similar to 
DISC1aa1-597, localising diffusely throughout the cytoplasm. This is unsurprising given the 
sequence homology between the two species. The overexpression of CP60 and CP69 protein 
showed a perinuclear clustered expression pattern that co-localises with clustered 
mitochondria. These clustered mitochondria have altered membrane potentials as evidenced 
by an inability to take up the mitochondrial dye, MitoTracker Red. This represents a novel 
molecular pathogenic mechanism. Taken together, the results suggest that, if the 
DISC1/DISC1FP1 chimeric protein is expressed in t(1;11) carriers, they could contribute to 
major mental illness via multiple pathogenic mechanisms.  
 
4.5 Discussion  
 
4.5.1 CP1 protein expression  
The CP1 immunofluorescence staining is extremely similar to that of DISC1 aa1-597. This is 
unsurprising given the open reading frame for CP1 differs from DISC1 aa1-597 by a single 
glycine at position 598 (Eykelenboom et al, 2012). CP1 is C-terminal truncated DISC1 aa1-
598. As a truncated species, CP1 will lack DISC1 aa599-854 for protein binding. Looking at 
important DISC1 interactors, DISC1 aa1-597 is capable of binding PDE4B (Millar et al, 
2005b), although a further PDE4B binding site is present in DISC1 aa611-650 (Murdoch et 
al, 2007). This may give CP1 altered PDE4 interaction properties compared to DISC1. 
However, the DISC1 novel variant, DISC1 LΔ78T9, which possesses a slightly longer ORF 
than CP1, shows only very weak binding to PDE4B (Newburn et al, 2011). DISC1 has been 
shown to bind to and inhibit GSK3β (Mao et al, 2009) and an exogenously expressed short 
DISC1 splice variant, encoding DISC1 aa1-347 alone, is capable of binding GSK3β (Newburn 




However, a direct NudE Neurodevelopment Protein 1 (NDEL1)/NUDEL and CP1 interaction 
would not occur, as NDEL1/NUDEL requires DISC1 aa727-845 to bind (Soares et al, 2011).  
Prior to the detection of the  chimeric transcripts in t(1;11) patient lymphoblastoid cell lines 
(Eykelenboom et al, 2012), DISC1 aa1-597 was examined in many laboratories as a novel 
species that could possibly be derived from the proximal der1 translocated chromosome 1 in 
t(1;11) carriers.  A comparison of in vivo DISC1 aa1-597 expression in mouse models and the 
possible consequences of CP1 expression in vivo is summarised in chapter 3 (see section 
3.6.2). Furthermore, a number of putative pathogenic mechanisms resulting from CP1 
exogenous expression in vitro may be proposed based on the high degree of homology shared 
with DISC1 aa1-597 and the established research on this species (see chapter 1). CP1 is 
therefore likely capable of redistributing DISC1 to a diffuse cytoplasmic expression pattern 
(Kamiya et al, 2005). This dominant-negative mechanism would be mediated by a self-
association domain at DISC1 aa403-504. CP1 exogenous expression may also induce 
mitochondrial pathology distinct from that of CP60 and CP69. Firstly CP1 overexpression 
could result in morphological alterations to mitochondria, inducing the formation of ‘ring’ or 
lariat shaped mitochondria in a subpopulation of transfected cells (Millar et al, 2005a). 
Secondly the expression of CP1 could possibly perturb mitochondrial bioenergetics, 
potentially reducing both cellular ATP and NADPH dehydrogenase (complex 1) levels. It is 
also likely that CP1 expression could impair both neurite outgrowth in PC12 cells (Ozeki et 
al, 2003; Pletnikov et al, 2007) and axonal elongation in hippocampal cultures (Taya et al, 
2007). The expression of CP1 in oligodendrocytes would likely result in the promotion of 
differentiation which is converse to the action of DISC1 expression which negatively regulates 
oligodendrocyte differentiation (Hattori et al, 2014). 
 
4.5.2 CP60 and CP69 protein expression 
CP60 and CP69 are indistinguishable when overexpressed and visualised by 
immunofluorescence in both COS-7 cells and mouse primary cortical neurones. The clustered 
expression pattern for these chimeric species bares similarity to the findings of a study that has 
emerged since the work in this thesis was completed and published. Ji et al., (2014) observed 
a clustered CP60 staining pattern with the exogenous expression of the DB7 construct in 
primary neurone cultures. The clustered expressed protein localisation and the induction of 
putative pathogenic mechanisms of mitochondrial dysfunction of CP60 and CP69 are distinct 
from the mitochondrial morphology and expression patterns of overexpressed WT- DISC1, 




Proteomics has been used to ascertain differences between DISC1 aa1-597 and CP69 protein. 
This approach used the expression of N-terminally truncated proteins MBP-ΔN597 and MBP-
ΔNCP69 (Eykelenboom et al, 2012), as the N-terminus of DISC1 is disordered and difficult 
to express in vitro and purify in sufficient quantities for biophysical analysis (Soares et al, 
2011). The MBP-ΔNCP69 protein had altered structure and formed larger protein assemblies 
that exhibited greater thermal stability than the MBP-ΔN597 protein (Eykelenboom et al, 
2012). This indicates that the additional protein structure from the 69 novel aa from DISC1FP1 
alters the interaction with DISC1 aa326-597 differently to that seen with MBP-ΔN597 protein 
alone. The observations from MBP-ΔNCP69 expression translate to CP60, given the high 
degree of sequence homology between CP60 and CP69. Furthermore, the production of large 
protein assemblies and alterations to the secondary structure seen due to the novel DISC1FP1 
aa’s present in MBP-ΔNCP69 (Eykelenboom et al, 2012) may be evidence of the biophysical 
alterations that contribute to the abnormal CP60 and CP69 clustered protein expression pattern 
with overexpression. An interpretation of the ‘clustering’ phenomenon observed in the 
immunocytochemistry is that that the large protein assemblies and secondary structure 
alterations occur to such an extent so as to promote the formation of CP60 and CP69 
aggregates. However, further biochemical testing is needed for definitive conformation of 
aggregation. DISC1 aggregation has been associated with a reduction in the number of 
mitochondria being transported within the neurone, suggesting that aggregation impacts on the 
regulation of mitochondrial transport (Atkin et al, 2012). Furthermore, aberrant DISC1 
detergent insoluble protein aggregates have been detected in post mortem brain tissue from 
subjects diagnosed with depression, bipolar disorder and schizophrenia (Leliveld et al, 2008; 
Leliveld et al, 2009). 
That the expressed CP60 and CP69 protein is indeed clustered or aggregated per se is open to 
interpretation. It is possible that the apparent clustered localisation is an artefact of these 
species being transported along with the mitochondria in a defective manner, given that DISC1 
could be trafficked with mitochondria as it is associates with components of the mitochondrial 
trafficking machinery (Ogawa et al, 2014). Alternatively, in line with the biophysical data 
(Eykelenboom et al, 2012) large protein assemblies of CP60 and CP69 could potentially bind 
to the outside of the mitochondria, where DISC1 has been observed to complex with Miro1 
and TRAK1 (Ogawa et al, 2014), where these chimeric species may form clusters or 
aggregates.  To be able to suggest that  the aberrant CP60 and CP69 protein formed  aggregates 
would require evidence these species may be involved in aggresomal pathways as occurs with 




the exogenously expressed CP60 and CP69 protein to establish their specific cellular and 
molecular properties as a putative mechanism of pathogenesis in the t(1;11) pedigree, aside 
from the observed effects in promoting mitochondrial dysfunction.  
In light of the aberrant protein produced from CP60 and CP69 exogenous expression, future 
work could look at whether these species show enhanced binding to overexpressed DISC1, via 
its self-association regions, by co-immunoprecipitation. This could be performed by co-
expressing FLAG tagged CP60 or CP69 with Myc or HA-tagged DISC1. The relative co-
immunoprecipitation of mutant and wild-type DISC1 would be detected by Western blotting 
combined with densitometry analysis. The biophysical data indicate that the CP60 and CP69 
proteins may exhibit increased self-association (Eykelenboom et al, 2012). It is possible that 
this would extend to altered binding to full-length DISC1. Immunofluorescence could be used 
in parallel, to look at chimeric protein co-expression with wild-type DISC1. This work would 
be a precursor to investigating how DISC1 binding partners are affected by the potential 
protein clustering or aggregation that may be induced by CP60 and CP69 overexpression. It 
would also be of interest to see how comparable the interactions with DISC1 binding partners 
are between CP60, CP69 and CP1. This would both possibly discover novel putative 
pathogenic mechanisms and build on the protein structural findings.  
The CP60 and CP69 protein is targeted to the mitochondria within cells. Structurally, the 
mitochondria appear clustered, co-localising with the overexpressed CP60 and CP69 protein. 
Targeting to mitochondria and the alteration of mitochondrial morphology has been observed 
with several other DISC species in vitro. The addition of GFP-tags to full length DISC1 
induces mitochondrial targeting, while the expression of DISC1 aa1-597 can produce ‘ring’ or 
lariat shaped mitochondria (Millar et al, 2005a). A DISC1 missense mutation has been 
identified that alters mitochondrial morphology. R37W is an ultra-rare DISC1 mutation 
identified in one individual of a cohort of individuals diagnosed with schizophrenia (Song et 
al, 2008). The DISC1 R37W mutation has also been observed in members of a Scottish family, 
two of whom suffered major depressive disorder and one that suffered from generalised 
anxiety disorder (Thomson et al, 2014). The expression DISC1-37W induces mitochondrial 
clustering (Ogawa et al, 2014). The novel protein species resulting from CP60 and CP69 
exogenous expression may alter some of the protein interactions that occur between the 
encoded DISC1 aa1-597 of these proteins and mitochondria, and/or intermediary species. 
DISC1 has been shown to interact with the mitochondrial protein, mitofilin (Park et al., 2010). 
Mitofilin is important in cristae morphology (John et al, 2005). DISC1 stabilises mitofilin, 




DISC1, analogous to the DISC1 aa1-597 sequence, is sufficient to bind with mitofilin and 
impairs mitochondrial bioenergetic function. The interaction between mitofilin and mouse 
DISC1 occurs inside the mitochondria (Park et al, 2010). DISC1 has been shown to associate 
with the mitochondrial transport machinery on the outside of the mitochondria (Ogawa et al, 
2014). It seems likely that CP60 and CP69 would also maintain such associations given both 
these species encode the motif required for interacting with TRAK1, the adaptor protein 
around which mitochondrial trafficking complexes are built. The possibility therefore exists 
for CP60 and CP69 to localise both inside the mitochondria potentially perturbing bioenergetic 
processes, and to affect trafficking mechanisms on the outside of the mitochondria.    
Functionally, the mitochondria show a dose dependent alteration to the mitochondrial 
membrane potential, Δψm, which is demonstrated by the impairment in the uptake of the 
fluorescent mitochondrial dye, MitoTracker Red.  The labelling of cultured neurones by 
MitoTracker Red can be impaired by the application of the metabolic inhibitor Carbonyl 
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), which depolarises the mitochondrial 
membrane potential, Δψm (Buckman et al, 2001). The mitochondrial clustering induced by 
CP60 and CP69 expression may be mechanistically associated with the alteration in membrane 
potential, Δψm. However, it should be noted that the fragmentation of mitochondria has been 
associated with abolished, increased, or unchanged mitochondrial membrane potential, Δψm, 
following experimental manipulation (Benard & Rossignol, 2008). Functionally, the 
mitochondrial membrane potential, Δψm has been associated with direction of neuronal 
transport. In neurones, mitochondria with high membrane potential predominantly travel in 
the direction of the growth cone, whilst those with a low membrane potential predominantly 
travel towards the cell body (Miller & Sheetz, 2004). If CP60 and CP69 induced a low 
mitochondrial membrane potential Δψm this could possibly explain the abundance of CP60 
and CP69 protein at the cell body in transfected neurone cultures. Impaired mitochondrial 
transport due to altered DISC1 expression has been previously detected using live cell-imaging 
(Atkin et al, 2011; Ogawa et al, 2014). It is possible that live cell-imaging could be used to 
test a hypothesis that CP60 and CP69 expression depolarize the mitochondrial membrane 
potential Δψm, and this, in turn, would favour net mitochondrial movement towards the cell 
body. This could be tested by using inducible CP60 and CP69 expression constructs. Cells 
could be stained with JC-1, a dye that can indicate the mitochondrial membrane potential, 
Δψm, with live cell imaging used pre- and post-induction of expression of CP60 or CP69, to 




Given more time it would have been of interest to implement additional tests to investigate 
mitochondrial dysfunction due to the exogenous expression of der 1 chimeric proteins. The 
quantification of an absolute mitochondrial membrane potential, Δψm for each species would 
enrich the interpretation of the immunocytochemistry data. A suitable method is provided by 
Gerencser et al., (2012), which measures the dynamics of a mitochondrially permeable 
fluorescent probe operating under a voltage clamp. The determination of the activity of 
mitochondrial respiratory chain complexes I–IV associated with DISC1/DISC1FP1 protein 
expression would also be beneficial and could be facilitated by single-wavelength 
spectrophotometry (Spinazzi et al, 2012). The findings could be compared with the diverse 
array of established research on respiratory complex deficits in major mental illness (see 
section 1.3.4). Additionally, the immunofluorescence paradigm discussed in this chapter could 
be adopted to investigate signs of mitochondrial apoptosis (Tait & Green, 2010). The COS-7 
cells could be cultured for a longer time, 36 hours, to enhance the window of opportunity for 
apoptosis to occur and then be co-stained for caspases.    
 
4.5.3 Endogenous der 1 DISC1/DISC1FP1 chimeras 
The exogenous expression of CP1, CP60 and CP69 in both the COS-7 cell lines and mouse 
primary cortical neurones shows pathogenic mechanisms that may arise from the 
consequences of altered cellular expression patterns and mitochondrial toxicity. There is no 
evidence of endogenous chimeric protein expression at the present time. To date, the der 1 
chimeric transcripts are detectable in t(1;11) cell lines,  though at low levels (Eykelenboom et 
al, 2012). The CP60 and CP69 transcripts may not be translated, due to a splice site 
downstream of the stop codon, which suggests these transcripts may be targeted for nonsense 
mediated decay. However, the transcripts are readily detected so, conversely, may be 
translated (Eykelenboom et al, 2012).  
Western blot analysis to detect endogenous chimeric proteins in t(1;11) lymphoblastoid cell 
lysates failed to detect endogenous expression of CP1, CP60 or CP69 protein. This involved 
the analysis of lysates expressing exogenous untagged CP1, CP60 and CP69 in parallel with 
t(1;11) lymphoblastoid cell lysates. The exogenously expressed CP1, CP60 and CP69 
contained protein bands specific to each respective chimeric species. These chimera-specific 
bands were not detected in the t(1;11) lysate, when probed with N-terminal DISC1 antibodies 
(Eykelenboom et al, 2012). The possibility remains that DISC1/DISC1FP proteins may have 
been present at low levels in the t(1;11) lymphoblastoid lysates which were beyond the 




Endogenous expression of CP1, given the phenotypes of DISC1 aa1-597 transgenic mice, may 
produce a phenotype similar to schizophrenia (see chapter 3). The expression of endogenous 
CP60 and CP69 would likely produce mitochondrial impairment even with low levels of 
expression. It is possible that CP60 and CP69 overexpression produces an alteration in 
mitochondrial network dynamics that results in the generation of clustered mitochondria. CP1 
expression likely produces ‘ring’ or lariat like mitochondria (Millar et al, 2005a) which could 
also represent changes in the mitochondrial network. It is also interesting to observe that the  
DISC1-37W mutant  (Ogawa et al, 2014) alters mitochondrial dynamics. Mutations to proteins 
involved in mitochondrial fission and fusion dynamics generally produce illness and 
disablement that is distinguishable from mental illness. Optic atrophy results from certain 
mutations to OPA1, (Delettre et al, 2000; Hudson et al, 2008). Mutations to Mfn2 and the 
mitochondrial fission protein Ganglioside-induced Differentiation-associated Protein 1 
(GPAD1) produce Charcot-Marie-Tooth disease which is associated with peripheral nerve 
degeneration, muscular atrophy and sensory impairment. Charcot-Marie-Tooth type 2A is 
caused by mutations to the mitochondrial fusion protein, Mfn2, resulting in altered axonal 
degradation and regeneration. Charcot-Marie-Tooth type 4 is caused by mutations to GAPD1, 
producing axonal demyelination (Liesa et al, 2009). Given the severity of the symptoms 
associated with mutations in mitochondrial fission and fusion proteins, if CP60 and CP69 were 
expressed endogenously, and they influence fission/fusion, the t(1;11) carriers could be 
expected to have a more heterogeneous phenotype. However, the major mental illness seen in 
t(1;11) carriers displays no unique features (Eykelenboom et al, 2012) 
Alternatively, in contrast to the fission-fusion dysfunction of the neurodegenerative diseases 
discussed above, it may be that the effects of CP60 and CP69 expression are more subtle. 
These species may possibly mediate pathogenesis by impinging on the mitochondrial 
trafficking machinery. As mentioned previously, full-length DISC1 binds with both Miro1 and 
TRAK1 as part of the mitochondrial transport complex (Ogawa et al, 2014) and is involved in 
mitochondrial trafficking (Atkin et al, 2011; Ogawa et al, 2014). Mutations to the 
mitochondrial transport machinery can have detrimental effects on mitochondrial trafficking. 
In Drosophila mutation of dMiro1 results in build-up of a pool of mitochondria in the cell 
body (Guo et al, 2005). Similar observations are also seen in Drosophila  studies with mutants 
of the TRAK1 orthologue milton, again mitochondria accumulate in the soma and are absent 
from the axon and synaptic processes (Stowers et al, 2002). Regarding DISC1 mutations and 
mitochondrial trafficking, the DISC1-37W variant does not promote anterograde 




endogenous DISC1 (Ogawa et al, 2014). Additionally, the expression of the disease associated 
DISC1 607F polymorphism (L607F) is associated with a reduction in the number of mobile 
mitochondria (Atkin et al, 2011). Given this evidence it would seem feasible that CP60 and 
CP69 could affect mitochondrial transport as a putative mechanism of pathogenesis in the 
t(1;11) pedigree. The TRAK1 binding site that is affected by the 37W mutilation  (Ogawa et 
al, 2014), would be retained in the DISC1/DISC1FP chimeras. 
The above proposals imply that the der 1 chimeras could mediate mitochondrial pathogenesis 
via altered fission-fusion dynamics or by abnormal mitochondrial trafficking. Since this thesis 
was initially submitted, evidence has emerged that observed that the exogenous expression of 
CP60 causes deficits to both mitochondrial transport and mitochondrial fusion (Norkett et al, 
2016) (i.e. pathogenic insults to these processes can co-occur). It is suggested these the 
impairments are mediated by dominant negative effects of CP60 on TRAK1-Miro1 and 
Mfn1/Mfn2, respectively. Given the high degree of structural homology between CP60 and 
CP69 it is extremely likely that these potential mechanisms of pathogenesis may also occur 
with CP69 expression.  
Findings from the DISC1-Boymaw mouse (Ji et al, 2014) are in line with the observation that 
the t(1;11) family do not show immediate evidence of mitochondrial fission-fusion based 
neurodegenerative disease, This model contains both the BD13 and DB7 fusion genes 
knocked-in, ORFs that correspond to those of DISC1/DISC1FP1 chimeric transcripts, 
encoding the C-terminal DISC1 fragment and CP60, respectively. The in vivo expression of 
these proteins produces a phenotype that includes reduced translation in both the hippocampus 
and primary neurones as well as reduction in rRNA levels in the hippocampus and cortex. 
Ketamine mediated hyperlocomotion was increased in the male mice as was a measure of PPI. 
The mice also displayed altered erythropoiesis and a decrease in the reduction of MTT. Taken 
together, these phenotypes do not immediately seem to relate to the mitochondrial 
pathophysiology seen with the in vitro expression of CP60 or CP69. However, Ji et al., (2014) 
used a theoretical model to explain the translation and rRNA deficits around the MTT assay 
findings and the observation that NADPH oxidoreductase function in the MTT assay was 
reduced with CP60 expression. The model of cellular signalling features NADPH 
oxidoreductase upstream of the transcription and rRNA dysregulation. It is proposed that 
mitochondrial oxidoreductase activity could impair ATP production and that this functional 
outcome is compatible with the observations that there is an impairment in the mitochondrial 
membrane potential, Δψm seen with CP60 and CP69 expression in vitro. The findings from 




and the highly similar species CP69 may be more complex than that of a direct extrapolation 
from the in vitro phenotypes (Eykelenboom et al, 2012). It may be the case that the differences 
in phenotype noted are underpinned by the contrasting methods in protein expression. The 
overexpression in vitro is a potent method of protein expression, whereas the transgenic 
expression may be more subtle, and thus mediate different effects.   
Comparing the symptoms of mitochondrial disorders to those of psychiatric disorders is one 
way to address whether the mental illness in t(1;11) carriers could be associated with 
mitochondrial dysfunction. What if mitochondrial dysfunction is associated with major mental 
illness in itself? For mood disorders, such as depression and bipolar disorder, a growing and 
converging body of evidence exists for mitochondrial abnormalities. These include: mutations 
to mitochondrial DNA, alterations to Ca2+ signalling and reductions in the levels of ATP in 
the brain (Manji et al, 2012). Research into schizophrenia has shown reduced mitochondrial 
density post-mortem; associated reductions to the neuropil; brain region-specific alteration of 
mitochondrial gene expression; and NADH dehydrogenase activity (Manji et al, 2012; Park et 
al, 2010). It may be possible in the future to carry out a non-invasive test on t(1;11) carriers 
such as neuroimaging to detect ATP levels in the brains of t(1;11) carriers and test the 
hypothesis regarding mitochondrial dysfunction and exogenous der 1 chimera expression. 
At the present time, post-mortem brain tissue is not available from a t(1;11) carrier, to probe 
for evidence of endogenous chimeric protein expression. However, t(1;11) induced pluripotent 
stem cells (iPSC’s) have been generated. This could be an avenue for future investigation into 
the possible expression of endogenous der 1 chimeric proteins. These t(1;11) iPSC’s could be 
differentiated down a number of neural pathways to produce a variety of post-mitotic neurone 
types, from which endogenous CP1,CP60 and CP69 protein expression could be investigated. 
The der 1 DISC1/DISC1FP1 immunofluorescence paradigm detailed in this chapter could be 
replicated on endogenous DISC1 species in the iPSC neurones along with Western blot 
analysis to try to detect endogenous CP1, CP60 and CP69. This Western blotting and 
immunofluorescence would entail the use of custom peptide antibodies that were targeted to 
epitopes specific to each chimeric protein. Mitochondrial function could be measured in iPSC 
and t(1;11) lymphoblastoid cells by looking at cellular and mitochondrial ATP levels, 
measuring the mitochondrial membrane potential, Δψm and addressing mitochondrial toxicity. 
 
A possible explanation for the lack of appreciable mitochondrial disease in the t(1;11) pedigree 
and the inability to detect endogenous chimeric proteins is that these species may be subject 




of chimeric proteins. Firstly, recent evidence has emerged that a small boymaw protein may 
be expressed via an internal ORF (Ji et al, 2015). This species appears to be subject to 
proteasomal degradation under basal conditions and is upregulated in response to a variety of 
stressors. Importantly, 59 of the 63 aa's in this boymaw protein are also present in CP60 and 
hence the majority will also be present in CP69. This implies that due to the DISC1FP1 aa's 
present in these chimeric species CP60 and CP69 may be subject to stress dependent regulation 
and could be targeted for rapid proteasomal degradation.  
Secondly, evidence of the potential for the aggregation of these chimeras arises from 
biophysical experiments expressing the epitope tagged truncate MBP-ΔNCP69 (Eykelenboom 
et al, 2012).  High molecular weight assemblies and an altered secondary structure were 
observed with the expression of MBP-ΔNCP69 in comparison to MBP-ΔN597. These findings 
may be indicative of a potential for aggregation in the CP69 species and are therefore are also 
likely to be present with CP60 expression. Furthermore, the immunocytochemistry of 
exogenously expressed CP60 and CP69 presented in this chapter displays a clustered cellular 
phenotype which may actually be the occurrence of aggregation. However, definitive 
biochemical testing of these species is needed to confirm this view. If indeed CP60 and CP69 
do form aggregates, the potential exists that these species would be capable of depleting 
endogenous DISC1. The sequestering of DISC1 from the cytoplasm has been noted by both 
WT-DISC1 aggregates (Atkin et al, 2012) as well as aggregated mutant DISC1 species with 
truncations to the distal C-terminus (Wen et al, 2014). Were CP1 to be exogenously expressed, 
this species could also be depleted by such a mechanism and be absorbed by CP60 or CP69 
aggregates. The underlying interactions would presumably be mediated by interactions of the 
DISC1 self-interaction-domain (Kamiya et al, 2005), which all of the der 1 chimeric species 
contain.  
Thirdly, these aggregates and the additional species bound within them may be targeted to 
aggrisome and subsequently be degraded by the autophagic pathway, as is the case for WT-
DISC1 aggregates (Atkin et al, 2012). In summary, by incorporating several lines of evidence 
the preceding text suggests a potential hypothesis as to why der 1 chimeric species have not 
been isolated endogenously. Succinctly, this is as follows: CP60 and CP69 may be stress 
regulated, then subject to rapid degradation, yet when present these species may aggregate 
depleting WT-DISC1 and CP1 from the cytoplasm, in turn these chimeric aggregates would 
also be degraded by cellular surveillance. Further experiments on t(1;11) derived cell lines 
could be implemented to test this hypothesis. This would entail the culturing of these cells in 




al., (2015) to investigate the small boymaw protein. To test the specific aggregation of CP60 
and CP69, the protocols followed Atkin et al., (2012) to study WT-DISC aggregation could 
be employed. 
Prior to the identification of the der 1 DISC1/DISC1FP1 fusion transcripts, the established 
pathogenic mechanism as a consequence of the t(1;11) was believed to be haploinsufficiency 
of DISC1 (Millar et al, 2005b). The possibility of aberrant DISC1 protein species as a 
pathogenic mechanism does not preclude that of haploinsufficiency as a co-occurring 
pathogenic insult. The existence of endogenous fusion proteins may seem unlikely, given the 
paucity of the transcripts (Eykelenboom et al, 2012). However, the transcripts still can be 
readily detected. Given the pleiotropic effect of the chimeras and that the mitochondrial 
dysfunction induced by CP60 and CP69 overexpression is apparent at low level expression, 
low level of exogenous fusion expression would likely be pathogenic. The novel mechanisms 
of molecular pathogenesis proposed by the der 1 DISC1/DISC1FP1 chimeras warrant further 
research. The next chapters will investigate whether MitoTracker Red uptake is impaired in 
















Chapter 5 - FACS analysis of MitoTracker Red 
fluorescence in t(1;11) lymphoblastoid cell lines 
 
5.1 Introduction 
When the chimeric species, CP60 and CP69, are overexpressed in COS-7 cells and primary 
cortical neurones, mitochondrial staining by MitoTracker Red is impaired (see chapter 4). The 
uptake of MitoTracker Red dye, a cationic molecule, into mitochondria is dependent on the 
mitochondrial membrane potential, Δψm (Poot et al, 1996). Therefore, if CP60 and CP69 
protein is expressed endogenously in translocation lymphoblastoid cell lines, it is possible that 
an impairment of the staining of the mitochondria in these cells by MitoTracker Red dye may 
occur. 
It is also likely that the CP1 species perturbs mitochondrial function. This chimeric species is 
highly similar to DISC1 aa1-597, with CP1 encoding DISC1 aa1-598. The overexpression of 
the murine equivalent to DISC1 aa1-597 protein downregulates mitofilin in vitro (Park et al, 
2010). Mitofilin is an inner membrane mitochondrial protein involved in the morphology of 
cristae and the knockdown of this protein results in the mitochondrial membrane potential, 
Δψm becoming increasingly negative (John et al, 2005). Therefore, it is possible that CP1 
overexpression would hyperpolarise the mitochondrial membrane potential, Δψm. This would 
be consistent with the presence of MitoTracker Red staining from immunocytochemistry data 
with CP1 overexpression (see chapter 4). The DISC1-mitofilin interaction and expression 
could also be a mechanism that explains the altered mitochondrial staining seen with the 
exogenous expression of CP60 and CP69. These species also encode DISC1 aa1-597 
(Eykelenboom et al, 2012; Zhou et al, 2008), and it is possible that the additional 60 and 69 
novel amino acids in these aberrant species could possibly confer an altered protein-protein 
interaction with mitofilin. This might explain the abolition of the mitochondrial membrane 
potential, Δψm observed with the overexpression of these aberrant protein species in vitro.  
At present, endogenously expressed DISC1/DISC1FP1 protein species have not been detected 
by Western blotting of t(1;11) lymphoblastoid cell lysates with N-terminal DISC1 antibodies 
(Eykelenboom et al, 2012). However, it may be that endogenously expressed chimeric protein 
species are present in t(1;11) lymphoblastoid cell lines below the threshold of the detection of 




FACS analysis can be used to measure the fluorescence intensity of MitoTracker Red stained 
lymphoblastoid cell lines (Pendergrass et al, 2004; Poot et al, 1996; Xu et al, 2005). With 
regard to mitochondrial dysfunction, mitochondrial poisons have been observed to decrease 
MitoTracker fluorescence in stained lymphoblastoid cell lines using flow cytometry. This 
includes: CCCP, an uncoupler of the electron transport chain and inhibitor of mitochondrial 
complexes, the complex II inhibitor, antimycin, and the complex IV inhibitor, sodium azide. 
However, the treatment of lymphoblastoid cells with rotenone, a complex 1 inhibitor, did not 
affect the fluorescence intensity of MitoTracker Red staining (Poot et al, 1996). Additionally, 
MitoTracker fluorescence alterations can be detected in patient cell lines. Barth syndrome is a 
rare multi-factorial disease caused by mutations in the gene Tafazzin (TAZ) which encodes an 
inner mitochondrial membrane phospholipid (Gonzalvez et al, 2013). FACS analysis of Barth 
syndrome patient derived lymphoblastoid cell lines, incubated with MitoTracker Red, detected 
increased MitoTracker fluorescence, indicative of mitochondrial pathology (Xu et al, 2005). 
Given this data, it was decided to use FACS analysis as a means to investigate if the 
MitoTracker Red fluorescence intensity of t(1;11)-family derived lymphoblastoid cell lines 
differs from that of karyotypically normal family controls. If CP1, CP60 and CP69 are 
endogenously expressed in translocation cell lines, it is possible that these aberrant proteins 
will alter the mitochondrial membrane potential, Δψm and therefore detectably alter 
MitoTracker Red fluorescence. 
This chapter will focus on both the development of the FACS analysis protocol and the 
subsequent experiments used to quantify the MitoTracker Red fluorescence intensity in 
translocation lymphoblastoid cell lines.  
 
5.2 FACS analysis performed 
This section will briefly cover FACS parameters that will be discussed in the following 
optimisation and experimentation section and gives typical examples of the data captured. To 
measure the baseline fluorescence, a sham (DMSO) treated lymphoblastoid cell line sample 
was assayed by FACS and captured by  FL1 vs FL2 parameters, the  FITC 530 nm and PE 585 
nm emission fluorescence  detector settings. Following the establishment of the sham samples 
fluorescence signal, a subjective gate, R1, was drawn to isolate cells with increased FL2 
fluorescence. These would be MitoTracker Red stained cells. The FACS analysis was then 
performed with the fluorescing cells. All data were displayed as FL1vs FL2 dot plots (see 
figure 5.2.A). The, geometric mean fluorescent intensity (GMFI), was collected for each of 









Figure 5.2.A: MitoTracker Red fluorescence in t(1;11) lymphoblastoid cell lines detected 
by FACS analysis. Unstained sham (DMSO) treated: normal karyotype control and 
translocation lymphoblastoid cell lines (top), MitoTracker Red stained cells (bottom). 
R1 region is a subjective gate drawn to detect MitoTracker Red fluorescing cells 
following the measurement of baseline fluorescence of unstained cells. MitoTracker 
Red stained fluorescing cells were then detected in the R1 gated region. Normal GMFI 
=7.17; % MitoTracker Red fluorescing cells gated = 80.00. Translocation GMFI = 5.23; % 
cells MitoTracker Red fluorescing cells gated = 82.60. Dot plots here depict typical 
examples of FACS analysis. Black dots depict unstained cell events, red dots depict 
MitoTracker Red cell events. 10,000 events recorded per dot plot. The dot-plots 
displayed are representative examples of the FACS analysis performed.
 
In parallel with the reading of lymphoblastoid cells’ MitoTracker fluorescence by FL1 vs FL2 




analysed using FSC vs SSC parameters. The data were then displayed on dot plots (see figure 
5.2.B). The FSC (forward scatter) is a measure of cell size, while SSC (side scatter) is a 
measure of the complexity and granularity of a cell. This analysis was a precautionary measure 
to guard against the possibilities of treatment effects falling outside of the expected 
fluorescence occurring in the MitoTracker Red incubated cells, or the cell lines assayed 
showing signs of apoptosis (Koopman et al, 1994). Importantly, the FSC vs SSC dot plots for 
the MitoTracker Red stained cells or sham (DMSO) controls did not show any appreciable 
differences (see figure 5.2.B, other cell line data not shown).  
 
5.3 MitoTracker Red incubation time optimisation for lymphoblastoid cell 
line fluorescence 
Prior to the generation of experimental FACS data, optimisation trials were carried out to 
determine how MitoTracker Red fluorescence varied with the length of incubation in 
lymphoblastoid cells lines. It was possible that MitoTracker staining of lymphoblastoid cells 
was highly sensitive to variations in incubation time or produced saturation effects which 
might have negatively affected the generation of FACS data.  
For the optimisation results covered here, and following experimental data, all of the 
lymphoblastoid cell lines that were analysed by FACS were unfixed. The fixing of cells stained 
with MitoTracker Red has been observed to impact both the resolution and fluorescence 
detected by FACS analysis (Gilmore & Wilson, 1999). For the optimisation, three different 
lymphoblastoid cell lines (under blinding) were incubated with MitoTracker Red for either: 
15, 30, 45 or 60 minutes or were incubated in parallel with sham (DMSO) treatment. Following 
this, the lymphoblastoid cells were analysed by FACS using FL1 vs FL2 analysis (see section 
5.2).  
Across all three cell lines assayed, the GMFI showed the trend of increasing with incubation 
time in the MitoTracker Red dye. However, this increase in GMFI between each 15 minute 
time point across all cell lines was not significant, as analysed by One-way ANOVA, 
F(3,8)=0.442, p=0.729. The percentage of MitoTracker Red fluorescing cells gated showed no 
clear trend with increasing incubation time with the MitoTracker stain. Although there 
appeared to be intra-experimental trends in the proportion of the MitoTracker Red fluorescing 
cells detected which were specific to each cell line, in the technical replications (see table 




to capture MitoTracker fluorescing lymphoblastoid cell lines. It is, therefore, possible that cell 




Figure 5.2.B: FSC vs SSC in MitoTracker Red stained t(1;11) lymphoblastoid cell 
lines detected by FACS analysis. Top: FSC vs SSC analysis of sham (DMSO) 
treated, normal karyotype control (left) and translocation lymphoblastoid cell 
lines (right). Bottom: FSC vs SSC analysis of the MitoTracker Red treated cells. 
Unstained cells with low SSC and FSC values are observed in both 
translocation and normal cell lines. Black dots depict unstained cell events, red 






















% of MITO 
fluorescing 
cells gated 
     GMFI 
(AU) 
 60 85.9 10.1 
Translocation 1 45 87.3 10.0 
 30 87.4 9.9 
 15 87.4 9.7 
    
 60 89.6 10.6 
Translocation 2 45 90.0 10.6 
 30 89.3 10.5 
 15 91.1 10.5 
    
 60 84.4 10.4 
Normal 45 84.8 10.5 
 30 87.0 10.4 
 15 87.3 10.1 
 
 
Table 5.3.A: Optimisation of the MitoTracker Red incubation time for 
lymphoblastoid cell lines for FACS analysis. One-way ANOVA shows no effect 
of treatment time on GMFI, p=0.729. The proportion of MitoTracker Red 
fluorescing cells gated appears to show consistency within each of the t(1;11)-
family derived and normal karyotype control lymphoblastoid cell lines. All three 
cell lines assayed were under blinding. FACS analysis per cell line recorded 
10,000 events using FL1 vs FL2 analysis (see figure 5.2.A). 
 
Following this optimisation, it was decided to use a 15 minute incubation time using 30nM 
MitoTracker Red dye. This reduction from the concentration of MitoTracker dye was 
introduced to prevent saturation of the lymphoblastoid cell lines. The incubation with 
lymphoblastoid cell lines with 30nM MitoTracker Red has been previously observed to be 









5.4 FACS analysis of MitoTracker Red fluorescence in translocation 
lymphoblastoid cell lines 
 
5.4.1 Background on statistical analysis of experimental replicates of 
MitoTracker Red staining of translocation cell lines assayed by FACS 
Before the statistical analysis of the FACS data to determine fluorescence intensity of the 
MitoTracker staining in t(1;11)-family derived lymphoblastoid cell lines, it is relevant that the 
experimental protocol is explained in the context of the replications performed. In this section, 
the individual experimental replicates were analysed. The analysis of the pooled experimental 
replicate dataset will be covered in section 5.4.4 onwards. In total, three experimental 
replicates were performed, each containing three translocation and three normal karyotype 
control lymphoblastoid cell lines. In an individual experimental replicate, two technical 
replicates were assayed per cell line. Each of these technical replicates contained a 
MitoTracker Red treatment and a sham (DMSO) treatment. The same lymphoblastoid cell 
lines were used across the three experimental replicates. This used the growing of new cell 
cultures between experiments. For clarification, the protocol for a single experimental 
replication is shown in figure 5.4.A.The three experimental replicates were carried out in order 
to have the minimum number of replicates required for generating a pooled experimental 
dataset that could be statistically analysed. However no a priori power tests were performed 
to determine if the use of three replicates is sufficient for statistical analysis. 
The reasoning to analyse the three experimental replicates separately is as follows. As each 
lymphoblastoid cell line comes from a unique individual, there will be background effects 
between all cell lines. Due to this independence, each cell line could, therefore, be classed as 
a single experimental unit (Lazic, 2010). Additionally, these cell lines were cultured in 
separate tissue culture flasks, although within the same incubator. Therefore, there is a level 
of independence in these individual experimental replicates that is beyond that seen in a single 
flask of cells that are split six times into tissue culture dishes and assigned equally into 
treatment or control groups, which would possess an n=1 (Cumming et al, 2007). As a 
consequence, it is proposed that the individual experimental replicates can be analysed as n=3. 
This is also taking into account that the internal technical replicates of repeating the 
MitoTracker FACS analysis twice per cell line are simply pseudo replicates measuring the 






Figure 5.4.A: Cartoon depicting the generation of an experiment replicate in the 
FACS analysis of MitoTracker Red fluorescence in t(1;11)-family derived 
lymphoblastoid cell lines. Flasks of translocation (blue) and normal karyotype 
controls (green) were cultured, with 3 different lymphoblastoid cell lines 
assayed per genotype. This is illustrated by the use of numbers for 
translocation cell lines and capitalised letters for normal cell lines. Per 
individual cell line, two technical replicates of 30nM MitoTracker Red and sham 
(DMSO) treatments were analysed by FACS to quantify MitoTracker GMFI. 
Following FACS analysis, these technical replicates were averaged by cell line 
and the GMFI by genotype was then statistically analysed. Consequently, (n=3) 
per experimental replicate. 
 
5.4.2 MitoTracker Red GMFI in translocation lymphoblastoid cell lines 
as statistically analysed per experimental replicate 
The treatment of lymphoblastoid cells with MitoTracker Red showed inconsistent results 
regarding genotype and the detected fluorescence. One of the three experimental replicates 
showed reduced MitoTracker staining in translocation lines (see figure 5.4.B). There was no 
significant difference in the MitoTracker Red GMFI between translocation and normal 
karyotype controls in experimental replicate 1, Student’s unpaired two-tailed t-test, t(4)=0.43, 
p=0.69. There was also no significant difference in the MitoTracker Red GMFI between the 
translocation and normal karyotype controls in experimental replicate 2, Student’s unpaired 
two-tailed t-test, t(4)=0.37, p=0.73. However, for experimental replicate 3 there was a highly 
significant difference in the MitoTracker Red GMFI translocation and normal karyotype,  






Figure 5.4.B: MitoTracker Red GMFI in t(1;11)-family derived lymphoblastoid cell lines by experimental replicate. Each 
experimental replicate compares FACS derived GMFI between translocation and normal karyotype control lymphoblastoid cell 
lines, (n=3, with two technical replicates per cell line). The horizontal line represents mean MGFI by genotype. Experimental 
replicate 3 shows a significant reduction in translocation MGFI, Student’s unpaired two-tailed t-test, df 4, *** p <0.001. The same 




GMFI in translocation cell lines is significantly lower than normal karyotype controls.  
It is unusual that in experimental replicates 1 and 2 the MitoTracker GMFI results parallel 
each other, yet experimental replicate 3 shows highly significant reduction in translocation 
lymphoblastoid cell line GMFI (see figure 5.4.B). It is important to note that these experiments 
are displayed in order of completion. Each experimental replicate of FACS analysis was 
performed three to four weeks apart to enable the growth of new cell cultures. Therefore, a 
possible explanation for the inconsistency between the GMFI data for experimental replicates 
may be the effect of practice in performing the experiment, with performance of the 
experiment improving with replications here. Another explanation could be that the cells in 
experimental replicates 1 and 2 were not confluent enough to express the translocation product 
at a level that would have impaired MitoTracker Red staining, in contrast with the cells in 
experimental replicate 3 which may have been fully confluent.  Alternatively, there may have 
been more generalised cell culture differences and treatment differences between the 
experimental replicates. Another possibility is that the percentage of MitoTracker Red 
fluorescing cells that were gated differs across experimental replicates, in such a manner as to 
bias the GMFI analysis. This is the topic of the next section. Finally, the three experiments’ 
GMFI data needs to be pooled and analysed to determine if the significant reduction in 
translocation GMFI seen with experimental replicate 3 is retained or abolished. This will be 
covered in section 5.4.5. 
 
5.4.3 Proportion of lymphoblastoid cells showing MitoTracker Red 
fluorescence by genotype per experimental replicate 
Analysis of the gating by genotype within an experimental replicate will inform if there is a 
significant difference in the number of MitoTracker stained cell events between translocation 
and control lymphoblastoid cell lines. Such differences could explain the lack of agreement in 
the experimental replicate MitoTracker Red GMFI results (see section 5.4.2). When 
interpreting the gating data, it is important to remember that the GMFI is calculated from both 
the numbers of fluorescing cells gated and the fluorescence intensity of that gated sub-
population. The following statistical analysis is performed on each of the three individual 
experimental replicates to compare the proportion of lymphoblastoid cells displaying 
MitoTracker Red fluorescence between the translocation and normal karyotype control 
genotypes. The sub-populations of lymphoblastoid cells with MitoTracker fluorescence do not   







Figure 5.4.C: Proportion of lymphoblastoid cells showing MitoTracker Red fluorescence by genotype per experimental replicate. 
Each experimental replicate compares the percentage of MitoTracker Red fluorescing cells gated for translocation and normal 
karyotype control lymphoblastoid cell lines, (n=3, with two technical replicates per cell line)  per experimental replicate by 
genotype. The horizontal line represents mean percentage cells fluorescing with MitoTracker Red by genotype. Student’s unpaired 








There was no significant difference in the proportion of MitoTracker Red fluorescing cells 
gated between translocation and normal karyotype controls in experimental replicate 1, 
Student’s unpaired two-tailed t-test, t(4)=0.61, p=0.58 There was no significant difference in 
the proportion of MitoTracker Red fluorescing cells gated between translocation and normal 
karyotype controls in experimental replicate 2, Student’s unpaired two-tailed t-test, t(4)=1.00, 
p=0.37. There was no significant difference in the proportion of MitoTracker Red fluorescing 
cells gated between translocation and normal karyotype controls in experimental replicate 3, 
Student’s unpaired two-tailed t-test t, t(4)=2.58, p=0.06, this is however, a of a trend towards 
significance.  
It is interesting that for experimental replicate 3 there is an increase in proportion of 
translocation cell events with MitoTracker staining that are gated compared to controls and 
that the difference is approaching significance. This suggests that, although the GMFI for 
experimental replicate 3 is reduced in translocation lymphoblastoid cell lines (see section 
5.4.1), this fluorescence measure is drawn from a larger (although not significantly different) 
population of cells compared to the karyotype control data. This would appear to support, 
rather than contradict, the observation that translocation cell GMFI is significantly reduced for 
experimental replicate 3.  
 
5.4.4 Background on statistical analysis of pooled experimental replicate 
data of MitoTracker Red staining of translocation cell lines assayed by 
FACS 
The pooling of the FACS data from the three experimental replicates raises further questions 
regarding cell culture data analysis. If each lymphoblastoid cell line is taken to be an 
experimental unit, then repeating the experiment with the same cell lines may be seen as using 
the same individuals (Lazic, 2010). However, this is not an entirely accurate depiction of what 
has occurred experimentally. In performing the three experimental replications pooled here, 
the cell lines used are from the same six individuals, but the cell cultures per single experiment 
were grown three to four weeks apart, being clones of the same cell line. Due to this, multiple 
potential stochastic environmental and experimental events could have occurred that introduce 
novel intra- and inter-experimental variability. This can be seen as a degree of biological 
independence that is not possible within a single experimental replicate. Therefore, the pooling 
of the data of the three experimental replicates may be seen to be a more robust analysis to 




 lines. Although it is understood that the hypothesis being tested is not analysing the ability to    
accurately culture cells within and between experiments.  
The pooled experimental data are also analysed with a two-tailed t-test. The pooling of the 
three experimental replicates has n=3 (Cumming et al, 2007) as this is the number of different 
lymphoblastoid cell lines per genotype in the experimental replicate dataset. 
 
5.4.5 MitoTracker Red GMFI in translocation lymphoblastoid cell lines as 
statistically analysed by pooled mean of experimental replicates 
The pooled t(1;11)-family derived MitoTracker Red fluorescence lymphoblastoid data 
are shown in figure 5.4.D. For the pooled experimental data there was no significant 
difference in the MitoTracker Red GMFI between translocation and normal karyotype 
controls, Student’s unpaired two-tailed t-test t(4)=0.64, p=0.56. The pooling of the 
experimental data does not support a reduction in the MitoTracker Red GMFI in 
translocation cell lines. This contrasts with the analysis of the experimental replicates 
individually in which experimental replicate 3 had a reduction in the GMFI in translocation 
lymphoblastoid cell lines (see section 5.4.2). 
__________________________________________________________________________ 
 
Figure 5.4.D: MitoTracker Red GMFI in t(1;11)-family derived lymphoblastoid 
cell lines by mean experimental replicate data. Each circle represents the mean 
lymphoblastoid GMFI by genotype from an experimental replicate, derived by 
FACS analysis (see figure 5.4.B). The horizontal line represents mean GMFI by 
genotype. n=3 independent experimental replicates, with two technical 
replicates per cell line. Student’s unpaired two-tailed t-test, df 4, p=0.56. FACS 







5.5.1 Disagreement in the MitoTracker Red GMFI data in translocation 
cell lines between experimental replicates 
The analysis of the MitoTracker Red GMFI data in t(1;11) derived lymphoblastoid cell lines 
shows disagreement between the experimental replicates when they are analysed separately. 
While one FACS replicate displays a highly significant reduction in the MitoTracker Red 
GMFI in translocation lymphoblastoid cells, the other two replicates show no difference in 
MitoTracker GMFI by genotype. The individual experimental replicates discussed have been 
analysed as independent experiments as it is believed they fulfil the criteria according to the 
experimental design used (Cumming et al, 2007; Lazic, 2010). This encompasses three 
individual patient cell lines per genotype. However, it would be expected that the experimental 
result was consistent with repeated analysis. The subsequent analysis of the pooled data of all 
three experimental replicates detects no difference in MitoTracker GMFI.  
The single experimental replicate that has a significant reduction in MitoTracker Red, a 
mitochondrial membrane potential, Δψm dependent dye (Poot et al, 1996), is supportive of the 
in vitro observations with the overexpression of chimeric protein species. The exogenous 
expression of CP60 and CP69 in COS-7 cells and primary neurone cultures results in impaired 
mitochondrial staining from MitoTracker Red due to the abolition of the mitochondrial 
membrane potential, Δψm (see chapter 4). However, why only a single significant reduction 
in MitoTracker GMFI in translocation cell lines is observed across replications remains 
unexplained. It is possible to speculate that the result may, alternatively, be the consequence 
of experimental error or a product of a practice effect on performing the FACS analysis. The 
latter view is supported as this replicate was the final FACS analysis of the three performed. 
Irrespective of these possible explanations, the disparity in the lymphoblastoid MitoTracker 
GMFI data is not the result of significant differences in the proportion of the sub-population 
of lymphoblastoid cells displaying MitoTracker Red fluorescence between genotype 
conditions. 
Given the disagreement in the data regarding the MitoTracker fluorescence in translocation 
lymphoblastoid cell lines, the following discussion sections will focus on alternative 
measurements of MitoTracker Red fluorescence and of the mitochondrial membrane potential, 
Δψm, within these cells. This would aim to further characterise the translocation 
lymphoblastoid cell lines for evidence supportive of endogenous chimeric protein species and 




5.5.2 The measurement of MitoTracker Red fluorescence and the 
measurement of the mitochondrial membrane potential, (Δψm)  
The use of MitoTracker Red alone is suitable for generating data on the intensity of 
fluorescence in patient lymphoblastoid cells with mitochondrial dysfunction (Xu et al, 2005). 
This analysis used GMFI as the measure of MitoTracker fluorescence. However, MitoTracker 
Red GMFI is not a direct measure of the mitochondrial membrane potential Δψm, merely a 
consequence of abnormal mitochondrial membrane potential, Δψm (Pendergrass et al, 2004; 
Poot & Pierce, 2001; Poot et al, 1996). The quantification of the mitochondrial membrane 
potential, Δψm itself, resulting from endogenous or exogenous DISC1/DISC1FP1 chimeric 
protein expression, is of greater interest to contextualise the observed mitochondrial 
pathophysiology than the quantification of the effects of these physiological changes upon 
MitoTracker dye uptake and florescence.   
The determination of the mitochondrial membrane potential  Δψm in a population of cells 
using a mitochondrial membrane potential,  Δψm dependent dye, such as MitoTracker Red, 
requires that both the cellular fluorescence and the mitochondrial mass of the fluorescing cells 
is known. Differences in the mitochondrial mass within cells would impact upon MitoTracker 
Red fluorescence as cells with greater mitochondrial mass would fluoresce more (Poot & 
Pierce, 2001). It remains possible that the mitochondrial mass varies both within the individual 
cell lines and between control and t(1;11) lymphoblastoid populations, given the mitochondrial 
clustering observed with the exogenous expression of CP60 and CP69 in vitro (see chapter 4). 
To counter any possible bias arising from such variations and to derive the mitochondrial 
membrane potential, Δψm, it is possible to use a membrane potential insensitive dye such as 
MitoTracker Green in conjunction with a membrane potential sensitive dye (here MitoTracker 
Red) during FACS analysis. The ratio of the MitoTracker Red fluorescence to the MitoTracker 
Green fluorescence produces a normalised mitochondrial membrane potential, Δψm value 
(Pendergrass et al, 2004; Poot & Pierce, 1999; Poot & Pierce, 2001).  
Given the disagreement in the results here measuring MitoTracker Red in translocation cell 
lines, it would be seem prudent to perform pilot experiments to detect the mitochondrial 
membrane potential, Δψm. From this work a priori power tests could be used to calculate the 
number of independent experimental replicates required to detect an effect of the translocation 





A ratiometric approach to correct for mitochondrial mass was not used initially as it was 
inferred that even with low levels of CP60 and CP69 expression in t(1;11) lymphoblastoid cell 
lines that MitoTracker Red fluorescence would be significantly impaired. This was thought to 
be irrespective of these species potential to induce mitochondrial clustering, given that the 
clustered mitochondria frequently do not show MitoTracker Red fluorescence (see chapter 4). 
However, with hindsight the potentially low levels of endogenously expressed CP60 and CP60 
may not be potent enough to abolish MitoTracker Red staining, merely to partly reduce the 
fluorescence. The magnitude of this effect in turn will be compromised by the size of the 
clustered mitochondria affected. Therefore the measurement of mitochondrial membrane 
potential, Δψm is a preferable metric to MitoTracker Red fluorescence alone.  
 
5.5.3 Future work to investigate the effect of DISC1/DISC1FP1 chimeric 
protein on the mitochondrial membrane potential, Δψm 
Despite the negative result for the pooled GMFI data, the use of FACS analysis to calculate 
the mitochondrial membrane potential, Δψm is an ideal way to further characterise the 
functional consequences of exogenous CP1 protein expression. The aim for future studies 
would be to determine the mitochondrial membrane potential, Δψm value for CP1 in 
comparison to DISC1 aa1-597 The hypothesis could focus on what is known of the interactions 
between the murine equivalent of DISC1 aa1-597 and mitofilin (Park et al, 2010) For the 
FACS analysis of CP1, given that this species is highly similar to DISC1 aa1-597, it is likely 
to downregulate mitofilin expression in vitro (Park et al, 2010) which, consequently, might 
hyperpolarise the mitochondrial membrane potential, Δψm (John et al, 2005). Further analysis 
of the mitochondrial membrane potential, Δψm in CP60 and CP69 expressing cells may not 
be required. This is because these species abolish the mitochondrial membrane potential, Δψm 
in the COS-7 cell lines and primary cortical neurons in the majority of expressing cells as 
evidenced by an impairment in MitoTracker Red staining (see chapter 4).   
If the proposed further FACS analysis, to determine the mitochondrial membrane potential, 
Δψm in translocation lymphoblastoid cell lines and exogenous expression of der 1 chimeric 
proteins in cell lines was initiated, the use of further statistical measures would be beneficial. 
The dot plots used in this chapter to display FSC vs SSC and FL1 vs FL2 data are saturated 
by events so that the displayed data are seen as solid blocks of colour, whereby a single dot 
may also represent more than one event at that given fluorescence intensity (see figures 5.2.A 
and 5.2.B). This output limits interpretation of FACS data. If quartile contour plots were used 




assayed would have had greater utility. Quantile contour plots separate the events by contours 
so that the location of the cell density is visualised (Herzenberg et al, 2006). In the analysis of 
the MitoTracker Red fluorescence in translocation cell lines the use of quantile contour plots 
could be utilised to determine if sub-populations of cells displayed reduced MitoTracker 
fluorescence within the overall population of fluorescing cells. 
In terms of adopting the MitoTracker Red FACS experimental protocol, Further cell lines from 
t(1;11) family members could be added to the experimental run to increase sample size per 
experiment. This would be a means to get a more accurate estimation of the translocation cell 
line mitochondrial membrane potential,  Δψm. Alternatively, the sample size of n=3 by 
genotype could be kept and a full biological replicate of the experiment could be performed, 
as a robust measure of experimental reproducibility (Lazic, 2010). This would entail either 
lymphoblastoid cell lines from a different n=3 of t(1;11) family members being used in 
experimentation or lymphoblastoid cell lines from the same individuals but different clones 
(Cumming et al, 2007). These experimental modifications are a response to the inconsistent 








Chapter 6 - Functional enrichment analysis of t(1;11) 
gene expression microarray data 
 
6.1 Introduction  
A further means to investigate the high incidence of major mental illness in the t(1;11) pedigree 
(Blackwood et al, 2001) is to use pathway analysis to identify biological processes and 
functions impacted by changes in gene expression that arise as a result of the translocation. 
Presently no post-mortem brain tissue is available from t(1;11) carriers therefore all of the 
cDNAs assayed for this analysis are derived from t(1;11)-family derived-lymphoblastoid cell 
lines that have been transformed by the Epstein–Barr virus (EBV). This study was 
implemented by Merck Sharp & Dohme, using a proprietary in house Rosetta chip. 
Consequently, a limitation is that the raw data was not available for alignment of the results 
with public domain data as is possible with Illumina chips.  
 
There are several ways by which the t(1;11) could influence gene transcription. Firstly, DISC1 
is subject to haploinsufficiency due to the translocation (Millar et al, 2005b). This would 
reduce the levels of DISC1 available to interact with binding partners and likely cause 
disruption to pathways in which DISC1 had a role in transcription. DISC1 has been observed 
to interact with Activating Transcription Factor 4 (ATF4) and ATF5 (Morris et al, 2005), 
transcription factors that have roles in stress response (Ameri & Harris, 2008) and nervous 
system development (Greene et al, 2009), respectively. DISC1 localises with ATF4 in the 
nucleus and inhibits ATF4 transcriptional activity at basal levels of cAMP (Malavasi et al, 
2012), whilst conversely augmenting the transcriptional repression of ATF4 at elevated levels 
of cAMP (Sawamura et al, 2005). PDE4D9 transcription is repressed by a DISC1 and ATF4 
regulated transcriptional repression complex, which undergoes dynamic regulation by cAMP 
signaling (Soda et al, 2013). Here, haploinsufficiency of DISC1 could lead to increased levels 
of PDE4D9 following loss of transcriptional repression due to a reduction in DISC1 levels, 
leading to fewer DISC1/ATF4 complexes. In contrast to ATF4, little is known regarding 
DISC1/ATF5 functional interactions. 
The binding of DISC1 to ATF4 and ATF5 represent downstream mechanisms of action 
affecting transcription, upstream mechanisms within pathways are also likely to occur. The 
knockdown of DISC1 has been demonstrated to result in the upregulation of GluN2A 
expression, mediated by increased PKA and CREB signaling Wei et al., (2014). The authors 




reduce cellular levels of PKA, impinging on the downstream CREB signaling and 
subsequently downregulating the transcription of GluN2A. The knockdown of DISC1 by Wei 
et al., (2014) could somewhat recapitulate an effect of haploinsufficiency of DISC, the 
interpretation being that half normal levels of DISC1 could lead to a partial upregulation of 
GluN2A. A further example of an upstream mechanism of gene expression regulation by 
DISC1, is GSK3β/DISC1 binding and the resulting inhibition of GSK3β (Mao et al, 2009). 
This promotes the stabilisation of β-catenin which translocates to the nucleus and participates 
in downstream gene activation via interaction with the T-cell factor/lymphoid enhancer factor 
(TCF/LEF) transcription factors. The haploinsufficiency of DISC1 may lead to greater levels 
of unbound GSK3β, which could phosphorylate β-catenin, targeting it for proteasomal 
degradation and so reducing the downstream activity of TCF/LEF mediated gene transcription. 
Due to DISC2 being a ncRNA and its antisense and parallel orientation to DISC1 (Millar et al, 
2000b) it has been proposed that this species may potentially function as a negative regulator 
of DISC1 mRNA levels (Chubb et al, 2008; Millar et al, 2000b,). Following this rationale, as 
a consequence of the t(1;11), such negative regulation of DISC1, could be impinged upon by 
the haploinsufficiency of DISC2. However, given the paucity of data on DISC2 it is difficult 
to predict what the functional effects of haploinsufficiency of DISC2 would be. It may be the 
case that DISC2 haploinsufficiency has a nominal overall effect. This is as it co-occurs against 
background of DISC1 haploinsufficiency and the half normal levels of each species may 
negate any detriment in function. Additionally, it is unknown if DISC1FP1 as a ncRNA 
(Eykelenboom et al, 2012; Zhou et al, 2010; Zhou et al, 2008), has any roles in transcriptional 
regulation, although this remains a possibility. 
DISC1/DISC1FP1 proteins could potentially impact upon gene transcription. This is assuming 
the chimeric transcripts are translated (Eykelenboom et al, 2012). The possibility then arises 
for aberrant protein-protein interactions to occur. The chimeric species could bind WT-DISC1 
via the DISC1 self-interaction domain (Kamiya et al, 2005) or with DISC1 interactors directly. 
This may be detrimental to the function of pathways associated with transcription in which 
DISC1 participates. Furthermore, a small American pedigree has been identified in which 
single instances of schizophrenia and schizoaffective disorder co-occur with a 4bp frameshift 
mutation at the distal region of DISC1 exon 12 (Sachs et al, 2005). This rare mutation is 
predicted to encode a truncated DISC1 species as a consequence of the frameshift introducing 
9 abnormal aa’s followed by a premature stop codon. Transcriptional analysis on forebrain 
neurons derived from iPSC’s generated from the American pedigree and analysed using RNA-




expressed genes were associated with synaptic fiction as well as major mental illness. 
Dysregulation also occurred to the transcript levels of multiple DISC1 interactors. The authors 
propose that the mutant species of DISC1 studied may induce transcriptisomal dysregulation 
as a common disease mechanism. The findings of Wen et al., (2014) may be highlighting the 
effects of mechanisms action that impinge upon gene expression similar to those proposed 
above for the DISC/DISC1FP1 chimeras. Overall the study by Wen et al., (2014) serves as an 
example that mutations to DISC1 can mediate alterations to transcription, which then brings 
to the fore the implications of endogenous DISC1/DISC1FP1 protein expression on 
transcription. However, further research is needed into the impact of mutant DISC1 species 
binding on transcription,  
In this chapter two ‘genes-of interest’ (GOI) lists will be analysed by functional enrichment 
programs. The first list, referred to as the unfiltered list is derived from the genes showing 
differential expression with a fold change cut-off of +/- 1.3, significant at p≤0.05 (see 
methods). This is a commonly used threshold for asserting expression differences. The second 
GOI list referred to as the neuronally filtered list, is the unfiltered GOI list with non-neuronally 
expressed genes removed (see methods). This was performed to generate a GOI list that was 
more brain-like and less blood like. Regarding this decision, the benefits and caveats of using 
blood as a proxy or surrogate for post-mortem brain tissue in gene expression microarray 
analysis will be covered in greater depth in the following section 6.2 The analysis of blood 
versus brain in gene expression microarray studies. 
In the interpretation of the t(1;11) lymphoblastoid cDNA microarray data, gene set analysis 
programs within the WEBGestalt suite of programs (Wang et al, 2013) will be used to analyse 
both the unfiltered and neuronally filtered GOI lists in parallel. The results of these analysis 
will be presented sequentially allowing for comparison between the results of these differing 
GOI lists. The programs used will include: 1) GOTree, to look at gene ontology (Zhang et al, 
2004) 2) Pathway Commons analysis (Cerami et al, 2011), 3) KEGG Analysis (Kanehisa et 
al, 2008) and 4) Wikipathways Analysis (Pico et al, 2008) to look at pathway enrichment, 5) 
Disease Enrichment Analysis (Jourquin et al, 2012) to determine at the enrichment of 
particular disease states relating to the GOI lists 6) Cytogenetic Band Analysis to see if genes 
are enriched to specific chromosomal loci and 7) Transcription Factor Target Analysis to see 
if gene sets associated with specific transcription factor motifs are enriched. All of these 
programs use over representation analysis in the calculation of gene enrichment. This method 




(Khatri et al, 2012). The results of these analysis aimed to further the knowledge into the 
pathogenesis of the major mental illness that is seen in the t(1;11) pedigree. 
 
6.2 The analysis of blood versus brain in gene expression microarray 
studies 
Blood is frequently used as a proxy or surrogate for brain tissue in gene transcription studies 
of neuropsychiatric disorders such as schizophrenia, bipolar disorder and major depressive 
disorder. In contrast to the CNS, blood can be collected via non-invasive methods that are easy 
to implement (de Jong et al, 2012). Additionally blood samples can be drawn at different stages 
of illness and from large numbers of subjects. The collection of such blood samples can be 
carried out under standardised controlled conditions using replicable blood processing 
protocols alongside well regulated sample preservation methods resulting in the harvesting of 
higher quality blood mRNA than that from post-mortem brain tissue (Jasinska et al, 2009). In 
contrast the harvesting of brain tissue must take place from post-mortem brain collections. 
This severely limits the number of subjects per study. Likewise, the limited number of 
lymphoblastoid cell lines assayed in this study is a potential caveat.  The use of brain tissues 
also introduces confounding factors, such as: post-mortem interval, the pH of brain tissue, the 
quality of mRNA extracted, the age of subjects, and the length of the agonal state, each of 
which can affect gene expression. (Lipska et al, 2006a). 
The applicability of blood-based expression findings to the central nervous system (CNS) has 
been the subject of several studies. The correlation between transcripts from blood versus from 
brain tissue has been found to be weak (Cai et al, 2010) or moderate (Sullivan et al, 2006). 
The gene expression of putative schizophrenia candidate genes also shows variation. 24% of 
schizophrenia candidate genes are identified as having co-expression in peripheral blood 
mononuclear cells with cerebellum tissue (Rollins et al, 2010) whereas Sullivan et al., (2006) 
identifies a 50% co-expression with a separate set of schizophrenia candidate genes between 
whole blood and post-mortem brain tissue from multiple brain regions. Additionally Sullivan 
(2006) identified multiple similarities in gene ontology between whole blood and CNS tissues, 
this includes: transcription factor activity, apoptosis, G-protein coupled receptor activity, 
cytokine activity, DNA replication and kinase activity. The disparities in the estimates of the 
similarities between gene expression between blood and brain likely arise due to 
methodological differences between studies, such as array types, the brain regions that tissue 




such evidence that blood is not identical to brain but bears a degree of similarity to brain, 
which may make blood a useful tissue to use as a proxy or surrogate to brain. Furthermore, it 
is important to consider that when looking at between-group differences in gene expression, 
the differences observed may still be informative as to the pathophysiology of illness 
irrespective of whether the sample mRNA assayed originates from blood or from brain. This 
is relevant even if blood only has a limited degree of similarity to brain. Additionally, it is 
important to note that the brain is structured with heterogeneous regionalised variations in glial 
and neuronal populations and, therefore, to simply call tissue originating from the brain post-
mortem “brain tissue” does not reflect the degree of variation present within the brain. 
One factor that might contribute towards correlation in gene expression levels between the 
blood and the brain is that both tissues are affected by circulating factors such as 
neurotransmitters and hormones. For example, the levels of Brain-derived Neurotrophic 
Factor (BDNF) in the blood and in brain tissue are observed to be similar in several mammal 
species (Klein et al, 2011). Furthermore, leukocytes possess an array of hormone and 
neurotransmitter receptors and in turn also produce hormones and neurotransmitters that are 
also common to brain tissue for use in bi-directional communication in the immune response 
(Blalock & Smith, 2007).  
This study measured gene expression in lymphoblastoid cell lines. In addition to the caveats 
that exist when comparing blood to brain, it is important to consider the effects of 
immortalisation of gene expression. Following transformation by the EBV, large gene 
expression differences are apparent between peripheral blood mononuclear cells and 
lymphoblastoid cell lines. However, Rollins et al, 2010 reported a 62% transcript commonality 
between the cell lines. Moreover, the effects of EBV transformation of lymphoblastoid cell 
lines on gene dysregulation appear to show little inter-subject variability and are specifically 
distributed throughout the genome. EBV transformation-induced changes in gene expression 
should have little effect on between-group comparisons, apart from when the effect of the 








6.3 Functional enrichment analysis of the t(1;11) gene expression 
microarray 
 
6.3.1 Comparing gene number in GOI and reference lists 
The initial, unfiltered microarray data mapped to 10,923 genes. After applying the criteria for 
differential expression (a fold change of +/- 1.3 and p≤0.05), 1,010 genes remained and 
compose the unfiltered GOI list. Therefore, for the unfiltered t(1;11) microarray data ~9.2% 
of the genes from the reference set are differentially expressed at the levels of the cut-offs. The 
reference list from the neuronally filtered GOI list contains 9462 genes and the neuronally 
filtered GOI list itself contains 889 genes. Therefore for the neuronally filtered data ~9.4% of 
the genes from the reference list are differentially expressed at the level the cut-offs. 
Additionally the neuronally filtered reference list contains ~13% fewer genes than the 
unfiltered reference list and the neuronally filtered GOI list contains ~12% fewer genes than 
the unfiltered GOI list.  
 
6.3.2 Cytogenetic band analysis 
Cytogenetic Band Analysis (http://bioinfo.vanderbilt.edu/webgestalt/analysis.php) was 
applied to the t(1;11) GOI lists. This analysis measures whether the GOI list is enriched for 
given chromosomal loci and aimed to exclude the possibility that loci other than the t(1;11) 
were responsible for mediating the differential expression changes observed. For the 
Cytogenic Band Analysis a significance level of p<0.05 was applied.  
The cytogenetic band analysis of the dysregulated genes in both the unfiltered GOI list and the 
neuronally filtered GOI list, fails to detect significant gene enrichment to specific chromosome 
loci. Using cytogenetic band analysis to derive the top 10 chromosomal loci per list, the 
unfiltered GOI list data has an adjusted p=0.60 (see table 6.3A) while the neuronally filtered 
GOI list has an adjusted p=0.42 (see table 6.3B). These p-values correspond to all of the 
chromosomal loci analysed per top 10 analyses.  
The results indicate no other significant loci are involved in the differential expression. 
However, it should be noted that this analysis is not sufficient to be able to exclude additional 
gene specific effects fixed by the t(1;11), such as the possibility that additional genes and SNPs 
in the vicinity of the der 1 and 11 loci may be inherited along with the t(1;11). Sullivan (2013) 
has speculated that a ‘hitchhiking’ effect analogous to this potential inherence mechanism may 




partitioned between t(1;11) carriers and non-carriers are not able to be accounted for in this 
analysis. For example, background genetic variation present in a sub-set of t(1;11) carriers 
could modulate the phenotype of major mental illness by acting additively of synergistically 
with the pathophysiological effects of the t(1;11). This may in part account for the spectrum 
of major mental illness observed in the t(1;11) pedigree, in conjunction with the contribution 
of non-shared environmental effects. 
 
Chromosome Position Observed Expected Ratio p-value 
18q12 6 2.48 2.42 6.05E-01 
10q11 6 2.48 2.42 6.05E-01 
13q22 4 1.38 2.9 6.05E-01 
5q 51 34.82 1.46 6.05E-01 
14q21 6 2.57 2.33 6.05E-01 
3p26 4 1.1 3.63 6.05E-01 
12p13 12 6.71 1.79 6.05E-01 
16q13 4 1.29 3.11 6.05E-01 
5q33 6 2.66 2.25 6.05E-01 
10q 39 26.82 1.45 6.05E-01 
 
Table 6.3.A: Cytogenetic Band Analysis for the unfiltered GOI list. Top 10 most 
significant results displayed. Observed and expected are measures of the 













Chromosome Position Observed Expected Ratio  p-value 
2q34 3 0.56 5.35 4.24E-01 
5q 46 31.88 1.44 4.24E-01 
3p26 4 1.03 3.89 4.24E-01 
10q21 6 2.06 2.92 4.24E-01 
10q11 6 1.78 3.38 4.24E-01 
10q 35 23.19 1.51 4.24E-01 
12p13 11 5.14 2.14 4.24E-01 
8p11 7 2.8 2.5 4.55E-01 
16q13 4 1.12 3.57 4.55E-01 
14q21 6 2.34 2.57 4.55E-01 
 
Table 6.3.B: Cytogenetic Band Analysis for the neuronally filtered GOI list. Top 
10 most significant results displayed. Observed and expected are measures of 
the number of genes and ratio is the observed number of genes/expected 
number of genes. 
 
6.3.3 GOTree Analysis 
Gene ontology tree machine, GOTree, is a web based gene ontology analysis (GO) program. 
In GOTree, GO categories are arranged hierarchically with the GO annotation being highly 
specific and precisely defined relating to a given set of co-regulated genes. GOTree output 
comprises three different categories to describe data on these gene products: (1) biological 
process (2)  molecular function and (3) cellular component (Zhang et al, 2004). 
(http://bioinfo.vanderbilt.edu/webgestalt/analysis.php). For the GOTree analysis a 
significance level of p<0.05 was applied.  
The GOTree analysis highlights GO categories exclusively associated with the cell cycle. This 
is irrespective of whether the output is generated using the unfiltered or the neuronally filtered 
GOI lists. The GO categories in the GOTree output are primarily found in the categories of 
biological process and cellular component (see tables 6.3.C and 6.3.D). Figure 6.3.A displays 
the cell cycle phases in conjunction with the associated GO categories. It is clear from this 
diagram that M-phase has numerous GO categories whereas S-phase only has 3, interphase 
has 2, and G2 has 3 shared transitional phases with M-phase. This would seem to suggest that 
differential gene expression in the t(1;11) microarray data results in the dysregulation of the 
cell cycle and predominantly within the M-phase. However, it is possible that within the GO 




example, interphase due to research bias. It may then be prudent to simply acknowledge that 
all of the phases of the cell cycle, bar G1 show an enrichment in GO annotation.  
The S-phase GO categories are solely concerned with DNA based processes, in line with S-
phase being principally involved with DNA replication (Alberts et al, 2008). The M-Phase 
includes GO categories that are fundamental components of mitosis and cytokinesis. This 
includes multiple GO categories pertaining to the kinetochore, which is a centromericaly 
located macromolecular structure that acts as a hub to link microtubules to chromosomes. As 
such the kinetochore is consequently involved in force generation that segregates 
chromosomes during mitosis (Cheeseman, 2014). Strongly associated with the kinetochore is 
the Ndc80 complex, which also receives a GO annotation associated with M-phase. The Ndc 
80 complex is involved in the anchoring of microtubules directly to the kinetochore (Wilson-
Kubalek et al, 2008). A range of studies in both cultured cell lines and primary neurones 
identify DISC1 as being localised at the centrosome (Bradshaw et al, 2008; Kamiya et al, 
2005; Kamiya et al, 2008; Miyoshi et al, 2004; Morris et al, 2003). In this GOTree analysis 
the centrosome appears as an enriched category. 
 
GO Term Observed Expected Ratio  p-value 
cell cycle phase 136 64.01 2.12 2.31E-15 
M phase 95 39.21 2.42 5.83E-14 
cell cycle 183 102.17 1.79 5.83E-14 
nuclear division 79 29.89 2.64 7.60E-14 
mitosis 79 29.89 2.64 7.60E-14 
mitotic cell cycle 126 60.93 2.07 7.86E-14 
cell cycle process 150 78.23 1.92 7.86E-14 
M phase of mitotic cell cycle 80 30.76 2.6 8.16E-14 
organelle fission 79 31.62 2.5 1.30E-12 
cell division 79 35.46 2.23 8.17E-10 
microtubule-based process 66 29.12 2.27 2.36E-08 
regulation of cell cycle process 70 32.58 2.15 7.16E-08 
condensed chromosome 38 13.04 2.91 2.70E-07 
chromosome segregation 35 11 2.98 3.49E-07 
spindle 47 18.94 2.48 3.59E-07 
cytoskeletal part 124 74.42 1.67 3.59E-07 
condensed chromosome kinetochore 25 7.04 3.55 4.82E-07 
microtubule cytoskeleton 105 60.62 1.73 4.82E-07 
condensed chromosome, centromeric region 26 7.52 3.46 4.82E-07 




chromosome, centromeric region 35 12.94 2.7 1.52E-06 
regulation of cell cycle 95 53.73 1.77 2.21E-06 
regulation of G2/M transition of mitotic cell cycle 13 2.21 5.88 4.43E-06 
sister chromatid segregation 19 4.61 4.12 4.99E-06 
kinetochore 27 9.04 2.99 5.75E-06 
microtubule cytoskeleton organization 47 20 2.29 6.16E-06 
cytoskeleton 152 103.63 1.47 1.14E-05 
mitotic sister chromatid segregation 18 4.42 4.07 1.28E-05 
microtubule 46 21.7 2.12 2.21E-05 
DNA replication 46 20.86 2.21 2.37E-05 
spindle pole 23 7.9 2.91 5.81E-05 
G2/M transition of mitotic cell cycle 29 10.76 2.69 6.20E-05 
spindle organization 21 6.82 3.08 0.0002 
cell cycle checkpoint 43 20.28 2.12 0.0002 
regulation of mitotic cell cycle 48 23.64 2.03 0.0002 
interphase 59 31.72 1.86 0.0002 
regulation of cell cycle arrest 44 21.91 2.01 0.0005 
chromosomal part 64 38.35 1.67 0.0008 
regulation of microtubule cytoskeleton 
organization 17 5.29 3.22 0.0009 
interphase of mitotic cell cycle 56 31.14 1.8 0.0009 
DNA packaging 23 8.75 2.63 0.001 
DNA metabolic process 95 61.99 1.53 0.001 
cell cycle arrest 54 29.99 1.8 0.0011 
microtubule motor activity 15 3.85 3.9 0.0011 
condensin complex 5 0.57 8.76 0.0012 
negative regulation of G2/M transition of mitotic 
cell cycle 7 1.06 6.62 0.0015 
regulation of mitosis 19 6.73 2.82 0.0017 
negative regulation of cell cycle 59 34.31 1.72 0.0017 
regulation of nuclear division 19 6.73 2.82 0.0017 
negative regulation of cell cycle process 21 7.88 2.66 0.0017 
chromosome condensation 10 2.21 4.52 0.0017 
condensed nuclear chromosome kinetochore 4 0.38 10.51 0.0022 
condensed chromosome outer kinetochore 6 0.95 6.31 0.0025 
DNA conformation change 27 11.92 2.27 0.0027 
attachment of spindle microtubules to 
kinetochore 8 1.54 5.2 0.003 
cytoskeleton organization 76 48.73 1.56 0.003 
chromosome 70 45.68 1.53 0.0044 
microtubule organizing center 58 36.16 1.6 0.0044 
condensed nuclear chromosome, centromeric 
region 6 1.14 5.25 0.0083 
non-membrane-bounded organelle 293 250.28 1.17 0.0093 




cytoplasmic microtubule 8 2.19 3.66 0.0146 
Ndc80 complex 3 0.29 10.51 0.0146 
condensed nuclear chromosome outer 
kinetochore 3 0.29 10.51 0.0146 
motor activity 18 6.57 2.74 0.0151 
centrosome 45 28.36 1.59 0.0187 
spindle microtubule 10 3.43 2.92 0.0224 
midbody 15 6.76 2.22 0.0345 
cytosol 196 164.25 1.19 0.036 
 
Table 6.3.C: GOTree Analysis of the unfiltered GOI list. Observed and expected 
are measures of the number of genes and ratio is the observed number of 
genes/expected number of genes. Biological process (Black), Cellular 
component (Red), Molecular function (Green). 
 
GO Term Observed Expected Ratio  p-value 
cell cycle phase 131 60.78 2.16 2.06E-15 
M phase 91 37.18 2.45 8.23E-14 
mitotic cell cycle 123 58.37 2.11 8.23E-14 
cell cycle process 144 74.07 1.94 9.63E-14 
mitosis 77 28.99 2.66 9.63E-14 
M phase of mitotic cell cycle 78 29.67 2.63 9.63E-14 
nuclear division 77 28.99 2.66 9.63E-14 
cell cycle 173 96.51 1.79 1.08E-13 
organelle fission 77 30.63 2.51 1.71E-12 
cell division 76 34.19 2.22 2.08E-09 
microtubule-based process 62 27.45 2.26 9.28E-08 
regulation of cell cycle process 66 30.82 2.14 2.24E-07 
chromosome segregation 35 11.56 3.03 2.24E-07 
condensed chromosome 37 12.6 2.94 3.37E-07 
spindle 45 18.04 2.49 8.26E-07 
cytoskeletal part 115 69.3 1.66 1.37E-06 
condensed chromosome, centromeric region 25 7.25 3.45 1.37E-06 
microtubule cytoskeleton organization 47 19.65 2.39 1.58E-06 
condensed chromosome kinetochore 24 6.87 3.49 1.59E-06 
sister chromatid segregation 19 4.43 4.29 2.42E-06 
mitotic prometaphase 25 7.42 3.37 4.07E-06 
regulation of G2/M transition of mitotic cell cycle 13 2.22 5.87 4.13E-06 
regulation of cell cycle 90 50.95 1.77 4.22E-06 
mitotic sister chromatid segregation 18 4.24 4.25 5.56E-06 




chromosome, centromeric region 33 12.6 2.62 8.18E-06 
G2/M transition of mitotic cell cycle 29 10.5 2.76 3.45E-05 
kinetochore 25 8.78 2.85 3.74E-05 
cytoskeleton 140 95.93 1.46 3.74E-05 
spindle pole 23 7.64 3.01 3.74E-05 
spindle organization 21 6.45 3.25 8.06E-05 
interphase 58 30.34 1.91 8.97E-05 
DNA replication 42 19.55 2.15 1.00E-04 
regulation of mitotic cell cycle 46 22.35 2.06 1.00E-04 
cell cycle checkpoint 41 19.46 2.11 3.00E-04 
interphase of mitotic cell cycle 55 29.76 1.85 4.00E-04 
microtubule 41 20.52 2 0.0004 
DNA packaging 23 8.48 2.71 6.00E-04 
regulation of microtubule cytoskeleton 
organization 17 5.2 3.27 7.00E-04 
regulation of cell cycle arrest 42 21 2 8.00E-04 
chromosomal part 61 36.27 1.68 0.0009 
cell cycle arrest 52 28.7 1.81 1.20E-03 
condensin complex 5 0.57 8.73 0.0012 
negative regulation of G2/M transition of mitotic 
cell cycle 7 1.06 6.61 1.60E-03 
negative regulation of cell cycle 57 32.75 1.74 1.60E-03 
chromosome condensation 10 2.22 4.51 0.0019 
attachment of spindle microtubules to 
kinetochore 8 1.44 5.54 0.002 
regulation of mitosis 18 6.26 2.88 0.002 
regulation of nuclear division 18 6.26 2.88 0.002 
condensed nuclear chromosome kinetochore 4 0.38 10.48 0.0022 
condensed chromosome outer kinetochore 6 0.95 6.29 0.0024 
cytoskeleton organization 73 46.33 1.58 0.0029 
regulation of microtubule-based process 18 6.45 2.79 0.0029 
mitotic spindle organization 11 2.79 3.94 0.0029 
DNA conformation change 26 11.37 2.29 0.0029 
chromosome 67 43.34 1.55 0.0043 
microtubule organizing center 55 34.17 1.61 0.0043 
microtubule motor activity 13 3.4 3.83 0.0066 
intracellular non-membrane-bounded organelle 278 235.58 1.18 0.0073 
non-membrane-bounded organelle 278 235.58 1.18 0.0073 
condensed nuclear chromosome, centromeric 
region 6 1.15 5.24 0.0073 
centrosome 44 26.82 1.64 0.0105 
Ndc80 complex 3 0.29 10.48 0.0144 
condensed nuclear chromosome outer 
kinetochore 3 0.29 10.48 0.0144 




midbody 15 6.49 2.31 0.0235 
motor activity 16 5.85 2.74 0.0265 
cytoplasmic microtubule 7 2.1 3.33 0.0466 
 
Table 6.3.D: GOTree Analysis of the neuronally filtered GOI list. Observed and 
expected are measures of the number of genes and ratio is the observed 
number of genes/expected number of genes. Biological process (Black), 





Figure 6.3.A: GO categories from the GOTree analysis of the t(1;11) microarray data and their relation to the cell cycle. Asterisk 
indicates cell cycle component is also a GO annotation. GO annotations associated with cell cycle phases using Alberts et al., 




The DISC1 interactome dataset is derived from the findings of yeast-two hybrid screens to 
identify DISC1 binding partners. The specific molecular and cellular properties of novel 
DISC1 interactors identified in the DISC1 interactome dataset has been characterised by GO 
(Camargo et al, 2006). GO analysis of the members of the DISC1 interactome shares common 
features with the analysis carried out on differentially expressed genes identified in carriers of 
the t(1;11) translocation. For biological processes this includes: microtubule-based process, 
mitosis, M-phase of the mitotic cell cycle, nuclear division, M-phase, mitotic cell cycle, 
chromosome segregation, sister chromatid cohesion, mitotic sister chromatid segregation and 
regulation of mitosis. The cellular component categories shared are:  kinetochore, spindle pole, 
microtubule, spindle microtubule, chromosome, centrosome, condensed chromosome. The 
common molecular function categories are: motor activity and molecular motor activity 
(Camargo et al, 2006).  Therefore from the DISC1 interactome dataset, DISC1 can be linked 
to proteins that have roles in cell cycle dynamics, in particular M-phase. The concordance 
between the DISC1 interactome dataset and the t(1;11) microarray data suggests that the 
molecular processes DISC1 interactors may be involved in (Camargo et al, 2006) are in turn 
dysregulated in t(1;11) lymphoblastoid cell lines. It is possible that the interactions of DISC1 
with binding partners identified in the interactome dataset is impaired due to 
haploinsufficiency within the t(1;11)-family derived lymphoblastoid cell lines (Millar et al, 
2005b) and that this is where the similarity in GO results originates from.  
There was very little difference between the GO categories highlighted using either the 
unfiltered or neuronally filtered GOI lists. The differences that occur between the two GOI 
lists in the GOTree analysis of the t(1;11) microarray data come from the p-value ranking of 
the GO categories and even then, there are marked similarities in the p-values of the highly 
significant GO categories. 
 
6.3.4 Pathway Commons Analysis 
Pathway Commons is a web based pathway analysis program that uses multiple publicly 
available pathway databases (Cerami et al, 2011) (http://www.pathwaycommons.org/about/ , 
http://bioinfo.vanderbilt.edu/webgestalt/analysis.php). For the Pathway Commons analysis a 
significance level of p<0.05 was applied.  
The Pathway Commons analysis of the t(1;11) microarray data is both supportive and yet 
different to the GOTree analysis of the data set. In the Pathway Commons data set, like the 




Commons analysis is broader in the scope of the pathways produced, with mitosis being a 
fraction of the cell cycle pathways detected and additionally non-cell cycle pathways are 
highlighted, that are primarily immunological as well as pathways that may be said to be 
auxiliary to the cell cycle (see tables 6.3.E and 6.3.F). In line with the GOTree analysis there 
was little difference in the analysis of the unfiltered GOI list data and analysis using the 
neuronally filtered GOI data. 
In summary, the mitotic cell cycle is the most significant pathway by three orders of 
magnitude. Mitosis is also highlighted as within M-phase, Mitotic M-M/G1 phases, Mitotic 
prometaphase, G2/M checkpoints, the G2/M transition, Mitotic G2-G2/M phases, Mitotic G1-
G1/S phases, G2/M DNA replication checkpoint and the mitotic spindle checkpoint pathways 
are detected.  S-phase is present by way of the DNA replication pathway, which is the fourth 
most significant result and by G1/S-specific transcription. G1 phase is represented in the data 
by pathways specifying transitions in the cell cycle. Mitotic M-M/G1 phases, G1/S-specific 
transcription, G0 and early G1, Mitotic G1-G1/S phases. G2 phase is represented in the data by 
checkpoints and transition phases. G2/M checkpoints, G2/M DNA damage checkpoints, G2M 
transition. Additionally, cell cycle checkpoints appears as a pathway in its own right.  
 
Pathway Observed Expected Ratio  p-value 
Cell Cycle, Mitotic 70 25.54 2.74 1.13E-12 
Polo-like kinase signalling events in the cell cycle 32 8.54 3.75 4.67E-09 
PLK1 signalling events 31 8.27 3.75 6.27E-09 
DNA Replication 55 21.68 2.54 8.59E-09 
M Phase 39 12.77 3.05 1.41E-08 
Mitotic M-M/G1 phases 49 20.03 2.45 2.42E-07 
Mitotic Prometaphase 27 8.18 3.3 1.20E-06 
Signalling by Aurora kinases 25 7.62 3.28 4.23E-06 
FOXM1 transcription factor network 14 2.85 4.92 1.18E-05 
G2/M Checkpoints 16 3.77 4.25 1.65E-05 
Aurora B signalling 14 3.03 4.62 2.50E-05 
Cyclin B2 mediated events 6 0.55 10.89 3.16E-05 
G1/S-Specific Transcription 8 1.1 7.26 8.62E-05 
Chromosome Maintenance 17 4.87 3.49 1.00E-04 
Kinesins 9 1.56 5.76 2.00E-04 
G0 and Early G1 9 1.65 5.44 4.00E-04 
Activation of ATR in response to replication stress 13 3.31 3.93 4.00E-04 





Table 6.3.E: Pathway Commons Analysis for the unfiltered GOI list. Observed 
and expected are measures of the number of genes and ratio is the observed 
number of genes/expected number of genes.  
 
Pathway Observed Expected Ratio  p-value 
Cell Cycle, Mitotic 69 25.24 2.73 1.64E-12 
Polo-like kinase signalling events in the cell cycle 32 8.41 3.8 2.55E-09 
PLK1 signalling events 31 8.13 3.81 3.40E-09 
DNA Replication 54 21.32 2.53 1.17E-08 
M Phase 38 12.62 3.01 3.42E-08 
Mitotic M-M/G1 phases 48 19.73 2.43 3.81E-07 
Signalling by Aurora kinases 25 7.57 3.3 3.83E-06 
Mitotic Prometaphase 26 8.23 3.16 4.88E-06 
FOXM1 transcription factor network 14 2.9 4.83 1.36E-05 
G2/M Checkpoints 16 3.74 4.28 1.36E-05 
Cyclin A/B1 associated events during G2/M 
transition 7 1.01 6.93 4.00E-04 
E2F mediated regulation of DNA replication 10 2.2 4.54 8.00E-04 
Cell Cycle Checkpoints 23 9.92 2.32 3.00E-03 
G2/M Transition 18 7.26 2.48 5.80E-03 
Nucleosome assembly 8 1.93 4.15 7.10E-03 
ATM pathway 40 22.69 1.76 7.10E-03 
Chk1/Chk2(CDS1) mediated inactivation of Cyclin 
B:CDK1 complex 4 0.46 8.71 7.10E-03 
Aurora A signalling 14 5.05 2.77 7.10E-03 
Deposition of New CENPA-containing 
Nucleosomes at the Centromere 8 1.93 4.15 7.10E-03 
E2F transcription factor network 14 5.14 2.72 8.80E-03 
Mitotic G2-G2/M phases 18 7.53 2.39 8.80E-03 
Mitotic G1-G1/S phases 23 11.3 2.04 1.45E-02 
Phosphorylation of Emi1 7 1.65 4.23 1.45E-02 
IL-12-mediated signalling events 17 7.35 2.31 1.60E-02 
Fanconi anaemia pathway 11 4.04 2.72 0.033 
Extension of Telomeres 8 2.48 3.23 0.0402 
CD40/CD40L signalling 12 4.78 2.51 0.0402 
Telomere Maintenance 9 3.03 2.97 0.0409 
Telomere C-strand (Lagging Strand) Synthesis 7 2.02 3.46 0.0455 
Reelin signalling pathway 7 2.02 3.46 0.0455 
G2/M DNA replication checkpoint 3 0.37 8.16 0.0476 




Aurora B signalling 14 3.09 4.54 3.02E-05 
Cyclin B2 mediated events 6 0.56 10.7 3.45E-05 
G1/S-Specific Transcription 8 1.12 7.13 9.63E-05 
Activation of ATR in response to replication 
stress 13 3.27 3.97 4.00E-04 
Chromosome Maintenance 16 4.77 3.36 4.00E-04 
G2/M DNA damage checkpoint 11 2.52 4.36 5.00E-04 
Cyclin A/B1 associated events during G2/M 
transition 7 1.03 6.81 5.00E-04 
G0 and Early G1 9 1.68 5.35 5.00E-04 
E2F mediated regulation of DNA replication 10 2.24 4.46 9.00E-04 
Kinesins 8 1.5 5.35 1.20E-03 
Cell Cycle Checkpoints 22 9.72 2.26 5.70E-03 
G2/M Transition 18 7.2 2.5 5.70E-03 
Aurora A signalling 14 4.96 2.83 7.90E-03 
Mitotic G2-G2/M phases 18 7.48 2.41 7.90E-03 
E2F transcription factor network 14 5.14 2.72 9.00E-03 
Nucleosome assembly 8 1.96 4.07 9.00E-03 
Chk1/Chk2(Cds1) mediated inactivation of Cyclin 
B:Cdk1 complex 4 0.47 8.56 9.00E-03 
Deposition of New CENPA-containing 
Nucleosomes at the Centromere 8 1.96 4.07 9.00E-03 
Mitotic G1-G1/S phases 23 11.31 2.03 1.52E-02 
IL-12-mediated signalling events 16 6.73 2.38 1.57E-02 
ATM pathway 38 22.44 1.69 1.57E-02 
Phosphorylation of Emi1 7 1.68 4.16 1.57E-02 
CD40/CD40L signalling 12 4.58 2.62 0.0286 
Extension of Telomeres 8 2.43 3.29 0.0352 
Telomere C-strand (Lagging Strand) Synthesis 7 1.96 3.57 0.0395 
TCR signalling in naïve CD8+ T cells 16 7.57 2.11 0.0497 
G2/M DNA replication checkpoint 3 0.37 8.02 0.0497 
Reelin signalling pathway 7 2.06 3.4 0.0497 
 
Table 6.3.F: Pathway Commons Analysis for the neuronally filtered GOI list. 
Observed and expected are measures of the number of genes and ratio is the 







As well as highlighting pathways that detail the four cell cycle phases, the Pathway Commons 
analysis brings up pathways that occur within the cell cycle. This data does not appear in the 
GOTree ontology. Polo-like kinase signalling events in the cell cycle and PLK1 signalling 
events are the second and third most significant pathways in the analysis. Polo-like 
kinase/PLK1 signalling is involved in the maturation and separation of the centrosomes and 
importantly, in the regulation of the assembly of functional bipolar spindles. These processes 
take place from G2 to M-phase respectively. Additionally Polo-like Kinase 1 (PLK1) has a 
role in the recovery of the cell following DNA damage being detected at the G2 checkpoint 
and also is involved in the signalling for cohesin removal from sister chromatids (Van De 
Weerdt & Medema, 2006).  
Signalling by Aurora kinases and Aurora A and Aurora B signalling also appears in the 
Pathway Commons analysis. The Aurora kinases contribute to the cell cycle to aid the 
dynamics of mitosis. Aurora A kinase functions to aid centrosome maturation from G2 to M-
phase and to control the formation of the bipolar spindle apparatus. Aurora A is required from 
the correct localisation and function of other proteins in the development of the spindle. Aurora 
B kinase has a variety of cell cycle roles including: sister chromatid cohesion and the 
destabilisation of incorrect microtubule attachments to the spindle pole and the disassembly 
of the mitotic spindle in telophase (Vader & Lens, 2008).  
The activation of ATR in response to stress appears in the Pathway Commons analysis as does 
the ATM pathway. Ataxia-telangiectasia Mutated (ATM) and ATM-and Rad3-Related (ATR) 
are the principle transducing kinases within the DNA damage response (DDR) signalling 
network. The DDR is associated with cell cycle checkpoints and functions to maintain 
genomic viability in DNA damaged cells or destroy cells with highly damaged genomes by 
apoptosis. The actions of ATM focus on double stranded DNA breaks, whereas ATR has a 
wider scope of function, also delaying with DNA lesions that may prevent replication 
(Marechal & Zou, 2013). Additionally in the Pathway Commons analysis Chk1/Chk2 (CDS1) 
mediated inactivation of Cyclin B: CDK1 complex features. The effector kinases of ATM is 
Checkpoint Kinase 2 (Chk2) and for ATR is Chk1. All of these kinases within the DDR are 
active at the DNA damage checkpoints within the cell cycle at G1, G2 and S-phase (Kastan & 
Bartek, 2004). 
The phosphorylation of Emi1 is a highly specific pathway that is enriched in the Pathway 
Commons analysis. Early Mitotic Inhibitor 1 (Emi1) also known as FBX05 is a protein 




(APC/C) during interphase (Di Fiore & Pines, 2008). The phosphorylation on Emi1 by PLK1 
results in the degradation of Emi1 (Hansen et al, 2004; Moshe et al, 2004). 
Transcription factors appear in the Pathway Commons analysis. Forkhead Box M1 (FOXM1) 
protein is a transcription factor that is required for entry into G1, G2 and mitosis (Costa, 2005). 
FOXM1 -/- mice show a reduction in PLK1 and Aurora B kinases. This indicates FOXM1 
expression is required for the expression of these cell cycle proteins (Krupczak-Hollis et al, 
2004).  
The E2F transcription factor network also appears in the Pathway Commons analysis as does 
E2F mediated regulation of DNA replication. The E2F family of transcription factors are 
involved in the regulation of the cell cycle. Sub-groups of the E2F family have roles in the 
progression through the cell cycle, cell cycle exit and differentiation, and transcriptional 
repression, respectively (Attwooll et al, 2004). Interestingly the E2F transcription factors 
E2F Transcription Factor 1 (E2F1) and E2F4 appear as the principle transcription factor 
bindings sites highlighted in the Transcription Factor Target Analysis.  
In the Pathway Commons analysis, pathways that are primarily associated with the immune 
system also appear. Interlukin-12 (IL-12)-mediated signalling events is present.  IL-12 is 
secreted by dendritic cells and matures naive T-cells into Th1 cells as part of the adaptive 
immune response (Macatonia et al, 1995). Within the immune response IL-12 signalling can 
also modify the function of other immune cell types such as enhancing the cytotoxic abilities 
of natural killer cells and cytotoxic T lymphocytes as well as bringing about the production of 
the cytokine INF-ᵞ (Trinchieri, 2003).  
CD40/CD40L signalling is listed in the Pathway Commons analysis. Cluster of Differentiation 
40 (CD40) and Cluster of Differentiation 40 Ligand (CD40L) are respectively, a receptor and 
ligand that are frequently associated with the adaptive immune response although are present 
in a variety of cell types. CD40 and CD40L function in a co-stimulatory capacity often 
secondary to other receptor based signalling mechanisms and are important in the activation 
of naive T cells, B-cells and macrophages (Schönbeck & Libby, 2001).  
Interestingly four pathways appear on the Pathway Commons analysis that have been 
researched as part of investigations into the pathophysiology of major mental illness. Kinesins 
are motor proteins that facilitate anterograde transport along microtubules  and are important 
in both intracellular transport (Hirokawa et al, 2009) and within spindle dynamics during 




(KIF5A), whereupon DISC functions axonally as a cargo-receptor for the localisation of the 
cargo complex NDEL/LIS/14-3-3ε (Taya et al, 2007). Additionally, in mitochondrial 
fractionations, the DISC1 disease associated structural variant 37W (R37W) (Song et al, 2008; 
Thomson et al, 2014) has been observed to have a two-fold greater association to kinesin 
within than WT-DISC1 (Ogawa et al, 2014).   
Reelin is a glycoprotein with a multifunctional role in brain development. During embryonic 
development reelin has a role in neuronal migration (D'Arcangelo, 2014). Postnatally reelin is 
involved in the development of apical dendrites and dendritic spines and in adulthood reelin 
functions to modulate synaptic plasticity with reelin enhancing long term potentiation 
(D'Arcangelo, 2014). Reelin has been associated with a number of neurodevelopmental 
diseases including schizophrenia, bipolar disorder, major depressive disorder and autism as 
well as with neurodegeneration via Alzheimer ’s disease (Folsom & Fatemi, 2013). For 
example, reelin levels have been observed to be reduced within the PFC in post-mortem brain 
studies from patients with schizophrenia and bipolar disorder (Guidotti et al, 2000), while the 
serum levels of reelin isoforms in the blood of patients with schizophrenia, bipolar disorder 
and major depressive disorder is markedly altered in isoform composition compared to 
controls (Fatemi et al, 2001). There is a connection between reelin signalling and DISC1. An 
epistatic interaction has been identified between the reelin SNP rs580884 and the DISC1 SNP 
rs3738401 in a neurogenomics study focusing on using an MRI derived intermediate 
phenotype of schizophrenia to identify gene interactions. The epistasis is associated with a 
reduction in cerebral tissue and with an increase in ventricular brain ratio (Andreasen et al, 
2011). It is possible that the reelin pathway dysregulation in the t(1;11) microarray data set is 
highlighting another means to contribute to the high level of major mental illness seen in the 
t(1;11) pedigree. However, it should be heeded that the p-value for this finding is just 
significant at p<0.05 at p=0.0455 and this pathway is several orders of significance less than 
the bulk of the cell cycle focussed results. 
Fanconi Anaemia is an autosomal recessive or X-linked disorder. Sufferers of this disease 
present a wide clinical phenotype due to the accumulation of spontaneous DNA damage 
arising from DNA interstrand crosslinking. Bone marrow failure is central to the disease along 
with congenital abnormalities and cancer is frequently seen. As such the Fanconi Anaemia 
pathway is proposed to be a means of maintaining genomic stability with research into the 
pathway encompassing amongst others, the fields of DNA repair, oncogenesis and the 
ubiquitination of protein (Moldovan & D’Andrea, 2009). The t(1;11) family do not appear to 




t(1;11) microarray analysis may simply highlight an enrichment of genes within the canonical 
Fanconi Anaemia pathway. Mutations is the gene FANCD2/FANCI-Associated Nuclease 1 
(FAN1) which is part of the Fanconi Anaemia pathway is associated with both schizophrenia 
and autism (Ionita-Laza et al, 2014). It is hypothesised that as FAN1 is involved in DNA repair 
the mutations may cause pathophysiological abnormalities by mediating aberrant DNA repair.      
In addition to the pathways listed above telomere functions also appear as a pathway within 
Pathway Commons analysis. Regarding the cell cycle, the passage of a cell through repeated 
cell cycles increases telomere length (Marcand et al, 2000). The pathway data may therefore 
be highlighting gene enrichment to telomere pathways arising from changes to telomere 
maintenance due to an overall cell cycle disruption in the t(1;11) lymphoblastoid cell lines. 
Furthermore, the shortening of telomeres has been associated with depression (Hartmann et 
al, 2010; Wikgren et al, 2012). 
 
6.3.5 KEGG Analysis 
KEGG pathway analysis is a web based pathway analysis program whereby the pathway maps 
are annotated from the databases of the Kyoto Encyclopaedia of Genes and Genomes 
(Kanehisa et al, 2008). (http://www.genome.jp/kegg/ 
,http://bioinfo.vanderbilt.edu/webgestalt/analysis.php). For the KEGG pathway analysis a 
significance level of p<0.05 was applied.  
In the KEGG analysis the cell cycle is the most significantly enriched pathway for both of the 
GOI lists analysed (see tables 6.3.G and 6.3.H). The second most enriched pathway is 
progesterone-mediated oocyte maturation, this pathway maps gene dysregulation downstream 
of progesterone signalling extracellularly and includes both signal transduction and the MAPK 
signalling pathways. The progesterone-mediated oocyte maturation pathway is predominantly 
upstream of the cell cycle and completely upstream of meiosis I and II. As such the enrichment 
of the progesterone modulated oocyte pathway can be seen as a precursor to oocyte maturation 
that includes cell cycle components. If taken superficially as an enrichment of progesterone 
mediated signalling the progesterone-mediated oocyte maturation pathway may be associated 
with major mental illness. Progesterone treatment has been observed to increase both the levels 
of BDNF protein and mRNA (Kaur et al, 2007). In sufferers of schizophrenia the serum levels 
of BDNF commonly show sexual dimorphism, however as to which sex has the higher serum 
level depends on the experimental methodologies and selection criteria used (Jindal et al, 




schizophrenia is partially dependent on sex steroid hormones such as progesterone (Hill, 
2012). 
The third most enriched pathway, oocyte meiosis, maps all of the meiotic cell cycle as well as 
condensed aspects of progesterone mediated oocyte maturation. As such, within oocyte 
meiosis prophase I occurs followed by germinal vesicle breakdown, meiosis I, interkinesis and 
meiosis II. Each of these steps in meiosis includes genes that are dysregulated. The pathway 
enrichment of oocyte meiosis can be taken as further evidence of cell cycle dysregulation 
within the differentially expressed genes from the t(1;11) lymphoblastoid cell lines of the 
original unfiltered and neuronally filtered GOI lists.  
In the KEGG analysis the only difference between the GOI lists was the order of magnitude 
of the significance of the pathway enrichment. Both the unfiltered GOI list and the neuronally 
filtered GOI list analysis brought up the same 3 enriched pathways.  
 
KEGG Pathway Observed Expected Ratio  p-value 
Cell cycle 25 9.46 2.64 7.00E-04 
Progesterone-mediated oocyte 
maturation 18 6.25 2.88 2.10E-03 
Oocyte meiosis 18 7.26 2.48 1.01E-02 
 
Table 6.3.G: KEGG Analysis for the unfiltered GOI list. Observed and expected 
are measures of the number of genes and ratio is the observed number of 





Table 6.3.H: KEGG Analysis for the neuronally filtered GOI list. Observed and 
expected are measures of the number of genes and ratio is the observed 
number of genes/expected number of genes. 
 
KEGG Pathway Observed Expected Ratio  p-value 
Cell cycle 24 9.44 2.54 2.10E-03 
Progesterone-mediated oocyte 
maturation 17 6.08 2.8 5.10E-03 




6.3.6 Wikipathways Analysis 
Wikipathways is a web based pathways analysis program whereby the curation of pathway 
data is mediated by the community (Pico et al, 2008). 
(http://bioinfo.vanderbilt.edu/webgestalt/analysis.php,http://www.wikipathways.org/index.ph
p/WikiPathways). In the Wikipathways analysis a significance level of p<0.05 was applied.  
The pathway enrichment in the Wikipathways analysis of Cell cycle and DNA replication (see 
tables 6.3.I and 6.3.J) is in agreement with results from GOTree, KEGG pathways analysis 
and the Pathway Commons analysis. The enrichment of the integrated Cancer pathway may 
be a by-product of the overall enrichment of cell cycle data within this analysis, given that the 
cell cycle and cancer are virtually synonymous. Such a pathway enrichment need not 
necessarily suggest that the t(1;11) pedigree have an increased susceptibility to cancer 
following this result, rather that the differentially expressed data pertaining to the cell cycle is 
dysregulated to a sufficient degree to produce this enrichment.  
The use of the different GOI lists in this analysis produces little difference in terms of final 
pathway enrichment. The analysis of the neuronal filtered GOI list over the original unfiltered 
GOI list merely produces a difference in the rankings of the enriched pathways. 
 
Wikipathway Observed Expected Ratio  p-value 
Cell cycle 22 8.82 2.49 5.50E-03 
DNA Replication 12 3.86 3.11 1.89E-02 
Integrated Cancer pathway 3 0.28 10.89 3.36E-02 
 
Table 6.3.I: Wikipathways Analysis for the unfiltered GOI list. Observed and 
expected are measures of the number of genes and ratio is the observed 









Wikipathway Observed Expected Ratio  p-value 
DNA Replication 12 3.74 3.21 1.25E-02 
Cell cycle 21 8.7 2.42 1.25E-02 
Integrated Cancer pathway 3 0.28 10.7 3.33E-02 
 
Table 6.3.J: Wikipathways Analysis for the neuronally filtered GOI list. 
Observed and expected are measures of the number of genes and ratio is the 
observed number of genes/expected number of genes. 
 
6.3.7 Transcription Factor Target Analysis 
To see if the dysregulated genes from the t(1;11) microarray data were targeted by specific 
transcription factors, Transcription Factor Target Analysis was performed 
(http://bioinfo.vanderbilt.edu/webgestalt/analysis.php). The gene sets for Transcription Factor 
Target Analysis are curated by MSigDB (Liberzon et al, 2011) 
(http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=TFT). For the 
Transcription Factor Target Analysis a cut-off of p<0.05 was applied.  
 The transcription factor gene sets that are identified are targeted by either the E2F1 
transcription factor or the E2F1 and E2F4 transcription factors in conjunction with a 
dimerization partner or refer to a transcription factor motif for which a specific transcription 
has yet to be identified (see tables 6.3.K and 6.3L)  
The dysregulated genes in the gene sets V$E2F1_Q6 and V$E2F1_Q3, have a promoter region 
between 2kb downstream or upstream of the transcription start site encoding a TTTSGCGS 
motif and NKTSSCGC motif, respectively and are both targets for E2F1.  
In the gene sets V$E2F1DP2_01 and  V$E2F1DP1_01 the dysregulated genes highlighted 
have a promoter region between 2kb downstream or upstream of the transcription start site 
encoding both TTTSSCGC and TTTCSCGC motifs. These dysregulated genes are targeted by 
E2F1 transcription factor in a heterodimer along with the transcription factors E2F 
Dimerization Partner 2 (TFDP2) and E2F Dimerization Partner 1 (TFDP1), respectively. 
Likewise the gene sets V$E2F4DP1_01 and V$E2F4DP2_01 have respective motifs of 
TTTSGCGC and TTTCSCGC. The dysregulated genes in these gene sets are targeted by E2F4 
heterodimer containing either TFDP1 or TFDP2, respectively, that interacts with the tumour 






Transcription Factor Gene 
Set Observed Expected Ratio  p-value 
E2F1 hsa_V$E2F1_Q6 34 16.54 2.06 2.15E-02 
E2F1 hsa_V$E2F1_Q3 31 16.26 1.91 2.24E-02 
E2F1 & 
TFDP2 hsa_V$E2F1DP2_01 31 15.89 1.95 2.24E-02 
Unknown hsa_V$E2F_Q6 31 16.17 1.92 2.24E-02 
E2F4 
p107/p130 & 
TFDP1 hsa_V$E2F4DP1_01 31 16.17 1.92 2.24E-02 
E2F1 & 
TFDP1 hsa_V$E2F1DP1_01 31 15.89 1.95 2.24E-02 
Unknown hsa_V$E2F_02 31 15.98 1.94 2.24E-02 
E2F4 
p107/p130 & 
TFDP2 hsa_V$E2F4DP2_01 31 15.89 1.95 2.24E-02 
Unknown hsa_V$E2F_Q4 31 16.44 1.89 2.65E-02 
Unknown hsa_GATTGGY_V$NFY_Q6_01 99 72.75 1.36 4.78E-02 
 
Table 6.3.K: Transcription Factor Target Analysis for the unfiltered GOI list. 
Observed and expected are measures of the number of genes and ratio is the 
observed number of genes/expected number of genes. 
 
The gene sets V$E2F_Q6, V$E2F_02, V$E2F_Q4 and GATTGGY_V$NFY_Q6_01 again 
target the dysregulated genes promoter region at plus or minus 2kb from the transcription start 
site. These gene sets contain the respective motifs of TTTSGCGS TTTSGCGC, TTTSGCGS 
and GATTGGY. However, these transcription factor binding sites do not match any known 
transcription factors.  
For the dysregulated genes within the gene sets associated with E2F1 and E2F4, a strong trend 
in the downregulation of gene expression is revealed when they were searched for within the 
microarray data (data not shown). In line with this the gene expression of E2F1 and E2F4 is 








Gene set Observed Expected Ratio  p-value 
Unknown hsa_V$E2F_02 30 15.33 1.96 2.38E-02 
E2F4 
p107/p130 & 
TFDP2 hsa_V$E2F4DP2_01 30 15.24 1.97 2.38E-02 
E2F4 
p107/p130 & 
TFDP1 hsa_V$E2F1DP1_01 30 15.24 1.97 2.38E-02 
Unknown hsa_V$E2F1_Q6 33 15.99 2.06 2.38E-02 
E2F1 & 
TFDP2 hsa_V$E2F1DP2_01 30 15.24 1.97 2.38E-02 
E2F1 & 
TFDP1 hsa_V$E2F4DP1_01 30 15.52 1.93 2.97E-02 
E2F1 hsa_V$E2F_Q6 30 15.71 1.91 3.40E-02 
Unknown hsa_V$E2F_Q4 30 15.99 1.88 3.72E-02 
E2F1 hsa_V$E2F1_Q3 29 15.52 1.87 4.63E-02 
 
Table 6.3.L: Transcription Factor Target Analysis for the neuronally filtered GOI 
list. Observed and expected are measures of the number of genes and ratio is 
the observed number of genes/expected number of genes.  
 
E2F1 and E2F4 are thought to have contrasting roles in the cell cycle. The overexpression of 
E2F1 propagates the movement of quiescent cells through G0 into S-phase (Johnson et al, 
1993). The overexpression of E2F1 is also associated with both p53-dependent (Kowalik et 
al, 1995; Qin et al, 1994)  and independent apoptosis (Nahle et al, 2002). Recent advances in 
the understanding of E2F1 function within the cell cycle have led to a dual role of E2F1 being 
proposed within oncogenesis. Classically E2F1 has been seen as a tumour suppressor 
participating in apoptosis following the detection of damage to DNA. However, recent 
research suggests that E2F1 may function within a tumour progression signalling pathway, 
whereby the activity of E2F1 promotes oncogenesis (Engelmann & Putzer, 2012).  
Whereas E2F1 is seen as an activator E2F, E2F4 is seen as a repressor that is associated with 
differentiation and growth suppression. For example, in oncogenesis E2F4 appears to function 




establishing of G2 arrest following DNA damage, preventing cell cycle progression  into M-
phase (Plesca et al, 2007).  
A role of E2F4 in differentiation is supported by evidence from animal models of E2F4 -/- 
transgenic mice. These animals are of reduced size and display evidence of altered cellular 
development to multiple cell lines, especially hematopoietic cell types, as well as possessing 
craniofacial abnormalities (Humbert et al, 2000; Rempel et al, 2000).  
The use of the differing unfiltered GOI and neuronal filtered GOI lists makes little difference 
in terms of the number of genes that appear in the gene sets, the analysis results are produced 
from essentially the same set of common set of 29-34 genes bar the result for 
hsa_GATTGGY_V$NFY_Q6_01 in the unfiltered GOI list . However the ranking of the 
significance of the gene set results differs markedly between the unfiltered GOI and the 
neuronal filtered GOI list analysis. The results for both analysis compliment the theme in the 
t(1;11) microarray data analysis of there being a dysfunction in the cell cycle occurring. 
 
6.3.8 Disease Association Analysis 
Disease Association Analysis is a web based program supported by Gene List Derived 
Automatically for You, which associates disease terms to gene lists of interest using PubMED 
sources (Jourquin et al, 2012). (http://bioinfo.vanderbilt.edu/glad4u, 
http://bioinfo.vanderbilt.edu/webgestalt/analysis.php). For the Disease Association Analysis a 
significance level of p<0.05 was applied. 
Aneuploidy is the most significant result for both the unfiltered and filtered GOI lists (see 
tables 6.3.M and 6.3.N). Aneuploidy is the condition whereby a cell exists that has either 
gained or lost one or more chromosomes resulting in the cell no longer containing the normal 
chromosome number for the given species. As such aneuploidy is associated with a variety of 
distinct disease pathologies. Aneuploidy arises due to abnormalities in the recombination of 
chromatids during either meiosis I or II, which commonly includes the premature separation 
of sister chromatids (Nagaoka et al, 2012). Cell and tissue specific aneuploidy is also 
characteristic of cancer. In cancer the genomic instability propagated by aneuploidy can lead 
to deficits in cell function mediated by alterations to the transciptosome and the proteome 





Disease Observed Expected Ratio  p-value 
Aneuploidy 27 8.91 3.03 1.00E-04 
Cancer or viral infections 75 46.94 1.6 1.31E-02 
Hodgkin Disease 22 9.19 2.39 2.90E-02 
 
Table 6.3.M: Disease Association Analysis for the unfiltered GOI list. Observed 
and expected are measures of the number of genes and ratio is the observed 







Table 6.3.N: Disease Association Analysis for the neuronally filtered GOI list. 
Observed and expected are measures of the number of genes and ratio is the 
observed number of genes/expected number of genes. 
 
However, it is extremely unlikely that the t(1;11) pedigree suffer from aneuploidy, such an 
occurrence would have been detected during the initial cytogenetic karyotyping of the t(1;11) 
pedigree (St Clair et al, 1990). It is possible that aneuploidy may be intrinsic to the 
lymphoblastoid cell lines assayed on the microarray. If lymphoblastoid cell lines are cultured 
for long periods of time, e.g. over 180 population doubling levels, they can immortalise 
gaining strong telomerase activity and aneuploidy. In this context immortalisation refers to the 
long-lifespan of such cells in culture rather than the process of the EBV transformation of the 
cell lines (Sugimoto et al, 2004). Although, as this is differential expression data such an 
explanation would require that only the t(1;11) lymphoblastoid cell lines assayed were 
immortalised and the control cell lines not. A more likely explanation is that aneuploidy is 
arising in the disease association due to a) the enrichment of cell cycle processes in general or 
b) due to the DNA damage and repair mechanisms associated with the translocation.  
Disease Observed Expected Ratio  p-value 
Aneuploidy 26 8.79 2.96 3.00E-04 
Immune System Diseases 47 25.34 1.85 1.03E-02 
Bronchiolitis 20 8.13 2.46 0.0329 
Bronchitis 20 8.51 2.35 0.0395 




Immune system diseases is also broad category for gene enrichment to occur in. The vast 
majority of the genes in this category are associated with immune function. This result may 
therefore reflect the dysregulation of immune function within Disease Association Analysis. 
The dysfunction of the immune system is fundamental to the pathophysiology of 
schizophrenia. The detrimental effects of immune dysfunction may occur at various points in 
neurodevelopment throughout the individual’s lifespan. This is evidenced by data from 
GWAS, post-mortem transcriptome studies, the study of peripheral biomarkers and animal 
models of maternal immune activation (Michel et al, 2012). Kinney et al., (2010), goes so far 
as to propose a unifying hypothesis on schizophrenia that focuses of vulnerabilities within the 
development of the immune system and its function in contrast to a neurodevelopmental 
hypothesis of schizophrenia. 
Cancer and viral infections is a broad category for gene enrichment to occur in. Multiple genes 
contributing to this result are either oncogenes or genes fundamental to cell cycle function. 
This result may arise from the wide scale enrichment of cell cycle pathways and ontology 
within this chapter and so the occurrence of this result probably reflects the involvement of 
cell cycle dysregulation in cancer within the Disease Association Analysis. It may also be the 
case that this classifier refers to instances where viruses act as cancer agents in oncogenesis 
(White et al, 2014). In the analysis of the neuroanally filtered GOI list cancer and viral 
infections just passes the significance level of p<0.05. 
Hodgkin’s disease also known as Hodgkin lymphoma is a form of cancer that originates from 
B-cells and is highly common in occurrence for a lymphoma (Küppers et al, 2012). The 
occurrence of Hodgkin disease in the Disease Association Analysis appears to be primarily 
due to the presence of multiple genes associated with immune function being dysregulated. A 
secondary contribution to Hodgkin’s disease being highlighted comes from the presence of 
several Hodgkin’s disease specific genes and from genes that may be exclusive to the 
unfiltered GOI list that pertain to B-cell mediated processes. 
Bronchitis is the transitory inflammation of the large airways of the lung associated with 
coughing in the absence of pneumonia. Pathologically the inflammation originates due to the 
infection of the epithelium of the bronchi  (Wenzel & Fowler III, 2006). Bronchiolitis is a 
respiratory infection that occurs in young children and affects the small airways of the lung. 
Pathologically the inflammation originates from the infection of respiratory tract epithelium 
(Smyth & Openshaw, 2006). Both the bronchitis and bronchiolitis results in the Disease 




these two results should not be interpreted as the t(1;11) pedigree having an enhanced 
susceptibility to respiratory diseases, rather that immune response, in particular inflammation 
is possibly altered in the t(1;11) lymphoblastoid cell lines assayed. Alterations in inflammation 
are thought to have a role in schizophrenia in adults (Kirkpatrick & Miller, 2013) while 
prenatal inflammation is itself a risk factor for schizophrenia (Miller et al, 2013). In the 
analysis of the neuroanally filtered GOI list both bronchitis and bronchiolitis just pass the 
significance level of p<0.05. 
 
6.4 Discussion 
The functional enrichment analysis of t(1;11) gene expression microarray data possess several 
limitations. The samples sizes are small and only technical replicates as opposed to sample 
replicates were performed. The lymphoblastoid cell lines used are at best likely to have a 
moderate correlation in transcript expression to that of post-mortem brain tissue (Cai et al, 
2010; Sullivan et al, 2006). No comparison with either fresh whole blood or fractionated blood 
has been performed, had this been done, confounding factors induced by EBV transformations 
of lymphoblastoid cell lines could possibly be identified.  Regarding the data analysis, the 
over-representation analysis based programs used do not accept fold change data nor do they 
account for relationships that may exist between genes (Khatri et al, 2012). Furthermore, it is 
extremely likely that the databases that support the pathway analysis and ontology programs 
are biased towards cancer-related processes, including the cell-cycle.  As a consequence of 
this further experimental work is required to determine whether the translocation has an effect 
on the cell-cycle or whether this finding reflects an intrinsic bias of pathway analysis programs. 
Additionally, multiple enrichment categories analysed are only marginally significant and as 
such may not replicate.     
 
6.4.1 Cell cycle dysregulation  
Looking at the output of multiple pathway analysis programs, there is clear evidence for 
alterations to the cell cycle and DNA replication in translocation carriers. Several of the 
functional enrichments also suggest that the translocation might affect immune function and 
inflammation.  
The involvement of aberrant cell cycle function in the pathogenesis of psychiatric illness is 




(ACG) using post-mortem brains of individuals with schizophrenia detects alterations to the 
cell cycle and categories associated with cell cycle using Ingenuity Pathway Analysis (IPA), 
by both network analysis and the analysis of molecular and cellular functions (Katsel et al, 
2008). The pattern of cell cycle dysregulation within the ACG suggests an over activity of the 
cell cycle possibly incurring the re-entry of cells into the cell cycle. Genes associated with G1 
activation, Cyclin D1 (CCND1) and Cyclin D2 (CCND2) are upregulated. Whereas genes 
associated with the downregulation of the cell cycle such as Cyclin-dependent Kinase Inhibitor 
1B (p27Kip1) and Cyclin-dependent Kinase Inhibitor 1C (p57Kip2) are downregulated. Overall 
this would suggest a progression from G1 to S-phase readily occurs in the ACG in 
schizophrenia. Additionally, genes associated with S-phase are also upregulated, suggesting 
that S-phase is also active (Katsel et al, 2008).  
Olfactory epithelial biopsies have been used to study the relationship between schizophrenia 
and the cell cycle (Fan et al, 2012; Féron et al, 1999; McCurdy et al, 2006). Féron et al., (1999) 
observed that the number of non-neuronal cells in mitosis in biopsies from patients with 
schizophrenia is two and a half times that for control cell biopsies. This has been replicated by 
comparing patients with schizophrenia to patients with bipolar I disorder as well as healthy 
controls. Again, the same proportional increase in mitosis for the cell biopsies from 
schizophrenia patients is seen, with no difference between bipolar individuals and controls 
(McCurdy et al, 2006). This is suggestive of an increased rate of proliferation occurring in 
schizophrenia. It is possible that the enrichment of mitosis categories in the GOTree and 
Pathway Commons analysis may have been highlighting such an enhancement of mitosis. 
However, it is equally possible that these enrichments may be highlighting a deficit in mitosis. 
Further experimentation is required to determine the underpinnings of the mitotic 
dysregulation in the t(1;11)-family derived lymphoblastoid cell lines.   
Gene expression microarray analysis of the olfactory epithelial biopsies from individuals with 
schizophrenia reveals enrichments relating to the cell cycle, in both DNA recombination and 
the positive regulation of cell proliferation, by GO (McCurdy et al, 2006). Furthermore, 
olfactory neurosphere-derived cells from patients with schizophrenia show altered cell cycle 
dynamics, with patient cells observed to spend a greater amount of time in S/G2/M-phases as 
opposed to G1. Interestingly, the cell cycle phase of the patient olfactory neurosphere-derived 
cells was two hours ahead of the control cell lines and in line with this the total length of the 
cell cycle was two hours shorter in the patient cell lines versus those of controls (Fan et al, 
2012). A future experiment, that would enrich the current data on cell cycle dysregulation in 




length of time t(1;11)-family derived lymphoblastoid cell lines spent in particular cell cycle 
phases. This would add a temporal aspect to the interpretation of the pathway analysis data. 
Regarding DISC1 function in relation to the cell cycle, the knockdown of mouse DISC1 in 
neural progenitors in the ventricular zone/sub-ventricular zone, results in a 2-3 fold increase 
in the number of progenitor cells exiting the cell cycle. In addition to this, altered 
differentiation is apparent (Mao et al, 2009). This is interesting as the t(1;11)-family derived 
lymphoblastoid cell lines assayed on the microarray have been shown to have half normal 
levels of DISC1protein expression (Millar et al, 2005b). It is possible that this may have the 
same premature cell cycle exit effect as the reduction of DISC1 induced by RNAi as performed 
by Mao et al., (2009). The expression of DISC1 aa1-597 in the inducible ΔhDISC1 mouse 
model results in the dysregulation of several cell cycle genes that are associated with the 
differentiation of oligodendrocyte precursor cells (Katsel et al, 2011). The DISC1/DISC1FP1 
species CP1 encodes DISC1 aa1-598. If expressed endogenously in the t(1;11)-family derived 
lymphoblastoid cell lines, CP1  could result in the same dysregulation of cell cycle genes 
observed by Katsel et al., (2011). However, CP1 protein has not been detected in the t(1;11) 
lymphoblastoid cell line by Western blot, although the species may be present below the 
threshold of detection (Eykelenboom et al, 2012). 
Multiple studies, in both cultured cell lines and primary neurones identify DISC1 as being 
localised at the centrosome (Bradshaw et al, 2008; Kamiya et al, 2005; Kamiya et al, 2008; 
Miyoshi et al, 2004; Morris et al, 2003). The centrosome features as a highlighted GO category 
in GOTree. In eukaryotes the centrosome functions as the major microtubule organising centre 
within the cell, whereupon the centrosome establishes and coordinates microtubule arrays to 
other intracellular structures during mitosis (Bettencourt-Dias & Glover, 2007). Several 
DISC1 interactors exist that are also centrosomal proteins, this includes: various BSS proteins, 
Coiled-coil Protein Associated with Myosin II and DISC1 (CAMDI), LIS1, NDE1, NDEL1, 
PCM1 and pericentrin (Brandon et al, 2004; Camargo et al, 2006; Fukuda et al, 2010b; 
Kamiya et al, 2008; Miyoshi et al, 2004; Ozeki et al, 2003; Shinoda et al, 2007). These 
proteins typically have roles with centrosomally mediated effects that contribute to 
neurodevelopment (Thomson et al, 2013). However, it may be that these centrosomal proteins 
also have roles in the cell cycle and so perhaps could in part explain some of the dysregulation 
of the cell cycle that is seen in the t(1;11) microarray analysis. For example, the importance of 
LIS1 in the cell cycle is highlighted in a series of experiments using mouse embryonic 
fibroblasts from LIS1 knockout mice that display a variety of mitotic defects (Moon et al, 




misegregation of chromosomes during anaphase, the presence of additional centromeres, 
abnormal mitotic spindle positioning and orientation and a reduction in the targeting of LIS1 
to kinetochores. It is possible that DISC1 at the centrosome binds LIS1 during the typical 
mitotic activity of LIS1. If this is the case such an interaction may be reduced in the t(1;11)-
family derived lymphoblastoid cell lines due to haploinsufficiency (Millar et al, 2005b). It 
may be then that reduced DISC1/LIS1 binding results in the propagation of mitotic deficits 
similar to those observed by Moon et al.,(2014). Future research into cell cycle dysregulation 
during mitosis in the t(1;11) family derived lymphoblastoid cell line could involve 
immunocytochemistry at the various stages of mitosis. This would use antibodies targeting 
DISC1 and DISC1 interactors that are located at the centrosome as well as visualising the 
kinetochore, the chromosomes and the α-tubulin of the mitotic spindle. The aim of this series 
of experiments would be to see what is actually occurring during the mitotic stages and to 
identify any aberrant function arising via reductions in the endogenous levels of DISC1 due to 
haploinsufficiency.         
Recent research identifies PDE4D9 as being active during mitosis, modulating the levels of 
both cAMP and PKA via the hydrolysis of cAMP. Inhibition of PDE4D9 results in the 
dysregulation of cell cycle transition with accelerated progress from S-phase to G2/M phase 
observed, alongside a rapid G2/M transition into a lengthened G1 phase (Sheppard et al, 2014). 
PDE4D9 is transcriptionally repressed by an ATF4/DISC1 complex. The loss of function of 
either component of the transcriptional repression complex results in an increase in PDE4D9 
transcription (Soda et al, 2013). It is possible that some of the cell cycle dysregulation detected 
by pathway analysis and GO may arise from alterations to PDE4D9 transcription and function, 
due to the t(1;11)-family derived lymphoblastoid cell lines assayed on the microarray being 
haploinsufficient for DISC1 (Millar et al, 2005b). The effects of haploinsufficiency of DISC1 
on PDE4D9 may be two-fold. Firstly the transcriptional repression by the DISC1/ATF4 
complex may be reduced, with half normal levels of DISC1 present, leading to an abundance 
of PDE4D9. Secondly there will be a reduction in the interactions between DISC1 and 
PDE4D9. This will be a reduction in the sequestering of PDE4D9 in a low activity state, as 
occurs between DISC1 and other PDE4s (Millar et al, 2005b; Murdoch et al, 2007). Overall 
the haploinsufficiency would engender a greater amount of PDE4D9 in cells that would in turn 
be more actively hydrolysing cAMP and, therefore, reducing PKA levels, actions that will 
have downstream signalling effects throughout the cell cycle.  
Multiple categories of G1 transitions appear in the Pathway Commons analysis. The length of 




G1 phases favour proliferative cell divisions, whereby neuronal cells re-enter the cell cycle. 
Long G1 phases favour differentiated divisions whereby differentiated cells exit the cell cycle 
(Calegari & Huttner, 2003). The lengthening of G1 phase to provide a pool of differentiated 
cells is of particular importance in mid-late corticogenesis (Dehay & Kennedy, 2007). 
Therefore it is possible that in the t(1;11)-family derived lymphoblastoid cell lines that G1 
phase has an altered phase length from that of control cell lines. This could lead to an alteration 
in the stoichiometry in the maintenance of proliferative/differentiated pools of cells which 
could impact on upstream corticogenesis. The length of G1 phase could be investigated in the 
future using time-lapse video microscopy.  
It may be that the enrichment of G2 phase pathways that is observed in the Pathway Commons 
analysis, reflects processes in cell cycle dysregulation that may have shortened or lengthened 
this phase. G2 phase length has also been associated with the differential production of 
proliferating cells and differentiated cells. The knock-down of the positive cell cycle regulator 
Cell Division Cycle 25B (CDC25B) results in the lengthening of G2 phase and favours the 
production of neural progenitors. Conversely at basal levels of CDC25B, when co-expressed 
with Cell Division cycle 25A (CDC25A), G2 phase is shorter and neurogenesis occurs with 
the production of differentiated cells occurs (Peco et al, 2012). . It is possible that G2 phase 
length alteration could be the precipitant of a process that may occur in the brains of the t(1;11) 
pedigree, that alters the balance in the production of proliferating versus differentiating cells 
during neurogenesis.  
GoTree and multiple pathway analysis programs identify DNA replication, which specifically 
occurs in S-phase, as being enriched for genes showing differential expression in carriers of 
the t(1;11) translocation The length of S-phase has also been observed to vary with the cell 
type emerging from the cell cycle. Proliferating apical and basal progenitors have been seen 
to spend a longer time in S-phase than apical and basal progenitors that differentiate into post-
mitotic neurones. It is inferred from this that the progenitors that are retained in the 
proliferating pool engage in a lengthier S-phase transition to ensure greater DNA quality 
control (Arai et al, 2011).  It is possible that the length of S-phase varies in the t(1;11) 
lymphoblastoid cell lines assayed which may affect cell fate determination as to whether cells 
emerge from the cell cycle as progenitors or as differentiated cells.   31L mice contain ENU 
induced point mutations that cause amino acid changes (Q31L) to DISC1 and result 
depression-like phenotype (Clapcote et al, 2007). 31L mice have been observed to possess a 
deficit in proliferating cells in the hippocampus  as evidenced by reduced number of 




mutation to Disc1 may induce cell cycle abnormalities that share underpinnings with the 
biological pathway deficits observed in this study.  
The widespread dysregulation of M-phase and in particular mitosis evident in the GOTree and 
Pathway Commons analysis may represent a process that could impact upon intrinsic cell 
asymmetry within neural stem cell populations within the t(1;11) pedigree. Cell asymmetry 
arises when a stem cell divides into phenotypically different daughter cells in terms of cell size 
and macromolecular continent. The asymmetry between the daughter cells results in 
differential cell fate determination. During mitosis the positioning of the mitotic spindle 
(asymmetric rather than centred) and the asymmetric accumulation of cell fate determinants 
within the dividing cell specify for asymmetrical as opposed to symmetrical cell division 
(Neumüller & Knoblich, 2009). It is possible that the dysregulation of mitosis in the t(1;11)-
family derived lymphoblastoid cell represents mechanisms by which intrinsic asymmetrical 
division in the brain could be perturbed. This could result in the final daughter cell phenotypes 
being fundamentally altered from those occurring in a normal developmental pathway in the 
absence of cell cycle dysregulation.   
Translating the blood based t(1;11) microarray data on cell cycle dysregulation to the actual 
functions of the brain in the t(1;11) pedigree may not be clear cut. It may be inappropriate to 
take a view with a single global brain based dysfunction in the cell cycle from the data. For 
example Benes et al., (2009) examined both bipolar and schizophrenia post-mortem brain 
samples from the strata oriens of the hippocampus and site specific deficits were apparent 
between the CA2/3 and CA1 regions in cell cycle gene expression. The site specific deficits 
were both within and between groups, suggesting that even within very local regions of the 
brain there can be differences in the cell cycle dysregulation associated with pathophysiology. 
As such an appropriate future experiment would be to run gene expression microarray analysis 
on multiple brain areas from post-mortem t(1;11) brain tissue to further elaborate on the cell 
cycle dysfunction regarding regional brain deficits. 
 
6.4.2 Immune function and inflammation enrichment 
Multiple genome wide association studies have found associations between the major 
histocompatibility complex (MHC) and schizophrenia (Consortium & 2, 2012; Consortium, 
2011; Hamshere et al, 2012; Lencz et al, 2013; Purcell et al, 2009b; Ripke et al, 2013a; Shi et 
al, 2009; Stefansson et al, 2009; Yue et al, 2011). The MHC locus at 6p21.32-p22.1 contains 




being integral to the adaptive, innate and autoimmune responses (Traherne, 2008). Key to the 
MHC is the ability to discern what is ‘self’ from ‘non-self’(Richard & Brahm, 2012).  
The findings of expression microarray and RNA-seq studies also demonstrate links between 
immunity and inflammation responses and schizophrenia. The enrichment of genes involved 
in the immune response has been highlighted by GO in a post-mortem brain FC microarray 
study, with the genes Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, 
Antitrypsin), Member 3 (SERPINA3), Interferon Induced Transmembrane Protein 2 (IFITM2), 
Interferon Induced Transmembrane Protein 3 (IFITM3) and Guanylate Binding Protein 1, 
Interferon-inducible (GBP1) that are related to inflammatory process being upregulated 
(Saetre et al, 2007). A post-mortem brain microarray study specific to the PFC observed a 
>50% upregulation in genes involved in chaperone or immune function, totalling 10 genes. Of 
these, five genes were identified as being involved in immune function and appear to co-
regulate expression. These genes are SERPINA3, IFITM3, Interferon Induced Transmembrane 
Protein 1 (IFITM1), Chitinase 3-like 1 (Cartilage Glycoprotein-39) (CHI3L1) and CD14 
Molecule (CD14) (Arion et al, 2007). Conversely in a microarray study of the superior 
temporal cortex, the downregulation of 70 genes associated with immune function was 
observed (Schmitt et al, 2011). While dysregulation of the expression of immune function 
associated genes has been observed in a PFC microarray study (Garbett et al, 2008). GO 
identifies significant enrichment in the humoral response following the expression microarray 
study using post-mortem DLPFC tissue and the subsequent analysis of shared genes between  
both individuals with schizophrenia and those with bipolar disorder (Shao & Vawter, 2008). 
In a peripheral blood monocyte microarray study the functional annotation by IPA using genes 
differentially expressed in subjects with schizophrenia reveals enrichment of immune 
function. Of the IPA annotations of the functions of the differentially expressed genes, 37% 
were observed to be involved with immune and inflammation processes. This included 
infectious disease; inflammatory response; respiratory and infectious disorder and 
inflammatory and immune response (Gardiner et al, 2013). Using RNA-seq to analyse post 
mortem hippocampal tissue, enrichment mapping reveals a cluster of predominantly 
upregulated genes that are categorised as having biological involvement in defence response; 
immune response and inflammatory response. Within the same hippocampal dataset from 
individuals diagnosed with schizophrenia, the mRNA of the genes Adenosine A2a Receptor 
(ADORA2A); Apolipoprotein L, 1 (APOL1), Insulin-like Growth Factor Binding Protein 4 
(IGFBP4), IFITM1, IFITM2 and IFITM3 that are involved in inflammation and the immune 




DLPFC using RNA-seq, Fillman et al., (2012) found the IPA category “inflammatory 
response” to be significantly enriched, due to the increased expression of the interleukins (IL), 
IL-6, IL-8 which are proinflammatory and anti-inflammatory cytokines and SERPINA3. 
Taken together the results of these microarray and RNA-seq studies suggest a role of immune 
and inflammatory dysfunction that is detectable in tissues acquired from adults with 
schizophrenia. 
Microarray array studies also implicate immunity and inflammation in the pathophysiology of 
major depressive disorder and bipolar disorder, although the area is less well studied than 
schizophrenia. In a microarray study using post-mortem PFC tissue from subjects that had 
suffered from depression, significant enrichment in the cytokine pathway was identified. This 
was due to the upregulation in expression of the interleukins 1α (IL-1α), IL-2, IL-3, IL-5, IL-
8, IL-9, IL-10, IL-12A, IL-13, IL-15, IL-18, as well as that of Interferon Gamma (IFNγ) and 
Lymphotoxin α, (cytokines with roles in the immune and inflammatory responses), suggesting 
a role for inflammation  in the aetiology of depression (Shelton et al, 2010). Microarray 
analysis of the PFC and orbitofrontal cortex from individuals diagnosed with bipolar disorder 
has shown a significant upregulation in the expression of genes associated with the immune 
response (Ryan et al, 2006).  
Alterations to immune function can be identified in first episode drug-naive schizophrenia 
patients (Cazzullo et al, 2001; Herberth et al, 2014). Taken together, these findings suggest 
that observations of altered immune function in schizophrenia cannot be entirely attributed to 
medication effects and may represent a primary pathogenic mechanism. The cytokine profile 
in both first episode and acutely relapsed schizophrenia patients has been compared by meta-
analysis of immune system dysfunction. This reveals that the cytokine dysregulation between 
both patient populations is similar and can be grouped into both state and trait markers. IL-1β, 
IL-6, and Transforming Growth Factor Beta (TGF-β), a cytokine with roles in immunity, are 
identified as state markers and are detectable at high concentrations during acute episodes of 
illness and are reduced when patients have reached a stable baseline following antipsychotic 
treatment.  IL-12, IFN-γ, Soluble IL-2 Receptor (sIL-2R) and Tumour Necrosis Factor Alpha 
(TNF-α) a proinflammatory cytokine with roles in immunity, are trait makers and as such are 
continually associated with schizophrenia even following antipsychotic medication (Miller et 
al, 2011). Such changes in immune function may have effects on the symptomology of 
schizophrenia. Severe impairments in cognition have been associated with inflammation in 
schizophrenia. These deficits can be ameliorated following treatment with anti-inflammatory 




associated with increased concentrations of IL-6 (Garcia-Rizo et al, 2012; Kim et al, 2000). 
The structure of the brain may be influenced by cytokine levels. Increased levels of IL-6 in 
first episode psychosis patients have been associated with a reduction in the volume of the left 
hippocampus (Mondelli et al, 2011). 
Inflammation and cytokine activity has been identified as a mechanism of pathogenesis in 
depression (Miller et al, 2009). Inflammation interacts with the vast majority of disease 
domains associated with depression including neurotransmitter metabolism, endocrine 
function and neuroplasticity. The meta-analysis of cytokine immune dysregulation in major 
depressive disorder identifies higher concentrations of IL-6 and TNF-α, to be associated with 
the illness (Dowlati et al, 2010). Altered levels of cytokines and other inflammatory markers 
may influence the symptomology of depression. Regarding cognitive function and 
inflammation in depression, increased Highly Sensitive C-reactive Protein (hsCRP) a marker 
for inflammation, is associated with lower psychomotor speed. However, increased levels of 
IL-6 in patients was not associated with any cognitive effects above baseline measurements 
(Krogh et al, 2014). Sleep disturbance is common in major depressive disorder and, 
interestingly, high concentrations of nocturnal levels of IL-6 and Soluble Intercellular 
Adhesion Molecule-1 (sICAM-1) have been associated with sleep disturbances at night in 
individuals suffering from major depressive disorder (Motivala et al, 2005). Cytokines may 
have an effect on brain morphology. High IL-6 levels have also been observed to be linked to 
low hippocampal volumes in patients with major depressive disorder (Frodl et al, 2012). 
The meta-analysis of cytokine prevalence in bipolar disorder identifies elevations in the 
concentrations of a number of inflammatory mediators. This includes: IL-4, IL-6, IL-10, sIL-
2R, Soluble IL-6 Receptor (sIL-6R), TNF-α, Soluble TNF Receptor-1 (sTNFR1) and IL-1 
Receptor Antagonist (IL-1RA) (significant in mania only) (Modabbernia et al, 2013). In 
bipolar disorder, the level of immune dysfunction including the concentrations of cytokines 
may be related to the phase or stage in the illness. In a study addressing the differences in 
cytokine levels between early stage and late stage bipolar disorder Kauer-Sant’Anna et al., 
(2009) observed that  TNF-α, IL-6 and IL-10 concentrations were increased in the early stages 
of bipolar disorder, within 3 years of the first manic episode, yet only TNF-α and IL-6 levels 
were elevated in the late stage of the illness, 10 years after diagnosis with bipolar disorder. 
Additionally IL-6 levels show a significant reduction between the early and late stages of 
bipolar disorder. It is suggested that such changes in endogenous cytokine levels may be of 
use as markers of disease progression in bipolar disorder. Analysis of the discrete phases of 




cytokine elevation. Brietzke et al., (2009) has shown  that mania is associated with increased 
levels of IL-2, IL-4 and IL-6. In depression, only IL-6 is increased, while eurythmic patients 
show no abnormalities in cytokine levels versus healthy controls. In contrast, Ortiz-
Domínguez et al., (2007) has shown elevated levels of IL-4 and TNF-α in mania coupled with 
low levels of IL-2 and in depression measured elevated levels of IL-6 and TNF-α compared to 
healthy controls. When comparing cytokine levels in the depressed phase and the manic phase, 
the manic phase was found to be associated with elevated IL-4 and reduced IL-1β and IL-6 
concentrations whilst these cytokine levels were reversed in the depressed phase. O’Brien et 
al., (2006) has reported no phasic difference between manic and depressed sufferers of bipolar 
disorder and has found increased TNF-α and IL-8 concentrations in both conditions. Taken 
together, these studies provide tentative support for the notion that cytokine levels are altered 
in a phase-specific manner in bipolar disorder. However, a lack of consistency between studies 
makes it difficult to determine the precise nature of these changes. This may due to the effects 
of sample sizes, medication effects or other methodological differences. 
Maternal immune activation is a risk factor for schizophrenia. The prenatal exposure of the 
foetus to infectious agents such as influenza, the intracellular parasite T. gondii and the Herpes 
simplex virus type 2 has been observed to increase the risk of schizophrenia in multiple 
epidemiological birth cohort studies (Brown & Derkits, 2010). Two hypotheses exist regarding 
maternal immune activation. The first sees the action of unique effects specific to the infectious 
agent producing aberrant neurodevelopment. The second, more prominent hypothesis, sees the 
action of a single common or common mechanisms that act to perturb neural development. 
The action of maternal immune activation coupled with an underlying genetic susceptibility 
in the foetus is proposed to result in an altered developmental trajectory being pursued in the 
fetal brain. This may result in aberrant cell division, migration patterns and axonal pathfinding 
occurring following an initial acute immune response. It is suggested that these developmental 
alterations are driven by an residual ‘immune scar’ of chronic inflammation that lasts 
throughout life (Horváth & Mirnics, 2014). The in utero elevation of cytokines, which is part 
of the immune response mechanism to infections agents, has also been associated with 
schizophrenia. The elevation of IL-8 during the second trimester of pregnancy, has been 
observed in mothers whose offspring later develop schizophrenia (Brown et al, 2004). 
Increased TNF-α levels have also been detected at birth in mothers whose offspring later 
develop psychosis as adults (Buka et al, 2001).  
DISC1 transgenic mouse models have used poly I:C, an inflammatory agent that mimics viral 




studies (Abazyan et al, 2010; Ibi et al, 2010; Lipina et al, 2013; Nagai et al, 2011). 100P mice 
contain N-ethyl-N-nitrosourea (ENU) induced point mutations that cause amino acid changes 
(L100P) to DISC1 and possess a schizophrenia-like phenotype (Clapcote et al, 2007) In 100P 
mice the induction of maternal immune activation via poly I:C exposed pregnant dams results 
in an exacerbation in schizophrenia-like behaviours, with deficits in prepulse inhibition (PPI) 
and latent inhibition (LI) becoming apparent in offspring. In contrast the poly I:C generated 
Q31L mice do not show any behaviours that are not shared with wild type controls. 
Interestingly the PPI and LI defects in the L100P mice can be ameliorated following treatment 
with anti-IL-6, an antibody that targets IL-6 (Lipina et al, 2013). The ΔhDISC1 inducible 
DISC1 aa1-597 mice model (Pletnikov et al, 2008) has been used to model maternal activation 
with pregnant dams injected with poly I:C (Abazyan et al, 2010). The ΔhDISC1/poly I:C mice 
feature a depression/anxiety-like phenotype with a dysregulation in cytokine levels being 
apparent. Abnormal brain morphology was observed, with decreased volumes in the right 
periaqueductal grey matter and right amygdala and a reduced spine density in the dentate 
gyrus. It’s noteworthy that in a study by Abazyan et al., (2010) that evidence of cytokine 
dysregulation was also seen when the DISC1 aa1-597 transgene was expressed solely, 
suggesting that DISC1 aa1-597 alone can influence endogenous cytokine levels. The 
constitutively active DN-DISC1 model that expresses DISC1 aa1-597 (Hikida et al, 2007) has 
also been used in the gene-environment modelling of maternal immune activation. This 
method used poly I:C injected into neonates (Ibi et al, 2010; Nagai et al, 2011). The DN-
DISC1/poly I:C mice possessed a wide array of deficits including an impairments in novel 
object recognition, fear memory, short-term memory, social interaction and an augmentation 
to MK-801 induced hyperactivity. Additionally parvalbumin-positive neuron staining was 
observed to be reduced (Ibi et al, 2010). Further investigations using the DN-DISC1/poly I:C 
paradigm highlighted how the model produced schizophrenia-like responses to antipsychotic 
medication treatment across a range of behavioural assays (Nagai et al, 2011). Overall the poly 
I:C gene-environment modelling maternal immune activation using DISC1 transgenic mice 
demonstrated how the poly I:C treatment was capable of modulating the phenotype of the mice 
at both the behavioural and anatomical level. 
Regarding the t(1;11) pedigree, maternal immune activation may serve to modulate the 
penetrance of the translocation, in that translocation carriers that are exposed to maternal 
immune activation would exhibit a more severe mental illness phenotype. Maternal immune 
activation could partly explain the immune system dysfunction and inflammation observed in 




schizophrenia suffered from maternal exposure to infectious agents. It remains possible though 
that maternal immune activation may have been a contributing factor to a few of the cases of 
schizophrenia in the t(1;11) pedigree, Such an occurrence may have led to ‘immune scarring’ 
and long term gene dysregulation  (Horváth & Mirnics, 2014) the latter of which may be 
detectible by expression microarray analysis. However, it must be stressed that maternal 
immune activation would be unlikely to account for all of the incidences of schizophrenia in 
the t(1;11) pedigree. Another explanation for the prevalence of immunity and inflammation 
associated processes in the pathway analysis of the microarray data could come from the 
endogenous presence of the DISC1/DISC1FP1 species CP1 in the lymphoblastoid cell lines. 
CP1 encodes DISC1 aa1-598 and is as such highly similar to DISC1 aa1-597, which has been 
shown to cause cytokine dysregulation (Abazyan et al, 2010). To date, however, expression 
of the CP1 protein has not been identified in t(1;11) lymphoblastoid cell lines. It is, however, 
possible that the species may be present at levels below the limits of detection of Western 
blotting (Eykelenboom et al, 2012). As such the exact origin and mechanism of action for the 
immune and inflammation responses highlighted in the t(1;11) microarray require further 
investigation. One potential future experiment could be to generate a humanised translocation 
mouse model and expose it to poly I:C in utero with a view to characterising the 
immunological disturbances and effects on behavioural and neuroanatomical phenotypes 
versus untreated translocation mice.   
From the Disease Association Analysis, three categories of genes involved with inflammation 
and immune function emerged. Interleukins are a class of cytokines that can mediate both 
proinflammatory and anti-inflammatory functions within the immune system. Genes involved 
in interleukin signalling, including Interleukin 4 Receptor (IL-4R), Interleukin Receptor Beta 
2 (IL-12RB2) Interleukin 13 Receptor Alpha 1 (IL-13RA1), Interleukin 21 Receptor (IL-21R), 
Interleukin Receptor 23 Alpha Subunit p19 (IL-23A) and Interleukin Receptor 27 Alpha (IL-
27RA), contribute to disease categories found to be enriched in the functional enrichment 
analysis. These interleukin receptors mediate both pro-inflammatory and anti-inflammatory 
responses by signal transduction. The tumour necrosis factor superfamily also appears in the 
Disease Association Analysis with Tumour Necrosis Factor Receptor Superfamily Member 
1B (TNFRSF1B), Tumour Necrosis Factor Receptor Superfamily Member 8 (TNFRSF8), 
Tumour Necrosis Factor Receptor Superfamily Member 9 (TNFRSF9) are all present in the 
functional enrichment analysis. The tumour necrosis factor superfamily are involved in 
mediating the pro-inflammatory response in both acute immune responses and the chronic 




light-chain-enhancer of activated B cells (NF-κB) is a transcription factor protein complex 
which has dual roles in both the immune and inflammatory responses (Tak & Firestein, 2001). 
Within the significant Disease Association Analysis results, an NF-κB subunit appears, 
Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-cells 2 (p49/p100). In 
addition, two kinases that modulate NF-κB activity appear. These are Nuclear Factor of Kappa 
Light Polypeptide Gene Enhancer in B-cells Inhibitor, Alpha (NFKBIA); and Nuclear Factor 
of Kappa Light Polypeptide Gene Enhancer in B-cells Inhibitor, Epsilon (NFKBIE).  The 
Disease Association Analysis results do not include any of the interleukins identified as 
significant by meta-analyses of cytokine expression in schizophrenia (Miller et al, 2011), 
bipolar disorder (Modabbernia et al, 2013), or major depressive disorder (Dowlati et al, 2010). 
However, in the Pathway Commons analysis a pathway for IL-12-mediated signalling events 
was found to be statistically enriched. IL-12 is seen as a trait marker for schizophrenia that can 
be detected even when individuals are taking antipsychotic medication and is present in a 
meta-analysis of cytokine alterations in schizophrenia (Miller et al, 2011). In contrast to IL-
12 being associated with schizophrenia the Disease Association Analysis highlights immune 
function and inflammation by the enrichment of interleukin associated genes and those 
involved in the tumour necrosis superfamily and NF-κB signalling, that are not directly 
identified with major mental illness by meta-analysis. 
The medication status of the members of the t(1;11) pedigree whose lymphoblastoid cell lines 
were assayed here is unknown. Medication could theoretically have affected gene expression 
in lymphocytes in a manner that was preserved beyond EBV transformation. For example the 
drug lithium, commonly used to treat bipolar disorder has been observed to promote the repair 
of double strand DNA breaks in hippocampal neurons (Yang et al, 2009). It may be that t(1;11) 
pedigree members taking lithium may derive some degree of neuroprotection from the cell 
cycle dysregulation seen in this analysis. Alternatively the observation of cell cycle 
dysregulation may originate from the use of drugs such as lithium that affect the cell cycle.  
Regarding medication and immune function, the use of various antipsychotics on drug-naive 
schizophrenia patients has been shown to be associated with the levels of CD19+ (B)- and 
CD3+ (T)-lymphocytes returning to the baseline levels of heathy controls (Maino et al, 2007). 
It is therefore possible that the antipsychotic medication that the t(1;11) carriers receive may 
confer some immunoprotective effects. Conversely, it may be that the antipsychotic drugs 
taken by the t(1;11) carriers could possibly be the source of the immune function and 





6.4.3 Outcome of using unfiltered versus the neuronally filtered GOI 
lists 
The analysis of the t(1;11) expression microarray data involved the use of both an unfiltered 
GOI list and a neuronally filtered GOI list. It was thought that the neuronally filtered GOI list 
may differ markedly from the unfiltered GOI list in terms of functional enrichment across 
analysis programs and may function as a more brain-like as opposed to blood based GOI list. 
However, only the Disease Enrichment Analysis had enrichment in multiple immune and 
inflammation disease categories specific to the neuronally filtered GOI list (See section 6.3.8). 
The differences in enrichment between the two GOI lists across programs was otherwise 
nominal. The use of the neuronally filtered GOI list as a more brain-like GOI list is also 
intrinsically misleading. It is explicit that the filtering to remove non-neuronal genes from the 
original GOI list is purely subtractive. There is no means to add in neuronal genes to the 
neuronally filtered GOI list that are absent in the lymphoblastoid cDNA. It is also possible that 
the use of the neuronally filtered GOI list may be an impediment when trying to compare 
results with other EBV-lymphoblastoid studies into major mental illness. Given these caveats 
it may be preferable to focus on the unfiltered GOI list results which are for the cell cycle 
highly similar to the neuronally filtered data but place less emphasis on immune function and 
inflammation in the pathogenesis of the t(1;11) pedigree. 
Taking into account both the limitations of this gene enrichment study and the need for further 
replication, the GOI based approach detailed here is nevertheless a means that offers some 












Chapter 7 - Final Discussion 
 
7.1 Summary of findings 
In this study I have looked at the t(1;11) pedigree, a family with a well characterised balanced 
autosomal translocation, which co-segregates with instances of bipolar disorder, schizophrenia 
and major depressive disorder (Blackwood et al, 2001). I have attempted to functionally 
characterise the t(1;11) for further putative mechanisms of pathogenesis.  These mechanisms 
may exist in parallel to, or may in part be dependent upon, another potential mechanism of 
pathogenesis, the haploinsufficiency of DISC1 that has been identified in t(1;11) 
lymphoblastoid cell lines (Millar et al, 2005b). The search for cellular processes that may be 
perturbed so as to contribute to pathogenesis in the t(1;11) pedigree has involved both the 
exogenous expression of DISC1/DISC1FP1 chimeras in COS-7 cells and primary cortical 
neurone cultures as well as the functional enrichment analysis of a t(1;11)-family derived 
lymphoblastoid gene expression microarray data. 
In this final chapter a summary of the findings of this thesis will be addressed, as well as future 
work and caveats and the wider relevance of this work to the field.  
 
7.2 Identification of a novel DISC1/DISC1FP1 transcript arising from the 
splicing of DISC1 to the DISC1FP1 EST AB371558 in lymphoblastoid cell 
lines 
The transcripts for two der 1 DISC1/DISC1FP1 chimeras, CP60 and CP69 that encode DISC1 
aa1-597 plus an additional 60 and 69 novel aa from DISC1FP1 have been isolated in t(1;11)-
family derived lymphoblastoid cell lines (Eykelenboom et al, 2012). The identification of a 
further DISC1FP1 EST, AB371588 leads to the possibility that other der1 and der 11 chimeric 
DISC1/DISC1FP1 species may arise due to the t(1;11). These novel chimeric species may be 
detectable as transcripts in t(1;11)-family derived lymphoblastoid cell lines. Using RT-PCR 
on t(1;11) lymphoblastoid cell lines a novel DISC1/DISC1FP1 chimeric species named CP1 
has been identified. The CP1 species is a der 1 chimeric species that is produced by the fusing 
of chromosome 1 where DISC1 is located, to chromosome 11 that encodes the DISC1FP1 
EST AB371588, as a result of the translocation. The CP1 species encodes the der 1 DISC1 
ORF proximal to the translocation which encompasses DISC1 aa1-597 plus an additional 




DISC1 aa1-597 is a glycine, which is a simple uncharged aa. Additionally, DISC1 aa598 is 
also a glycine, so the CP1 transcript can be seen to encode DISC1 aa1-598. Given the simple 
uncharged nature of the glycine encoded at aa598 by CP1, it would seem likely that 
exogenously expressed CP1 protein would behave similarly to exogenously expressed DISC1 
aa1-597 protein.  
 DISC1 aa1-597 has been the subject of extensive research as a dominant negative truncated 
species as a possible mechanism of pathogenesis in the t(1;11) pedigree. DISC1 aa1-597 has 
been studied in vitro (Brandon et al, 2005; Hattori et al, 2014; Kamiya et al, 2005; Millar et 
al, 2005a; Morris et al, 2003; Ozeki et al, 2003; Pletnikov et al, 2007; Taya et al, 2007) and 
in vivo (Hikida et al, 2007; Niwa et al, 2013; Pletnikov et al, 2008). This theory is seen as an 
alternative though not mutually exclusive explanation of pathogenesis seen in the t(1;11) 
pedigree to that of the haploinsufficiency of DISC1 (Millar et al, 2005b) The identification of 
endogenous CP1 protein would likely result in the studies into DISC1 aa1-597 being fully 
accepted into the cannon of DISC1 research relating to the t(1;11) pedigree, such is the 
similarity between the CP1 and DISC1 aa1-597 species. It may be possible to predict what 
phenotypic features CP1 would produce when expressed in vivo from the features evident in 
the DN-DISC1 (Hikida et al, 2007) and ΔhDISC1 (Pletnikov et al, 2008), DISC1 aa1-597 
mouse models. Common to both of these models are the features of enlarged lateral ventricles 
and a reduction in parvalbumin-positive interneurons, therefore, it would be reasonable to 
predict that a similar phenotype may arise from the in vivo expression of CP1 in the human 
brain. 
The corresponding der 11 species resulting from AB371588/DISC1 cryptic splicing has been 
previously identified (Eykelenboom et al, 2012) and so was not studied here. This transcript 
contains an ORF encoding a C-terminal DISC1 truncate. 
The potential for further novel DISC1/DISC1FP1 chimeric species exists. Translin-Associated 
Factor X (TSNAX) plays a role in the neuronal binding and trafficking of RNA (Li et al, 
2008).  The TSNAX gene is located upstream of DISC1and the intragenic splicing of TSNAX 
to DISC1 creates several TSNAX/DISC1 transcripts. (Millar et al, 2000a). The majority of the 
TSNAX/DISC1 transcripts encode novel exons that insert premature stop codons, separating 
the TSNAX and DISC1 ORFs (Millar et al, 2000a). However, one of the transcripts amplified 
from TSNAX exon 4 is spliced directly to exon 2 of DISC1 conserving the ORF. Therefore this 
transcript encodes a potential TSNAX/DISC1 chimeric protein. Furthermore this ORF has 




lines it is possible that the DISC1 ORF in this TSNAX/DISC1 transcript could also splice with 
DISC1FP1, giving rise to the possibility of a TSNAX/DISC1/DISCFP1 transcripts  
Interestingly, the TSNAX/DISC1 transcript with the read-through ORF has been identified in 
brain tissue (Millar et al, 2000a). A later study by Nakata et al., (2009) identifies several 
TSNAX/DISC1 transcripts that start at TSNAX exon 1. However, these transcripts all include 
premature stop codons in the ORF that would interrupt the production of a TSNAX/DISC1 
chimeric protein.  
More promising for the production of additional der 1 chimeric species are the alternative 
splice variants of DISC1 that have been identified in foetal brain tissue (Nakata et al, 2009). 
The DISC1 alternative splice variant transcripts that could potentially produce novel der 1 
DISC1/DISC1FP1 chimeric species, including: DISC1Δ5Δ6 (lacking exons 5 and 6 and 
terminating at exon 13); DISC1Δ7Δ8* (lacking DISC1 exons 7 and 8 terminating at exon 9);  
DISC1Δ7Δ8Δ9 (lacking exons 7-9 terminating at exon 10); DISC1Δ7Δ8Δ9 (lacking exons 7-
9 terminating at exon 11); DISC1Δ8 (lacking exon 8 terminating at exon 9) and DISC1Δ8 
(lacking DISC1 exon 8 terminating at exon13. Novel der 1 DISC1/DISC1FP1 chimeric species 
produced by the cryptic splicing of the ORF of these DISC1 splice variants to DISC1FP1 may 
confer additional aberrant functions and altered protein behaviour arising through the absence 
of specific DISC1 exons. Additionally, it is apparent from the work of  Nakata et al., (2009) 
that the various DISC1 alternatively spliced transcripts would encode a variety of novel der 11 
DISC1/DISC1FP1 transcripts. However it is likely that these species would encode N-terminal 
truncates of the der 11 DISC1 ORF of varying length, analogous to the potential der 11 DISC1 
C-terminal truncate detailed in Eykelenboom et al., (2012). This is because on the der11 the 
DISC1FP1 ESTs spliced to DISC1 produce ORFs with multiple upstream stop codons present 
and the only feasible ORF is internal to the DISC1 component of the chimeric transcript. To 
date these experiments to identify der 1 or der 11 DISC1/DISC1FP1 chimeras produced by 
DISC1 alternative spliced variants have not been attempted.      
 
7.3 The exogenous expression of DISC1/DISC1FP1 species in order to 
characterise possible pathogenic mechanisms operating within the 
t(1;11) pedigree 
Chimeric transcripts encoding CP60 and CP69 have been detected in t(1;11)-family derived 
lymphoblastoid cell lines (Eykelenboom et al, 2012) and, until now, both CP60 and CP69 
protein have not been studied in vitro. Protein products corresponding to the 




fraction and absent in the lysate fraction when assayed by Western blot, in contrast to FLAG-
DISC1 which appears in both fractions. It is possible that the localisation of CP60 and CP69 
protein to the pellet fraction is indicative of these species possessing novel aberrant properties. 
Biophysical characterisation of MBP-ΔNCP69, an N-terminal truncated species encoding 
DISC1 aa326-597 and 69 aa from DISC1FP1, provides further insight into CP60 and CP69 
protein. In this species the DISC1 N-terminus is absent as it is predicted to be highly disordered 
and is known to be difficult to purify (Soares et al, 2011). A series of biophysical experiments 
have compared MBP-ΔNCP69 expression to that of a species encoding DISC1 aa326-597, 
MBP-ΔN597. From this it is revealed that the addition of a novel 69 aa to DISC1 aa1-597 
results in the formation of larger protein assemblies that show increased thermal stability and 
have a unique secondary structure (Eykelenboom et al, 2012). It is possible that the protein 
assemblies and the secondary structure variation detected confer altered protein behaviour that 
results in localisation of CP60 and CP69 protein to the pellet.  
Qualitative analysis of exogenously expressed FLAG-CP60 and FLAG-CP69 in COS-7 cells 
using fluorescence microscopy and immunocytochemistry reveals these species to possess a 
predominantly clustered expression pattern. This is discernible from the punctate expression 
pattern of FLAG-WT-DISC1 and the diffuse expression pattern of FLAG-DISC1 aa1-597. In 
contrast, separate immunocytochemistry experiments show that the CP1 species, encoding 
DISC1 aa1-598, which is extremely similar to DISC1 aa1-597, has the same diffuse expression 
pattern as DISC1 aa1-597. Therefore the additional novel 60 and 69 DISC1FP1 aa of CP60 
and CP69, respectively, confer an altered and novel cellular localisation pattern to these 
chimeric species. 
Qualitative analysis of MitoTracker Red staining aimed to phenotype the mitochondrial 
morphology of mitochondria in COS-7 cells exogenously expressing the DISC11/DISC1FP1 
chimeras CP60 and CP69. In this analysis fewer than 30% of the cells counted expressing 
FLAG-CP60 and FLAG-CP69 species are visibly stained with MitoTracker dye. In contrast 
~95% of the cells expressing either FLAG-WT-DISC1 or DISC1 aa1-597 show mitochondrial 
staining. The mitochondria in FLAG-CP60 and FLAG-CP69 expressing cells that showed 
MitoTracker fluorescence displayed a similar clustered morphology to that seen for expression 
pattern of exogenous FLAG-CP60 and FLAG-CP69. In comparison to this, in both FLAG-
WT-DISC1 and FLAG-DISC1 aa1-597 expressing cells, mitochondria were readily visible 
with MitoTracker Red staining and possess a tubular morphology. A separate, 
immunocytochemistry experiment in which CP1 was expressed in COS-7 cells and compared 




DISC1/DISC1FP1 chimeric species is associated with mitochondria that stain with 
MitoTracker Red and are tubular in appearance. This result is unsurprising given the very high 
degree of similarity between DISC1 aa1-597 and the CP1 chimeric species. 
In order to visualise mitochondria that do not stain with MitoTracker Red, co-staining with 
antibodies for CVα, a mitochondrial subunit, and for Cytochrome c, an inner mitochondrial 
membrane protein, was attempted in both COS-7 cells and primary cortical neurones. This 
enabled the visualisation of clustered mitochondria in cells expressing exogenous CP60 and 
CP69 that did not otherwise show MitoTracker Red fluorescence. It is inferred that the 
mitochondrial dysfunction evident in cells expressing exogenous CP60 and CP69 likely occurs 
due to an impairment in the mitochondrial membrane potential, Δψm. This is because 
MitoTracker Red staining is impaired by the collapse or depolarisation of the membrane 
potential, Δψm (Buckman et al, 2001). 
The DISC1/DISC1FP1 chimeras CP1, CP60 and CP69 could potentially be pleiotropically 
pathogenic. Given the extremely high similarity in the expression of CP1 to DISC1 aa1-597, 
it is very likely that mechanisms of pathogenesis that have been established for DISC aa1-597 
would also result from CP1 expression both in vivo and in vitro (see previous section). 
Importantly all three chimeric transcripts encode a DISC1 self-association domain at DISC1 
aa403-504 (Kamiya et al, 2005). Therefore, CP1, CP60 and CP69 could interact with 
endogenous DISC1, potentially in a dominant negative manner and additionally form 
complexes with each other. For CP60 and CP69, both the clustering of the expressed protein 
and the induced mitochondrial dysfunction are potential mechanisms of pathogenesis. The 
clustering of the expressed protein may have an effect on the localisation of endogenous 
DISC1 and/or DISC1 interactors by binding WT-DISC1, it may also be that the clustered 
protein could potentially form aggregates that are pathogenic. This is as endogenous DISC1 is 
capable of pathogenic aggregation (Atkin et al, 2012). The mitochondrial clustering and the 
apparent collapse of the mitochondrial potential, Δψm could have a variety of detrimental 
effects including: the reduction of cellular ATP levels, the disruption of mitochondrial 
transport, the production of deficits in synaptic signalling, the impairment of action potential 






7.4 Further investigation of the molecular dysfunction resulting from the 
DISC1/DISC1FP1 chimeric species: FACS analysis of mitochondrial 
fluorescence in t(1;11) lymphoblastoid cell lines 
Given that CP60 and CP69 show impaired staining with the fluorescent mitochondrial dye 
MitoTracker Red it was proposed to investigate the fluorescence of MitoTracker Red in t(1;11) 
–family derived lymphoblastoid cell lines. At present the DISC1/DISC1FP1 chimeric proteins 
have not been isolated in t(1;11) lymphoblastoid cell lines (Eykelenboom et al, 2012), but it 
may be that these species are below the threshold of detection. It is possible that FACS analysis 
of MitoTracker Red fluorescence in t(1;11)-family derived lymphoblastoid cell lines may be 
able to detect a reduction in MitoTracker Red fluorescence as a consequence of endogenous 
DSIC1/DISC1FP1 expression. Such an occurrence might suggest the existence of endogenous 
DISC1/DISC1FP1 expression. In this series of experiments the experimental replicates of 
MitoTracker Red stained t(1;11) lymphoblastoid cell lines versus karyotype controls show 
enough biological independence to justify statistical analysis as separate experiments of n=3. 
This is due to the biological independence of the three t(1;11) lymphoblastoid cell lines per 
replicate and the independence in conditions between the cultured flasks of cells (Cumming et 
al, 2007; Lazic, 2010). One of the three experimental replicates performed on the t(1;11)  
lymphoblastoid cell lines showed a significant reduction in MitoTracker Red fluorescence in 
comparison to karyotypically normal controls.  However, when the three experimental 
replicates are pooled and analysed as one data set the MitoTracker Red fluorescence in t(1;11) 
lymphoblastoid cell lines was not found to be significantly different from karyotype  controls. 
 It is possible that the single positive result from an experimental replicate is the result of a 
practice effect given this experimental replicate was the final series of experimental replicates 
assayed. It is also possible that the negative result from the pooled data that detects no 
significant difference in MitoTracker Red fluorescence between t(1;11) lymphoblastoid cell 
line and karyotype controls is in fact a true result. Further work needs to be done regarding 
MitoTracker Red florescence and t(1;11) lymphoblastoid cells perhaps using the 







7.5 Analysis of t(1;11) gene expression microarray data using functional 
enrichment programs 
The assessment of t(1;11)-family derived lymphoblastoid cell lines by gene expression 
microarray aimed to identify putative pathogenic mechanisms operating within the t(1;11) 
pedigree via differential gene expression and subsequent analysis by functional enrichment 
programs. The original unfiltered GOI list was filtered to remove blood specific non-neuronal 
genes creating a neuronally filtered GOI list that was putatively more brain based. The 
reasoning behind this being that blood based gene expression can be significantly different to 
that of brain based gene expression (Cai et al, 2010; Rollins et al, 2010; Sullivan et al, 2006). 
Lymphoblastoid cell lines were used in the microarray analysis rather than neuronal material 
as at the time this was the only (t;1;11) material available. As such, the two GOI lists, filtered 
and unfiltered, were analysed for functional enrichment in parallel. 
In the functional enrichment analysis the enrichment of both the cell cycle and immune 
function and inflammation are highlighted in multiple instances and may serve as novel 
putative pathogenic mechanisms within the t(1;11) pedigree. The GOTree analysis features an 
enrichment for a wide variety of categories that are associated with M-phase, that in particular 
are components of mitosis. In Pathways Commons analysis a broad spectrum of pathways are 
enriched. This expands upon the cell cycle category enrichments seen in GOTree by 
highlighting enrichments in all four cell cycle phases, S-phase, G2-phase, M-phase and G1-
phase, each occurring several times. Importantly the mitotic cell cycle is the most significantly 
enriched pathway for both GOI lists. In Pathways Commons analysis pathways that have 
associations with DISC1 are enriched, including the reelin signalling pathway (Andreasen et 
al, 2011) and kinesins (Ogawa et al, 2014; Taya et al, 2007). Immune function pathways are 
also enriched in the Pathways Commons analysis, of particular note is the appearance of IL-
12-mediated signalling. This cytokine appears to be of relevance to inflammation and 
immunity in schizophrenia as a trait marker (Miller et al, 2011)  
The results of the investigation of the t(1;11) microarray data using both KEGG and 
Wikipathways pathway analysis also focus heavily on cell cycle dysregulation, with the cell 
cycle pathway enriched in both programs. Disease Association Analysis identifies enrichment 
pertaining to diseases. Hodgkin’s disease appears on the unfiltered GOI analysis and this 
disease pathway is identified as principally containing genes with a role in immune function. 
The remaining analysis of the neuronally filtered GOI list has a strong emphasis on immune 
function and inflammation with the enrichment of bronchitis, bronchiolitis and immune system 




greatest differences in the outputs between the unfiltered GOI list and the neuronally filtered 
GOI list. For all other functional analysis programs these two lists produce markedly similar 
results with slight differences in the rankings of p-values for enriched categories. 
The dysregulation of the cell cycle evident in the t(1;11) microarray analysis may produce 
multiple forms of pathogenesis that could in part explain the high incidence of major mental 
illness in the t(1;11) pedigree. Given that M-phase and specifically the enrichment of mitosis 
occurs, it is possible that the basal rate of proliferation is altered in t(1;11) lymphoblastoid cell 
lines which could impact on neurodevelopment and adult brain function if this also occurs, for 
example, in neural progenitors. There is evidence that neural precursor deficits which could 
arise from impaired neuronal proliferation, may be associated with depression. The transgenic 
inhibition of neurogenesis in adult mice reduces the number of precursor cells within the 
hippocampus and produces a depression-like phenotype (Snyder et al, 2011). In humans, 
evidence from post mortem brain tissue in elderly sufferers of depression, has detected 
reductions in  neuronal precursors within the hippocampus (Lucassen et al, 2010). 
Interestingly, post-mortem examination on brain samples from sufferers of major depressive 
disorder who underwent antidepressant treatment, reveals a greater number of neuronal 
progenitors within the dentate gyrus, compared to unmediated sufferers (Boldrini et al, 2012; 
Boldrini et al, 2009). This increase in the number of neuronal progenitors was correlated with 
an increase in dentate gyrus size. In the case of the t(1;11) perigee if alterations to the neural 
progenitors or neuronal precursors occurred this could consequently reduce the number of 
newly borne neurones. Given the nature of the genetic insult in the t(1;11) pedigree, this 
detriment to neurogenesis could potentially occur throughout development. 
The alterations to S-phase, G2-phase, and G1-phase may be indicative of changes to the length 
of these phases that has been shown to influence the differential production of proliferating 
and differentiated cells within the brain (Arai et al, 2011; Dehay & Kennedy, 2007; Peco et 
al, 2012). However, at present using pathway analysis alone it is impossible to determine 
specific spatial or temporal alterations to cell cycle phases. Regarding DISC1 function, DISC1 
localises to the centrosome (Bradshaw et al, 2008; Kamiya et al, 2005; Kamiya et al, 2008; 
Miyoshi et al, 2004; Morris et al, 2003)  which is an enriched category within GOTree. Within 
the cell cycle it is possible that the binding of DISC1 with DISC1 interactors that possess roles 
in the cell cycle may be reduced by the haploinsufficiency of DISC1 that occurs in t(1;11) 
lymphoblastoid cell lines (Millar et al, 2005b). This may result in abnormalities in cell cycle 
mechanisms that affect the dynamics of mitosis. Additionally, the expression of DISC1 aa1-




involved in the differentiation of oligodendrocyte precursor cells (Katsel et al, 2011). It is 
possible that the expression of the DISC1/DISC1FP1 species CP1 that is virtually 
indistinguishable from DISC1 aa1-597 may also affect cell cycle gene expression.   
The occurrence of immune function and inflammation associated categories in the functional 
analysis of the t(1;11) microarray data, highlight these processes as putative mechanisms of 
pathogenesis in the t(1;11) pedigree. Members of the t(1;11) pedigree have been diagnosed as 
suffering from schizophrenia, depression or bipolar disorder, all three of these disorders have 
been linked to immune dysfunction. The meta-analysis of studies into the relationship between 
mental illness and immunity identify roles for elevated cytokine levels in schizophrenia (Miller 
et al, 2011) depression (Dowlati et al, 2010) and bipolar disorder (Modabbernia et al, 2013). 
For schizophrenia an immune function related process that has been identified as a mechanism 
of pathogenesis is maternal immune activation. This is an established risk factor for 
schizophrenia and arises due to the foetus being exposed prenatally to infectious agents 
(Brown & Derkits, 2010). Maternal immune activation has been studied using gene 
environment modelling on DISC1 transgenic mice (Abazyan et al, 2010; Ibi et al, 2010; Lipina 
et al, 2013; Nagai et al, 2011). The use of the inflammatory agent poly I:C in such modelling 
frequently modulates the phenotype of the transgenic mice. In 100P mice the prenatal exposure 
to poly I:C results in the exasperation of a schizophrenia-like phenotype (Lipina et al, 2013). 
Likewise in the DN-DISC mouse line neonatal exposure to poly I:C results in the production 
of a schizophrenia-like phenotype (Ibi et al, 2010; Nagai et al, 2011). The maternal immune 
activation of ΔhDISC1 mice produces a depression/anxiety-like phenotype (Abazyan et al, 
2010). Additionally the expression of DISC1 aa1-597 in ΔhDISC1 mice alone has been 
observed to dysregulate the levels of cytokines (Abazyan et al, 2010). Therefore the expression 
of the DISC1/DISC1FP1 species CP1 which is highly similar to DISC1 aa1-597 may also 
induce the dysregulation of the levels of cytokines.  
Maternal immune activation within the t(1;11) pedigree could serve to modulate the phenotype 
of mental illness by the penetrance of the translocation. However it is unlikely to have occurred 
with such frequency in the t(1;11) pedigree to explain all of the instances of schizophrenia. At 
present it requires further investigation to identify the specific molecular underpinning of the 
enrichment in immune function and inflammation related categories in the t(1:11) gene 
expression microarray data. 
Following the analysis of both the unfiltered and neuronally filtered GOI lists it appears that 




limited surrogate for a brain derived GOI list. Focusing on data derived from the unfiltered 
GOI list would only reduce the number of categories that show immune function association 
and have little effect on the impact of cell cycle dysregulation.  
Figure 7.5.A. displays the main putative mechanisms of pathogenesis that have been 
investigated in this thesis, that are reviewed in this chapter so far, including the cell cycle 
dysfunction and enrichment of immune function and inflammation evident in the t(1;11) 
microarray data. The results of the exogenous expression of the DISC1/DISC1FP1 chimeras 
are also depicted. 
 
7.6 Caveats 
To date the DISC1/DISC1FP1 chimeras have only been identified as transcripts. Efforts to 
identify endogenous DISC1/DISC1FP1 chimeric protein using the DISC1 N-terminal 
antibody R47 in t(1;11)-family derived lymphoblastoid cell lines have produced a negative 
result (Eykelenboom et al, 2012). The exogenous expression of CP1, CP60 and CP69 in this 
study indicates these species are likely to have pluripotent mechanisms of pathogenesis. 
However the endogenous expression of DISC1/DISC1FP1 chimeras must be supported with 
experimental data in order for these species to be considered a mechanism of pathogenesis 
within the t(1;11) pedigree. It remains possible that the DISC1/DISC1FP1 chimeras are 
expressed below the detection threshold of the Western blotting used so far (Eykelenboom et 
al, 2012) and that even at low levels of expression these species could produce detrimental 
cellular effects. Further research is needed to try to detect these species endogenously in tissue 
from the t(1;11) pedigree. 
In the dysregulation of the cell cycle that is highlighted by multiple pathways analysis 
programs in the t(1;11) gene expression microarray analysis the various cell cycle phases are 
enriched and in particular mitosis within M-phase is altered. However the use pathway analysis 
alone cannot give spatial, temporal or mechanistic data relating to the dysregulation occurring 
in these phases. As such it is impossible to determine if a given phase has been seen to lengthen 
or shorten due to differential gene expression. Further research is needed into determining the 
specific changes that occur to the cell cycle phases to enable more accurate predictions to be 







Figure 7.5.A: Putative pathogenic mechanisms that may possibly operate in the t(1;11) pedigree. The effects of exogenous 
expression of CP60 or CP69 (left), the effects of exogenous CP1 expression (right). DISC1/DISC1FP1 protein (green). Cellular 
effects derived from functional enrichment analysis of the t(1;11) gene expression microarray as labelled. Dysregulated cytokines 




The highlighting of cell cycle dysregulation in functional enrichment analysis could possibly 
be the result of an intrinsic bias in the pathway enrichment and ontology programs. This is as 
the databases that support these programs have the tendency to over-represent cancer processes 
including the cell cycle. Ideally a series of experiments would be implemented to validate the 
notion of intrinsic cell cycle dysregulation within t(1;11)-derived cell lines. 
The use of t(1;11) lymphoblastoid cell lines as a surrogate for neural material in the t(1;11) 
gene expression microarray may have resulted in a narrower spectrum of enriched pathways 
being highlighted than would occur had t(1;11) post-mortem brain tissue or iPSC-derived 
neural material been assayed. The main findings from this work that the cell cycle is 
dysregulated and that immune function and inflammation is enriched do not represent brain 
specific pathways per se. It is likely that the absence of brain specific pathways in the 
functional enrichment analysis of the t(1;11) microarray data arises due to the underlying 
differences in transcript expression between blood and brain (Cai et al, 2010; Sullivan et al, 
2006) rather than as a limitation of the analysis programs used.   
 
7.7 Future work 
In order to determine if the DISC1/DISC1FP1 chimeras are expressed endogenously, the ideal 
experiment would involve post-mortem brain tissue from the t(1;11) pedigree. At present such 
tissue is not available. However, neural precursors and neurones have been developed from 
t(1;11)-derived iPSC’s. The use of iPSC-derived neurones to investigate neuropsychiatric 
illness represents a paradigm shift over previous studies, being a more disease relevant model 
than patient lymphoblastoid cell lines. When assayed with peptide antibodies with epitopes 
specific to the chimeras, these t(1;11) iPSC’s may be a promising avenue of investigation to 
detect DISC1/DISC1FP1 species endogenously. It is possible that iPSC’s driven down a neural 
differentiation pathway may possess a greater level of expression of the chimeras than that of 
t(1;11) lymphoblastoid cell lines. In the intervening time since this thesis was initiated, these 
experiments have been carried out. DISC1/DISC1FP1 chimeric transcripts have been 
identified in iPSC-derived neurones, but as yet endogenous chimeric proteins have not been 
detected (JK Millar personal communication). 
The work of Nakata et al., (2009) on the identification of alternative DISC1 splice variants 
suggests that it should be possible to identify additional novel der 1 and der 11 
DISC1/DISC1FP species in vitro. Further RT-PCR on t(1;11)-family derived lymphoblastoid 




putative chimeras. However, such an investigation should be mindful of the possibility that 
some of these transcripts may well be transcription errors, as possibly evidenced by the 
occurrence of premature stop codons within many of these species.     
The interaction between DISC1 and the DISC1/DISC1FP1 chimeras could be characterised. 
Firstly co-immunoprecipitation of WT-DISC1 with CP1, CP60 or CP69 could be performed 
and analysed by densitometry to address the effect of the DISC1 self-association domain 
(Kamiya et al, 2005) on the binding between these species. It is possible that the additional 60 
and 69 aa in CP60 and CP69, respectively, confer altered binding properties with WT-DISC1 
to these chimeras. Secondly, immunocytochemistry could be used to investigate how the 
cellular and mitochondrial phenotypes of the DISC1/DISC1FP1 chimeras present when co-
expressed with exogenously expressed WT-DISC1. It is possible dominant-negative effects 
may be present due to chimeric species expression or that WT-DISC1 may in part ameliorate 
the pathogenic effects of the chimeras. Finally, the process of characterising interaction of 
DISC1 interactors with the DISC1/DISC1FP1 chimeras by co-immunoprecipitation and 
immunocytochemistry could be implemented. This would aim to establish whether further 
pathogenic interactions occur due to co-expression alongside the chimeric species.  
At present, it is unknown if/how CP60 and CP69 expression affects mitochondrial motility. 
Given the observation the CP60 and CP69 are associated with a reduction in the mitochondrial 
membrane potential, Δψm, it is possible that the expression of these chimeras would lead to a 
net movement of mitochondria towards the cell body. This is because there is evidence that 
mitochondrial movement in the direction of the cell body is favoured by a low membrane 
potential, Δψm (Miller & Sheetz, 2004), although this remains controversial. Mitochondrial 
movement in relation to mitochondrial membrane potential, Δψm perturbations could be 
assessed using inducible CP60 and CP69 expression constructs. Cells could be stained with 
JC-1, a dye which is mitochondrial membrane potential, Δψm sensitive. Live cell imaging 
could be performed both pre- and post-induction of expression of the chimeric proteins, to 
visualise resulting alterations to mitochondrial motility and JC-1 staining. 
The mitochondrial mass of cells needs to be corrected for the FACS analysis of t(1;11) 
lymphoblastoid cell lines stained with MitoTracker Red in order to determine if the negative 
result in this series of experiments is a true negative. A future experiment could use  co-staining 
with MitoTracker Green, given this dye is non-mitochondrial membrane potential, Δψm 
dependent, as a means to identify mitochondrial mass (Pendergrass et al, 2004). The ratio of 




normalised mitochondrial membrane potential, Δψm which is a more robust metric as opposed 
to that of MitoTracker Red fluorescence alone. In addition to the study of t(1;11) 
lymphoblastoid cell lines, the mitochondrial membrane potential, Δψm for exogenously 
expressed CP1 and DISC1 aa1-597 could also be calculated. This work would further 
characterise the exogenous expression of DISC1/DISC1FP1 chimeras and aid in the 
interpretation of established immunocytochemistry data.  
Regarding the (1;11) microarray, the gene expression changes need to be validated via 
quantitative RT-PCR. Quantitative measurement of t(1;11) lymphoblastoid cell line protein 
should also be implemented. This could be achieved by Western blotting and reverse phase 
protein lysate microarray, when high quality antibodies for species can be found. A mass 
spectrometry based quantitative proteomics approach could be pursued when suitable 
antibodies are unavailable.  
The specific temporal alterations that may occur to the cell cycle phases highlighted in the 
analysis of the t(1;11) microarray, could also be investigated. A suitable approach would be to 
use live cell imaging or FACS analysis to determine the lengths of S-phase, G2-phase, M-
phase and G1-phase as well as the total cell cycle length in comparison to karyotypically 
normal controls. 
To follow up the t(1;11) microarray result of cell cycle dysfunction, immunofluorescence 
could be used to detect expression of DISC1 at the centrosome with co-staining of DISC1 
interactors within t(1;11) lymphoblastoid cells as well as the visualisation of the kinetochore 
and the α-tubulin of the mitotic spindle. Specifically, this would aim to investigate if the 
haploinsufficiency of DISC1 in the t(1;11) lymphoblastoid cells (Millar et al, 2005b) causes 
dysfunction of DISC1 at the centrosome which could in turn possibly perturb cell cycle 
dynamics.  
To investigate the possibility of maternal immune activation as a means to modify the 
penetrance of the t(1;11), a humanised translocation mouse model could be generated and mice 
could be treat with the inflammatory agent poly I:C when pregnant. The resulting offspring 
could be characterised using a range of neurobehavioral assays to determine how maternal 
immune activation effects the resulting phenotype in comparison to translocation mice that 
were not exposed to poly I:C in utero. It is possible that poly I:C exposed translocation mice 
would express a unique mental illness-like phenotype as a result of the neonatal activation of 




Microarray analysis of t(1;11)-derived iPSC’s differentiated down neuronal pathways could 
be performed as a means to validate the findings of the t(1;11) lymphoblastoid cell line gene 
expression microarray. Additionally, it is possible that (1;11)-derived neurones would also 
show novel pathway enrichment to brain specific categories as well as the possible enrichment 
to the cell cycle, immune function and inflammation.  
 
7.8 Relevance of this thesis to the field 
This thesis has investigated the putative pathogenic mechanisms that may result from the 
t(1;11). Further work is required to build upon and replicate the findings of this study (see 
section 7.7). However, the results presented in this thesis demonstrate the utility of a family-
based approach to investigating the aetiology of major mental illness. Although the t(1;11) is 
unique to the pedigree studied here, it is possible that the putative mechanisms of pathogenesis 
identified in this family might also represent risk mechanisms in unrelated sufferers of 
schizophrenia, bipolar disorder and major depressive disorder.  Studies of Alzheimer’s disease 
set a precedent for the use of a family study methodology to identify rare mutations in 
pedigrees that in turn highlight pathogenic mechanisms, which represent a risk mechanism in 
ill, non-mutation carrying individuals (Cruchaga et al, 2012; Kim et al, 2009). For example 
rare mutations in A Disintegrin and Metalloprotease Domain 10 (ADAM10), a cell surface 
protein, confer reduced α-secretase activity and increase amyloid-β levels (Kim et al, 2009). 
Possible examples of putative pathogenic mechanisms from this study that may share common 
pathways and therefore may be translatable to the general population of sufferers with major 
mental illness are as follows: 
 The characterisation of DISC1 CP60 and CP69 revealed a clustered mitochondrial phenotype 
and loss of the mitochondrial membrane potential, Δψm. These observations are supportive of 
previous studies that establish DISC1 as being predominantly localised to the mitochondria 
(James et al, 2004) and of DISC1 mutants (Millar et al, 2005a; Ogawa et al, 2014) having 
involvement in mitochondrial dysfunction as a possible pathophysiological mechanism in 
major mental illness. It may be that the mitochondrial dysfunction triggered by CP60 and CP69 
acts upon common mitochondrial pathways that have been found to be perturbed in individuals 
neuropsychiatric disorders (Manji et al, 2012). Disturbance of mitochondrial pathways has 
been found to produce defects in synaptic plasticity and alterations to long-term cellular 
resilience. 
Pathway analysis of the t(1;11) microarray highlights an enrichment in immune function and 




phenotypes that has functional enrichment in cytokine abnormalities, may share common 
biological origins with other studies into major mental illness, immune function and 
inflammation. It may be that the potential cytokine dysfunction in the t(1;11) pedigree operates 
within mechanisms of pathogenesis in common with the findings of research into the meta-
analysis of immune dysregulation in bipolar disorder (Modabbernia et al, 2013), schizophrenia 
(Miller et al, 2011) and major depressive disorder (Miller et al, 2009).    
Family studies are able to detect rare variants with large effect sizes; in comparison GWAS 
permits the identification of common sequence and copy number variants, so far with small 
effect sizes in the field of psychiatry. Family studies and GWAS thus both have a role in 
identifying genetic variants (Lee et al, 2012) within populations, albeit with specificities as to 
how frequently occurring and how large an effect size a given variant has. A rare variant, such 
as the t(1;11) would not be detected by GWAS analysis of a large, unrelated population and 
would contribute to the ‘missing hereditability’ (Manolio et al, 2009). In a family study, the 
investigation of a relatively homogenous population leads to the enrichment of the variant 
therefore changes in gene expression arising as a result of the t(1;11) that may be more easily 
detectable and attributable to the translocation. Moreover, a family-based approach mitigates 
the issue of population stratification, which plagues GWASs. Additionally, there will also be 
greater homogeneity with respect to shared environmental effects 
In this study, the effects of the t(1;11) translocation were assessed by comparing carriers and 
non-carriers of the translocation. Translocation carriers were not segregated by clinical 
diagnosis. The reasoning behind this is that this study sought to address mechanisms of 
putative pathogenesis within the t(1;11) pedigree that are common to the various psychiatric 
diagnoses observed in the family. Furthermore, there is epidemiological evidence for 
aetiological overlap between bipolar disorder and schizophrenia (Lichtenstein et al, 2009) as 
well as evidence from GWAS regarding shared loci between psychiatric disorders 
(Consortium, 2013; Purcell et al, 2009a). By studying all t(1;11) carriers together, regardless 
of diagnosis, this study has attempted to identify the common biological mechanisms that act 
upstream of clinically distinct psychiatric disorders. Were the t(1;11) microarray data to be 
segregated by diagnosis, which would only be possible for schizophrenia and major depressive 
disorder as a bipolar sample size is too small, it might be the case that differential effects in 
the enrichment of immune function and inflammation may be apparent. For example, 
individuals with schizophrenia (Miller et al, 2011) may show an altered profile of cytokine 
enrichment compared to sufferers of major depressive disorder (Dowlati et al, 2010). It is also 




my variation in the MHC locus. The MHC locus has frequently been enriched in schizophrenia 
GWAS (Consortium & 2, 2012; Consortium, 2011; Hamshere et al, 2012; Lencz et al, 2013; 
Purcell et al, 2009b; Ripke et al, 2013a; Shi et al, 2009; Stefansson et al, 2009; Yue et al, 
2011) and has not shown significant enrichment in GWAS Mega-analysis for major depressive 
disorder (Ripke et al, 2013b). Additionally, a recent schizophrenia GWAS detected the 
enrichment of immune function enhancers as causal variants, with greatest enrichment 
occurring to B-cell lineages expressing CD19 and CD20 (Consortium, 2014). This finding was 
present even when the MHC locus was removed from analysis by filtering. However the 
analysis of t(1;11) pedigree associated data by diagnosis is beyond the scope of this thesis, but 
could be focus for future research. In addition to this, it is possible that the varying 
presentations of psychiatric illness in the t(1;11) pedigree are in part the result of different 
environmental contributions in conjunction with the genetic insult. It would be impossible to 
mimic these deleterious environmental influences in lymphoblastoid cell lines or iPSC’s.   
 
 7.9 Relevance of this thesis to other studies into DISC1/DISC1FP1 
chimeric species 
Regarding studies by others into the pathophysiology of DISC1/DISC1FP1 chimeras, firstly, 
two studies that have emerged since the experiments in this thesis were completed, that also 
observe that the CP60 species localises predominantly to the pellet fraction in Western blotting 
(Ji et al, 2014; Zhou et al, 2010). Secondly, a transgenic mouse model that expresses both 
CP60 and the der 11 C-terminal DISC1 truncate has been devised (Ji et al, 2014). This mouse 
model predominantly shows deficits in translation and a reduction in rRNA levels as well as a 
decrease in the reduction of MTT. It could be hypothesised from the in vitro expression of 
CP60 that the resultant mitochondrial dysfunction may have made this species embryonically 
lethal in vivo. The transgenic mice may be viable due to the in vivo expression of CP60 being 
markedly lower than the in vitro overexpression, therefore producing damaging but not fatal 
molecular and cellular insults. However, alternatively it may be that the phenotype of these 
animals is modulated by the co-expression of the C-terminal DISC1 truncate. Additionally, at 
present this mouse model has not been directly phenotyped for mitochondrial pathologies, so 
the observations from the in vitro findings of clustered mitochondria and an inferred loss of 
the mitochondrial membrane potential, Δψm, observed in this study cannot as yet be confirmed 
in vivo. Although, the authors suggest that the decrease in the reduction of MTT and associated 
reduction in NADPH oxidoreductase function has the potential to be associated with a 




the loss of the mitochondrial membrane potential, Δψm observed with the exogenous 
expression of CP60 and CP69 in vitro as seen in Eykelenboom et al., (2012). 
Recently it has been observed that an internal ORF in Boymaw encodes a 7kDa protein (Ji et 
al, 2015). 59 of the 63aa in this species are present in CP60. Importantly, the Boymaw protein 
exhibits mitochondrial targeting, which may account for part of the mechanism of 
mitochondrial pathogenesis mediated by CP60 and CP69.  
 
 7.10 Final Comments 
The study of the t(1;11) pedigree permits investigation into the mechanisms by which a rare 
genetic lesion increases risk for a spectrum of psychiatric conditions. In this thesis, putative 
pathogenic mechanisms have been identified that might contribute to the high incidence of 
mental illness seen in the t(1;11) pedigree. These mechanisms include mitochondrial 
dysfunction, abnormal cellular protein localisation, perturbation of the cell cycle and 
dysregulation of immune function and inflammation. Further work is now required to extend 
the present results. It is essential that efforts are made to ascertain the presence of chimeric 
protein species in t(1:11) tissue. The putative pathogenic mechanisms identified in this thesis 
may also contribute to the onset of schizophrenia, bipolar disorder and major depressive 
disorder in individuals who do not possess the translocation. Therefore the study into the 
molecular pathogenesis within the t(1;11) pedigree may be informative as to mechanisms of 
psychiatric illness in the general population. Ultimately, the work presented in this thesis may 
result in improved understanding of the aetiology of these conditions, which in turn might lead 
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We identified Disrupted-In-Schizophrenia 1 (DISC1) as a
genetic risk factor for major mental illness, through study of
a large Scottish family multiply affected with schizophrenia,
bipolar disorder and major depressive disorder, that results
from inheritance of a balanced t(1;11)(q42.1;q14.3) chromo-
somal translocation (1). On chromosome 1, the t(1;11) trans-
location directly disrupts DISC1 and its non-coding antisense
partner DISC2 (2). Perturbed expression of one or both
genes is therefore likely to be directly involved in disease
pathogenesis. Independent genetic linkage and association
data support the involvement of the DISC locus in schizophre-
nia, schizoaffective disorder, bipolar disorder, recurrent major
depression, and most recently autism spectrum disorders, in
multiple populations (3,4).
DISC1 is a scaffold protein now known to be essential for
many critical brain processes, including regulation of neural
precursor proliferation and differentiation (5), migration of
newborn neurons within the developing cortex (6) and adult
hippocampus (7), integration of newborn neurons into the
existing neural circuitry (7), modulation of dendritic spines
(8) and synapse formation/composition (7,9). If dysregulated
by the t(1;11) translocation through the disruption of DISC1,
it is conceivable that any or all of these processes could con-
tribute to abnormal brain development and function, thereby
triggering psychiatric illness.
Although we have previously provided evidence for haploin-
sufficiency as the disease mechanism in translocation carriers
(10), we now provide evidence for an additional level of com-
plexity. The translocation fuses DISC1 to a gene on chromo-
some 11, DISC1 Fusion Partner 1 (DISC1FP1), also known
as Boymaw (11), resulting in the production of various aberrant
chimeric transcripts with novel protein-coding potential. The
proteins encoded by these transcripts consist of C-terminally
truncated DISC1—in some instances fused to 1, 60 or 69
novel amino acids encoded by the DISC1FP1 sequence. The
60 and 69 additional amino acids increase the a-helical
content of DISC1 in vitro, resulting in the formation of abnor-
mally large protein assemblies that exhibit increased thermal
stability. When exogenously expressed, these abnormal chimer-
ic proteins are predominantly targeted to mitochondria, where
they induce abnormal morphology and abolish mitochondrial
membrane potential. Overall, our data suggest that dysregulated
mitochondrial function in proliferating cells and neurons may
contribute to disease pathogenesis in translocation carriers.
RESULTS
Abnormal chimeric DISC1 transcripts result from the
t(1;11) translocation
A gene referred to as Boymaw has previously been noted as
spanning the chromosome 11 translocation breakpoint in the
t(1:11) family (11). Analysis of expressed sequence tags
(ESTs) indicates that transcripts produced from this gene
(Fig. 1A) are alternatively spliced, utilizing multiple alterna-
tive exons and, in exon 5, alternative splice donor sites
(Fig. 1B). This gene possesses no significant open reading
frames (ORFs) and is therefore most likely a non-coding
RNA gene.
DISC1 and the chromosome 11 gene are oriented such that
the translocation causes gene fusion. Consequently, in lym-
phoblastoid cell lines, the derived 1 and 11 chromosomes
(der 1 and der 11) may give rise to chimeric transcripts con-
sisting of DISC1 exons 1–8 fused to breakpoint distal exons
of the chromosome 11 gene, or to breakpoint proximal
exons of the chromosome 11 gene fused with DISC1 exons
9–13, respectively (11).
Analysis of chimeric transcript expression using lympho-
blastoid cell lines derived from t(1;11) translocation carriers
demonstrated that such transcripts are indeed produced
(Fig. 2A). Thus, the disrupted gene on chromosome 11 has
been officially named DISC1 Fusion Partner 1 (DISC1FP1)
(12) to reflect this biological mechanism, although it has also
been referred to using the AceView (13) name Boymaw (11).
Reverse transcription PCR (RT-PCR) analysis using primer
pairs designed to amplify chimeric transcripts from both the
der 1 and der 11 chromosomes combined with sequencing
detected the fusion of DISC1 exon 9 to DISC1FP1 exon 3a
or exon 4, as well as the fusion of DISC1FP1 exon 2 to
DISC1 exon 8 in cell lines carrying the translocation (Fig. 2A).
Breakpoint proximal, but not distal, DISC1 transcript
levels are reduced by the t(1;11) translocation
We have previously demonstrated that DISC1 transcription
occurs from the disrupted DISC1 allele on chromosome 1,
and that DISC1 transcript levels, quantified using PCR
primers specific for exon 2, are reduced (10). In this extended
study, we used SYBR green real-time PCR to quantify DISC1
expression in lymphoblastoid cell lines derived from t(1;11)
family members, utilizing primer pairs designed proximal to
the translocation breakpoint, either within exon 2 or spanning
exons 4–6 (detecting wild-type DISC1 transcripts plus tran-
scripts produced from the der 1 chromosome), or distal to the
translocation breakpoint, within exon 9 (detecting wild-type
Figure 1. Schematic of DISC1FP1 (not to scale). (A) DISC1FP1 genomic
structure showing all known exons (numbered according to 11 and 34).
Arrow indicates alternatively spliced exon 5. (B) ESTs from DISC1FP1.
Asterisks mark positions of translation stop codons predicted to be utilized
in chimeric transcripts arising from the der 1 chromosome. CK000409 and
BU599486 encode CP60 and CP69, respectively, both terminating within
exon 6. AB371558 encodes CP1, which terminates within exon 3a.
Human Molecular Genetics, 2012, Vol. 21, No. 15 3375
 at E
dinburgh U







DISC1 transcripts plus transcripts produced from the der 11
chromosome).
We confirmed the reduction in DISC1 transcript expres-
sion levels using primer pairs proximal to the t(1;11) break-
point (Fig. 2B, P , 0.05 for exon 2 primers, P , 0.01 for
exon 4–6 primers). In contrast, the exon 9 primers did not
detect a decrease in DISC1 expression in translocation car-
riers compared with normal karyotype controls (Fig. 2B). Al-
together, assuming that DISC1 expression from the
non-disrupted allele is unaltered by the translocation, these
quantitative data demonstrate that chimeric transcripts pro-
duced from the der 1, but not the der 11, chromosome are
scarce. The der 1 chimeric transcripts are predicted to
have splice junctions downstream of the translation stop
codon (Fig. 1B), a feature of aberrant transcripts that
marks them for nonsense-mediated mRNA decay (14).
These transcripts may therefore be targeted and degraded
by this cellular surveillance mechanism and depleted from
the cell. In contrast, there are no obvious stability issues
for chimeric transcripts from the der 11 chromosome. This
interpretation is complicated by the theoretical possibility
that the exon 9 primer pair also detects DISC2 transcripts,
which overlap DISC1 exon 9, although DISC2 is expressed
at unquantifiably low levels in lymphoblastoid cell lines
(data not shown).
The translocation-carrying cell lines used in this analysis
were derived from one unaffected carrier, and one and four
carriers diagnosed with schizophrenia or severe recurrent de-
pression, respectively. Although the sample numbers are
low, it is worth pointing out that the quantitative measures
Figure 2. Chimeric transcript expression in t(1;11) family-derived lymphoblastoid cell lines. (A) RT-PCR detects chimeric transcripts in translocation cell lines.
(Left) Schema of the fused genes on each derived chromosome. Black and grey boxes represent DISC1 and DISCFP1 exons, respectively. Arrows denote primers
used in this analysis. (Middle) Amplified PCR products. 2VE, N and T represent negative controls, normal karyotype cell lines and translocation cell lines,
respectively. The DISC1FP1 exon 2-DISC1 exon 9 primer pair generated two products corresponding to the inclusion/exclusion of the alternatively spliced
DISC1FP1 exon 3. Data from the DISC1 exon 7-DISC1FP1 exon 3a primer pair are shown as three lanes spliced together from a single gel. (Right)
RT-PCR products were sequenced to confirm chimeric transcript amplification. (B) Real-time PCR quantification of DISC1 expression levels. Each dot repre-
sents a single cell line. Open, black and grey circles represent no diagnosis, schizophrenia and recurrent major depression, respectively. Horizontal lines represent
the mean of each group. Statistical significance was determined independently for each primer pair using a two-tailed t-test to compare the group mean expres-
sion levels.
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gave no indication of a relationship between DISC1 transcript
levels and diagnosis.
Predicted abnormal DISC1 protein species encoded by the
chimeric transcripts
Transcripts fusing DISC1 exons 1–8 with DISC1FP1 exons
4-end encode abnormal proteins consisting of DISC1 amino
acids 1–597 fused at the C-terminus to novel amino acids
encoded by DISC1FP1. Alternative splicing of DISC1FP1
exon 5 induces a frameshift, resulting in the addition of 60
or 69 novel amino acids (Table 1). These proteins will be re-
ferred to as Chimeric Protein 60 and 69 (CP60 and CP69).
Transcripts fusing DISC1 exons 1–8 with DISC1FP1 exon
3a encode DISC1 amino acids 1–597, plus a single glycine
derived from the DISC1FP1 sequence (Table 1). This
protein will be referred to as CP1. Since there is normally a
glycine at position 598 in DISC1, CP1 essentially corresponds
to DISC1 amino acids 1–598.
Chimeric transcripts produced from the der 11 chromosome
contain an internal ORF corresponding to amino acids 669–
854 of the DISC1 C-terminus. This ORF is unlikely to be
translated because DISC1FP1 is apparently non-coding; there-
fore, the sequence upstream of the DISC1 ORF is unlikely to
provide the signals necessary for translation initiation.
Fusion protein 69 exhibits altered structure and thermal
stability
We speculated that the addition of 60 or 69 novel amino acids
would alter the properties of the N-terminal DISC1 fragment
encoded by the chimeric transcripts. We selected DISC1
Table 1. Abnormal DISC1 protein species encoded by transcripts produced from the der 1 chromosome
Nucleotide sequences are shown above, and the corresponding translated amino acid sequence below. Der 1-derived chimeric transcripts are predicted to contain
DISC1 exons 1–8, encoding amino acids 1–597, but for simplicity only amino acids 593–597 are shown. DISC1-derived nucleotides are in lower case, the codon
and amino acid (glycine) at the junction are in bold type, lower case italics denote the alternatively spliced region at the 3′ end of DISC1FP1 exon 5 (the short and
long forms of the exon are designated 5S and 5L, respectively) and underlining marks the alternative amino acids within CP60 and CP69.
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amino acids 326–597 for analysis, fused to maltose-binding
protein (MBP) tags, based upon considerations of domain delin-
eation, predicted protein disorder in the N-terminus of native
DISC1 and likely consequences for protein expression,
purification, and finally on the assessment of secondary struc-
ture for the C-terminus of native DISC1 (15). This DISC1
region was expressed both by itself (MBP-DN597) or fused to
the novel 69 amino acids of CP69 (MBP-DNCP69, Fig. 3A),
Figure 3. Biophysical characterization of CP69. (A) Schematic of the recombinant proteins MBP-DN597 and MBP-DNCP69, drawn to scale. (B) Following
amylose affinity purification, size exclusion chromatography separates the recombinant protein (140 ml peak) from co-purifying contaminants (later
peaks); CV: 320 ml. (C) SDS–PAGE purification gel of MBP-DN597 and MBP-DNCP69 proteins. AAP, amylose affinity purification; SEC, size exclusion chro-
matography. Arrows indicate monomers and dimers. (D) Mean hydrodynamic diameters of three independent protein preparations for each of MBP-DN597 and
MBP-DNCP69 determined by DLS. (E) Mean melting temperatures of three independent protein preparations for each of MBP-DN597 and MBP-DNCP69 deter-
mined by DLS at increasing temperatures. (F) CD spectra of MBP-DN597 (0.12 mg/ml) and MBP-DNCP69 (0.11 mg/ml) in the far-UV range is shown, with
mean residue ellipticity and wavelength (measured from 280 to 185 nm) plotted along the y-axis and x-axis, respectively. (G) Deconvolution of the CD spectra
using different algorithms and data sets.
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selected because it is the longest of the chimeric proteins.
Following purification from Escherichia coli, each product
was detectable as two major species (75 and 150 kDa for
MBP-DN597 and 80 and 160 kDa for MBP-DNCP69) on an
SDS–PAGE gel (Fig. 3B and C). The molecular weights of
these species correspond to the predicted molecular weights
of the protein monomers and SDS-resistant dimers (respective-
ly, 76.8 and 153.6 kDa for MBP-DN597, and 85.1 and
170.2 kDa for MBP-DNCP69). The identities of these species
were confirmed by mass spectrometry (Supplementary Mater-
ial, Figs S1 and S2).
Measurement of native purified protein size (hydrodynamic
diameter) using dynamic light scattering (DLS) revealed that
MBP-DNCP69 forms larger species compared with
MBP-DN597, although this fell just short of statistical signifi-
cance (P ¼ 0.056, Fig. 3D). In support of this, the initial size ex-
clusion chromatography also suggests that the MBP-DNCP69
assembly has a larger hydrodynamic diameter (Fig. 3B). The
thermal stability of each protein was then assessed by taking
DLS readings at steadily increasing temperatures and measur-
ing the point at which changes in protein structure occur.
MBP-DNCP69 exhibits a consistently higher melting point
than MBP-DN597 (P ¼ 0.003, Fig. 3E). Altogether, the
increased size and higher melting point of MBP-DNCP69
suggest that the addition of 69 novel amino acids induces the
formation of larger structures with increased stability.
Far-UV circular dichroism (CD) spectra were then recorded
to estimate the secondary structure content. Both MBP-DN597
and MBP-DNCP69 exhibit a pronounced double-negative
minimum at 208 and 222 nm and one positive peak at
193 nm in the far-UV range (Fig. 3F), a characteristic of
folded proteins with a high a-helical content (16). However,
MBP-DNCP69 displays significantly more pronounced nega-
tive and positive ellipticity centred in these regions, when
compared with MBP-DN597, implying a greater propensity
towards a-helices and indicating that secondary structure vari-
ation exists as a result of the novel 69 amino acids. Indeed,
upon spectral deconvolution using three combinations of algo-
rithms and reference sets (17–21), the MBP-DNCP69 struc-
ture is estimated to possess 1.4–1.8 times greater
a-helical content and lower b-strand composition compared
with MBP-DN597 (Fig. 3G).
Analysis of the novel 60 and 69 DISC1FP1 residues shows a
strong disagreement between three secondary structure predic-
tion programs (22–24) (Fig. 4); PsiPred predicts several low-
confidence b-strands for this region, whereas JPred3 and
Porter predict an abundance of a-helices. The CD spectroscopy
results revealing elevated a-helical content in MBP-DNCP69
are in agreement with the latter predictions. PCoils/Coils
(25,26) did not predict any coiled-coil motifs. Although the
presence of the MBP tag precludes direct comparison with
other CD studies that investigated the C-terminal region of
DISC1 (27), altogether these data imply an overall mixed a/b
fold for this region.
Thus, it appears that the addition of 69 amino acids from
DISC1FP1 introduces clear differences in secondary structure
compared with the control truncated DISC1 protein, resulting
in the formation of larger, more stable protein assemblies.
CP60 and CP69 are mitochondrial proteins that induce
mitochondrial dysfunction
DISC1 has been detected at multiple subcellular locations, in-
cluding the centrosome (28), nucleus (29), mitochondria (30),
Golgi (31) and synapse (32). C-terminally truncated DISC1
(amino acids 1–597) instead adopts a predominantly diffuse
cytoplasmic distribution (Fig. 5A) (6). In COS7 cells, FLAG-
tagged CP1 also adopts a diffuse cytoplasmic distribution
(Fig. 5A), confirming that these two proteins most likely have
highly similar properties.
FLAG-CP60 and FLAG-CP69, however, are strongly tar-
geted to mitochondria in COS7 cells, where they alter mitochon-
drial morphology from the normal extended tubular structure to
abnormal perinuclear clusters (Fig. 5A). Intriguingly, the major-
ity of these abnormal clustered mitochondria do not take up the
mitochondrial membrane potential-dependent dye mitotracker
(Fig. 5A), indicating that chimeric protein expression inhibits
normal mitochondrial function. Importantly, this loss of
membrane potential occurs even when the chimeric proteins
are exogenously expressed at the lowest levels detectable
using this method (Fig. 5A). However, co-staining with the
mitochondrial marker cytochrome c reveals that the mitochon-
dria remain intact (Fig. 5A). DISC1 has previously been
reported to induce mitochondrial dysfunction, including
altered mitochondrial NADH activity (33). This enzyme partici-
pates in oxidative phosphorylation, a process which generates
and maintains the mitochondrial membrane potential, thus the
loss of mitochondrial membrane potential in cells expressing
CP60 or CP69 possibly indicates a deleterious effect upon mito-
chondrial NADH activity. In cultured primary cortical neurons
from the CD1 mouse strain [days in vitro (DIV) 5], or the
C57BL/6 mouse strain (DIV 11), FLAG-CP60 and
FLAG-CP69 induce the same mitochondrial clustering and
the loss of membrane potential (Fig. 5B and Supplementary Ma-
terial, Fig. S3). Altogether, these data show that the altered bio-
physical properties demonstrated for CP69, and most likely
possessed by CP60 also, correlate with profoundly altered func-
tion within proliferating cells and neurons.
Figure 4. Secondary structure predictions for the DISC1FP1-derived amino
acids of CP60 and CP69, using three prediction programs: PsiPred3, JPred3
and Porter.
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Figure 5. Exogenous chimeric protein expression in COS7 cells and cultured CD1 mouse primary neurons. (A) Immunofluorescence detection of FLAG-tagged
DISC1 (green), mitochondria (MitoTracker Red CMXRos) and cytochrome c (pink) in COS7 cells. Asterisks indicate cells transfected with CP60 or CP69,
marking cells with low-, medium- or high-level expression. Scale bars represent 20 mm. (B) Immunofluorescence detection, as above, in primary mouse cortical
neurons. Asterisks indicate cells transfected with CP60 or CP69. Scale bars represent 10 mm.
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Investigating chimeric protein expression in
lymphoblastoid cell lines
Identification of DISC1 chimeric transcripts prompted us to re-
examine our previous report of reduced DISC1 protein expres-
sion as a result of the t(1;11) translocation (10). We expressed
untagged CP1, CP60 or CP69 in COS7 cells, and investigated
isoform expression using DISC1 antibody R47, specific for the
N-terminal head domain (30). This demonstrated that CP1 is
abundant in soluble lysates, whereas CP60 and CP69 partition
predominantly to the pellet produced during cell lysis
(Fig. 6A), as has been noted previously for a related DISC1
chimeric protein (34). However, a small proportion of each
chimeric protein is also detectable within the soluble lysates.
In addition to full-length DISC1, R47 detects a triplet of
species of 71–80 kDa (30). CP1 (predicted molecular
weight of 64.5 kDa) migrates between the 71 and 75 kDa
species, whereas CP60 and CP69 (predicted molecular
weights of 71.8 and 72.8 kDa, respectively) migrate between
the 75 and 80 kDa species, thus each chimeric protein is dis-
tinct from the endogenous species detected by R47 on immu-
noblots (Fig. 6B).
We next examined lymphoblastoid cell lines derived from
members of the t(1;11) family. Our previous analysis
focused on lysates, and did not detect any abnormal species
in translocation cell lines (10). In this study, we examined
pellets. The same triplet of bands at 71–80 kDa is detectable
in both lysates and pellets, with no additional species detect-
able in cell lines carrying the translocation (Fig. 6C). The
chimeric proteins are thus either not expressed, or are
present below the level of detection using this antibody. The
latter is consistent with the production, but apparent low ex-
pression/predicted short lifespan, of chimeric transcripts
from the der 1 chromosome.
We also used a-DISC1 (35), an antibody specific for a
translocation breakpoint distal DISC1 epitope that should
detect the C-terminal fragment, amino acids 669–854,
encoded by chimeric transcripts from the der 11 chromosome.
Although the antibody clearly detects full-length DISC1 in the
lymphoblastoid cell lines, it failed to detect any novel species
in translocation cell lines that could correspond to this frag-
ment (predicted molecular weight of 20.9 kDa, Fig. 6D).
Thus, as with the N-terminal chimeric proteins, this fragment
is either not expressed, or is present but below the detection
limit of the antibody.
DISCUSSION
Although the t(1;11) translocation is a unique genetic event,
understanding its molecular consequences in full may help
explain the very high penetrance of this mutation and inform
on other clinical mutations (15). Aberrant DISC1 proteins
putatively arising from the der 1 chromosome lack the final
257 amino acids, required for interaction with a number of
important binding partners, including NDE1/NDEL1 (15). C-
terminal truncation will thus abolish critical interactions
(36), while maintaining others that require amino acids 1–
Figure 6. Chimeric protein expression in t(1;11) family-derived lymphoblastoid cell lines. (A) Overexpressed untagged CP69 partitions predominantly to pellets
from transfected COS7 cells, as detected using antibody R47. L, lysate; P, pellet; +, transfected; -, non-transfected. Arrow marks CP69. CP60 expression is
indistinguishable from that of CP69 (data not shown). (B) Migration of CP1, CP60 and CP69 with respect to endogenous species expressed in COS7, as detected
by R47, shown only in lysates for clarity. Endogenous species sizes are indicated. -, non-transfected. Arrows mark the positions of overexpressed chimeric pro-
teins. (C) Detection of endogenous species by R47 in lymphoblastoid cell line pellets. N, normal karyotype. Endogenous species sizes are indicated, including
full-length DISC1 at 100 kDa. T, translocation. (D) Detection of endogenous species by a-DISC1 in lymphoblastoid cell line lysates. N, normal karyotype; T,
translocation. The asterisk marks the predicted size of the hypothetical translation product of chimeric transcripts arising from the der 11 chromosome.
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597, such as GSK3b (5,36). Phosphodiesterase 4 (10) utilizes
multiple contact sites within amino acids 1–597 that are
sufficient for DISC1/PDE4 interaction (10), but also a C-
terminal site that is abolished by the translocation (37),
which may consequently dysregulate this complex and
dynamic interaction. Altogether, these few examples demon-
strate that expression of C-terminally truncated DISC1 is
likely to have pleiotropic effects at the cellular level. The
importance of this is illustrated by the demonstration that, in
vivo, expression of amino acids 1–597 by in utero electropor-
ation in mice blocks neuronal migration within the developing
cortex (6), whereas its transgenic expression in mice induces
phenotypes resembling characteristics of human mental
illness including enlarged lateral ventricles, and various be-
havioural deficits (38,39). The shortest aberrant species
encoded by transcripts from the der 1 chromosome is CP1,
which essentially corresponds to DISC1 amino acids 1–598.
CP1 localization is indistinguishable from the aberrant local-
ization of amino acids 1–597 (6); thus, we conclude it is a
comparable species that is likely to behave in a similar
manner.
Over and above the multiple effects of expressing amino
acids 1–597, the additional 60 or 69 novel amino acids in
CP60 and CP69 alter the structure of DISC1 amino acids
326–597, leading to the production of larger, more stable
protein assemblies. This is intriguing because detergent-
insoluble DISC1 aggregates have been detected previously in
post-mortem brain samples from psychiatric patients (40,41).
Altogether these observations highlight aberrant DISC1 assem-
bly as a possible disease mechanism in psychiatric illness
(40,41). The abnormal structure of CP60 and CP69 is predicted
to adversely influence protein interactions, and is most likely
related to their extreme effects upon mitochondrial morph-
ology and membrane potential, effects which are not induced
by amino acids 1–597 alone. However, CP60 and CP69 are
very scarce in the translocation-carrying lymphoblastoid cell
lines used in this study, if indeed they are expressed at all, so
these data must be interpreted with caution. That said, we
have demonstrated that even expression of these chimeric pro-
teins at the lowest detectable levels is sufficient to induce mito-
chondrial dysfunction; thus, it is likely that any endogenous
expression of these proteins would be deleterious.
It is not possible to properly assess the contributions of CP1,
CP60 and CP69 to disease pathogenesis in translocation car-
riers until neural material is available for analysis. Induced
pluripotent stem cell technology is the most likely route to
this, and will be available in the not-too-distant future. Until
then, we can only speculate that, because DISC1 is expressed
extensively in the developing and adult brain, and expression
of CP1, CP60 and CP69 is driven by the DISC1 promoter, it is
likely that at some time chimeric transcripts will be produced
at some level in the brain of t(1;11) carriers. Although this spe-
cific disease mechanism is unique to translocation carriers, it is
notable that C-terminal truncation, addition of GFP tags and
the ‘ultra-rare’ putative causal mutation R37W, identified in
a single schizophrenic patient (42), all increase DISC1 mito-
chondrial targeting and induce abnormal morphology
(Ogawa et al., manuscript in preparation) (43), whereas the
schizophrenia-associated variant L607F influences neuronal
mitochondrial transport (44). The psychiatric illness suffered
by translocation carriers displays no unique features, thus it
likely arises from dysregulation of a pathway common to
other unrelated patients. Similarly, the abnormal chimeric
DISC1 species, though unique, may act through a common
pathway. We propose that this common pathway involves
mitochondrial dysfunction. Mitochondria are essential for
multiple processes within most cells, due to their role in the
provision of energy and calcium homeostasis, as well as
their role in apoptosis, either for the clearance of damaged
cells or in programmed cell death. In the brain, neurons are
particularly sensitive to mitochondrial dysfunction, because
mitochondria must be transported to distal dendrites for the
supply of energy and calcium buffering to the synapse (45).
DISC1 is known to be critical for neural precursor prolifer-
ation and differentiation, neuronal migration and integration
and synaptic signalling within the developing and adult
brain (46). It is conceivable that many, if not all, of these pro-
cesses would be compromised by mitochondrial dysfunction,
if the chimeric proteins CP60 and CP69 are indeed expressed
in the brains of t(1;11) translocation carriers, coupled with
reduced expression of DISC1 at other subcellular locations,
such as the synapse, nucleus and centrosome, due to the loss
of normal DISC1 expression from the translocated allele.
MATERIALS AND METHODS
Bioinformatic methods
Chromosome 11 ESTs and DISC1 sequences were examined
using the UCSC genome browser (http://genome.ucsc.edu).
Predicted cDNA produced by the translocation was evaluated
for coding potential, using the ExPASy TRANSLATE tool
(www.expasy.org). Molecular weight calculations were also
carried out using the ExPASy TRANSLATE tool and the
ExPASy Compute Mw tool. Protein secondary structure pre-
dictions were made by submitting amino acid sequences inde-
pendently to PsiPred (23), Jpred3 (22) and Porter (24).
Cell culture and transfection
This study utilized lymphoblastoid cell lines derived from
members of the t(1;11) translocation family, either with a
normal karyotype or carrying the balanced translocation.
Translocation carriers included unaffected family members
as well as those diagnosed with either schizophrenia or
severe recurrent depression. Lymphoblastoid cell lines were
grown in RPMI (Gibco) supplemented with 10% fetal calf
serum (Gibco) under standard conditions, with a 75%
medium change every 2–3 days. Karyotypes of cell lines
used in this study were confirmed by chromosome banding
of metaphase spreads. All lymphoblastoid cell lines were
grown and harvested concurrently to minimize any effects
upon gene expression due to variable growth conditions.
COS7 cells were maintained in Dulbecco’s modified
Eagle’s medium (Invitrogen) containing 10% fetal bovine
serum at 378C in a 5% CO2 humidified atmosphere. Cortical
neuron cultures were prepared from embryonic day (E) 18
mouse fetuses (CD1 or C57BL/6) as described previously
(32), grown on cover slips coated with Poly-D-lysine and
maintained in Neurobasal medium supplemented with 2% of
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B-27 and 2 mM Glutamax (all from Invitrogen) at 378C with
5% CO2. Transfection of cultured cells and cortical neurons
at 5 or 11 DIV was conducted using Lipofectamine 2000 (Invi-
trogen) according to the manufacturer’s instructions.
RT-PCR analysis
RNA was prepared using the Qiagen RNeasy extraction kit,
and cDNA was prepared using the First Strand cDNA synthe-
sis kit (Roche) according to the manufacturer’s instructions.
PCR, to detect novel DISC1 chimeric transcripts, was
carried out using Thermostart Taq polymerase (Abgene). A
typical reaction contains 2 ml of 10× PCR reaction buffer,
1.2 ml of 25 mM magnesium chloride, 0.5 ml of dNTPs (of a
10 mM stock), 0.25 ml of forward and reverse primers (of a
300 ng/ml stock), 0.1 ml of Taq polymerase, 2 ml of DNA tem-
plate and 13.7 ml of sterile water to a final volume of 20 ml.
These reactions were cycled using a touchdown PCR pro-
gramme as follows: [958C, 15 min; 948C, 1 min; 708C, 30 s
(228C/cycle); 728C: 30 s] × 6 cycles, followed by (948C:
1 min; 608C: 30 s; 728C: 30 s) × 34 cycles, or for amplifica-
tion of transcripts encoding CP1: hot start 958C: 2 min, fol-
lowed by (958C: 30 s; 608C: 30 s; 728C: 30 s) × 35 cycles.
Products were resolved using standard agarose gel electro-
phoresis.
For quantitative measurements, DISC1 expression was mea-
sured using the SYBR Green Real-time PCR Detection
System (Bio-Rad Laboratories Ltd). For the quantification of
DISC1 in t(1;11) family cell lines, a single reaction contained
7.5 ml of SYBR Green 2× Master Mix (Bio-Rad Laboratories
Ltd), 0.25–0.5 ml of forward and reverse primers (stock con-
centration of 300 ng/ml), 3 ml of template cDNA and distilled
water to a final volume of 15 ml. The reactions were cycled
using the MyiQ Single-Colour Real-Time PCR Detection
System (Bio-Rad Laboratories Ltd) as follows: 958C: 3 min
(1 cycle); 958C: 10 s; 668C: 30 s; 728C: 45 s (40 cycles), fol-
lowed by melt curve analysis: 558C: 10 s (+0.58C per cycle
for 80 cycles). Relative DISC1 expression levels were calcu-
lated using the MyiQ Gene expression macro (Bio-Rad La-
boratories Ltd), which utilizes the deltaCT method and
corrects for primer amplification efficiencies (http://medgen.
ugent.be/~jvdesomp/genorm) (47). DISC1 expression levels
were normalized using the geometric mean of
Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and
Phosphofructokinase (PFK), and the use of each housekeeping
gene gave the same results. The same panel of 10 cell lines
(four normal, six translocation) was used for each assay.
Results were obtained for all cell lines in each assay, with
the exception of one translocation cell line when primers spe-
cific for DISC1 exons 4 and 6 were used. This failed assay was
not repeatable since the RNA sample in question was spent.
Data were analysed by two-tailed t-test (GraphPad Prism).
PCR product sequencing
Single PCR products were treated with ExoSAP-IT (GE
Healthcare) prior to direct sequencing. Multiple PCR products
were resolved by LMP agarose gel electrophoresis and
extracted using the QIAquick gel extraction kit (Qiagen)
prior to direct sequencing. Alternatively, purified PCR
products were cloned using the TOPO TA cloning kit (Invitro-
gen) according to the manufacturer’s instructions. BigDye
Terminator sequencing of PCR products or plasmid DNA
was carried out using 1 ml of BDv3.1, 1.5 ml of 5× sequen-
cing buffer, 1 ml of DNA template and 6 ml of dH2-
O. Reactions were cycled as follows: 968C: 1 min (1 cycle);
968C: 10 s; 508C: 5 s; 608C: 4 min (25 cycles); 48C hold. Se-
quencing chromatograms were analysed using Chromas
(version 1.45) (48).
Primer sequences
The primers used to detect DISC1 expression by real-time
PCR in t(1;11) cell lines were as follows: Exon 2 forward 5-
GAACGTGGAGAAGCAGAAGG, reverse 5-CAGAGAAC
TGGAGGAGCCAG; Exons 4–6 forward 5-AGCCTGCACT
TTCAACTTCC, reverse 5-AGTTGCTGCTCTTGCTCCTC;
Exon 9 forward 5-AGAGAGAGAAGGGCTGGAGG,
reverse 5-GTCTCCTGGTGCTCCACTTC.
The housekeeping primers used were as follows: Gapdh
forward 5-GGGAGCCAAAAGGGTCATCA, reverse 5-GTG
GCAGTGATGGCATGGAC; hPFK forward 5-AGAGCGTT
TCGATGATGCTT, reverse 5-GTGTTCCTCCCAGTCG
TCAT.
Primers used to amplify DISC1 chimeric transcripts were as
follows: Derived 1 DISC1 chimeric transcript: Exon 4 DISC1
forward 5-AGCCTGCACTTTCAACTTCC, DISC1FP1 exon
4 reverse 5-AAGACCCACAGATGGAATCG; Derived 1
DISC1 chimeric transcript: Exon 6/7 DISC1 forward 5-AAG
GAGCCTCCAGGAAAGAA, DISC1FP1 exon 3a reverse 5-
CAAGAAATGCCAAAGTGAGTTC; Derived 11 DISC1
fusion with BU599486: exon 2 forward 5-GGGACCTGG
AATTGAAGAGA, DISC1 Exon 9 reverse 5-GTCTCCTGG
TGCTCCACTTC.
Primers used for the mutagenesis of recombinant DISC1/





A pcDNA3.1 expression construct carrying full-length N-
terminally FLAG-tagged DISC1 has been described previous-
ly (37). ORFs encoding human DISC1 amino acids 1–597,
plus the 60 or 69 residues from DISC1FP1 (CP60 or CP69),
were synthesized by GeneArt (Invitrogen) and inserted,
untagged, in pcDNA3.1. To generate tagged versions of
CP60 and CP69, N-terminal FLAG-tags were subsequently
added. N-terminally FLAG-tagged DISC1 amino acids 1–
597 and 1–598 were also in pcDNA3.1.
An ORF encoding N-terminally His-tagged human DISC1
amino acids 326–597, plus the 69 residues from DISC1FP1,
was codon-optimized for expression in E. coli and synthesized
by GeneArt (Invitrogen, Supplementary Material, Fig. S1).
The ORF was recombined sequentially into pDONR-221 (Invi-
trogen) and pETG-40A (A. Geerlof, EMBL) vectors using BP
and LR clonase (Invitrogen), adding an N-terminal MBP tag.
This construct will be referred to as MBP-DNCP69. A control
construct, lacking the additional 69-residues (MBP-DN597),
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was generated by the introduction of two stop codons after the
final wild-type DISC1 residue, using a QuikChange II Site-
Directed Mutagenesis Kit (Agilent Technology). The cloned
constructs were confirmed by sequencing.
Recombinant protein production
Identical expression and purification conditions were used for
MBP-DN597 and MBP-DNCP69. Constructs were first trans-
formed into E. coli BL21 Star (DE3) (Invitrogen) and grown
in 2XTY medium containing 100 mg/ml carbenicillin to an
optical density of 0.6 at 378C (at 600 nm). Protein expression
was induced with 1 mM IPTG (isopropyl b-D-thiogalactoside)
and cultures were grown at 378C for 3 h before harvesting by
centrifugation (5500g, 48C, 15 min) and pellets snap-frozen
and stored at 2708C until required. For purification, bacterial
pellets were spun down and resuspended in amylose-affinity
purification buffer (AAP buffer: 20 mM Tris/200 mM NaCl/
1 mM EDTA/1 mM DTT/10% glycerol, pH 7.4) containing
Complete protease inhibitor cocktail (Roche) at 50 ml of
buffer per litre of culture pellet. Cells were lysed using a TS
Cell Disruptor (Constant Systems, 22 kPsi), centrifuged at 50
000g for 1 h and the supernatant filtered through 0.2 mm
Whatman cellulose nitrate membrane filters. The lysate was
loaded onto an 8 ml amylose-sepharose affinity column (New
England BioLabs), using an ÄKTApurifier (GE Healthcare).
Non-specific proteins were washed out with 10 column
volumes (CV) of AAP buffer and the protein (MBP-DN597 or
MBP-DNCP69) eluted using 10 CV of AAP buffer containing
10 mM maltose. Eluted protein was further purified by size-
based separation using a 320 ml HiLoad 26/60 Superdex
200 pg column (GE Healthcare), to which 1.5 CV of storage
buffer (25 mM HEPES/200 mM NaCl/10% glycerol, pH 7.4 at
108C) was applied. The fractions containing proteins
(MBP-DN597 or MBP-DNCP69) were confirmed by SDS–
PAGE, and were subsequently concentrated using 10 kDa
MWCO Vivaspin Sample Concentrators (Sartorius Stedim
Biotech). The identity of individual SDS–PAGE-purified
protein bands (MBP-DN597 and MBP-DNCP69) was con-
firmed by MALDI-TOF mass spectroscopy, using a Voyager
DE-STR MALDI-TOF mass spectrometer (Applied Biosys-
tems). The spectral data were processed using Data Explorer
software (Applied Biosystems) and the peptide masses searched
using GPMAW 8.0 software (49), after creating a database with
the specific modified sequences of MBP-DN597 and
MBP-DNCP69. The identified peptides, found using
GPMAW, were cross-checked with the observed peaks in the
raw data in Data Explorer and found to match (Supplementary
Material, Fig. S2).
Biophysical characterization
The mean hydrodynamic diameter for each protein batch was
determined by DLS on a Zetasizer Auto Plate Sampler
(Malvern Instruments), with percentage number used as the
output format. Each DLS measurement was performed on puri-
fied protein that was initially centrifuged for 15 min at 24 000g
in a desk-top centrifuge and 100 ml aliquots loaded into a
384-well plate for analysis with the laser set at 830 nm. Size dis-
tribution of each protein construct was determined by
performing three independent runs of three measurements (18
× 10 s readings of each sample) at 108C. DLS is an extremely
sensitive tool for detecting the onset of aggregation resulting
from protein melting and was thus used to estimate the
thermal melting points of the proteins (50) by heating the
sample from 10 to 808C with 28C increments. Results from
three independent batches of each protein (MBP-DNCP69 and
MBP-DN597) were compared by two-tailed, unpaired t-tests.
To investigate secondary structure, protein was desalted into
10 mM phosphate buffer (8 mM Na2HPO4/2 mM NaH2PO4, pH
7.4), using pre-equilibrated PD-10 columns (GE Healthcare)
and then diluted to 0.11 mg/ml (MBP-DNCP69) or 0.12 mg/
ml (MBP-DN597), as measured using a V-550 UV-VIS spectro-
photometer (JASCO) based on absorbance at 280 nm and the
theoretical extinction coefficient of the respective protein
sequences. CD analysis was performed on a J-810 spectropolari-
meter (JASCO) at 258C, using a 0.1 cm cuvette (Starna), and
with wavelengths in the far UV-range of 185–280 nm. Each
CD spectrum represents the average of five scans (data pitch:
0.1 nm; scan speed: 10 nm/min; response time: 2 s) and was cor-
rected by subtraction of the respective spectrum obtained for its
desalted buffer solution (five-scan average accumulation). The
obtained raw spectrum signal was then converted from ellipti-
city (millidegrees) into mean residue ellipticity (degrees cm2
per dmol per residue), to allow for concentration and protein
size-independent spectrum measurement for comparison pur-
poses, using the Spectra Manager software. The spectra were
then submitted to DICHROWEB (21) for deconvolution into
secondary structure components utilizing the analysis programs
CDSSTR or CONTIN (18–20), with reference sets ‘Dataset 3’
or SP175 (17).
Immunocytochemistry
To visualize mitochondria, MitoTracker Red CMXRos (Invi-
trogen) was added to the culture medium at a concentration
of 50 nM and incubated for 30 min at 378C prior to fixation.
Cells were fixed in 3.7% formalin for 10 min at room tempera-
ture, followed by permeabilization with methanol at 2208C
for 5 min. Cells were then blocked in PBS containing 3%
bovine serum albumin for 20 min, and incubated with
primary antibodies for 2 (neurons) or 1 h (COS7) at room tem-
perature on a platform shaker, followed by incubation with
secondary antibodies for 1 h at room temperature. Dilution
of primary antibodies is as follows: anti-FLAG rabbit poly-
clonal (1:5000; Sigma), anti-cytochrome c mouse monoclonal
(1:2000–3000; Mitosciences/Abcam). Secondary antibodies
were Alexa Fluor 488 goat anti-rabbit (A11008) and Alexa
Fluor 647 chicken anti-mouse (1:2000; Invitrogen). Confocal
images were acquired with a Zeiss LSM510 microscope, and
non-confocal images (Supplementary Material, Fig. S3) were
captured using a Zeiss Axioskop 2 MOT epifluorescence
microscope.
Immunoblotting
Lysates were prepared in ice-cold RIPA buffer containing
Complete Protease Inhibitor Cocktail (Roche). Lysates were
solubilized by incubation for 1 h at 48C on a rotary wheel
and centrifuged at 24 000g for 30 min. Following
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centrifugation, pellets were separated from supernatants and
sample buffer added to each. 3–8 or 15% polyacrylamide
gels were used to separate proteins for analysis with the R47
or a-DISC1 antibodies, respectively. Samples were separated
at 150 V and then transferred to PVDF membranes for analysis.
DISC1 R47 (30) and a-DISC1 (35) antibodies were used to
analyse DISC1 protein expression. Prior to incubation with the
R47 primary antibody, membranes were blocked overnight at
48C in PBS 0.2% Tween (PBST) containing 5% Marvel. The
R47 primary antibody was incubated at a 1:100 dilution in
PBST for 1 h at room temperature. Prior to incubation with
a-DISC1, membranes were blocked in TBS 0.1% Tween
(TBST) containing 1% Marvel for 30 min at room tempera-
ture. The a-DISC1 primary antibody was incubated at
1:2000 in TBST/1% Marvel overnight at 48C. Membranes
were washed with either PBST or TBST followed by second-
ary antibody incubation. Goat anti-rabbit secondary antibodies
(HRP conjugates, DakoCytomaten) were incubated at 1:3000
(in PBST or TBST as appropriate) for 20 min at room tem-
perature. Membranes were processed using ECL Plus (GE
Healthcare).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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Annex A1 - Optimisation of the HSII bioluminescence 
assay to measure cellular ATP in COS-7 cells and 
t(1;11) lymphoblastoid cell lines  
 
A1.1 Methods 
This annex focuses on the optimisation of a flash luciferase assay, the HSII ATP 
bioluminescence Kit (Roche), referred to henceforth as the HSII assay. The methods detailed 





Below are listed the details the chemical reagents used in the production of this annex. The 
source each chemical reagent is stated alongside, in brackets. Where relevant, the soloution 
that a reagent is suspended in is stated. 
 
Bicinchoninic Acid (Sigma) 
Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (Tocris) made up in DMSO 
Copper II Sulphate (Sigma) 
 
A1.1.2 Cell culture 
 
A1.1.2.1 Cell seeding density 
For generation of cells for lysis in the HSII assay with the exogenous expression of 
DISC1/DISC1FP1 species, 2.5x106 COS-7 cells were seeded and grown overnight in 10cm 
dishes  prior to transfection. In the HSII serum starvation optimisation 3.25x106 COS-7 cells 
were seeded and grown overnight. 
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A1.1.2.2 Serum starvation 
In the serum starvation of COS-7 cells, the DMEM/10% FCS vol/vol was aspirated and 
replaced with DMEM/1% FCS vol/vol 18 hours prior to the CCCP treatment. This condition 
is referred to as the low serum condition while the other parallel COS-7 cultures that remained 
cultured in DMEM/10% FCS are referred to as the normal serum condition. The following 
day the COS-7 cells were harvested. 
In the serum starvation of the lymphoblastoid cell lines, for two consecutive days the 
lymphoblastoid cell line media was topped up with an additional 10ml of RPMI/10% FCS 
vol/vol. On the following day the media was aspirated to leave only 20ml of conditioned media 
and the flocculated cells. To this 17ml of pre-warmed RPMI/1% FCS vol/vol was added. This 
condition is referred to as the low serum condition and the other parallel lymphoblastoid 
cultures that were remained cultured in RPMI/10% FCS are referred to as normal serum 
condition. The following day the lymphoblastoid cells were harvested. 
 
A1.1.2.3 Drug treatment 
CCCP was used as a means to reduce cellular ATP. For the HSII assay, COS-7 cells receiving 
CCCP treatment were cultured in 10cm dishes to 75-90% confluency. In the method 
development of the serum starvation/CCCP treatment the cells were untransfected, in 
experimental assays, the COS-7 cells had been transfected 18-24 houses previously with  
pcDNA 3.1 (+) empty vector plasmid. The media was aspirated and the cells washed twice in 
warm PBS. 10ml of pre-warmed media (see table 2.3.A) was then applied to each culture dish. 
The 100mM CCCP stock was diluted in sterile DMSO (Sigma) to a 1:1000 stock, then 
delivered to the culture dishes to give final concentrations of 10µM-100µM CCCP. The cells 
were incubated with CCCP for two hours at 37°C and 5% CO2. The serum starvation/CCCP 
treatment method development was produced in parallel with sham treat (DMSO) cells. 
Following incubation the CCCP or DMSO, the COS-7 cells were harvested and lysed along 
with the other dishes of COS-7 cells that exogenously expressed protein, for use in the HSII 
assay. 
For immunocytochemistry the CCCP was delivered to 1ml of media (see table 2.3.A) from a 
100mM CCCP stock and serial diluted in sterile DMSO (Sigma) to give a final concentration 
of 20µM CCCP. The cells were incubated with CCCP for two hours at 37°C and 5% CO2. The 
serum starvation/CCCP treatment method development was produced in parallel with sham 
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(DMSO) cells. Following incubation the CCCP or DMSO the COS-7 cells were fixed and 
permeabilized. 
 
A1.1.2.4 Transfection of plasmids into eukaryotic cells 
The FACS analysis in this annex, uses COS-7 cells transiently transfected (see section 2.3.2) 
with a pMAX-GFP (Lonza) construct which expresses green fluorescent protein (GFP). 
 
A1.1.3 Protein-related methods 
 
A1.1.3.1 Antibodies 
The Western blotting in the annex uses an anti-Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) antibody (Millipore) raised in mouse, used at 1:100,000 for 1 hour. 
 
A1.1.3.2 Cell lysates 
 
A1.1.3.2.1 COS-7 Harvesting and lysis  
In the method development of the HSII assay, three different COS-7 cell harvesting and lysis 
protocols were trialed. All of the protocols use the HSII lysis buffer (Roche). The following 
protocol is the method used to harvest and lyse COS-7 cells in the cell seeding optimisation 
and is the method recommended by Roche. To harvest the COS-7 cells for use in the HSII 
assay as per manufacturer’s instructions the media was aspirated and the cells washed twice 
with warm PBS.  100µl or 230µl of HSII lysis buffer was then applied per well of COS-7 cells, 
for the cell seeding and harvesting optimisations, respectively. After five minutes the lysate 
was removed from the wells and the soluble protein lysate was then separated from the 
insoluble pellet fraction by pipette. The use of this method in the development of the HSII 
assay was abandoned following the cell harvesting and lysis optimisation. 
The following protocol was only trialed within the cell harvesting and lysis optimisation. The 
Cell Dissociation Buffer, Hanks Based (Gibco), was seen as a means detach cells for counting 
prior to lysis with minimal stress during harvesting. The media was aspirated and the cells 
washed twice in prewarmed PBS. 1ml of prewarmed cell dissociation buffer was aliquoted per 
well and the cells which were then left to detach at room temperature in the tissue culture hood 
for 1-2 minutes. 2.5ml of prewarmed media (see table 2.3.A) was then added per well to 
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resuspend the COS-7 cells. A sample of the resuspended cells was applied to a 
haemocytometer and the cell number estimated using microscopy. The resuspended cells were 
then transferred to a 15ml Falcon tube and centrifuged at 1000rpm for five minutes and the 
supernatant removed. 2.5ml of PBS was then added to the Falcon tube and the cells centrifuged 
at 1000rpm for five minutes, twice. Following the removal of the supernatant the COS-7 cell 
pellet was lysed using 230µl of HSII lysis buffer. The whole cell lysate was then transferred 
to an epindorph and placed a rotary wheel at 20-30rpm for 30 minutes at 4°C and then spun at 
13,000rpm by centrifuge for 20 minutes. The soluble protein lysate was then separated from 
the insoluble pellet fraction by pipette. 
The following protocol is the method of cell harvesting and lysis that was adapted to process 
COS-7 cells in the HSII assay as a result of the cell harvesting and lysis optimisation. This 
protocol is markedly similar to the production of lysates for Western analysis. The media was 
aspirated and the cells washed twice with warm PBS. 230µl of HSII lysis buffer was then 
applied per well of COS-7 cells, and cell lysis was aided with mechanical agitation from a cell 
scraper. The whole cell lysate was then transferred to an epindorph and placed a rotary wheel 
at 20-30rpm for 30 minutes at 4°C and then spun at 13,000rpm by centrifuge for 20 minutes. 
The soluble protein lysate was then separated from the insoluble pellet fraction by pipette. In 
the final adaption of this protocol, 1ml of HSII lysis buffer was used. 
 
A1.1.3.2.2 Lymphoblastoid harvesting and lysis  
The media in a confluent T75 culture was aspirated off to the 5ml mark. The remaining media 
and flocculated cells were removed into a falcon by pipette and centrifuged at 500rpm for five 
minutes. The supernatant was then removed and 10ml of PBS added to the cell pellet which 
was then centrifuged at 500rpm for five minutes. The supernatant was then removed and the 
cells lysed in 400µl of HSII lysis buffer and the whole cell lysate taken up and down a 25 
gauge needle x10 to mechanically aid lysis. A further 100µl of HSII lysis buffer was added to 
the lysate. The lysate was then placed a rotary wheel at 20-30rpm for 30 minutes at 4°C and 
then spun at 13,000rpm by centrifuge for 20 minutes. The soluble protein lysate was then 
separated from the insoluble pellet fraction by pipette 
 
A1.1.3.3 Measuring the protein concentration of cell lysates 
The BCA assay was used to determine the protein concentration of both the COS-7 and 
lymphoblastoid whole cell lysates. Quick Start Bovine Serum Albumin Standards (Bio Rad), 
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of concntrations 0.125-2.0mg were also assayed to enable sample concentration determination. 
The master mix of BCA solution was produced from a 50:1 of BCA: Copper II sulphate. For 
each standard 25ul of protein was added 500ul master mix, for each sample 35ul of protein 
was added to 700ul master mix. The samples were then vortexed both before and after 
incubating the reaction at 37°C for 20 minutes.  
Following vortexing, 200ul of each solution was loaded by automatic pipette into a 96-well 
plate. All lysates were loaded in triplicate, all protein standards were loaded in duplicate. The 
96-well plate was read on a Synergy 2 (BioTek) plate reader 592nm. The BCA assay data was 
analysed by linear regression and plotted using the Gen5 software (BioTek). As the assayed 
protein standards were premade BSA and loaded as duplicate technical replicates, a high R2  
value for the  linear regression of 0.998 was aimed for. In the analysis of the whole cell protein 
lysates assayed, a coefficient of varience (CV%) of 0.1-2 was aimed for, given that these 
samples were ran as technical replicates in triplicate. As method development progressed and 
experimental technique developed these levels if accuracy were obtained. 
To determine the protein concentration in lymphoblastoid cell lysates, which were often of 
high protein concentration, 1/3 or 1/5 dilutions of these lysates in HSII lysis buffer were ran 
on the BCA assay. The readings were then scaled up.  
 
A1.1.3.4 Standardisation of protein concentration  
With the determination of the whole cell lysate concentration by the BCA assay, samples of 
the whole cell lysates were diluted to 0.4mg/ml with additional HSII lysis buffer. This gave 
10µg protein per well when 25ul of standardised whole cell lysates was loaded into the 96-
well plate. As 5x25ul of experimental replicates were to be ran per lysate in the HSII assay, 
the production of the standardised protein was scaled accordingly. Initial COS-7 serum 
starvation experimentation produced less protein per plate (data not shown). To accommodate 
this, the cell lysates from these experiments were diluted to 0.34mg/ml, with 8.5µg of protein 
run in 25ul per well.  
In the method development for the serum starvation of lymphoblastoid cells, whole cell 
lysates, were diluted 0.4, 0.8, 1.6mg/ml, using additional HSII lysis buffer. This 





A1.1.4 HSII assay 
 
A1.1.4.1 HSII assay ATP standards  
ATP standards of known concentration were run on the HSII assay in order to derive the 
concentration of ATP in the whole cell lysate assayed. A stock solution of 16.5mM ATP was 
produced by the solubilisation of lyophilised ATP (Roche) with Dilution Buffer (Roche). A 
series of serial dilutions using further Dilution Duffer was used to generate ATP standards 
with a range of concentrations:  
 
ATP standards for the quantification of whole cell ATP in COS-7 cell lysates version 1: 
ATP concentrations (µM) 1000, 100, 10, 1, 0.1, 0.01, 0.001, 0.0001 
-used in sections A1.3.1-A1.3.6. 
 
ATP standards for the quantification of whole cell ATP in COS-7 cell lysates version 2: 
ATP concentrations (µM) 1000, 300, 100, 30, 10, 3, 1, 0.1, 0.01,  
Implemented to narrow the range and increase the number of points in the linear part of the 
curve. 
-used in sections A1.3.7 onwards. 
 
ATP standards for the quantification of whole cell ATP in lymphoblastoid cell lysates 
ATP concentrations (µM) 100, 30, 10, 6, 3, 1, 0.5, 0.1, 0.01 
-used in sections A1.4.1 onwards. 
 
50ul per well of each ATP standard was loaded into the 96-well plate per experiment. The 
ATP standards were produced on the day of experimentation and kept on ice until the loading 







A1.1.4.2 HSII Assay protocol 
To run the HSII assay and measure the ATP concentration of whole cell lysates by luciferase 
luminescence, 25µl of each whole cell lysate was loaded into a black walled 96-well plate in 
technical replicates of five. To each of the whole cell lysates was added 25µl of Dilution 
Buffer.  Then, 25µl of each ATP standard was loaded in triplicate to the empty wells. To each 
of the ATP standards 25µl of HSII lysis buffer was added. This gave both the whole cell lysates 
and the ATP standards contained 50µl of the same stoichiometry of dilution buffer and lysis 
buffer. A 50µl H2O sample was loaded as a blank. The loaded plate was left to incubate at 
room temperature for five minutes following loading. All loading was done by automatic 
pipette.  
The Luciferase reagent was delivered by the Synergy2 (BioTek) plate reader by automated 
injection. To produce the luciferase, one bottle of luciferase reagent (Roche) was dissolved in 
10ml of Dilution Buffer, and then kept on ice, and the vessel wrapped in aluminium foil to 
minimise exposure to light. The luciferase was connected to the Synergy2 pate reader 
following the loading of the 96-well plate.  
The Synergy2 plate reader was set to detect emission at 562nm. The luciferase was injected at 
50µl of per well of the luciferase to the whole cell lysates and the ATP standards. The 
programming and analysis on the Synergy2 plate reader of the HSII derived ATP 
concentration data was automated by Gen5 software (BioTek). The whole cell lysate ATP 
concentrations were derived from the ATP standard curve. A CV% of 0.1-2 was aimed for 
from the five technical replicate luminescence readings per sample. This would enable the 
HSII assay to be able to detect differences in whole cell ATP concentrations of 10% between 
different samples. As method development progressed and experimental technique developed 









A1.2 Introduction  
Chapter 4 established that the exogenous expression of the DISC1/DISC1FP1 chimeras, CP60 
and CP69, in both COS-7 cells and cortical neurones produces mitochondrial dysfunction. It 
seems possible, given that CP60 and CP69 display a reduction in the mitochondrial membrane 
potential, Δψm as detected by impaired MitoTracker Red staining, that these species may also 
reduce cellular ATP levels. This is because a sustained mitochondrial membrane potential, 
Δψm is required to generate torque to drive F1F0 ATP synthase, to generate ATP from ADP 
(Dimroth et al, 2000). The exogenous expression of the third chimera, CP1, may also have a 
detrimental effect on mitochondrial function. CP1 possesses a  highly similar ORF to that of 
DISC1 aa1-597 (Eykelenboom et al, 2012). The exogenous expression of DISC1 aa1-597 in 
COS-7 cells produces structural mitochondrial changes, with ring mitochondria observed in a 
sub-population of transfected cells (Millar et al, 2005). Bioenergetic activity is also altered 
with the expression of a truncated murine equivalent to DISC1 aa1-597 being capable of 
reducing both cellular ATP levels and NADH dehydrogenise (complex I) activity (Park et al, 
2010). It therefore seems reasonable to investigate whether expression of the 
DISC1/DISC1FP1 chimeras would impact upon mitochondrial bioenergetic activity in terms 
of cellular ATP levels. 
ATP is the principal metabolic substrate for intracellular metabolic pathways (Schapira, 2006). 
A constant source of ATP is required for the generation of action potentials in the neurone, 
with ATP delivered throughout the axon by mobile transported mitochondria (Sheng, 2014). 
At the synapse, ATP is required for vesicle transport, the recycling of the synaptic membrane 
and maintenance of the synaptic membrane potential (Ly & Verstreken, 2006). Localised ATP 
is also essential in the assembly of the synapse at the presynaptic nerve terminal (Lee & Peng, 
2008). In vivo studies, using 31p-MRS neuroimaging to detect ATP levels in the brains of 
individuals affected by schizophrenia, have found decreased levels of ATP in both the basal 
ganglia (Fujimoto et al, 1992) and in the frontal lobes (Volz et al, 2000).  
The optimisation of the HSII assay aimed to firstly detect the cellular ATP level in COS-7 
cells exogenously expressing FLAG-tagged CP1, CP60 and CP69. Secondly the HSII assay 
was to be optimised to quantify cellular ATP in lymphoblastoid cell lines, to enable the 
measurement of cellular ATP in t(1;11)-family derived lymphoblastoid cell lines. 
The overall HSII assay procedure went through a series of optimisation steps. These 
improvements were rational modifications to the basic HSII assay to aid reproducibility of 
results. An order of experimentation for the final HSII assay methodology is shown in figure 
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A1.3.A. The optimisation of the individual experimental protocols will be discussed in the 
following sections.  
This annex comprises the HSII assay method development and refinement of experimental 
techniques performed to date. Unfortunately experimentation was discontinued due to 
personal illness and consequently, the final experimental assays to detect the levels of cellular 
ATP in COS-7 cells exogenously expressing the DISC1/DISC1FP1 chimeras and within 
t(1;11) lymphoblastoid cell lines were never completed. This research is included in this thesis 
as a means to discuss the work that was accomplished and to enable the critique of the method 
developments pursued, addressing both the positive and negative outcomes established. 
 
A1.3 Optimisation of the HSII assay to analyse cellular ATP in COS-7 cells 
exogenously expressing DISC1/DISC1FP1 chimeras 
 
A1.3.1 Generation of an ATP standard curve to detect cellular ATP in COS-7 
cells exogenously expressing DISC1/DISC1FP1 proteins 
Initial optimisation of the HSII assay involved the generation of an ATP standard curve from 
a serial dilution of ATP known standards. A standard curve of ATP bioluminescence was 
generated following the injection of luciferase reagent into the ATP standards. The ATP 
standard curve was then used to derive the ATP concentration of the sample lysates assayed 
following the luciferase catalysed bioluminescence. This initial curve covers a range of 
standards at concentrations of 1x10-4 to 1x103µM ATP (see figure A1.3.B). As the method 
development progressed, a standard curve was used that contained a more narrow range of 
ATP values, with more ATP standards in the exponential phase of the standard curve. This 
curve covers a range of 1x10-2 to 1x103µM ATP (see figure A1.3.B). These modifications to 
the standard curve were to improve the accuracy of cellular ATP concentration derivation. 





Figure A1.3.A: Flow chart displaying the method developments in the HSII 
assay optimisation to date. 
 
A1.3.2 Optimisation of COS-7 seeding density for the HSII Assay 
Following ATP standard curve generation, the development of the HSII assay progressed to 
identifying an optimum seeding density of COS-7 cells for lysis. The COS-7 cells were mock 
transfected 24 hours after seeding to model the final experimental procedure, the cells were 
then harvested by lysis with the HSII lysis buffer 24 hours post-transfection. To do this, COS-
7 cells were seeded in culture dishes at a range of densities, from 1x105 to 5x105 cells in 1x105 
increments. The cells were then lysed and run on the HSII assay to identify the cell density 








Figure A1.3.B: Development of a standard curve to measure ATP bioluminescence using the HSII assay within COS-7 cells 
exogenously expressing DISC1/DISC1FP1 chimeric proteins. The initial ATP standards used have a series of redundant 
ATP standards at the lowest concentrations of ATP assayed and few ATP standards within the exponential phase of the 
curve (left). To rectify this a standard curve was generated with a narrower rage with a greater number of ATP standards 
within the exponential phase (see section A1.3.7 onwards). A new standard curve was generated from ATP standards of 
known concentration per experimental replicate. 
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The cellular ATP data shows the trend of the ATP concentration increasing along with the 
COS-7 cell seeding density (see table A1.3.A). The CV% shown is a normalised measure of 
the variability, here derived from the five technical replicates that make the mean ATP 
concentration. 
COS-7 Cell Seeding 
Density 
Mean Cellular ATP 
(µM/50µl) 
CV% 
5x105 71 13.8 
4x105 61 16.0 
3x105 26 9.3 
2x105 24 2.8 
1x105 11 2.6 
 
Table A1.3.A: Effect of COS-7 cell seeding density on cellular ATP levels. The 
cellular ATP level increases with the COS-7 seeding density. Note that the CV% 
also increases with cell seeding density. This is likely present due to 
unfamiliarity with the protocols at this stage of method development. Mean 
cellular ATP values are derived from technical replicates (n=5). 
 
The lysates produced from COS-7 cells seeded at densities of 2x105 to 5x105 cells produce 
cellular ATP concentrations that lie on the linear slope of the ATP standard curve (see figure 
A1.3.B). However, this optimisation data shows an increase in CV% with cell seeding. The 
large variation was seen to be tolerable as the observation of a trend was sufficient to drive the 
optimisation forward at this stage in method development. In light of this variability with the 
higher cell densities it was decided to focus on 1x105 and 3x105 COS-7 seeding densities for 
further method design. 
 
A1.3.3 Optimisation of cell harvesting for the HSII Assay 
The method of harvesting the COS-7 cells was also optimised. The procedure used to lyse 
cells may influence both the final concentration of ATP in the lysate and the reproducibility 
of the HII assay. Here COS-7 lysates were produced from cell seeding densities of either 1x105 
or 3x105 cells. These cultures had been mock transfected 24 hours prior to harvesting. The 
cells were then harvested by three different procedures, all of which used the HSII lysis buffer 
to lyse cells. These are referred to as: the Cell Dissociation Buffer procedure; the HSII lysis 
buffer alone procedure; the HSII lysis buffer & scraping procedure. 
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The Cell Dissociation Buffer (Roche) procedure aimed to see if the number of COS-7 cells 
could be counted on the day of experimentation, lysed and then run on the HSII assay. This 
was seen as a means to control variability in culture size that may have occurred between COS-
7 seeding and the cell culture growth in the parallel cultures used for experimentation. 48 hours 
following the initial cell seeding, the Cell Dissociation Buffer was applied to adherent COS-7 
cells from culture dishes to dissociate the cells. The total number of cells in each culture was 
then derived using a haemocytometer. It was calculated that the culture seeded with 1x105 cells 
now contained 1.9x105 cells and the culture seeded with 3x105 cells contained 5.5x105 cells. 
These two cultures of COS-7 cells were then lysed with the HSII lysis buffer. This crude lysate 
was solubilised on wheel, spun down via centrifugation and the solubilised protein was then 
separated from the pellet. The lysates were then run on the HSII Assay to determine ATP 
concentration.  
The HSII lysis buffer procedure simply involved the lysis of the cells in the culture well with 
the HSII lysis buffer. These lysates were then run on the HSII Assay. This procedure is similar 
to Roche guidelines for the HSII Assay. 
The HSII lysis buffer & scraping procedure involved the lysis of the COS-7 cells in the culture 
dish agitated by the use of a cell scraper, without the cells being counted. This procedure also 
ensured that the lysate produced contained all of the cell debris. The crude lysates produced 
were then processed in the same manner as the Cell Dissociation Buffer crude lysates, being 
solubilised on the wheel and the lysate supernatant extracted following centrifugation before 
being run on the HSII Assay. 
Overall, with regard to the initial cell seeding densities, the cell harvesting procedures that 
produced the highest ATP concentration to those that elicited the lowest ATP concentration 
were: HSII lysis buffer & scraping; HSII lysis buffer alone; Cell Dissociation Buffer (see table 
A1.3.B). That the HSII lysis buffer and scraping is more robust in the final cellular ATP 
concentration produced than the use of the HSII lysis buffer alone is unsurprising, given that, 
in addition to the cell scraping, the former also involves the protein solubilisation and 
separation of the soluble from the insoluble protein fraction. For the Cell Dissociation Buffer 
procedure, it is possible that the extra processing of the COS-7 cells in the procedure and, 
specifically, the use of the Cell Dissociation Buffer itself results in the lower cellular ATP 
concentration.  
These data generally reveal lower ATP concentrations relative to cell seeding density than the 
initial seeding density optimisation data (see table A1.3.A). Here, only the cell seeding density 
A1-14 
 
of 3x105 cells harvested with the HSII lysis buffer & scraping lies on the linear part of the ATP 
standard curve (see figure A1.3.B). However, in this harvesting optimisation data, the 
coefficient of variance for the conditions is largely within acceptable levels (see A1.3.B) 
unlike the data on cell seeding density (see table A1.3.A). At this stage of optimising the HSII, 
it was necessary to acknowledge that there may be problems in using cell seeding density as a 
means to produce reliability in ATP concentration. It can be concluded, from the harvesting 
optimisation, that the use of the HSII lysis buffer, in conjunction with the use of a cell scraper, 
produced the largest cellular ATP concentration of the three procedures tested. The use of the 




Table A1.3.B: Optimisation of cell harvesting protocol. The cellular ATP level 
increases with the COS-7 seeding density. In the Cell Dissociation Buffer 
protocol, the COS-7 cells are disrupted and counted then lysed with HSII lysis 
buffer. In the HSII Lysis buffer condition, the cells are lysed with no mechanical 
agitation in contrast to the HSII Lysis buffer & scraping protocol which uses a 
cell scraper. The HSII Lysis buffer & Scraping protocol produces the greatest 
cellular ATP levels and was incorporated into the ongoing method 
development. All protocols were tested using initial seeding densities of 1x105 
and 3x105 COS-7 cells. Mean cellular ATP values are from n=2 technical 
replicates. This involved 2 plates of COS-7 cells. 
 
A1.3.4 Optimisation of protein assays for use in the standardisation of 
protein concentration in the HSII assay 
Concern about the reproducibility of experiments that used seeding density as a means to 
normalise the cell lysates run on the HSII assay, led to other means of standardisation of the 





Cell Dissociation Buffer 1x105 1.71 5.76 
Cell Dissociation Buffer 3x105 3.34 7.61 
HSII Lysis Buffer Alone 1x105 3.59 3.60 
HSII Lysis Buffer Alone 3x105 7.19 5.00 
HSII Lysis Buffer & Scraping 1x105 6.40 4.16 
HSII Lysis Buffer & Scraping 3x105 12.77 3.11 
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cell lysates being sought. This involved the initially produced cellular lysates being ran on a 
protein assay and the protein concentrations then quantified. Following this, the original 
lysates were all standardised to a single common protein concentration. The uniform protein 
concentration was used in the standardisation of all future HSII assay lysates, enabling a 
greater reproducibility in the HSII assay, eliminating errors arising from variation in the size 
of the COS-7 cultures lysed.  
Firstly, for the standardisation of cell lysates to a given protein concentration, optimisation 
needed to be undertaken to determine which COS-7 lysate protein concentration produced an 
ATP concentration that lay within the linear part of that standard curve. Initial investigation 
into a suitable protein assay focused on the Bradford assay (BioRad) as a colorimetric method 
of protein quantification. However, the results seemed highly variable and did not appear to 
scale with the experimental conditions used (data not shown). Communication with Roche 
clarified these problems. The HSII lysis buffer impairs the action of the Bradford assay, 
preventing effective protein quantification. Roche suggested the use of the BCA assay, another 
colorimetric method of protein determination. 
In the optimisation of protein standardisation using the BCA assay, three dishes of mock 
transfected COS-7 cells were lysed with HSII lysis buffer and run on the BCA assay against 
known protein standards (BioRad). For lysate samples 2 and 3, the coefficient of variance was 
within an acceptable range. However the CV% for sample 1 was extremely large, due to 
problems with technical replicates (see table A1.3.C). Despite this all three mean protein 
concentrations were carried forward and used in the next phase of the optimisation.  
Each of the three original lysates (see table A1.3.C), were then diluted to produce a range of 
protein concentrations using additional HSII lysis buffer. The final protein concentrations 
produced were 0.25mg/ml, 0.30mg/ml, 0.35mg/ml and 0.40mg/ml. This now gave 12 diluted 
protein lysates, three replicates per lysate at each protein concentration. The HSII assay was 
then run with standardised protein lysates and the cellular ATP concentration for each of these 
COS-7 lysates was calculated. The results were pooled by protein concentration and linear 
regression analysis was performed to look at the relationship between cellular ATP and protein 
concentration. As the protein concentration of the COS-7 lysates increases so too does the 
cellular ATP concentration within those lysates, ATP concentration = -11.95 + lysate protein 
concentration x 124.6, R2 = 0.46 (see figure A1.3.C).  
Following this optimisation it was decided to use the BCA assay to quantify the protein in the 
HSII lysates, enabling the dilution of the HSII lysates to a standard concentration of 
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0.40mg/ml. At this concentration, the COS-7 lysates contained a mean cellular ATP 
concentration of 37.9µM (see figure A1.3.C). A cellular ATP concentration of this size 
adequately falls on the liner phase of the ATP standard curve. A potential source of error in 
this calculation comes from the carrying over of the original COS-7 lysate sample that had a 
high coefficient of variance for use in the linear regression. However, in practice, the use of 
normalising COS-7 cell lysates to 0.40mg/ml in sections A1.3.5-A1.3.7 produced cellular ATP 
concentrations that lay on the linear phase of the ATP standard curve, irrespective of treatment.  
 
COS-7 Lysate Protein Conc. (mg/ml) CV (%) 
   
1 0.426 26.411 
2 0.457 1.49 
3 0.438 2.841 
 
Table A1.3.C: Determination of the protein concentration in mock transfected 
COS-7 HSII lysates using the BCA assay. Three parallel 10cm dishes seeded 
with 2.5x105 COS-7 cells were mock transfected and 24 hours later lysed with 
HSII lysis buffer. The lysed protein was then incubated with the BCA assay. The 
absorbance at 562nm due to presence of solubilised protein was then 
measured. The protein concentration as a mean of (n=3) technical replicates 
was then derived. 
  
A1.3.5 FACS analysis to monitor the transfection efficacy of exogenously 
expressed DISC1/DISC1FP1 proteins in COS-7 cells 
The transfection efficacy between experimental replicates could be a possible source of 
variability in the HSII assay ATP data. Consequently, FACS analysis of exogenous GFP 
expression from COS-7 cells that were transfected in parallel with pMAX-GFP, at the time of 
the initial experimental DISC1/DISC1FP1 transfections, was used as means to establishing the 
transfection efficacy of the DISC1/DISC1FP1 chimeras.  
The method for detecting transfection efficacy that was developed for use on the day of the 
running of the HSII assay is as follows: firstly a sample of untransfected COS-7 cells were 
analysed by FACS to establish the background COS-7 autofluorescence; a subjective gate was 






Figure A1.3.C: Effect of protein concentration on cellular ATP in COS-7 cell 
lysates as measured by the HSII assay following quantification of protein and 
the standardisation of lysates. Cellular ATP concentration increases with 
protein concentration, ATP concentration = -11.95 + lysate protein 
concentration x 124.6, R2 = 0.46. The mean cellular ATP ± SEM, is derived from 






Figure A1.3.D: FACS analysis of fluorescence in COS-7 cells exogenously expressing GFP. The population of COS-7 cells assayed 
is represented by the black dots. I) The R1 gated region was drawn following the FACS analysis of the unstained cells in order to 
capture GFP fluorescing COS-7 cells. II) Gating of GFP fluorescing cells GMFI = 139.58. 87.51% of this COS-7 cell sample analysed 
by FACS are detected in the R1 region, this is taken as a measurement of the transfection efficacy of pMAX-GFP. III) FSC vs SSC 
analysis of the of COS-7 cells that were expressing GFP. The FCS vs SSC analysis suggests that the sample of COS-7 cells 
transfected with GFP analysed by FACS does not show signs of early apoptosis which may have occurred as a result of the 




A sample of COS-7 cells exogenously expressing GFP, from the same experimental 
transfection as the FLAG-tagged DISC1/DISC1FP1 chimeras, was then analysed by FACS. 
The following results are typical for the FACS analysis of the fluorescence of exogenously 
expressed GFP in COS-7 cells. The percentage of GFP fluorescing cells gated = 87.51, GMFI 
= 139.58 (see figure A1.3.D.ii). Primarily the focus of this GFP FACS assay was the 
percentage of GFP fluorescing cells gated, which was taken to be an indicator of the 
transfection efficacy within the DISC1/DISC1FP1 chimera transfection for use in the HSII 
assay. The high level of GFP expression observed in figure A1.3.D.ii is not dissimilar to the 
99% transfection efficacy stated by Invitrogen for COS-7L cells, for the Lipofectamine 2000 
transfection reagent used (Invitrogen, n.d.). 
The FSC vs SSC analysis of the COS-7 sample exogenously expressing GFP was run as a 
simple means to check the integrity of these cells (see figure A1.3.D.iii). The FSC, forward 
scatter is a measure of cell size, while SSC side scatter is a measure of the complexity and 
granularity of a cell. It was possible that the transfection process could have stressed the 
transfected cells. For example, if a series of events were clustered in the upper left side of the 
plot,  with a lower FSC and higher SSC than that seen in figure A1.3.D.iii, this could be an 
indication of apoptosis occurring within the cell population assayed (Koopman et al, 1994).  
The use of this method to quantify GFP expression is acknowledged as being an indirect means 
of assessing the transfection efficacy of the DISC1/DISC1FP1 chimeric protein species. 
Divergences in the percentage GFP expression between experiments may give cause to 
exclude HSII experiments from further data analysis.  
 
A1.3.6 Initial whole cell ATP data from the COS-7 lysates exogenously 
expressing the DISC1/DISC1FP1 chimeras run in the HSII assay with a 
CCCP positive control 
A positive control was required for use in the HSII assay, to reproducibly alter cellular ATP 
levels and to conclusively establish that the HSII assay had successfully been run to 
completion. The positive control chosen, CCCP belongs to a class of mitochondrial poisons, 
uncouplers, which are ionophores that act to uncouple oxidative phosphorylation from ATP 
synthesis (Benard & Rossignol, 2008). CCCP treatment has a dual action that is concentration 
dependent. Low concentrations of CCCP cause the collapse of the mitochondrial membrane 
potential, Δψm and at higher concentrations the uncoupling of oxidative phosphorylation from
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ATP synthesis occurs. The optimum concentration of CCCP to reduce cellular ATP is 
dependent on the cell line used and the length of treatment. For example, in HeLa cells, 10µM 
CCCP has been shown to reduce cellular ATP by 20% following a 45 minute incubation 
(Legros et al, 2002). Whereas, 50µM  CCCP treatment to Jurkat T-ALL cells reduces cellular 
ATP by 63% within six hours (de Graaf et al, 2002). For use with COS-7 cells it was decided 
to use a final concentration of 20µM CCCP incubated with COS-7 cells for two hours. The 
use of this concentration and incubation time was an adaption of the ‘CCCP assay’ developed 
by Ishihara et al., (Ishihara et al, 2006; 2003), which uses CCCP to collapse the mitochondrial 
membrane potential, Δψm, producing mitochondrial fragmentation, as a means to study 
mitochondrial fission and fusion. 
The following analysis of HSII assay data (n=3) on COS-7 cells exogenously expressing 
FLAG-tagged CP1, CP60 and CP69 includes a 20µM CCCP treatment as a positive control. 
FACS analysis was performed on COS-7 cells exogenously expressing GFP that had been 
transfected in parallel to the experimental constructs to estimate the transfection efficiency of 
the chimeric species across the HSII assay replicates (see section A1.3.5). The percentage of 
GFP fluorescing cells gated by FACS was 89.7% ± 2.2; the GMFI 1293.2 A.U. ± 735.5 (data 
is expressed as mean  SEM, (n=3)). From this, it was inferred that there was a comparable 
transfection efficacy across these experimental replicates. The following HSII assay data 
analysed here were grouped following the exclusion of other experimental runs on the basis 
of either anomalous FACS or CCCP results.  
The grouped cellular ATP data from the HSII assay were normalised to be either: (1) 
percentage of the FLAG-DISC1 cellular ATP concentration (see figure A1.3.E); (2) 
percentage of the empty vector cellular ATP (see figure A1.3.E); (3) percentage of the GFP 
fluorescent COS-7 cells gated by FACS (the transfection efficacy) for statistical analysis (see 
figure A1.3.E). Irrespective of the means of normalisation used, no significant difference was 
found between the experimental treatment conditions. One-way ANOVA of the cellular ATP 
data, from the analysis of COS-7 cellular lysates exogenously expressing the 
DISC1/DISC1FP1 chimeras normalised to be a percentage of the empty vector cellular ATP 
(n=3), showed no significant effect of treatment condition, F(6,14)=0.31, p=0.90. One-way 
ANOVA of the cellular ATP data from the analysis of COS-7 cellular lysates, exogenously 
expressing the DISC1/DISC1FP1 chimeras, normalised to be a percentage of the FLAG-
DISC1 cellular ATP (n=3) showed no significant effect of treatment condition, F(6,14)=0.81, 
p=0.57. One-way ANOVA of the cellular ATP data from the analysis of COS-7 cellular lysates 
exogenously expressing the DISC1/DISC1FP1 chimeras, normalised to be a percentage of the 
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GFP stained COS-7 cells gated by FACS (a measure of the transfection efficacy (n=3)), 
showed no significant effect of treatment condition, F(6,14)=0.12, p=0.99. 
The non-normalised data for the three experiments also highlighted that there was substantial 
inter-experimental variability in the range of the cellular ATP readings (see figure A1.3.E). 




Figure A1.3.E: Initial analysis of the exogenous expression of DISC/DISC1FP1 
chimeric species in COS-7 cells on cellular ATP. Cellular ATP data plotted as a 
percentage of the FLAG-DISC1 cellular ATP. One-way ANOVA shows no 
significant effect of treatment, p=0.57 (top left). Cellular ATP data plotted as a 
percentage of the empty vector cellular ATP, pcDNA3.1. One-way ANOVA 
shows no significant effect of treatment, p=0.90 (top right). Cellular ATP data 
plotted as a percentage of the GFP cells gated as a measure of transfection 
efficacy within an independent replication of the HSII assay. One-way ANOVA 
shows no significant effect of treatment, p=0.99 (bottom left). For the non-
normalised cellular ATP data, one-way ANOVA shows no significant effect of 





exogenously expressing the DISC1/DISC1FP1 chimeras without normalisation (n=3), showed 
no significant effect of treatment condition, F(6,14)=0.12, p=0.99. There are interexperimental 
differences that are up to 8-fold in magnitude within experimental conditions in the non-
normalised data. This high level of variability suggests that the HSII assay results was not 
suited to data normalisation, as such a method produces misleading analysis that suggests a 
far greater uniformity of results, when the normalised experimental data are pooled. 
Given this degree of inter-experimental variation and lack of any significant alterations in 
cellular ATP between conditions, it was decided to both optimise the CCCP positive control 
and address means of combating potential sources of error in the HSII assay. In this analysis, 
the lack of significant alteration in cellular ATP following CCCP treatment is a cause of 
concern given CCCP has been observed to reduce cellular ATP in highly similar luminescence 
assays (Legros et al, 2002; Migita et al, 2007). It may be that the concentration of CCCP used 
here was too low for the COS-7 cell line and required further optimizing or that the cell culture 
conditions for incubation required further optimisation. It was necessary to have a positive 
control within the assay to demonstrate that the assay has run to completion in order to confirm 
that an alteration in cellular ATP can be detected. Given this, the use of CCCP as a positive 
control run on the HSII assay to produce a replicable alteration in cellular ATP was further 
optimised (see section A1.3.9).  
This section highlights that there were underlying problems with the HSII assay protocol at 
this stage of method development that precluded accurate cellular ATP measurement. This 
may have arisen from error in the normalisation of protein concentration of the sample lysates, 
or possibly from incorrect loading of the 96-well plate. The normalising of the HSII cellular 
ATP data by the protein densitometry data derived from the standadised lysates could 
potentially ameliorate such errors. The densitometry analysis on the resulting bands could then 
be used in the normalisation of the HSII assay cellular ATP data. The next section will focus 
on method development for densitometry to normalise HSII assay cellular ATP data. 
 
A1.3.7 The Development of a densitometry analysis method to normalise 
HSII assay cellular ATP data 
The ANOVA analysis for the HSII assay results that ran COS-7 lysates containing 
exogenously expressed CP1, CP60 and CP69 found no significant differences between 
conditions when these data were normalised (see figure A1.3.E). Importantly, the HSII assay 
data had high inter-experimental variability. Consequently, Western blotting and densitometry 
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were seen as a means to correct some potential sources of experimental error in the HSII assay. 
This would entail normalising the HSII assay whole cell ATP data to protein levels. To do 
this, samples of the standardised protein lysates that were run on the HSII assay were analysed 
by Western blot, using a loading control antibody, GAPDH. The density of the resulting 
protein bands were quantified by densitometry. These density values were then used to 
normalise the corresponding cellular ATP data. This method should correct for variation in the 
number of cells lysed per sample.  
The first step was to ensure that the HSII lysis buffer contained protease inhibitors. The use of 
protease inhibitors is fundamental for the storage of protein in solution prior to analysis by 
Western blot to prevent protein degradation by proteases. Communication with Roche 
indicated that the HSII lysis buffer did not contain protease inhibitors. Importantly, Roche 
were not able to provide information as to how the addition of protease inhibitors to the HSII 
lysis buffer would impact on the performance of the HSII assay to measure cellular ATP. In 
order to address this issue, the HSII assay was run with COS-7 lysates produced using two 
different lysis buffers: the standard HSII lysis buffer, used in all HSII method development up 
until this section, and the HSII lysis buffer containing a protease inhibitor tablet (PIT) to inhibit 
protease activity in the lysates.   
The performance of the HSII assay does not appear to be impeded by the addition of the Roche 
PIT to the HSII lysis buffer. There is no significant difference between the cellular ATP levels 
in HSII buffer lysed COS-7 cells and those lysed with HSII lysis buffer containing a PIT 
(Student’s unpaired two-tailed t-test; t=0.85, p=0.44, (n=3), (see figure A1.3.F). The HSII 
assay lysis buffer containing the PIT was then used for cell lysis in all of the following HSII 
assay experiments. This enabled protein storage with minimal degradation for subsequent 
Western blot analysis.   
The second step was to attempt to normalise the HSII assay from an experimental replicate 
with COS-7 cell lysates that exogenously expressed FLAG-tagged CP1, CP60 and CP69 and 
lysed with the HSII lysis buffer containing the PIT. The aim of this was to test the densitometry 
protocol. Firstly, the HSII assay was run and the corresponding protein lysates per treatment 
were assayed in parallel by Western blot. GAPDH was chosen as the initial loading control 
for use in densitometry as the given anti-GAPDH antibody used is highly potent. This was a 
precautionary measure to offset any difficulties detecting sufficient quantities of protein for 
























Figure A1.3.F: The addition of a Roche protease inhibitor tablet does not impair 
the quantification of cellular ATP levels by HSII assay. Student’s unpaired two-
tailed t-test revealed no significant difference in the cellular ATP levels between 
COS-7 cells lysed using HSII lysis buffer or HSII lysis buffer containing a PIT, 
p=0.44. Cellular ATP is expressed as mean ± SEM, (n=3) experimental 
replicates. 
 
With equal volumes of protein loaded per condition and probing with anti-GAPDH, the anti-
GAPDH bands produced appeared to be of appropriate intensity for densitometry analysis (see 
figure A1.3.G). Two CCCP treatments, 20µM and 50µM, were utilised in this run of the HSII 
assay to provide ongoing positive control optimisation. 
The anti-GAPDH density values appear to be of a similar order of magnitude across the range 
of treatments. This is expected, given all of the protein loaded was assumed to be of the same 






Figure A1.3.G: Detection of GAPDH in COS-7 protein lysates produced using 
HSII lysis buffer. Lysates are from COS-7 cells exogenously expressing FLAG-
tagged DISC1/DISC1FP1 and DISC1 species and CCCP treatments. The HSII 
protein lysates had been standardised to 0.4mg/ml prior to blotting. The GAPDH 
protein detected by Western blotting was to be analysed by densitometry as a 
means to normalise the cellular ATP data. Equal volume of protein was loaded 
per lane. 
 
The use of three different types of data normalisation demonstrates how densitometry analysis 
could possibly be applied to normalise an experimental dataset. The data normalisation 
referred to as Normalised ATP is derived from ATP/(Density/1x105) and created values of the 
same order of magnitude as the cellular ATP. Normalised ATP expressed as a percentage of 
Empty Vector response, is the cellular ATP normalised to protein density then expressed as a  
percentage of the normalised ATP level seen for the COS-7 cells treated with pcDNA3.1(+). 
A similar method of normalisation was used for the normalised ATP as a percentage of FLAG-
DISC1. This shows the densitometry normalisation for a treatment as percentage of the 
normalised ATP level for the COS-7 cells expressing FLAG-DISC1. As these data in table 
A1.3.D are from a single experiment, no conclusion can be drawn about what the values  
represent in terms of the effect of the exogenous expression of DISC1/DISC1FP1 in COS-7 
cells on cellular ATP. However, the data represented in table A1.3.D and figure A1.3.G serve 





Table A1.3.D: Normalisation of cellular ATP data for the exogenous expression 
of DISC/DISC1FP1 chimeric species in COS-7 cells to anti-GAPDH densitometry 
intensity. Western blotting of protein lysates corresponding to those run on the 
HSII assay were used to normalise the HSII assay cellular ATP levels. 
Normalised ATP is the cellular ATP/density normalisation adjusted to be same 
order of magnitude as the cellular ATP. Normalised ATP as a percentage of 
Empty Vector response is the densitometry normalisation for a treatment as a 
percentage of the normalised ATP level for COS-7 cells treat with pcDNA3.1(+). 
Normalised ATP as a percentage of DISC1 is the densitometry normalisation for 
a treatment as percentage of the normalised ATP level for COS-7 cells 
expressing FLAG-DISC1. Data is (n=1) independent experiment. 
The use of densitometry to normalise multiple experimental data sets i.e. (n=3) independent 
experimental replicates of the HSII assay would need additional critical scrutiny. It is possible 
that the Western blotting itself could introduce error into data sets. In practice, the initial 
cellular ATP data, the anti-GAPDH Western blotting, the densitometry data and the final  
Normalised cellular ATP data for multiple experimental runs of the HSII assay were examined 
for sources of error before the pooling of data for statistical analysis. A particular source of 
error in the method covered here is the use of Western blotting with a single antibody. 
GAPDH, detected here, is itself involved in cellular respiration as part of the glycolytic 
pathway and is predominantly located in the cytoplasm. However, during stress GAPDH may 
undergo post-translational modifications and oligomeric state changes (Tristan et al, 2011). 
These structural alterations are associated with GAPDH localising at subcellular structures 
including the cytoskeleton, mitochondria and nucleus, where GAPDH has dual roles in cell 
death and cell survival. Due to this, it would be prudent to have antibodies to loading control 
proteins from a range of cellular compartments to counter bias from using the results gained 
from a single antibody. The antibodies could have been optimised and used to re-probe blots 
Treatment Density Cellular 
ATP  
(µM/50µl) 
Norm. ATP Norm. ATP  
as %  EV 
Norm. ATP 
as %  FLAG-
DISC1 
Empty vector 11341 24.62 21.71 100 115 
F.DISC1 12772 24.08 18.86 87 100 
F.DISC1 aa1-597 13261 22.54 17.00 78 90 
F.CP1 10624 21.44 20.18 93 107 
F.CP60 12181 23.94 19.66 91 104 
F.CP69 12598 22.58 17.92 83 95 
20µM CCCP  10896 22.80 20.93 96 111 
50µM CCCP  10236 27.33 26.70 123 142 
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for use in densitometry for the normalisation of the cellular ATP data. The development of 
densitometry analysis as a method to normalise the initial HSII assay cellular ATP data would 
be used more extensively in the method development for CCCP treatment of COS-7 cells as a 
positive control for the HSII assay (see section A1.3.9). 
 
A1.3.8 Identification of exogenously expressed FLAG-tagged 
DISC1/DISC1FP1 species in COS-7 cell lysates produced with HSII lysis 
buffer 
It may have also been necessary post-assay to confirm that the correct exogenously expressed 
FLAG-tagged chimeric species were present in the lysates that had been run in the HSII assay. 
To identify that the FLAG-tagged DISC1/DISC1FP1 species transfected had been expressed 
in the COS-7 cells lysed with the HSII lysis buffer and run in the HSII assay, samples of both 
the resulting lysate and pellet fractions were analysed by Western blot. The requirement to run 
pellet fractions, is because CP60 and CP69 proteins are predominantly isolated within this 
fraction and appear to be insoluble (see section 3.3.1). However, it was likely that CP1, which 
encodes DISC1 aa1-598, would be predominantly expressed in the lysate fraction. This is 
because a highly homologous species to CP1, DISC1 aa1-597, is detected in the lysate fraction 
using the N-terminal DISC1 antibody R47, when exogenously expressed in COS-7 cells 
(Millar et al, 2005).  
The Western blot of the COS-7 lysate pellet fraction, produced using the HSII lysis buffer, 
detects all of the FLAG-tagged DISC1/DISC1FP1 species and also FLAG-DISC1 and FLAG-
DISC1 aa1-597. The molecular weights of protein bands in the pellet blot (see figure A1.3.F) 
are similar to the predicted molecular weight of the given species assayed. FLAG-CP1 and 
FLAG-DISC1 aa1-597 have bands at molecular weights of ~60kDa, the species predicted 
molecular weights being 65kDa and 64kDa respectively. The protein bands for FLAG-CP60 
and FLAG-CP69 are detected at ~75kDa, this is similar to their respective, predicted molecular 
weights of 72kDa and 73kDa. In the pellet blot, FLAG-DISC1 protein is observed at ~95kDa, 

















Figure A1.3.H: Detection of exogenously expressed FLAG-tagged DISC1/DISC1FP1 proteins in COS-7 cell pellet and lysate 
produced using HSII lysis buffer. Only FLAG-CP1 and FLAG-DISC1 aa1-597 are detected in the cell lysate and are indistinguishable 
(right). The signal intensity for this blot was weak; this is an overnight exposure. Unusually FLAG-DISC1 was not detected in the 
lysate . The protein bands across all treatments in the lysate, likely represent artefacts, all DISC1 species are detected in the pellet. 







The Western blot of the COS-7 lysate lysate fraction produced using the HSII lysis buffer (see 
figure A1.3.H) was developed overnight as the signal intensity was very weak. Both DISC1 
aa1-597 and CP1 species can be isolated in the lysate fraction and the resulting protein bands 
are indistinguishable, reflecting the high degree of sequence homology between the two 
proteins. However, both species are detected in the lysate at ~70-75kDa. In line with previous 
observations (see section 3.3.1), FLAG-CP60 and FLAG- CP69 are not isolated in the lysate 
fraction. This was further evidence that the additional 60 and 69 amino acids derived for 
DISC1FP1 that are present in CP60 and CP69 respectively, result in altered localisation of 
protein compared to that seen with DISC1 aa1-597 alone or the CP1 species. 
 
However, FLAG-DISC1 was not detected in the lysate blot, although FLAG-DISC1 was 
present in the pellet blot (see figure A1.3.H). Possible explanations for these anomalous 
observations include: (1) the HSII lysis buffer was not stringent enough to solubilise DISC1 
protein; (2) inappropriate antibody dilution (the signal intensity from the protein here was 
poor); (3) experimental error. In terms of method development, figure A1.3.H should be 
considered as a means that was tried to detect the FLAG-DISC1 species in COS-7 lysates 
produced using the HSII lysis buffer, rather than as an experiment principally focussed on the 
DISC1 species exogenous expression.  
The use of Western blot of the pellet fraction of COS-7 lysates run on the HSII assay probed 
with anti-FLAG was a suitable means to detect the expression of the FLAG-tagged DISC1 
species. All of the FLAG-tagged DISC1/DISC1FP1 species can be detected in the pellet 
fraction (see figure A1.3.H). However, as the pellet fraction produces smeared bands, this 
method could never be used to quantify FLAG-tagged DISC1 species expression by 
densitometry (see section A1.3.7). The use of the lysate blot to both qualify and possibly 
quantify all of the FLAG-tagged DISC1 species expressed is not a viable alternative method. 
This is because CP60 and CP69 are not present at detectable levels in the soluble fraction (see 
figure A1.3.H) and is in line with established Western blotting of untagged CP60 and CP69 
lysed using RIPA and PBS-Triton (see figure 3.3.A).   
 
A1.3.9 The optimisation of CCCP as a positive control for the HSII assay 
using a serum starvation procedure 
The initial attempts at detecting the effect of the exogenous expression of the 
DISC1/DISC1FP1 chimeric species on whole cell ATP using the HSII assay, failed to detect 
any significant difference between the conditions (see section A1.3.6). Importantly, these 
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assays were run with a 20µM CCCP treatment as a positive control that was expected to reduce 
whole cell ATP levels, given that CCCP is a potent uncoupler of oxidative phosphorylation 
(Benard & Rossignol, 2008). To establish that the HSII assay has technically run successfully 
and can reproducibly detect alterations in cellular ATP levels it would be prudent to further 
optimise a CCCP treatment for the HSII assay.  
CCCP has been successfully used by others to reduce the level of cellular ATP in an assortment 
of cell lines. For example, the treatment of MDCK cells with 10µM CCCP produced  ~ 25%  
reduction in cellular ATP levels measured using a luciferin-luciferase assay (Migita et al, 
2007). HeLa cells treated with 10µM CCCP showed ~20% decrease in cellular ATP levels, as 
detected with a Roche Bioluminescence Assay (Legros et al, 2002). The treatment of Jurkat-
Bcl-2 cells with 25µM CCCP produced 39% decrease in cellular ATP levels, detected using 
HPLC (de Graaf et al, 2002). This body of work indicates that it is feasible to use CCCP as a 
positive control to reduce cellular ATP levels in COS-7 cells. However, the optimum CCCP 
concentration for the treatment of the COS-7 cells still needed to be identified.     
Although the treatment of COS-7 cells with 20µM CCCP had not produced a significant 
reduction in cellular ATP levels so far in the HSII assay (see section A1.3.6), it was of interest 
to establish the mitochondrial phenotype of these cells. Evidence of fragmentation of the 
mitochondrial network in CCCP treated COS-7 cells suggested that CCCP treatment was still 
viable for use as a positive control and that further optimisation was required given the 
potential structure/function relationships in the mitochondria with the CCCP treatment 
(Benard et al, 2011; Benard & Rossignol, 2008). For example, using immunocytochemistry, 
mitochondrial fragmentation can be observed in HeLa cells following incubation with 20µM 
CCCP (Ishihara et al, 2006; Ishihara et al, 2003). 
A similar protocol to that used by Ishihara et al., (2006; 2003)  was used to see if mitochondrial 
fragmentation occurred following the incubation of COS-7 with 20uM CCCP. The anti-CV 
stained mitochondria in the CCCP treated COS-7 cells appeared fragmented compared to the 
tubular mitochondria of the sham (DMSO) treated cells, as visualised with fluorescence 
microscopy (see figure A1.3.I). This established that 20µM CCCP treatment was capable of 
inducing mitochondrial fragmentation, a structural alteration, yet the use of this concentration 
of CCCP had so far failed to produce alterations to cellular ATP levels using the current HSII 





To optimise a CCCP positive control for use in the HSII assay both CCCP concentration and 
culture medium serum concentration were co-varied as treatments to COS-7 cells. This was to 
identify which combination of conditions would possibly elicit the greatest alteration in 
cellular ATP as detected by the HSII assay. The CCCP treatment was applied at 20, 50 and 




















Figure A1.3.I: CCCP treatment of COS-7 cells induces mitochondrial 
fragmentation. Immunostaining: anti-CVα (Red) and DAPI (blue). The 
mitochondrial network in sham DMSO treat cells is tubular. Fragmentation of 
the mitochondrial network was observed following a 2 hour incubation with 
20µM CCCP, an uncoupler of oxidative phosphorylation. Protocol adapted from 








20µM CCCP Sham 
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The high serum condition discussed in this section is DMEM containing 10% FCS (vol/vol). 
This is the culture medium used for the DISC1/DISC1FP exogenous expression for both ICC 
and the HSII assay thus far (see chapter 4 and section A1.3.6). Here, the low serum incubation 
for the COS-7 cells aimed to reduce any variability in basal ATP levels between the dishes of 
COS-7 cells used for experimentation. Serum starvation can be used as a means to reduce basal 
cellular activity (Codeluppi et al, 2011). 
It was possible that such background variation in basal cellular ATP levels may have 
contributed to variability of the initial experimental data with the DISC1/DISC1FP1 
overexpression in COS-7 cells (see section A1.3.6). The low serum condition discussed in this 
section is a serum starvation procedure involving the reduction in culture medium FCS, 18hrs 
prior to lysis. This entailed the COS-7 cell culture medium being changed from DMEM 
containing 10% FCS (vol/vol) and being substituted with DMEM containing 1% FCS 
(vol/vol).  
The serum starvation data reported here result from the method development in the HSII assay 
protocol so far. In the optimisation of CCCP as a positive control, (n=3) experimental 
replicates were performed. This involved the determination of cellular ATP levels using the 
HSII assay, Western blotting of the protein lysates (see figure A1.3.J) and densitometry 
analysis on the resulting anti-GAPDH bands. A 3 x 2 (CCCP x Serum) univariate analysis of 
variance was implemented to assess the effects of FCS serum levels and CCCP concentration 
on COS-7 ATP level (normalised to the ATP level in sham-treated cells). There was a 
significant effect of serum level F(1,15) = 9.90, p<0.01 and of CCCP concentration F(1,15) = 
34.73, p<0.001, as well as a significant interaction between serum level and CCCP 
concentration F(1,15) = 9.65, p<0.01, (n=3). Figure A1.3.K shows that, in the low serum 
condition with the increase in concentration of CCCP, there is an increase in the concentration 
of cellular ATP. However, the trend for the high serum treatment is less clear. It appears that 
there is no increase in cellular ATP with increased CCCP dose although this is difficult to 
interpret due to the high degree of variance seen in the 50µM CCCP/high serum condition. 








Figure A1.3.J: Anti-GAPDH Western blotting of HSII lysates for COS-7 cells 
cultured in high/low FCS media and incubated with the mitochondrial poison 
CCCP. (n=3) independent experiments. 
 
 
Figure A1.3.K: The CCCP optimisation data normalised using the 
corresponding anti-GAPDH density intensity and expressed as a percentage of 
the high/low serum sham (DMSO) normalised ATP concentration. Univariate 
analysis of variance reveals a significant effect of serum level p<.01, a 
significant effect of CCCP concentration p<.001 and a significant interaction 
between serum level and CCCP concentration p<.01 Data is mean ± SEM. (n=3) 
independent experiments.  
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For future optimisation, the results indicate that a 100µM concentration of CCCP applied to 
COS-7 cells cultured in low FCS media would elicit a maximal alteration in the level of 
cellular ATP. However, the direction in the change of ATP in the low serum/CCCP conditions 
demonstrates an increase in cellular ATP. This was unexpected. CCCP treatment on cell lines 
typically results in a reduction in cellular ATP being detected (de Graaf et al, 2002; Legros et 
al, 2002; Migita et al, 2007). An increase in cellular ATP is observed by de Graaf et al., in 
FL5.12 cells following incubation with 100µM CCCP, although these cells were cultured in 
IMDM 10% FCS (vol/vol). In this instance it was hypothesised that the increase in cellular 
ATP arises through upregulation of cytosolic ATP generation via glycolysis. It is possible that 
the serum starvation in COS-7 cells, in the optimisation of CCCP covered in this chapter, also 
results in such an upregulation of ATP levels via glycolysis. This could explain the resulting 
increased cellular ATP levels following addition of CCCP rather than a decrease in cellular 
ATP as expected. The molecular underpinning of the serum starvation results in this section 
can be investigated using other drug treatments that affect cellular respiration. The 
mitochondrial and cytosolic respiratory components could be isolated by the use of drugs 
specific to each cellular compartment. In this section, the HSII assay methodology is capable 
of reproducibly detecting an alteration in cellular ATP. Further work is needed to establish 
why an increase in ATP is observed. 
 
A1.4 Development of a luciferase bioluminescence assay to investigate 
cellular ATP levels in t(1;11) family derived lymphoblastoid cell lines 
The HSII assay needed to be optimised to assay t(1;11)-family derived lymphoblastoid cell 
lines to observe if the t(1;11) affects cellular ATP levels. The results could then be compared 
with cellular ATP data for COS-7 cells exogenously expressing DISC1/DISC1FP1 proteins, 
to determine if any alterations in cellular ATP in translocation cells lines could possibly be 
attributed to endogenous chimeric proteins.  
This lymphoblastoid cell line method development work followed the attempts to optimise 
CCCP as a positive control for the HSII assay (see section A1.3.9) and included the use of 
high-10% FCS (vol/vol) and low-1% FCS (vol/vol) serum cultured lymphoblastoid cells. The 
subsequent HSII assay optimisation cellular ATP data was normalised to anti-GAPDH 




A1.4.1 Generation of an ATP standard curve to detect cellular ATP in 
lymphoblastoid cell lines 
Initial attempts to measure the cellular ATP level in lymphoblastoid cell lines produced 
cellular ATP levels that were extremely low compared to the COS-7 cellular ATP optimisation 
data (data not shown). Consequently, a greater range of ATP standards was used in the lower 
half of the standard curve than is seen in the COS-7 ATP standard curve. This approach was 




Figure A1.4.A: Development of a standard curve to measure ATP 
bioluminescence using the HSII assay within t(1;11)-family derived 
lymphoblastoid cell lines. For the measurement of ATP bioluminescence in 
lymphoblastoid cell lines, more ATP standards were placed in the lower half of 
the curve than is seen in the COS-7 ATP standard curve. 
 
A1.4.2 Optimising lymphoblastoid cell line protein lysates for the HSII assay  
Following the generation of an ATP standard curve adapted to measure lymphoblastoid 
cellular ATP (see figure A1.4.A), the identification of a protein concentration that produced a 
cellular ATP concentration that fell on the exponential phase of the standard curve still needed 
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to be  identified. To optimise the protein concentration loaded into the HSII assay, a normal 
karyotype control and a translocation lymphoblastoid cell line were lysed. The HSII cell 
lysates were standardised to protein concentrations of 0.4mg/ml and 0.8mg/ml for kaytoype 
controls and 0.8mg/ml and 1.6mg/ml for translocation lymphoblastoid cell lines, respectively. 
The cellular ATP content of these lysates was determined using the HSII assay. Following the 
Western blotting of the same lymphoblastoid cell lysates (see figure A1.4.B), the HSII assay 




Figure A1.4.B: Anti-GAPDH Western blotting of HSII lysates for lymphoblastoid 
cell lines cultured in high/how FCS media with cell lysates loaded at different 
protein concentrations. Blot has 1 normal karyotype control (N) and 1 t(1;11)-
family derived lymphoblastoid cell line (T) loaded.  
 
The normal cell line data appears to both show concentration dependent and serum treatment 
dependent differences in the cellular ATP data (see table A1.4.A). Importantly, all of the  
normal cell lysate cellular ATP data lie on the exponential phase of the lymphoblastoid ATP 
standard curve (see section A1.4.1), with the exception of the low serum/0.4mg/ml condition. 
However, in the translocation cell line, cellular ATP levels were very low in comparison, 










Treatment Density Cellular ATP 
(µM/50µl) 
Norm. ATP 
(N) High serum (0.4mg/ml)  580619 13.90 23.94 
(N) Low serum (0.4mg/ml)  472490 5.76 12.20 
(N) High serum (0.8mg/ml)  801570 35.09 43.77 
(N) Low serum (0.8mg/ml)  830155 11.70 14.09 
(T) High serum (0.8mg/ml)  1074385 0.29 0.27 
(T) Low serum (0.8mg/ml)  997059 0.94 0.94 
(T) High serum (1.6mg/ml)  1290301 0.59 0.46 
(T) Low serum (1.6mg/ml)  1345556 2.39 1.77 
 
Table A1.4.A: Normalised cellular ATP level in lymphoblastoid cells cultured in 
high and low serum media, assayed at a range of protein concentrations. The 
cellular ATP levels of normal karyotype control (N) and t(1;11)-family derived 
(T) lymphoblastoid cell lines lysates was determined by the HSII assay. Protein 
concentration of cell lysate assayed is given in brackets. Anti-GAPDH Western 
blots of lysates run on the HSII assays were subjected to densitometry analysis 
and used to normalise the cellular ATP levels. The normal lymphoblastoid cell 
line shows protein concentration-dependent cellular ATP levels within serum 
type. The translocation cell line appears not to have been lysed sufficiently for 
cellular ATP to be detected accurately. One culture of a translocation cell line 
and one culture of a normal lymphoblastoid cell line were assayed, (n=1) 
experiment.  
 
These translocation lymphoblastoid results are of a similar order of magnitude to the previous 
lymphoblastoid HSII optimisation data (data not shown). The translocation anti-GAPDH 
results were interpreted as being due to the incomplete lysis of the lymphoblastoid cells by the 
HSII lysis buffer. It is possible that previous attempts to optimise the HSII assay for 
lymphoblastoid cell lysates also suffered from this problem (data not shown).  
The following lymphoblastoid cell HSII optimisation data were generated after the 
implementation of an attempt to enhance lysis of lymphoblastoid cells by passing the cell 
lysates up a 25-gauge syringe needle to mechanically enhance lysis. The optimisation featured 
one normal karyotype control and two t(1;11)-family derived lymphoblastoid cell lines. Given 
the previous low ATP readings that may have arisen due to incomplete cell lysis, all of the 
lysate assayed was standardised to a protein concentration of 0.4mg/ml. This concentration 
was adopted because this was the lowest protein concentration assayed at high serum levels 
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that lay sufficiently on the standard curve and, because the modification of the lysis protocol 
was expected to yield a greater concentration of ATP than previous optimisation assays.  
The cellular ATP values observed for all the lymphoblastoid cell lines assayed following the 
use of a syringe needle to enhance lysis ranged from 18.70-28.22µM ATP (see table A1.4.B). 
These ATP concentrations adequately lie on the exponential phase of the lymphoblastoid ATP 
standard curve (see figure A1.4.A). This was interpreted as being a consequence of the 
modified cell lysis protocol. The standadised protein levels used in the HSII assay were 
analysed by Western blot and probed with anti-GAPDH (see figure A1.4.C).  
 
Treatment Density Cellular ATP  
(µM/50µl) 
Norm. ATP 
(N) High serum   1677329 23.172 13.81 
(N) Low Serum   1356862 18.664 13.76 
(T1) High serum   1614640 24.009 14.87 
(T1) Low Serum   1539611 18.702 12.15 
(T2) High serum   1924628 20.593 10.70 
(T2) Low Serum  1361104 28.221 20.73 
 
Table A1.4.B: Normalised cellular ATP level in lymphoblastoid cells cultured in 
high and low serum media. The cellular ATP levels of normal karyotype control 
(N) and t(1;11)-family derived (T1) and (T2) lymphoblastoid cell lines lysates was 
determined by the HSII assay. Protein concentration of the cell lysate assayed 
is given in brackets. Anti-GAPDH Western blots of lysates run on the HSII assay 
were subjected to densitometry analysis and used to normalise the cellular ATP 
levels. All cell lysates were run on the HSII assay at 0.4mg/ml. The cellular ATP 
concentrations detected here lie on the exponential phase of the ATP standard 
curve irrespective of culture serum level. One culture of normal and two 









Figure A1.4.C: Anti-GAPDH Western blotting of HSII lysates for lymphoblastoid 
cell lines cultured in high/low FCS media. Equal volume of protein at 0.4 mg/ml 
loaded per lane. One normal karyotype control (N) and two t(1;11)-family 
derived lymphoblastoid cell lines(T) assayed.  
 
The blot bands were then analysed via densitometry and this densitometry data was then used 
to normalise the HSII assay data (see table A1.4.B). However, no clear serum dependent effect 
is seen with the cellular ATP or the normalised ATP data. This optimisation appears to show 
that with the modification to cell lysis lymphoblastoid cell lysates standardised to 0.4mg/ml, 
with 10ug of protein assayed, produces cellular ATP levels that lie the linear phase of the 
standard curve for both high and low serum conditions.     
An HSII assay optimisation experiment was run with 3 normal karyotype control and 3 
translocation lymphoblastoid cell lines. Additionally, one of the lymphoblastoid cell lines was 
run with both 100µM CCCP and sham (DMSO) treatments. This was a pilot of a possible final 
experimental design using a CCCP positive control (see section A1.3.9). The cells that 
received the CCCP treatment were observed to immediately disperse from the flocculated 
lymphoblastoid cell aggregates. However, when run on the HSII assay, the optimisation 
experiment itself produced very low ATP values (data not shown). From this it was concluded 
that further method development was required on the harvesting and lysis of lymphoblastoid 
cell lines.  
 
A1.5 Discussion 
The HSII assay method development was discontinued due to personal illness and, as a result 
the final experimental assays to detect the levels of cellular ATP in COS-7 cells exogenously 
expressing the DISC1/DISC1FP1 chimeras and within t(1;11) lymphoblastoid cell lines were 
never accomplished. However, given that considerable effort went into the research reported 
in this thesis, it was felt that it should be included with a view to producing a commentary on 
A1-40 
 
the practical issues encountered and the positive and negative outcomes established. The 
following discussion aims to cover the ongoing method development issues with the HSII 
assay protocol that needed to be rectified before pursuing such final experiments. 
Further normalisation of the HSII assay data is needed using additional loading control 
antibodies. This would be to explore any issues relating to the use of GAPDH alone as a 
loading control to generate data for densitometry as a possible source of error. GAPDH protein 
is expressed in the cytosol and is part of the glycolytic pathway (Tristan et al, 2011). As such, 
it is possible that the anti-GAPDH densitometry used in the COS-7 optimisation of CCCP (see 
section A1.3.9) may have led to anomalous results if the low serum/CCCP treatments indeed 
do cause an upregulation of glycolysis. Suitable loading control antibodies to be used in place 
of anti-GAPDH include anti-β-actin, anti-α-tubulin and anti-β-tubulin.  
It is unknown as to how the exogenous expression of the DISC1/DISC1FP1 chimeric species 
and the resulting impact on mitochondrial function would affect endogenous GAPDH protein 
levels in the expressing COS-7 cells. In the future, it may also be possible to reprobe blots 
produced to normalise the HSII assay to look for proteins associated with mitochondrial 
structure or mitochondrial signalling pathways and enrich the cellular ATP data with this 
information. For example, it may be worth observing if levels of cytochrome c protein are 
uniform across all transfected DISC1 species given there appears to be no difference in the 
cytochrome c immunocytochemical results (see section 4.4).  
An efficient method for the quantification of lymphoblastoid cell line cultures needs to be 
developed. This is to enable the replicable growth of cultures that are of sufficient size to be 
lysed effectively. It also likely that the means of lysing the lymphoblastoid cultures also needs 
to be reviewed given that the use of a 25 gauge syringe to encourage full cell lysis appears to 
be effective only occasionally. The simplest means to do this would be to heuristically 
establish the optimal amount of lysis reagent to use with a cell population of given size that in 
turn produces an acceptable level of cellular ATP released. 
At present no means of stopping cellular reactions within the HSII assay has been applied. It 
is unknown as to whether it is possible that cellular reactions still occur after lysis. However 
the incorporation of the use of perichloric acid around the time of lysis would ensure that 
cellular reactions, including ATP synthesis, are stopped, possibly removing a potential source 
of experimental variation. 
Regarding the anomalous CCCP positive control optimisation data, ATP synthesis could be 
blocked by other means to further investigate the increase in cellular ATP seen with CCCP 
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treatment in COS-7 cells cultured in low serum media. 2 deoxy glucose (2DG) and oligomycin 
could be used both separately and together, to block glycolytic, mitochondrial and both 
glycolytic and mitochondrial ATP synthesis, respectively (Benard & Rossignol, 2008). 2DG 
is a glucose molecule that cannot undergo glycolysis, and as such, specifically perturbs ATP 
generation by glycolysis, whereas oligomycin is a potent inhibitor of ATP synthase. A protocol 
using both of these respiratory active agents could be used in the further optimisation of a low 
serum condition with oligomycin as a positive control to lower cellular ATP and 2DG as a 
means to prevent a rise in cellular ATP by glycolytic pathways. 
Had the HSII assay been run with COS-7 cell lysates exogenously expressing 
DISC1/DISC1FP1 chimeric species, the corresponding immunocytochemistry experiments 
(see chapter 4) would need to be repeated with the cells cultured in low serum conditions. It 
would be important to phenotypically characterise the effect low serum conditions have on 
mitochondrial morphology and the distribution of the exogenous chimeric protein when 
interpreting cellular ATP data. In the low serum treatment, it is possible that mitochondria 
elongate as an adaption to the increased bioenergetic demand due to the starvation of the cells. 
Such a change in mitochondrial network shape could be the result of increased mitochondrial 
fusion (Westermann, 2012). 
The starvation of cells by serum (Gomes et al, 2011) or nutrient starvation (Rambold et al, 
2011) results in elongation of the mitochondrial network due to phosphoregulation of 
mitochondrial fission protein, Drp1. This reduces Drp1 mediated fission, with an increasingly 
tubular mitochondrial morphology observed. When serum starvation is used in conjunction 
with starvation of both glycine and glucose there is an increase in the percentage of tubular 
mitochondria (Rambold et al, 2011). Likewise, the mitochondria elongate when mouse 
embryonic fibroblasts are serum starved by having DMEM/10% FBS media replaced with a 
Hanks balanced salt solution containing 10mM HEPES (Gomes et al, 2011). Of these two 
different methodologies, the low serum condition reported in this chapter bears greater 
similarity to  that of Rambold et al. (2011), though the time frame used for the low serum 
treatment with COS-7 cells is ~9 times longer. It, therefore, seems possible that serum 
starvation may change the morphology of mitochondria in culture. This is particularly relevant 
with regard to what would happen to the clustered mitochondrial shape observed in COS-7 
cells exogenously expressing CP60 and CP69. 
A further problem with the use of serum starvation protocols is that they can affect signalling 
pathways in both a temporal and cell line dependent manner. Pirkmajer & Chilbalin (2011) 
observed, under starvation conditions, that variation is seen in the level of protein 
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phosphorylation in both the Adenosine Monophosphate-activated Protein Kinase (AMPK) and 
Extracellular-signal-Regulated Kinase 1/2  (ERK1/2) signalling cascades and, also to a lesser 
extent in the mTOR pathway. These findings are from both primary cultures and cell lines 
incubated under absolute serum starvation or serum starvation using 0.5% (wt/vol) BSA. 
These observations serve to highlight the caution required when interpreting serum starvation 
data. It is, therefore, possible that serum starvation may affect the signalling pathways in the 
COS-7 and lymphoblastoid cell lines differently if culturing these cells in low serum 


















Annex A2 - Attempts to detect exogenously expressed 
CP60 and CP69 in COS-7 lysates by Western blot  
 
A2.1 Exogenously expressed CP60 and CP69 do not partition to the 
soluble fraction   
Upon receipt from GENEART, the untagged CP60 and CP69 constructs housed in a 
pcDNA3.1(+) vector backbone were transiently transfected into COS-7 cells and the cell lysate 
analysed using Western blot. The immunoblot was probed with the N-terminal DISC1 
antibody R47 (James et al, 2004). Importantly, the positve control, FLAG-DISC1 was detected 
at a molecular weight of ~100kDa in the 2 minute exposure, as expected. Unfortunately, 
FLAG-DISC1 expression was somewhat obscured in the overnight exposure. No bands were 
detected that could be interpreted as being specific CP60 and CP69 protien species in either 
the 2 minute or overnight exposures. The non-specific bands shared with CP60 and CP69 
lysates and the empty vector control (pcDNA3.1(+)) were clearly visible in the overnight 
exposure. Taken together, these two pieces of pre-experimental data were seen to indicate that 
CP60 and CP69 protein was not readily detectable in the soluble fraction. It should be noted 
that all lysates were produced with RIPA lysis buffer, therefore the potency of the lysis buffer 























Figure A2.1.A: Attempts to detect exogenous CP60 and CP69 protein in cell 
lysates. Western blotting detected exogenously expressed FLAG-DISC1 in the 
soluble fraction at ~100kDa using the N-terminal DISC1 antibody R47 (1:1000), 
as depicted in 2 minute exposure. Irrespective of exposure length. Lanes ran 
with untagged CP60 and CP69 only displayed non-specific bands that were also 
evident in the empty vector (E.V) condition, pcDNA3.1 (+). Irrespective of 
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